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During viral infection, HIV encounters a number of cellular proteins, so-called restriction factors, 
that inhibit its replication at different stages of the viral life cycle. One such factor is tetherin 
(CD317/BST2), which is an interferon inducible transmembrane protein that inhibits virus release 
from infected cells by tethering budding virions to the plasma membrane. Tetherin antagonism is 
highly conserved and various enveloped viruses encode antagonist proteins including HIV-1 Vpu, 
HIV-2 Env, SIV Nef or KSHV K5. Tetherin is expressed as two isoforms that differ in the length of 
their cytoplasmic tail. The longer isoform contains an important tyrosine based endocytic and 
signalling motif that is not present in the shorter one. The data presented in this thesis show that 
Vpu proteins from the pandemic HIV-1 group M were the only lentiviral tetherin antagonists tested 
that exhibited differential activity against the two isoforms. These Vpu alleles are considerably more 
active against the long, signalling form of human tetherin. In addition, this group of Vpu proteins 
target human long tetherin for endosomal degradation. This adaption of Vpu may have implications 
for the recent evolution of HIV-1 and the role of tetherin in the pathogenesis of pandemic HIV/AIDS. 
Vpu binds to and antagonises tetherin by preventing it from reaching the cell surface and re-
routing it for endosomal degradation. This requires the phosphorylation of two serines in the 
cytoplasmic tail of Vpu that recruit the SCFβTRCP1/2 ubiquitin ligase complex. However, whether the 
final ubiquitin-dependent degradation of tetherin is essential for Vpu to counteract its antiviral 
activity is unclear. Data presented in this thesis aims to re-evaluated this question and indicates 
that Vpu phosphorylation can be decoupled from SCFβTRCP1/2 recruitment and tetherin degradation. 
The phospho-mutant phenocopies a Vpu trafficking mutant and both are unable to bind to clathrin 
adaptors AP-1 or AP-2 in the presence of tetherin. Direct linkage of the Vpu mutants to the clathrin 
machinery rescues their function without restoring β-TrCP interaction of the phospho-mutant. 
Altogether, these data suggest that the phosphorylation of Vpu and its interaction with tetherin 
regulate its binding to clathrin adapters, which may be the crucial step in tetherin counteraction prior 
to ubiquitin-dependent degradation. 
Recently, the multispanning transmembrane proteins serine incorporator (SERINC) 3 and 5, 
have been identified to potently restrict HIV-1 virion infectivity and both are targeted by the 
accessory protein Nef. The data presented here confirm previous findings and further characterize 
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Chapter 1 Introduction 
1.1 The HIV Pandemic 
Almost thirty-five years ago in 1981, acquired immunodeficiency syndrome (AIDS) was first 
described in the United States in homosexual men presenting with unusual opportunistic infections 
and a compromised immune system (Gottlieb et al. 1981). Two years later, the virus now known as 
human immunodeficiency virus 1 (HIV-1) was isolated from patient samples and identified as the 
causative agent (Barré-Sinoussi et al. 1983; Gallo et al. 1983). In 2008, the Noble Prize in 
Physiology or Medicine was awarded to Françoise Barré-Sinoussi and Luc Montagnier for their 
discovery of HIV-1. Five years after the first reports of HIV-1, another virus causing AIDS was 
isolated from patients in western Africa and named human immunodeficiency virus 2 (HIV-2) (Clavel 
et al. 1986). While it was only distantly related to HIV-1, it was more closely related to a simian 
immunodeficiency virus (SIV) infecting and causing immunodeficiency in captive macaques, 
SIVmac. Later, it was found that this infection was not a natural infection of macaques, which may 
explain its pathogenicity in this host (Apetrei et al. 2006; Apetrei et al. 2005). Subsequently, SIVs 
were identified in a broad range of primates from sub-Saharan Africa including African green 
monkeys, sooty mangabeys and chimpanzees. However, in most natural hosts SIV infections were 
non-pathogenic. HIV-1 and HIV-2 cluster together with SIVs in a phylogenetic lineage. It has been 
suggested that cross-species transmission occurred most likely due to hunting and handling of 
infected bushmeat (Peeters et al. 2002).  
HIV-1 is the result of the zoonotic transmission of chimpanzee SIV (SIVcpz) to humans. There 
have been at least four independent cross-species transmissions that led to the emergence of HIV-
1 group M, N, O and P. Group M is responsible for the vast majority of HIV-1 infections world-wide, 
while groups N, O and P are non-pandemic and confined to central Africa. Group O (outlier) was 
discovered in 1990 as the causative agent of tens of thousands of infections and is confined to 
Cameroon, Gabon and surrounding countries (Mauclère et al. 1997; Peeters et al. 1997). For group 
N (non-M and non-O) only thirteen cases have been reported, all but one discovered in Cameroon 
(Simon et al. 1998; Vallari et al. 2010). Group P is the least prevalent with only two isolates found 
to date that both originated in Cameroon (Plantier et al. 2009; Vallari et al. 2011). Group M and N 
are very closely related to SIVcpz found in the central chimpanzee subspecies Pan troglodytes 
troglodytes from south Cameroon (SIVcpzPtt), indicating that these virus groups are of SIVcpzPtt 
origin (Keele et al. 2006; Van Heuverswyn & Peeters 2007). In contrast, SIVcpzPts infecting eastern 
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chimpanzees (Pan troglodytes schweinfurthii, Pts) has so far not been found to be transmitted to 
humans. SIVcpz itself is a recombinant of SIVs infecting red-capped mangabeys and Cercopithecus 
species, including greater spot-nosed, mustached and mona monkeys (Bailes et al. 2003). Although 
all four HIV-1 groups are closely related to SIVcpzPtt, due to greater sequence similarity to SIV 
infecting gorillas (SIVgor), HIV-1 groups P and O were potentially transmitted to humans via gorillas 
from southern and central Cameroon, respectively (D’arc et al. 2015).  
HIV-2, which is restricted to western Africa, is more closely related to SIVs infecting sooty 
mangabeys (SIVsmm) and multiple cross-species transmissions have occurred (Huet et al. 1990; 
Hirsch et al. 1989; Gao et al. 1992; Chen et al. 1996). Infection is associated with lower viral loads, 
which may explain the lower transmission rates. Compared to HIV-1 infection, a greater proportion 
of people infected with HIV-2 do not progress to AIDS.  
Of all the HIV zoonoses, it was HIV-1 group M that spread most efficiently in humans and is 
responsible for the HIV pandemic, accounting for over 98% of all HIV infections worldwide. Genetic 
evidence suggests that HIV-1 group M emerged from the region around Kinshasa, the capital of 
the Democratic Republic of Congo (DRC), formerly known as Zaire, and it was estimated that the 
group M common ancestor dates back to the 1920s (Korber et al. 2000; Worobey et al. 2008; Faria 
et al. 2014). Transportation and migration in and around Kinshasa facilitated the spread of HIV-1 
group M to other regions in central Africa (Gray et al. 2009). Group M has diversified in humans to 
form nine subtypes or clades: A, B, C, D, F, G, H, J and K. Clade B is responsible for most of the 
infections found in Europe and the United States. Phylogenetic studies suggest that a single African 
strain of clade B was transferred to Haiti and subsequently the United States in the 1960s where it 
spread internationally, becoming the most geographically dispersed subtype (Gilbert et al. 2007; 
Hemelaar et al. 2011). In contrast, subtype C, which accounts for around 50% of all HIV-1 infections 
worldwide, spread efficiently especially in southern Africa.   
HIV is transmitted via body fluids such as blood, semen, vaginal secretions or breast milk, and 
it is primarily a sexually transmitted disease (Hladik & McElrath 2008; Cohen et al. 2011). In 2014, 
36.9 million people were living with HIV worldwide, most of them in sub-Saharan Africa. Since 2000, 
25.3 million people have died of AIDS related illnesses (www.UNAIDS.org). Even though infection 
rates have decreased in recent years there were still approximately two million new infections 
reported in 2014. Highly active antiretroviral therapy (HAART) has become more and more 
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accessible even in developing countries, which is one of the reasons for the reduced number of 
AIDS-related deaths. However, there is neither an efficient vaccine nor a broadly applicable cure 
for HIV infection.  
 
1.2 HIV Genome and Structure 
HIV-1 belongs to the family of the Retroviridae. These are enveloped viruses with a positive-
sense single-stranded RNA (ssRNA) genome that have a similar structure and genomic 
organisation. Characteristically, the retroviral genomic RNA is converted into DNA by the virally-
encoded reverse transcriptase (RT) and is integrated into the host genome by the virally-encoded 
integrase (IN). HIV-1 belongs to the retroviral genus of lentiviruses (‘lente-‘, latin for slow) and these 
viruses cause chronic persistent infections in different mammalian species.  
The 9.7 kb HIV-1 proviral DNA encodes nine viral genes. Common to all replicating retroviruses 
are the gag, pol and env genes (Figure 1.1 A). Pol encodes three enzymes: RT that converts the 
genomic HIV RNA into the proviral DNA, IN that integrates the proviral DNA into the host cell 
genome to form the provirus and the protease (PR) that is responsible for the maturation of budding 
viral particles by cleaving the Gag poly-protein into the main structural components of the virus. 
These are matrix (MA), capsid (CA), nucleocapsid (NC) and p6. Env encodes for the two 
glycoproteins, the surface (SU) gp120 and the transmembrane (TM) gp41. Gp120 binds to CD4 on 
the target cell, which induces conformational changes in the Env spike and enables co-receptor 
CCR5/CXCR4 binding. This is followed by the fusion of the virion with the host cell membrane 
mediated by gp41 (Wilen et al. 2012). HIV-1 encodes six more regulatory and accessory proteins 
Tat, Rev, Vif, Vpr, Vpu and Nef. Tat is a regulatory protein that interacts with cellular proteins and 
binds the trans-activation response (TAR) sequence in the viral RNA. This promotes viral 
transcription elongation. Rev, also a regulatory protein, binds to the Rev responsive element (RRE), 
which is a cis-acting RNA sequence in the env gene. Rev binding to RRE facilitates efficient nuclear 
export of unspliced or partially spliced viral mRNAs. Vif, Vpr, Vpu and Nef are proteins that regulate 
innate and adaptive host cell immune functions (Swanson & Malim 2008). The proviral DNA is 
flanked at each end by a long terminal repeat (LTR). The 5’ LTR serves as a promoter for the 
initiation of transcription of the viral genome. The 3’ LTR is required for the polyadenylation signal 
(polyA tail). Like cellular mRNAs, the viral RNA is polyadenylated at the 3’ end and capped with 7-
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methylguanosine at the 5’ end. Further important elements in the viral genome include the primer 
binding site (PBS) that is required for the annealing of the cellular tRNALys3, which initiates reverse 
transcription, the ψ packaging signal that is responsible for the incorporation of the viral RNA into 
the budding virion through interaction with the NC, the polypurine tracts (PPT) for plus strand DNA 
synthesis, a dimerization sequence, splice donor and splice acceptor sites. 
The HIV-1 particle has a diameter of approximately 100 nm. It contains two copies of the viral 
genomic RNA. RT and the genomic RNA are enclosed by NC and together with IN and PR 
surrounded by the conically shaped capsid (Figure 1.1 B). The capsid is made up of hexameric CA 
subunits and is surrounded by the MA, which in turn is connected to the envelope formed by the 
host cell lipid bilayer (Sundquist & Kräusslich 2012). 
 
Figure 1.1 HIV-1 proviral genome and particle structure. (A) Schematic representation of the proviral HIV-
1 genome containing the nine open reading frames of HIV-1: gag, pol, vif, vpr, tat, rev, vpu, env and nef. 
Abbreviations: LTR (long terminal repeat), U5 (5’ untranslated region), R (repeat element), U3 (3’ untranslated 
region), MA (matrix), CA (capsid), NC (nucleocapsid), PR (protease), RT (reverse transcriptase), IN 
(integrase), SU (surface), TM (transmembrane), TAT (trans-activator of transcription), ψ (packaging signal), 
PBS (primer-binding site for tRNALys3), RRE (rev response element), PPT (polypurine tract). (B) Schematic 
representation of the HIV-1 virus particle. 
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1.3 The HIV Replication Cycle 
The HIV-1 replication cycle starts with the binding of the viral envelope protein subunit gp120 
to the cellular receptor CD4, expressed primarily on helper T cells and macrophages. 
Conformational changes in gp120/41 then facilitate co-receptor CC-chemokine receptor 5 (CCR5) 
or C-X-C chemokine receptor type 4 (CXCR4) binding followed by the fusion of the viral particle 
with the target cell and the translocation of the viral core into the cytoplasm. The single-stranded 
RNA is then reverse transcribed into double-stranded DNA (dsDNA) and forms the pre-integration 
complex (PIC) together with the viral MA (p17), CA (p24), viral IN, viral RT, the accessory protein 
viral protein R (Vpr) and several host cell-derived proteins. The PIC travels to the nucleus utilising 
the cellular microtubules for anterograde transport and there is evidence that the capsid is still 
associated with the PIC upon arrival at the nuclear pore (Matreyek & Engelman 2011; Peng et al. 
2014; Hulme et al. 2015). This is followed by nuclear import and integration of the dsDNA into the 
host cell genome or dead-end formation of 2-LTR circles. Importantly, while most retroviruses 
cannot enter the nucleus until the nuclear membrane breaks down during cell division, lentiviruses 
infect non-dividing cells by hijacking cellular nuclear import pathways (Matreyek & Engelman 2011). 
The transcription of the viral genes depends on cellular transcription factors such as NF-κB and 
specificity factor 1 (SP1). They initiate the binding of the cellular RNA polymerase II to the TATA 
box at the 5’ LTR and initiate mRNA transcription. Tat binding is required for efficient elongation 
and the subsequently produced mRNA is exported from the nucleus. Translation and protein 
processing occurs in the cytoplasm by the cellular machinery. Proteins and genomic RNA are then 
trafficked to the plasma membrane where they assemble into viral particles and bud from the host 
cell membrane. Maturation of the particle is mediated by the viral protease to form the fully infectious 
particle. A schematic of the viral life cycle is depicted in Figure 1.2 and in the following sections of 











Figure 1.2 HIV-1 replication cycle. The infection begins when the envelope (Env) glycoprotein trimers 
engage the target cell receptor CD4 and the membrane-spanning co-receptor CCR5 (step 1), leading to fusion 
of the viral and cellular membranes and entry of the viral particle into the cell (step 2). Partial core shell 
uncoating (step 3) facilitates reverse transcription (step 4), which yields the PIC. Following import into the cell 
nucleus (step 5), PIC-associated IN orchestrates the formation of the integrated provirus, aided by the host 
chromatin-binding protein lens epithelium-derived growth factor (LEDGF) (step 6). Proviral transcription (step 
7), mediated by host RNA polymerase II (RNA Pol II) and positive transcription elongation factor b (P-TEFb), 
yields viral mRNAs of different sizes. Partially spliced and unspliced mRNAs require the viral Rev protein and 
the host protein CRM1 for nuclear export (step 8). mRNAs serve as templates for protein production (step 9), 
and genome-length RNA is incorporated into viral particles with protein components (step 10). Viral-particle 
budding (step 11) and release (step 12) from the cell is mediated by ESCRT (endosomal sorting complex 
required for transport) complexes and ALIX and is accompanied or soon followed by protease-mediated 
maturation (step 13) to create an infectious viral particle. Each step in the HIV-1 life cycle is a potential target 
for antiviral intervention; the sites of action of clinical inhibitors (white boxes) and cellular restriction factors 
(blue boxes) are indicated. INSTI, integrase strand transfer inhibitor; LTR, long terminal repeat; NNRTI, non-
nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor. (Figure from 
Engelman & Cherepanov 2012). 
 
1.3.1 Attachment and Entry 
The first step of the viral life cycle consists of binding to and entering the target cell. Figure 1.3 
depicts a schematic of the important steps in this process. Initial viral attachment to the cell can be 
rather non-specific through host cell proteins such as heparin sulphate proteoglycans, ɑ4β7 
integrins or pattern recognition receptors (PRR), like the dendritic cell-specific intercellular adhesion 
molecule 3-grabbing non-integrin (DC-SIGN) (Geijtenbeek et al. 2000; Saphire et al. 2001; Arthos 
et al. 2008). These attachment factors are cell type dependent and are not essential for HIV entry, 
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but can enhance infection of target cells. Also, viruses can move along the cell plasma membrane 
using host cell transport pathways, before reaching sites on the target cell with increased receptor 
expression that are favourable for HIV entry (Lehmann et al. 2005; Sherer et al. 2010). The first 
essential step is the binding of the the viral Env gp120 subunit to the main receptor of HIV entry, 
CD4 (Figure 1.3).  
HIV-1 Env is a glycosylated trimer comprised of heterodimers formed by gp120 and gp41. The 
gp120 subunit is responsible for receptor binding. It contains five relatively conserved domains (C1-
C5) and five variable regions (V1-V5) that all contain a loop structure, apart from V5. The variable 
regions have a fundamental role in co-receptor binding and immune evasion, particularly V3 
(Hartley et al. 2005). The number of Env trimers that is required to facilitate entry, known as the 
entry stoichiometry, is currently under debate, with reports ranging from 1 to 19 trimers (Reviewed 
by Brandenberg et al. 2015).  
It was known for a long time that CD4 is the main receptor used for HIV-1 entry. HIV-1 
preferentially infects CD4+ T cells, blocking antibodies to CD4 inhibit infection and Env can be co-
immunoprecipitated with CD4. Moreover, CD4 expression promotes infection in non-permissive 
human cells (Dalgleish et al. 1984; Klatzmann et al. 1984; Maddon et al. 1986; McDougal et al. 
1986). CD4 is a member of the immunoglobulin superfamily and its cellular function is to enhance 
T cell receptor (TCR) signalling. The binding of CD4 and HIV gp120 is followed by rearrangements 
in the V1/V2 regions of gp120 and, subsequently, leads to the formation of the bridging sheet 
(Kwong et al. 1998). These events are critical for the second step of HIV-1 entry: binding of Env to 
the co-receptor.   
HIV-1 can either use CCR5 or CXCR4 as a co-receptor for entry. Depending on the co-receptor 
usage, there are R5 (CCR5 user), X4 (CXCR4 user) or R5X4 (where both co-receptors can be 
used) HIV strains (Berger et al. 1998). Interestingly, only R5 and R5X4 viruses are transmitted 
efficiently and X4 or R5X4 viral species are mainly found late in infection, even though target cells 
express high levels of CXCR4 (Keele et al. 2008; Schuitemaker et al. 1992; Connor et al. 1997). 
This may potentially be due to host restriction on X4 HIV transmission (reviewed by Margolis & 
Shattock 2006). A switch in co-receptor usage over the course of infection occurs in nearly 50% of 
untreated infected individuals and was implicated in disease progression (Scarlatti et al. 1997; 
Connor et al. 1997). Differences in co-receptor tropism among different HIV-1 clades may be a 
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result of differing host biology or environmental differences such as co-infections. This may depend 
on the geographical area an infected individual lives in (Wilen et al. 2012).  
The final step of HIV-1 entry is the fusion of the viral membrane with the host cell. Upon binding 
to the co-receptor, the hydrophobic fusion peptide in gp41 is exposed and inserted into the host cell 
membrane, thereby, tethering both host and viral membranes. Each gp41 fusion peptide in the Env 
trimer folds at a hinge region, which brings the amino-terminal helical region (HR-N) and the 
carboxy-terminal helical region (HR-C) together to form a six helical bundle (6HB) (Chan et al. 1997; 
Weissenhorn et al. 1997). Subsequently, the fusion pore is formed and the viral contents are 
released into the host cell cytoplasm (Reviewed by Melikyan 2008).  
HIV-1 does not require a low pH to promote host cell entry (McClure et al. 1988). This does not 
necessarily mean that HIV fuses at the plasma membrane. Whilst there is evidence for cell surface 
fusion, it has also been demonstrated that complete fusion can require endocytosis, which may be 
dependent on the viral strain or cell type (Stein et al. 1987; Miyauchi et al. 2009; Uchil & Mothes 
2009). Furthermore, host cell entry via cell-cell transmission was shown to be enabled via formation 
of the so-called virological synapse between an infected cell and a target cell, which is characterized 
by recruitment of CD4, CCR5 and CXCR4. Infected dendritic cells (DCs) catalysed infection of co-
cultured T cells without being productively infected themselves and HIV was shown to be able to 
migrate to the DC-T cell interface (Cameron et al. 1992; McDonald et al. 2003).  
 
 
Figure 1.3 Schematic representation of HIV binding and entry. HIV Env, comprised of gp120 and gp41 
subunits, first attaches to the host cell, binding CD4 (1). This causes conformational changes in Env, allowing 
co-receptor binding, which is mediated in part by the V3 loop of Env (2). This initiates the membrane fusion 
process as the fusion peptide of gp41 inserts into the target membrane, followed by six-helix bundle formation 




1.3.2 Reverse Transcription 
Once the viral core has reached the cytoplasm, the viral RNA genome needs to be reverse 
transcribed into DNA to enable integration into the host genome. This is a common feature of all 
retroviruses, thus all of them encode a RT and IN. The discovery that some viruses have an 
enzymatic activity that copies RNA into DNA, reverse transcription, was made more than a decade 
before the identification of HIV-1 (Baltimore 1970; Mizutani et al. 1970). The first anti-HIV drug to 
be approved by the U.S. Food and Drug Administration (FDA), azidothymidine (AZT), is an inhibitor 
of RT and today a large proportion of the anti-HIV drugs in use inhibit this viral enzyme.  
RT is produced from the Gag-Pol polyprotein that is cleaved by the viral PR. On the one hand, 
this enzyme acts as a DNA polymerase, copying either RNA or DNA into DNA and on the other, it 
has RNase H function and degrades RNA that is part of an RNA-DNA duplex. The mature lentiviral 
RT is a heterodimer. One RT subunit is the 560 amino acid long p66. The smaller subunit, p51, 
contains the first 440 amino acids from p66 (Lightfoote et al. 1986). There are two domains in p66: 
a polymerase and a RNase H domain and both are enzymatically active in the mature RT. The 
structure of the polymerase domain resembles a human right hand with fingers, a palm, a thumb 
and connecting subdomains (Kohlstaedt et al. 1992). The structure of p51 is similar to that of p66 
as it contains the same four subdomains. Their arrangement, however, differs and while p66 plays 
a catalytic role, p51 is a structural component of the RT (Kohlstaedt et al. 1992; Jacobo-Molina et 
al. 1993). However  
The majority of the reverse transcription of the viral genomic RNA into DNA takes place in the 
newly infected cell. Nevertheless, there have been reports that the synthesis of the viral DNA starts 
already before infection of the target cell due to the limited presence of nucleotides in viral particles 
(Lori et al. 1992; Trono 1992; Huang et al. 1997). Reverse transcription takes place in the so-called 
reverse transcription complex (RTC), which contains several viral proteins including MA, CA, NC, 
IN and Vpr (Fassati & Goff 2001). The roles of these components are not yet fully understood. In 
later stages of the DNA synthesis process the RTC transitions into the preintegration complex (PIC) 
and is transported to the nucleus. The capsid shell is at least partially lost at some stage before 
nuclear entry and this process is called uncoating. In what order all these events take place is still 
unclear. The requirement for CA in nuclear entry and possibly integration suggests that capsid 
uncoating is not completed before nuclear entry (Matreyek & Engelman 2011; Peng et al. 2014; 
Hilditch & Towers 2014; Hulme et al. 2015). The timing of these processes also impacts on the 
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immune sensing of HIV-1 reverse transcription intermediates in the cytoplasm (Reviewed by 
Jakobsen et al. 2015).  
A schematic representation of reverse transcription is depicted in Figure 1.4. For reverse 
transcription to occur, two components are required. Firstly, a template, which is provided by the 
HIV genomic plus strand RNA. Secondly, a primer, which is the host cell-derived tRNALys3 that is 
complementary to a sequence near the 5’ end of the viral genomic RNA called the primer binding 
site (PBS) and is incorporated into budding HIV virions. The tRNA hybridises to the PBS and RT-
mediated DNA polymerisation occurs to create a DNA-RNA duplex. The RNA in a DNA-RNA duplex 
serves as a substrate for the RNase H that cleaves off the 5’ end of the viral RNA and exposes the 
newly synthesized minus strand DNA (Figure 1.4 B). As both ends of the genomic viral RNA are 
direct repeats (R), the newly synthesized minus strand DNA can transfer to the 3’ end of the viral 
RNA. Importantly, this can be either of the two copies of single stranded RNA that are packaged 
into the virion (Hu & Temin 1990; van Wamel & Berkhout 1998). Minus strand DNA synthesis then 
continues across the full length of the viral RNA, accompanied by RNA degradation by RNase H. 
However, RNase H is unable to degrade a resistant purin-rich sequence in the genomic RNA called 
the polypurine tract (PPT). The PPT serves as a primer for the initiation of plus strand DNA 
synthesis. There are two PPTs in the HIV genome, one located near the 3’ end of the RNA and one 
in the middle of the genome, the central PPT. In contrast to the central PPT, the 3’ PPT is essential 
for plus strand DNA synthesis initiation, but the central PPT increases the ability to complete plus-
strand synthesis (Charneau et al. 1992). The minus strand is copied from the 3’ PPT onwards, 
including the 18 nucleotides of the tRNALys3 primer. The tRNA is then degraded by RNase H, 
however, HIV-1 RT cleaves all but one nucleotide off, leaving one A at the 5’ end of the minus 
strand (Pullen et al. 1992; Smith & Roth 1992). Then the second, plus strand transfer occurs. As 
the 3’ end of the plus strand contains the 18 nucleotides from the tRNA primer that are 
complimentary to the minus strand 3’ end, both sequences anneal and DNA synthesis continues 
with both the minus and the plus strand extended to the end of both templates. The reverse 
transcription DNA product is longer than the genomic RNA as the ends of the DNA contain parts 
from both ends of the genomic RNA meaning that each end of the viral DNA has the same 
sequence, U3-R-U5. These so-called long terminal repeats (LTR) determine the ends of the 
provirus and are the substrate for integration by the viral IN.  
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Most patients are productively infected by only one single HIV virus as determined by 
phylogenetic reconstruction of the founder virus sequence (Salazar-Gonzalez et al. 2009). There is 
a high level of variation in viral sequences within patients, suggesting that mutations occur during 
the viral life cycle (Coffin 1995; Keele et al. 2008). Being able to mutate quickly plays a key role in 
the virus’ ability to evade the host immune system and also in the development of resistance to 
anti-HIV drugs. The high level of variability of HIV has made vaccine development difficult. One 
explanation for the number of mutations occurring in HIV during replication is that the viral RT has 
no proofreading function and therefore, mutations are not corrected. It has so far not been possible 
to separate the contribution of the viral RT and the host cell RNA polymerase II, which transcribes 
the integrated provirus, to the virus mutation rate (O’Neil et al. 2002). The combined error rate for 
RT and RNA pol II is approximately 2 x 10-5 per bp per replication cycle (Mansky & Temin 1995; 
Abram et al. 2010). Furthermore, HIV-1 also exhibits a higher level of recombination compared to 
other retroviruses (Onafuwa et al. 2003). The viral RT can switch between the two packaged 
genomic RNA templates during minus strand DNA synthesis. For a sequence change to occur, it is 
required that the virus producing cell is infected with more than one virus. Double infection, for 
example due to transfer of multiple viruses across the virological synapse, occurs more frequently 















Figure 1.4 Retroviral reverse transcription converts the single-stranded RNA genome into double-
stranded DNA. (A) The viral RNA genome (blue) with a tRNA primer annealed near the 5′ end. (B) RT initiates 
reverse transcription and generates a minus-strand DNA (orange). RNase H activity of RT degrades the RNA 
template (dashed line). (C) Minus-strand transfer occurs between the R sequences at both ends of the genome 
allowing minus-strand DNA synthesis to continue. (D) This is accompanied by RNA degradation. A purine-rich 
sequence (PPT), adjacent to U3, is resistant to RNase H cleavage and serves as the primer for the synthesis 
of plus-strand DNA. (E) Plus-strand synthesis continues until the first 18 nucleotides of the tRNA are copied, 
allowing RNase H cleavage to remove the tRNA primer. The RNase H of HIV-1 RT leaves the rA from the 3′ 
end of the tRNA attached to minus-strand DNA. (F) Second (plus-strand) transfer. (G) Extension of the plus 
and minus strands leads to the synthesis of the complete double-stranded linear viral DNA.  
 
1.3.3 Nuclear Import and Integration 
Once the HIV-1 dsDNA is synthesized it is transported into the nucleus where it can be 
integrated into the host cell genome to serve as a template for transcription of viral genes and viral 
genomic RNA. The viral DNA associates with IN, and forms the preintegration complex (PIC), which 
contains a range of viral and host cell proteins. Lentiviruses are able to infect non-dividing cells, 
which separates them from simpler retroviruses. The PIC must be able to cross the nuclear 
membrane to deliver the proviral DNA and proteins that are essential for integration into the nucleus. 
The viral component that is absolutely crucial in this process is CA (Yamashita & Emerman 2004; 
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Yamashita et al. 2007). However, the process of nuclear entry is still not fully understood. There 
are several proteins in the PIC that exhibit nuclear localization properties, including MA, CA and IN. 
Cellular proteins have also been implicated in the nuclear import of the PIC, such as transportin 3 
(TNPO3), or the nucleoporins 358 (NUP358) and 153 (NUP153) and cleavage and polyadenylation 
specificity factor 6 (CPSF6) (Reviewed by Hilditch & Towers 2014). Interestingly, CA mutants show 
altered cellular co-factor dependence for nuclear entry as well as a retargeted integration site 
preference.  
A schematic representation of viral DNA integration into the host genome is shown in Figure 
1.5. The first step involves the 3’ end processing of the viral DNA. Two nucleotides are removed 
from each 3’ end of the blunt ended viral DNA (Figure 1.5 A-B). This is followed by the DNA-strand 
transfer. The 3’ ends of the viral DNA attack phosphodiester bonds on opposite strands of the host 
cell target DNA (Figure 1.5 C). The gaps and two-nucleotide overhangs are then repaired by cellular 
enzymes and the integration is completed. This leads to a five base pair duplication of the target 
DNA flanking the proviral DNA (Figure 1.5 D-E). For integration in vitro only the viral IN and the 
terminal sequences in the viral DNA are absolutely required (Bushman et al. 1990).  
IN has three domains that are structurally distinct. A catalytically active central core domain 
and N- and C-terminal domains. While a full structure of HIV IN binding to DNA is not available, the 
structure of the prototype foamy virus (PFV) intasome was solved (Maertens et al. 2010). Structural 
data show that PFV IN forms a homotetramer and binds to and deforms target DNA, which 
correlates with reports that DNA distortion promotes HIV DNA integration (Bor et al. 1995). 
Raltegravir was approved in 2007 by the FDA as the first integrase inhibitor used in anti-HIV 
therapy. Structural data revealed that it blocks the access of target DNA to the viral IN and also 
displaces the viral DNA 3’ ends from the IN active site, thereby disrupting catalysis.  
Integration site selection does not appear to be random. Development of high-throughput 
screens enabled the analysis of HIV integration sites in infected cells and showed that HIV favours 
integration into active transcription units that are characterized by high G/C content, a high gene 
density, high CpG island density, short introns, high frequency of Alu repeats, but also certain 
epigenetic modifications such as histone modifications (Wang et al. 2007; Brady et al. 2009). The 
efficiency of integration is also determined by cellular proteins such as LEDGF, a protein that 
contains a chromatin binding domain and an A/T hook domain potentially for DNA binding 
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(Cherepanov et al. 2003). LEDGF tightly binds IN via its C-terminus and tethers IN and the viral 
DNA to the chromatin, targeting them to transcription units for integration. Knockdown of LEDGF 
leads to an infectivity defect at the integration step, which is demonstrated by inhibited provirus 
formation and concomitant increased formation of 2-LTR circles, which are unintegrated, dead end 
products of viral DNA (Farnet & Haseltine 1991; Llano et al. 2006; Shun et al. 2007). An increase 
in 2-LTR circle formation can also be observed in the presence of an integration inhibitor, 
suggesting this may be the reason for the inhibitory effect of a LEDGF knockdown (Arts & Hazuda 
2012). Recently it was reported that HIV-1 integration preferentially occurs in peripheral regions of 
the nucleus, proximal to the nuclear pore in areas of open chromatin (Marini et al. 2015). These 
findings correlate with the important role of NPC components in HIV-1 infection, because these co-
factors are enriched for HIV integration sites in chromatin immunoprecipitations (Brass et al. 2008; 




















Figure 1.5 Integration of the HIV proviral DNA into the host genome. (A) HIV-1 proviral dsDNA. (B) IN 
catalyses 3’ terminus processing, generating reactive 3′-hydroxyl groups at both ends of the viral DNA. (C) 
The two 3′-hydroxyl viral DNA ends mediate the strand transfer and ligatiion with the host DNA. (D) Strand 
transfer results in a five-base, single-stranded gap and a two-base overhang at the 5′-ends of the viral DNA. 







1.3.4 Transcription and Nuclear Export 
Once the proviral DNA is integrated into the host genome it can serve as a template for the 
transcription of viral mRNAs and genomic RNA. Like all other retroviruses, HIV-1 uses the 5’ LTR 
as the promoter for the initiation of transcription. The HIV-1 LTR contains several regulatory 
elements that serve as binding sites for cellular transcription initiation factors (Rittner et al. 1995). 
The core promoter contains three tandem SP1 binding sites, a TATA box and a highly active initiator 
sequence (Jones et al. 1986; Garcia et al. 1989). The transcription factor IID (TFIID) and its 
associated co-factor TBP-associated factor (TAF) bind to the TATA box and recruit RNA 
polymerase II (RNAP II) to the LTR. In addition, there are enhancer regions in the LTR that contain 
NF-κB binding motifs. These can be engaged by both NF-κB and nuclear factor of activated T cell 
(NFAT) to enhance transcription (Nabel & Baltimore 1987; Liu et al. 1992). This is particularly 
important for virus replication in primary T cells (Alcamí et al. 1995). HIV-1 also requires the 
transactivating factor Tat for transcription, which regulates transcription elongation (Kao et al. 
1987). In the absence of this factor, RNAP II pauses at the promoter and transcription elongation 
fails. Tat recognizes a regulatory viral RNA element downstream of the transcription initiation site, 
the transactivation-responsive region (TAR). This region forms a highly stable, nuclease-resistant 
stem-loop structure (Berkhout et al. 1989; Selby et al. 1989).  The cellular positive acting elongation 
factor P-TEFb is an important co-factor for Tat and plays an essential role in transactivation. It 
contains a cyclin component (CycT1) that forms a stable complex with the cyclin-dependent kinase 
9 (CDK9), Tat and the TAR RNA (Wei et al. 1998). The binding of Tat to P-TEFb leads to 
conformational changes in the CDK9 subunit, which activates the enzyme (Tahirov et al. 2010). 
The kinase then phosphorylates the negative elongation factor (NELF), which leads to its 
dissociation from the TAR RNA (Fujinaga et al. 2004). Furthermore, Spt5, a subunit of the DRB 
sensitivity-inducing factor (DSIF), is phosphorylated, which converts this elongation inhibitor into a 
positive elongation factor (Bourgeois et al. 2002; Yamada et al. 2006). In addition to the removal of 
these blocks to elongation, CDK9 also hyperphosphorylates the C-terminal domain (CTD) of the 
RNAP II, which enhances its processivity (Isel & Karn 1999). Protein complexes containing Tat and 
P-TEFb also contain a range of other cellular transcription activators or co-activators including 
AFF4, ENL, AD9 or ELL2 (He et al. 2010; Sobhian et al. 2010). Figure 1.6 shows a schematic 






Figure 1.6 HIV-1 transcription transactivation by Tat. Transcription initiation is strongly induced by NF-kB. 
The Tat/P-TEFb complex (including CDK9 and CycT1 and the accessory elongation factors including ELL2) 
is recruited to the elongation complex via binding interactions with TAR RNA. This activates the CDK9 kinase 
and leads to hyperphosphorylation of RNAP II, Spt5, and NELF. The phosphorylation of NELF leads to its 
release. The presence of hyperphosphorylated RNAP II and Spt5 allows enhanced transcription of the full HIV-
1 genome.  
 
The HIV-1 primary transcripts are subjected to extensive splicing events to generate more than 
40 different spliced mRNAs that can be found in infected cells. These are completely spliced ~1.8 
kb mRNAs that encode for Tat, Rev and Nef, but there are also unspliced (~9 kb) and partially 
spliced (~4 kb) mRNAs encoding Vif, Vpr, Vpu, Env, Gag and Pol (Figure 1.7). The pre-mRNA is 
associated with a large complex of cellular factors that facilitate RNA splicing, the so-called 
spliceosome. Exonic and intronic splicing enhancers (ESEs and ISEs respectively) facilitate splice 
site recognition and interact with SR proteins. Exonic and intronic splicing silencers (ESSs and ISSs 
respectively) repress splicing and are bound by members of the heterogenous ribonuclear protein 
(hnRNP) family. For optimal virus replication the viral mRNA splicing needs to be tightly regulated 
to balance mRNA and genomic RNA production (reviewed by Karn & Stoltzfus 2012). Unspliced 
and incompletely spliced transcripts are usually degraded in the nucleus. However, some of the 
HIV-1 coding mRNAs are not fully spliced, but still needed for viral protein production. Therefore, 
HIV-1 expresses the regulator of expression of virion proteins (Rev) that facilitates the transport of 








Figure 1.7 HIV-1 mRNA splicing. (A) Early phase of mRNA expression. Only the completely spliced ~1.8 kb 
mRNA encoding Tat, Rev and Nef is exported into the cytoplasm by the normal nuclear export cellular pathway 
and translated. The unspliced ~9 kb and incompletely spliced ~4 kb mRNAs are retained in the nucleus where 
they undergo splicing or degradation. (B) Late phase of mRNA expression. When Rev concentrations in the 
nucleus exceed a threshold, Rev binds to the RRE in the env gene to mediate export to the cytoplasm and 
translation of ~9 kb and ~4 kb mRNAs. 
 
A schematic of the nuclear transport process is depicted in Figure 1.8. Rev interacts with a 
highly structured stem loop RNA element that is located in the env gene and the RRE (Malim et al. 
1989). All mRNA species that are incompletely or unspliced, such as those encoding Gag, Pol and 
Env, require Rev for nuclear export and expression. The fully spliced mRNAs that encode Tat, Rev 
and Nef are exported to the cytoplasm even in the absence of Rev by the cellular transport 
pathways that also transport cellular mRNAs. In the fully spliced mRNAs the region that contains 
the RRE is removed. In the case of the unspliced/partially spliced mRNAs Rev binds the RRE, 
which is followed by additional binding of Rev monomers to the complex (Malim & Cullen 1991; 
Zapp et al. 1991). The export occurs via the nuclear pore complex (NPC). RRE-bound Rev interacts 
with the karyopherin family member Crm1 through its C-terminal nuclear export signal (NES) 
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(Köhler & Hurt 2007). Members of the karyopherin family bind their cargo in the presence of the 
GTP-bound form of Ran GTPase. After export, the GTP hydrolyses to GDP through RanGAP and 
RanBP1. This destabilizes the Rev complex and leads to its dissociation from the RRE (Fischer et 
al. 1995). Rev is then transported back into the nucleus through binding to the nuclear import factor 
importin-β (Henderson & Percipalle 1997).  
 
 
Figure 1.8 HIV-1 Rev transport cycle. Rev binds unspliced or incompletely spliced mRNA transcripts through 
RRE and interacts with Crm1. This complex crosses the nuclear membrane by interaction with nuclear pore 
proteins. In the cytoplasm, Ran-GTP is converted into Ran-GDP leading to the release of Rev, Crm1 and viral 
mRNA. Crm1 is transported back into the nucleus and Rev binds to importin-β together with Ran-GDP to 
facilitate transport back into the nucleus. Once in the nucleus Ran-GDP is converted into Ran-GTP and Rev 
is released to initiate another nuclear export cycle of viral mRNA. 
 
1.3.5 Translation and Viral Assembly 
Once the mRNAs are transported into the cytoplasm, the cellular translation machinery 
produces the viral proteins. All viral mRNAs contain a poly(A) tail at their 3’ end and a 7-methyl-
guanosine cap at their 5’ end. Translation can be initiated when the small 40S ribosomal subunit 
and eukaryotic initiation factors (eIFs) are recruited to the viral mRNA, followed by scanning until 
the ribosome encounters an authentic AUG translation initiation codon. The 60S subunit is then 
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recruited to form the 80S ribosomal complex and the mRNA is translated into the according amino 
acids. Once the termination codon is reached the protein is released and the ribosome is recycled 
for another round of translation. Translation initiation, however, can be difficult in the highly 
structured regions of the HIV-1 mRNA that include the TAR, PBS, poly(A) hairpin and RNA 
packaging sequences, as these interfere with the cellular ribosomal scanning process. Several 
mechanisms have been reported to overcome this problem. Posttranscriptional control elements 
(PCEs) that bind RNA enhance translation initiation. Examples are the DEIH helicase RHA and 
RNA binding proteins SRp40 and SRp55 that enhance the translation of Gag (Bolinger et al. 2010; 
Swanson et al. 2010). Internal ribosome entry sites (IRES) in viral mRNAs have been described for 
Picornaviridae. They promote the recruitment of the 43S ribosome independently of 5’ cap binding. 
Whether IRES activity exists in the HIV-1 genome is under debate (Reviewed by Bolinger & Boris-
Lawrie 2009). The mRNA encoding Env is bicistronic and contains an overlapping upstream open 
reading frame encoding Vpu. For efficient Env expression a mechanism is employed that is called 
5’ cap-dependent ribosome shunting. The scanning ribosome can jump over large regions of the 
mRNA before it recognises the correct AUG codon (Krummheuer et al. 2007). Another mechanism 
evolved by retroviruses is programmed frameshifting that ensures translation of certain viral 
proteins. This is facilitated by specific sequence and structural signals in the mRNA. HIV-1 requires 
a -1 frameshift to shift from the gag reading frame to the pro and pol reading frame, which occurs 
around 5% of the times that Gag is translated. Two cis-acting elements are required for this process. 
The ‘UUUUUUA’ “slippery” sequence that leads to a slippage during translation and a stem-loop 
pseudoknot structure that increases the time that the ribosome is associated with the slippery 
sequence (Brierley & Dos Ramos 2006). 
HIV-1 assembly occurs at the host cell plasma membrane and is orchestrated by the HIV-1 
Gag and Gag-Pro-Pol polyproteins. They induce the required steps for plasma membrane binding, 
protein-protein interactions that are necessary to form a spherical particle, concentrating HIV-1 Env 
on the plasma membrane and packaging the genomic RNA via its packaging signal. All these 
events take place simultaneously at the plasma membrane through conformational changes in Gag 
and eventually lead to the budding of the viral particle using the cellular endosomal sorting 
complexes required for transport (ESCRT), and the maturation of the virion (Figure 1.9).  
Gag molecules assemble to form an immature virus particle at the plasma membrane. The 
polyproteins traffic to the PM and sort into detergent-resistant, lipid raft membrane microdomains 
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(Ono & Freed 2001). Membrane targeting requires the myristoylation of the MA domain in Gag and 
specific lipids in the plasma membrane, phosphatidyl inositol biphosphate (PI(4,5)P2) (Ono et al. 
2004). Binding of MA to these lipids leads to the exposure of the N-terminal myristoyl group that 
can then mediate stable anchoring of Gag to the PM. This so called myristoyl switch is furthermore 
facilitated by Gag multimerization and was proposed to be regulated by tRNA binding to MA (Tang 
et al. 2004; Kutluay et al. 2014).  
HIV-1 Env traffics to the PM independently of Gag. Both Env and Vpu are translated on the 
rough endoplasmic reticulum (ER). Env is sorted to the PM through the cellular secretory pathway 
where it is glycosylated. It assembles into trimeric complexes that are processed into the 
transmembrane (TM, gp41) and surface (SU, gp120) subunits by the cellular protease furin, before 
the complexes are delivered to the PM via cellular vesicular transport pathways. The intracellular 
tail of gp41 is responsible for the sorting of Env into “raft”-like domains and mediates the interaction 
with the Gag subunit MA to promote the incorporation. On average, 7-14 Env trimers are found on  
a mature HIV-1 virion (Zhu et al. 2006). Therefore, Gag MA mediates plasma membrane binding 
and recruitment of Env to sites of viral budding. The central Gag domain CA mediates all protein-
protein interactions that are required to assemble the immature lattice of the virion and will later 
form the conical capsid shell of the mature viral core. The NC domain of Gag is responsible for 
capturing the two copies of the full length HIV-1 genomic RNA. This requires two zinc-finger motifs 
in NC as well as the Ψ packaging site in the genomic RNA that is located in the 5’ region spanning 
the major splice donor site and the Gag initiation codon (Reviewed by D’Souza & Summers 2005). 
The C-terminal p6 domain of Gag has binding sites for several proteins and mediates the packaging 
of the HIV-1 Vpr protein. Furthermore, this domain contains two late assembly domains that bind 
to the ESCRT components TSG101 or ALIX and are essential for the budding of the virion as 
detailed in section 1.3.6. In addition to the viral components, there are also cellular molecules that 
are packaged into the budding virion, such as the tRNALys3 that anneals to the PBS in the viral 
genome and serves as the primer for the next round of reverse transcription. The virus membrane 
is acquired during budding and is derived from the host cell plasma membrane. It is enriched for 
raft lipids such as sphingomyelin, cholesterol, saturated fatty acids and phosphatidyl serine 







Figure 1.9 HIV-1 assembly, budding and maturation. (A) Schematic illustration showing the different stages 
of HIV-1 assembly, budding, and maturation. (B) The HIV-1 Gag polyprotein and its different domains; arrows 
indicate the five sites that are cleaved by the viral PR during maturation. (C) Schematic model showing the 
organization of the immature HIV-1 virion. (D) Schematic model showing the organization of the mature HIV-
1 virion. (Adapted from (Sundquist & Kräusslich 2012)). 
 
1.3.6 Viral Budding and Release 
During assembly of all the required HIV components at the plasma membrane and HIV-1 Gag 
polymerization, the budding and release of the new virion is induced. These events are mediated 
by the cellular ESCRT machinery that is recruited by the HIV-1 p6 late domains. Late domains are 
not restricted to HIV-1, but are used by a broad range of enveloped viruses to recruit the ESCRT 
machinery for viral release (Martin-Serrano & Neil 2011). Apart from facilitating viral budding, 
ESCRT pathways are responsible for cellular processes involving membrane fission events, such 
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as releasing vesicles into endosomal multivesicular bodies and abscission of two separating 
daughter cells during cytokinesis (Reviewed by Hurley & Hanson 2010). The HIV-1 Gag subunit p6, 
responsible for recruiting the ESCRT machinery, contains two different late domain motifs that bind 
and recruit early acting ESCRT factors. The primary late domain is a four amino acid sequence 
PTAP (Pro-Thr/Ser-Ala-Pro) that interacts with the N-terminal ubiquitin E2 variant (UEV) domain in 
the TSG101 subunit, which belongs to one of the ESCRT complexes, ESCRT-I (Martin-Serrano et 
al. 2001; Garrus et al. 2001; VerPlank et al. 2001). PTAP motifs can also be found in cellular 
proteins such as HRS that recruit ESCRT to endosomal membranes (Ren & Hurley 2011). 
Therefore, HIV-1 p6 appears to mimic a cellular ESCRT recruiting motif of membrane-specific 
adaptors (Pornillos et al. 2003). Additionally, there is a second late domain in HIV-1 p6, YPXL (Tyr-
Pro-X-Leu, “X” can vary in sequence and length). It interacts with a conserved hydrophobic groove 
in the V domain of the ESCRT-associated factor ALIX. This late domain however, appears to be 
less critical for HIV-1 replication than PTAP (Strack et al. 2003; Fujii et al. 2009). Furthermore, the 
Bro domain found at the N-terminus of ALIX can interact with NC, which is involved in virus release 
(Popov et al. 2008). Also, the E3 ubiquitin ligase NEDD4L has been implicated in viral release 
through its interaction with the C-terminus of HIV-1 CA. This suggests that ubiquitination of Gag 
through NEDD4L may facilitate late domain recruitment of the ESCRT machinery. However, the 
effect of NEDD4L on release is modest (Chung et al. 2008). 
The human ESCRT pathway contains more than thirty proteins. The minimal core set of 
ESCRT proteins required for HIV-1 budding is depicted in Figure 1.10. Both TSG101 and ALIX 
recruit another ESCRT complex, ESCRT-III and VPS4 complexes that then mediate the membrane 
fission necessary for virus budding, before ESCRT components are recycled. The human ESCRT-
III complex comprises the charged multivesicular body protein (CHMP) families. Particularly 
important for HIV-1 budding are CHMP2 and CHMP4 (Morita et al. 2011). How TSG101/ ESCRT-I 
recruits the core ESCRT-III and VPS4 complex is not fully understood, but it is well characterized 
for ALIX. Late domain binding induces conformational changes in ALIX and leads to its dimerization 
and activation and subsequent ESCRT-III recruitment. The ALIX Bro domain binds to C-terminal 
helices of CHMP4 proteins, which is thought to induce CHMP4 polymerization into filaments within 
the virion neck. Recruitment and polymerization of CHMP2 exposes C-terminal motifs that bind the 
N-terminal MIT domain of the VPS4 ATPase. VPS4 molecules assemble into a complex of two 
stacked hexamer rings that are linked through CHMP5/LIP5 and that is enzymatically active. There 
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are three models of how membrane fission occurs: the spiral, the tube and the dome model, 
whereas the dome model is the most accepted. CHMP4 filaments, possibly in complex with CHMP2 
and other ESCRT-III components, spiral into the neck of the budding virion and form a closed dome 
that constricts and promotes fission. Hydrolysis of ATP by VPS4 assists in fission completion and 
mediates the disassembly of the filaments and release of ESCRT-III subunits into the cytoplasm 
(Reviewed by Sundquist & Kräusslich 2012). The different ESCRT complexes will be discussed in 




Figure 1.10 Recruitment of the cellular ESCRT machinery for HIV-1 budding. Late domain motifs within 
p6Gag bind directly to the UEV domain of the TSG101 subunit of the heterotetrameric ESCRT-I complex (red, 
with bound ubiquitin in black) and the V domain of ALIX (blue). These interactions result in the recruitment of 
the ESCRT-III proteins of the CHMP2 and CHMP4 families (green), which apparently polymerize into a “dome” 
that promotes closure of the membrane neck. They also recruit the VPS4 ATPases (purple), which completes 
the membrane fission reaction and uses the energy of ATPase to release the ESCRT-III from the membrane 






The final step of the viral life cycle is the maturation of the virus into a fully infectious particle 
that is able to infect another target cell. This requires the proteolytic processing of the Gag and 
Gag-Pro-Pol polyproteins by the viral PR. This is a multistep process that involves conformational 
changes and subunit rearrangements and starts simultaneously with the budding of the virion. Both 
polyproteins are cleaved at five sites each to create MA, CA, NC, p6, PR, RT and IN. MA remains 
associated with the inner leaflet of the viral membrane, whereas CA forms the typical HIV-1 conical 
core structure that consists of around 1200 CA molecules that form a net of hexagons and 
pentagons called the “fullerene cone”. The capsid core is closed at both ends, which is facilitated 
through the addition of twelve pentagonal defects. The CA subunits interact via their N- and C-
terminal domains. The C-terminal domains also make inter-ring contacts (Ganser et al. 1999; Briggs 
et al. 2006; Ganser-Pornillos et al. 2008). The HIV-1 capsid plays essential roles at various steps 
of the viral life cycle such as in reverse transcription and nuclear entry, and capsid stability is crucial 
for these processes. The capsid also surrounds and encases the nucleocapsid and genomic RNA 
(Reviewed by Sundquist & Kräusslich 2012).  
The HIV-1 protease is an aspartic acid protease that forms a homodimer wherein the active 
site traverses the dimer interface. In the context of the Gag-Pro-Pol polyprotein PR is inactive. 
Unprocessed PR constructs dimerize only very weakly, but can form transient complexes with 
catalytic activity. This can induce auto-processing of the N-termini and leads to the formation of a 
stable dimer with full catalytic activity (Tang et al. 2008). Once active, PR appears to recognise the 
overall structure of its substrate rather than a specific sequence (Prabu-Jeyabalan et al. 2002). The 
PR-induced cleavage events in the viral particle lead to the activation of the fusogenic acivity of Env 
(Murakami et al. 2004; Wyma et al. 2004), the stabilization of the RNA dimer and its chaperoning 
by the nucleocapsid (Moore et al. 2009; Rein 2010) and the disassembly of the immature lattice to 
form the conical capsid. The fully infectious virus is then equipped to infect a new target cell. 
 
1.4 HIV Pathogenesis and the Host Innate Immune Response 
HIV is mainly transmitted via the mucosal surfaces of genital or rectal tissue during sexual 
contact. It is thought that infection originates from only one virus, the transmitted/founder virus, that 
then disseminates to other lymphoid tissues (Keele et al. 2008).  
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The course of HIV infection can be divided into different stages. During the initial phase (~1-2 
weeks), also known as the eclipse phase, the virus starts to replicate and spreads from the initial 
site of infection to other tissues and organs. At this stage, viremia and antiviral immune response 
are still low. In the first few weeks of infection the virus causes considerable damage to the host. In 
particular, CD4+ T cells are dramatically depleted in tissues other than the peripheral blood, such 
as the gut-associated lymphoid tissue (GALT). Within the next weeks, during the acute phase, 
viremia increases considerably (commonly up to 107 copies of RNA per ml) and many infected 
CD4+ T cells can be found in the blood and lymph nodes. Infected individuals may exhibit flu-like 
symptoms including fever and enlarged lymph nodes. The immune response starts to generate 
antibodies against all viral proteins and mounts a CD8+ T cell response that is directed against viral 
antigens. At the end of the acute phase, viremia starts to decline due to a certain degree of immune 
control, to reach what is known as the viral set point (1-105 copies/ml). The next phase of HIV 
infection, the chronic phase, is characterized by a stable or slowly increasing viremia. 
Simultaneously, CD4+ T cell levels in the blood fall gradually. This phase can persist for years or 
even decades and is usually asymptomatic, which means that patients may not be aware of their 
infection. When CD4+ T cell counts drop below a certain level (~200 cells/µl) defining the onset of 
AIDS, the host immune system is so compromised that viremia rises and opportunistic infections 
start to occur, which eventually lead to the death of the patient. If left untreated, the mortality rate 
of HIV-1 infection is 95% (Reviewed by Coffin & Swanstrom 2013).  
The two major drivers of HIV-1 pathogenesis are CD4+ T cell depletion and systemic 
inflammation. Interestingly, only a small proportion of the host’s CD4+ T cells are productively 
infected and further, direct killing by HIV does not explain the death of bystander cells, which 
accounts for the majority of CD4+ T cell death. It was shown that infection of naïve T cells is aborted 
early after entry, before reverse transcription is completed (Doitsh et al. 2010). This leads to the 
accumulation of DNA in the cytoplasm, which is sensed as a danger signal by the interferon gamma 
inducible protein 16 (IFI16) in infected CD4+ T cells. As a result, the cell starts a proinflammatory 
defence program, which leads to caspase-1-induced pyroptosis of the cell. In addition, this 
programed cell death leads to the release of interleukin-1β to trigger further immune responses 
(Monroe et al. 2013; Doitsh et al. 2014). Therefore, this host immune response may contribute to 
the pathogenic, systemic inflammation and CD4+ T cell loss characteristic of HIV-1 infection.  
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Upon viral infection, the host’s immune system reacts to the intruding pathogen with an early, 
nonspecific innate response and, at a later point during infection, with a highly specific adaptive 
immune response. Early events during acute infection have been proposed to be critical for the 
course of HIV infection. The antiviral immune response comprises proinflammatory cytokines, 
certain innate immune cells, the complement system and interferon-inducible, cellular antiviral 
proteins (Reviewed by Carrington & Alter 2012; Guha & Ayyavoo 2013). The main cell types 
involved in the early immune response and proinflammatory cytokine production are dendritic cells 
(DCs), macrophages, natural killer (NK) cells and neutrophils. They express various pattern 
recognition receptors (PRRs) that enable them to sense pathogen-associated molecular patterns 
(PAMPs) such as protein motifs, carbohydrates or nucleic acids that are unique to pathogens and 
usually not present in the host cell. The sensing of PAMPs by PRRs induces downstream signalling 
and the induction of transcription factors that then mediate the expression of proinflammatory 
cytokines and type I IFN. DCs are the major source of high levels of IFN during early infection and 
they express diverse PRRs.  
One group of PRRs are Toll-like receptors (TLRs) that are present on the cell surface or in 
intracellular compartments and are able to sense viral PAMPs such as glycoproteins, nucleic acids 
or unmethylated CpG DNA. RNA viruses, like HIV-1, trigger an innate immune response through 
TLR7/TLR8, which leads to the activation of DCs and the release of type-I IFN and TNF-ɑ  (Beignon 
et al. 2005). Additionally, TLR2 and 4 have been implicated in innate responses to HIV-1. Due to 
differential induction of type-I IFN they are associated with increased or decreased HIV 
transmission, respectively (Thibault et al. 2009). Furthermore, TLR9 has been reported to directly 
bind to gp120 to induce DC activation and type-I IFN secretion, which leads to the activation of NK 
cells (Martinelli et al. 2007). Another example of PRRs are the RIG-I-like receptors (RLRs) that 
recognize HIV RNA in the cytoplasm (Solis et al. 2011).  
Other cellular proteins that can sense viral, cytoplasmic DNA, such as retroviral RT products, 
are the aforementioned IFI16 and the cyclic guanosine monophosphate-adenosine 
monophosphate (cGAMP) synthase (cGAS) (Gao et al. 2013; Jakobsen et al. 2013). Both activate 
the adaptor protein stimulator of interferon genes (STING) that then mediates the expression of 
type-I IFN and other cytokines. It has been shown that cGAS can sense HIV-1 infection in dendritic 
cells and macrophages and that this was dependent on the viral capsid (Rasaiyaah et al. 2013; 
Lahaye et al. 2013). Capsid interaction with CPSF6 or cyclophilins was shown to be required for 
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avoiding sensing by cGAS. While the CPSF6 or cyclophilin binding mutants N74D or P90A, 
respectively, in capsid triggered innate sensors and led to an inhibition of viral replication 
(Rasaiyaah et al. 2013). Interestingly, the cellular protein TREX1 has been shown to inhibit HIV 
sensing in infected cells (Yan et al. 2010a). This 3’ exonuclease binds to cytosolic viral DNA and 
digests it, thereby preventing its recognition by cellular PRRs and subsequent interferon induction 
that would inhibit viral replication.  
Among the most important innate immune cells in the response to viral pathogens are NK cells, 
which are activated and expand upon stimulation by IFN-ɑ and IL-15. They express inhibitory killer 
immunoglobulin-like receptors (KIR) that interact with MHC-I molecules on other host cells, which 
leads to the inhibition of the NK cell. Many viruses have been shown to downmodulate MHC-I from 
the surface of the infected cell to avoid viral antigen presentation and detection by CD8+ T cells. 
The lack of surface MHC-I expression is an activation signal for NK cells, but additional activating 
signals are required before killing of the infected cell is induced. Stress ligands such as MIC-A and 
ULBP-1/2 that are usually upregulated upon viral infection are recognised by the C-type lectin NK-
cell (NKG2D) receptor. Expression of these stress ligands can even be sufficient to overcome the 
inhibitory effect of MHC-I recognition by NK cells (Raulet 2003; Zhang et al. 2005). HIV-1 Nef 
induces the downregulation of MHC-I molecules from the cell surface in a selective manner. While 
MHC-I HLA-A and HLA-B are removed, other MHC-I molecules remain on the cell surface, and this 
is thought to be a mechanism of avoiding NK cell killing. In addition, Nef downmodulates the 
expression of some NK cell activating NKG2D ligands (Cerboni et al. 2007). Thus, HIV is able to 
overcome NK cell mediated killing of the infected cell. 
During acute infection, HIV-1 infected individuals produce high levels of circulating type-I IFN. 
Importantly, IFN expression leads to the induction of interferon stimulated genes (ISGs). Various 
restriction factors such as APOBEC3G, TRIM5ɑ, tetherin, SAMHD1 and MX2 belong to this group 
of proteins and are able to inhibit viral replication at distinct steps of the viral life cycle. They will be 




1.5 Cellular Restriction Factors and the Role of HIV-1 Accessory 
Proteins 
HIV-1 encodes several accessory proteins including Vif, Nef, Vpu and Vpr.  Whilst they are 
dispensable in some in vitro experimental settings, there is accumulating evidence for their 
essential role in viral replication in vivo. In particular, they modulate the host cell environment in a 
variety of ways that allow the virus to evade the antiviral immune response. This includes the 
antagonism of cellular antiviral factors. Whilst various host cell proteins are required for efficient 
HIV-1 replication, the host cell expresses a range of proteins that are detrimental for the virus. Viral 
infectivity varies greatly depending on the cell line used under experimental conditions and so does 
the requirement for HIV-1 accessory proteins. Analysis and comparison of permissive and non-
permissive cells led to the discovery of restriction factors for HIV-1 that inhibit at various steps of 
the viral life cycle and are antagonised by HIV-1 accessory proteins. Most of these restriction factors 
are induced by IFN to some degree (Reviewed by Malim & Bieniasz 2012).  
The first retroviral restriction factor to be identified was a protein encoded in mice, known as 
Friend virus susceptibility factor-1 (Fv1), that can block murine leukemia virus (MLV) replication 
(Best et al. 1996). There are two allelic variants in inbred mice, Fv1n and Fv1b that inhibit infection 
with B-tropic or N-tropic MLV, respectively, whereas heterozygous Fv1n/b mice are resistant to both 
MLVs. Fv1 is similar to an endogenous retroviral gag gene and the mechanism of inhibition is 
thought to require viral capsid binding to block the transit of proviral DNA to the nucleus  (Hilditch 
et al. 2011). However, its precise mode of action remains to be determined.  
In the following section the cellular restriction factors APOBEC3G, TRIM5ɑ, tetherin, SAMHD1, 
Mx2, and SERINC5/3 and their antagonism by HIV and/or SIV accessory proteins will be discussed 
in more detail.  
 
1.5.1 APOBEC3G and HIV Vif 
The virion infectivity factor (Vif) is a 23 kDa protein that is required for viral replication in primary 
cells such as CD4+ T cells, but is dispensable in other cell lines. Cell fusion experiments between 
permissive and non-permissive cell types suggested the existence of a dominantly acting restriction 
factor and a cDNA subtraction-based screen revealed Apolipoprotein B messenger RNA editing 
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enzyme catalytic polypeptide-like 3G (APOBEC3G) to be the restriction factor of Vif-deficient HIV-
1 (Simon et al. 1998; Sheehy et al. 2002).  
APOBEC3G (A3G) belongs to a family of proteins comprising eleven members in humans. It 
is expressed widely in human tissues and particularly in hematopoetic cells where it is partially 
inducible by type 1 interferon (Koning et al. 2009; Refsland et al. 2010). All APOBEC proteins have 
one or two zinc-coordinating domains with polynucleotide (RNA or DNA) cytidine deaminase activity 
(Z domains) that mediate the post-synthetic editing of cytidine residues to uridines, and therefore, 
change the nucleotide sequence. A3G has two of these domains. The C-terminal Z domain 
mediates the deamination with a sequence specificity of 5’CCCA (deaminated C underlined), 
whereas the N-terminal Z domain does not have catalytic activity, but mediates the packaging of 
A3G into assembling virions and is also recognised by HIV Vif (reviewed by Malim 2009). In the 
absence of Vif, A3G is incorporated into budding virions through RNA and nucleocapsid interaction 
of the N-terminal Z-domain (Bogerd & Cullen 2008). A3G forms dimers in an RNA-dependent 
manner, however, the relevance of dimerization for its antiviral function is unclear (Huthoff et al. 
2009). It associates with the RTC and induces the deamination of up to 10% of the cytidines in the 
newly synthesized single-stranded negative-strand viral DNA, which leads to the loss of genetic 
integrity and functional inactivity (Harris et al. 2003; Mangeat et al. 2003; Zhang et al. 2003; Yu et 
al. 2004). A certain low level of APOBEC3 induced viral mutation has also been reported to 
contribute to viral diversification and was implicated in immune escape and development of drug 
resistance (Wood et al. 2009; Kim et al. 2010; Sadler et al. 2010). Additionally, it was suggested 
that A3G leads to a general decrease in viral cDNA levels in infected cells (Iwatani et al. 2007; 
Bishop et al. 2008).  
Other members of the APOBEC3 family that have antiviral activity are APOBEC3D (A3D), 
APOBEC3F (A3F) and APOBEC3H (A3H). They share A3G’s mechanism of action and are 
counteracted by Vif. However, they have different target site preferences for deamination: 5’TC or 
5’GC.  
HIV-1 Vif efficiently counteracts A3G by recruiting a cellular ubiquitin ligase complex including 
cullin 5 (CUL5), elongins B and C, RING-box protein 2 (Rbx2), and also the transcription co-factor 
core binding factor β (CBFβ) (Yu et al. 2003; Jäger et al. 2012; Zhang et al. 2012). This leads to 
the polyubiquitination and proteasomal degradation of A3G and prevents incorporation into 
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assembling virions. Furthermore, counteraction of APOBEC3 is species-specific for HIV and SIV 
Vif proteins and was suggested to be an important barrier to zoonotic transmission in primates 
(Gaddis et al. 2004; Compton & Emerman 2013; Etienne et al. 2013).  
 
1.5.2 TRIM5ɑ and the HIV Capsid  
In many non-human primate cells, HIV-1 replication is blocked even though virus entry does 
occur. It became apparent that a dominant cellular antiviral factor targeted the HIV-1 capsid protein 
with similarity to the murine Fv1 protein and that this factor was present in primate cells (Hofmann 
et al. 1999; Towers et al. 2000; Cowan et al. 2002; Besnier et al. 2002). It was identified as the 
cellular tripartite motif (TRIM)-containing protein 5ɑ (TRIM5ɑ) and was discovered when rhesus 
macaque genes were screened for their ability to restrict HIV-1 in human cells (Stremlau et al. 
2004).  
TRIM5ɑ belongs to a family of proteins that contains around 70 members of which several have 
been implicated to have antiviral function, including TRIM5, TRIM11, TRIM15, TRIM19, TRIM22, 
TRIM28 and TRIM31. Most research however, focuses on TRIM5 and only the TRIM5ɑ isoform has 
antiretroviral activity in humans. All TRIM family members have a similar domain organization 
(Nisole et al. 2005). They contain an N-terminal RING domain with E3 ubiquitin ligase activity, one 
or two B-box type 2 domains required for the formation of higher order multimers and a central 
coiled-coil domain that, in the case of TRIM5, is required for dimerization. The C-terminal domain 
can vary and in TRIM5ɑ this domain is called B30.2 or PRYSPRY and mediates protein-protein 
interactions. The SPRY domain is responsible for recognising the substrate, i.e. viral capsid, in the 
cytoplasm of infected cells. Interestingly, this domain shows signs of rapid evolution among species’ 
sequences (Sawyer et al. 2005; Song et al. 2005; Johnson & Sawyer 2009). It is comprised of three 
hypervariable segments (V1-V3), where V1 determines the antiretroviral specificity (Perez-
Caballero et al. 2005; Sawyer et al. 2005; Stremlau et al. 2005).  While human TRIM5ɑ is very 
potent in blocking N-MLV or equine infectious anaemia virus (EIAV) infection it is inactive against 
wild type HIV-1, although this may depend on the HIV isolate (Hatziioannou et al. 2004; Keckesova 
et al. 2004; Perron et al. 2004; Battivelli et al. 2010).  However, HIV-1 replication is potently inhibited 
by old world monkey TRIM5ɑ. In general, a certain species’ TRIM5ɑ is inactive against viruses that 
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have adapted to the host, but potently restricts viruses infecting other hosts, which indicates that it 
can be an effective barrier to cross-species transmission (Hatziioannou et al. 2006).  
Cyclophilin A (CypA), a host cell chaperone protein, has been shown to be able to bind lentiviral 
capsid via a surface loop. Whilst the role of this binding is unclear, it can affect the sensitivity of 
capsid to TRIM5ɑ (Berthoux et al. 2005; Keckesova et al. 2006; Stremlau, Song, et al. 2006). In 
owl monkeys and some species of macaque a retro-transposition event placed CypA into the TRIM5 
locus, which resulted in the expression of a chimeric TRIM-CypA fusion protein called TRIMCyp. 
The CypA domain replaced the PRYSPRY domain in this protein (Sayah et al. 2004; Liao et al. 
2007; Brennan et al. 2008; Newman et al. 2008; Virgen et al. 2008; Wilson et al. 2008). Capsids 
from lentiviruses that bind to CypA are restricted by TRIMCyp.  
Both TRIM5ɑ and TRIMCyp inhibit viral replication by directly binding the capsid of restriction-
sensitive virus and inducing premature uncoating, thereby disrupting the RTC and blocking reverse 
transcription (Stremlau et al. 2006). TRIM5ɑ assembles into hexagonal structures that interact with 
the hexagonal lattice of the capsid (Ganser-Pornillos et al. 2011). The formation of higher order 
multimers mediated by the B-box domain was suggested to increase the efficiency of the interaction 
between TRIM5ɑ and capsid and therefore enhance antiviral activity (Perez-Caballero et al. 2005). 
The disassembled viral components are then degraded by the proteasome, which depends on the 
E3 ubiquitin ligase activity of the RING domain and also leads to a faster turnover of TRIM5ɑ itself 
(Kutluay et al. 2013; Diaz-Griffero et al. 2006).  
Neither ubiquitin nor proteasomal degradation are essential for the antiviral function of TRIM5ɑ. 
In fact, no function of TRIM5ɑ has been shown to be absolutely crucial for its antiviral activity, apart 
from its ability to bind capsid and to form multimers. It may be possible that TRIM5ɑ inhibits viral 
replication in more than one way, which could result in redundancy. It was also suggested that 
TRIM5ɑ inhibits reverse transcription and nuclear import independent of its role in uncoating (Roa 
et al. 2012; Wu et al. 2006). Importantly, no virally encoded antagonist of TRIM5ɑ has been 
identified, but evasion of restriction is achieved by capsid mutations.  
TRIM5ɑ was shown to be an innate sensor of retroviral infection, triggering immune activation 
upon capsid binding (Pertel et al. 2011). This was suggested to be connected to its restriction of 
retroviral reverse transcription (Fletcher et al. 2015). The TRIM5ɑ RING E3 ubiquitin ligase together 
with the UBC13-UEV1A E2 ubiquitin ligase complex mediate the synthesis of Lys63-linked ubiquitin 
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chains that recruit the TAK-1 kinase complex. This leads to the activation of transcription factors 
NF-κB and activator protein 1 (AP1) and subsequently proinflammatory cytokine and type-I IFN 
production, further stimulating the antiviral state. In addition, other TRIM family members have also 
been implicated in stimulating the innate, antiretroviral immune response (Uchil et al. 2013).  
 
1.5.3 SAMHD1 and Vpx 
Infection of certain resting primary cells such as monocytes, dendritic cells (DCs) or quiescent 
CD4+ T cells by HIV-1 is relatively inefficient. However, it can be enhanced in vitro by the expression 
of the HIV-2 or SIVmac viral protein X (Vpx), which increases the number of reverse transcription 
products and has also been found to associate with an E3 ubiquitin ligase complex containing 
DCAF1, CUL4A and DDB1 (Goujon et al. 2008; Srivastava et al. 2008). Therefore, it was suggested 
that Vpx antagonises a cellular restriction factor present in cells that are non-permissive to HIV-1 
infection. The sterile alpha motif domain and histidine-aspartate domain-containing protein 1 
(SAMHD1) was shown to be a Vpx-interacting protein in co-immunoprecipitates and identified as a 
HIV-1 restriction factor (Laguette et al. 2011; Hrecka et al. 2011). 
SAMHD1 plays a role in the cell-intrinsic innate immune response and regulation of IFN 
production. Polymorphisms in this protein in humans are associated with the Aicardi-Goutières 
syndrome (AGS), a neurological condition characterized by high levels of type-I interferon 
expression and upregulation of IFN-stimulated genes, which mimics congenital viral infections (Rice 
et al. 2009; Crow & Rehwinkel 2009). SAMHD1 contains a conserved N-terminal sterile alpha motif 
(SAM) domain and a C-terminal region that is required for the Vpx-induced recruitment of the E3 
ubiquitin ligase complex and subsequent proteasomal degradation and inactivation of SAMDH1 
(Ahn et al. 2012). Furthermore, it has a catalytic histidine-aspartate (HD) domain that exhibits 
triphosphohydrolase activity that is responsible for converting dNTPs into deoxynucleosides and 
triphosphate (Goldstone et al. 2011; Lahouassa et al. 2012; Powell et al. 2011; Goncalves et al. 
2012; Franzolin et al. 2013). This decreases the level of dNTPS in the cytoplasm and it was 
suggested that this would limit the availability of dNTPs for viral reverse transcription and thereby 
inhibit viral replication. This is supported by the fact that HIV-2 Vpx increases the cellular levels of 
dNTPs and that exogenous addition of dNTPs to the culture medium bypasses SAMHD1-induced 
viral restriction (Lahouassa et al. 2012). 
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Whether the NTPase activity is the main antiviral activity of SAMHD1 was challenged by the 
observation that phosphorylation of residue T592 in SAMHD1 inhibited antiviral function without 
affecting NTPase activity and thus there may be an alternative mode of action (White et al. 2013; 
Welbourn et al. 2013; Yan et al. 2015). SAMHD1 also contains a nucleic acid binding domain 
overlapping the HD domain and has been reported to have nuclease activity towards single-
stranded RNA or RNA in DNA/RNA hybrids (Beloglazova et al. 2013; Ryoo et al. 2014). It was 
proposed that SAMHD1 targets the viral RNA for degradation before reverse transcription can 
occur.  
Structural data suggests that SAMHD1 forms dimers and, upon dGTP binding, tetramers 
(Goldstone et al. 2011; Ji et al. 2013; Hansen et al. 2014; Miazzi et al. 2014). While tetramerization 
does not seem to be required for the proposed nuclease activity of SAMHD1, it is essential for its 
dNTPase activity (Brandariz-Nuñez et al. 2013; Ryoo et al. 2014). The relative importance of 
dNTPase and nuclease activity of SAMHD1 and whether they are relevant for its antiviral function 
is a matter of debate. Conflicting reports supply evidence for the importance of both, but it is difficult 
to combine them in  a single model (Reviewed by Ballana & Esté 2015).  
Vpx is derived from a duplication or recombination event of the lentiviral vpr gene. HIV-2 and 
some SIVs encode both Vpx and Vpr, whereas HIV-1 only encodes the Vpr protein. Only a few Vpr 
proteins from SIVs infecting Sykes’ monkeys, De Brazza’s monkeys and African green monkeys 
and the Vpx proteins from HIV-2 and some SIVs, including SIVmac (macaque) and SIVsmm (sooty 
mangabey), have been found to be able to counteract SAMHD1(Lim et al. 2012). Why HIV-1 does 
not encode a countermeasure for SAMHD1 is so far unknown. It was suggested that SAMHD1-
mediated restriction could be beneficial in the context of reduced recognition of viral reverse 
transcription products by cellular innate sensors such as cGAS and therefore, counteraction of this 
restriction factor by HIV-1 may not be essential (Gao et al. 2013; Lahaye & Manel 2015).  
 
1.5.4 The Role of HIV-1 Vpr 
The small 14 kDa protein Vpr is conserved among all primate lentiviruses. It became apparent 
that Vpr is essential for efficient viral replication in vivo when rhesus macaques were infected with 
a vpr-mutated SIVmac, where it was associated with attenuated pathogenesis (Lang et al. 1993; 
Hoch et al. 1995). Furthermore, it is required for efficient in vitro replication in macrophages (Connor 
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et al. 1995). Various roles have been ascribed to Vpr, including influencing reverse transcription, 
nuclear import of the PIC, interfering with cell cycle progression, regulation of apoptosis and 
transactivation of the HIV-1 LTR (Reviewed by Guenzel et al. 2014). As mentioned previously, 
some SIV Vpr proteins are able to induce the degradation of SAMHD1, however, HIV-1 Vpr is 
unable to do so. Vpr is packaged into assembling and budding virions via interaction with Gag p6, 
which indicates that it may be involved in early steps of the viral life cycle after host cell entry. It 
comprises a flexible N-terminus, a three alpha-helical domain and a flexible C-terminus and 
localizes to the nucleus and the nuclear membrane in infected cells.  
The most established function of Vpr is its ability to induce cell cycle arrest in the G2/M 
transition phase, which is supported by the fact that HIV-1 infected individuals have higher numbers 
of CD4+ T cells in the G2 phase. It was suggested that this function may be beneficial for the virus, 
as there is increased transcription during the G2 phase (Goh et al. 1998). To induce cell-cycle 
arrest, Vpr recruits a DDB1-CUL4 E3 ubiquitin ligase complex that was suggested to interfere with 
the DNA replication machinery (Wen et al. 2007; Hrecka et al. 2007). It was proposed that Vpr 
induces the degradation of a cellular factor that is required for the progression of the cell cycle into 
the M phase. Recently, the structure-specific endonuclease (SSE) regulator SLX4 complex, 
containing DCAF1, MUS81-EME1 and SLX4, was shown to interact with Vpr (Laguette et al. 2014). 
Vpr and DCAF1 recruit the polo-like kinase 1 (PLK1), which then activates the SLX4-associated 
endonuclease MUS81-EME1 that can cleave DNA. This inappropriate activation of the SLX4 
complex that leads to chromosome instability and cell cycle arrest was suggested to be the mode 
of action of Vpr. The ability of various Vpr proteins to interact with SLX4 positively correlates with 
their ability to induce cell cycle arrest (Berger et al. 2015).  
SLX4 belongs to the Fanconi Anemia (FA) protein family and mutations in these proteins have 
been associated with susceptibility to cancer and abnormal IFN production. In addition to cell cycle 
arrest induction, the SLX4 complex is also thought to be involved in the degradation of HIV-1 
reverse transcripts. Around 90% of all viral reverse transcripts do not integrate and it has been 
demonstrated that degradation of these transcripts by cellular proteins such as TREX1 prevents 
recognition by the innate immune system and IFN induction (Suspène & Meyerhans 2012; Yan et 
al. 2010). The components of the SLX4 complex have been shown to be essential in the prevention 
of IFN induction upon infection and this has been attributed to reverse transcript degradation 
(Laguette et al. 2014).  
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1.5.5 MX2 Inhibits Early Stages of HIV Replication 
The human myxovirus resistance protein 2 (MX2 or MXB) was recently identified as an IFN-
inducible inhibitor of early post-entry HIV-1 infection (Goujon et al. 2013; Kane et al. 2013; Liu et 
al. 2013). It induces a block prior to nuclear import, but after reverse transcription. The viral 
determinant of restriction was proposed to be viral CA, however, the mechanism of antiviral action 
is still unclear. Mutations in CA that relieve the sensitivity to MX2 restriction do also interfere with 
binding to cyclophilin A, nucleoporins NUP153 and NUP358, and CPSF6, but do not abrogate 
binding to the MX2 (Fribourgh et al. 2014; Fricke et al. 2014; Liu et al. 2015).  
MX proteins are highly conserved among vertebrates. Most mammals, including humans, have 
two mx genes encoding MX1/MXA and MX2/MXB. They are members of a family of dynamin-like 
GTPases. Neither are constitutively expressed, but are IFN-inducible and share 63% sequence 
identity as well as a similar structure (Gao et al. 2011; Fribourgh et al. 2014). They have an N-
terminal GTPase (G) domain and a C-terminal stalk domain. Both domains are connected via a 
tripartite bundle signalling element (BSE). In the case of MX1, the stalk domain is essential for 
oligomerization and the BSE domain transmits conformational changes between C- and N-terminal 
domain upon GTP binding and hydrolysis (Haller et al. 2010; Gao et al. 2010; Gao et al. 2011). It 
localises to the cytoplasm and was shown to interact with intracellular membranes such as the 
membranes of the smooth endoplasmic reticulum/Golgi intermediate compartment. MX1 inhibits a 
broad range of RNA and DNA viruses, such as avian influenza A viruses (FLUAV), La Crosse virus, 
Thogoto virus, measles virus, VSV, or hepatitis B virus, but not HIV-1, by blocking diverse steps of 
the viral life cycle (Reviewed by Haller et al. 2015). While GTPase activity and oligomerization 
beyond dimerization are required for MX1 induced inhibition of viruses, they are dispensable for the 
anti-HIV-1 function of MX2 (Pitossi et al. 1993; Ponten et al. 1997; Gao et al. 2010; Dicks et al. 
2015). 
MX2 is expressed as two isoforms that differ in the length of their N-terminus (Melén et al. 
1996). The shorter 76 kDa isoform lacks an N-terminal nuclear localization signal (NLS)-like motif 
that is required for antiviral function (Busnadiego et al. 2014; Goujon et al. 2014). This motif is 
required for the localization of long 78 kDa MX2 to the cytoplasmic face of the nuclear pore. 
Furthermore, the N-terminal region contains a triple arginine motif (residues 11 to 13) that is 
essential for antiviral function, potentially due to the ability to bind capsid (Goujon et al. 2015; 
Schulte et al. 2015). In fact, the N-terminal 91 amino acids of MX2 are sufficient for its anti-HIV-1 
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activity and this can be transferred to MX1 in chimeric proteins (Goujon et al. 2014; Busnadiego et 
al. 2014; Matreyek et al. 2014; Goujon et al. 2015). The mechanism of MX2’s antiviral action 
remains to be determined. Whether it inhibits nuclear import of viral components or interferes with 
cellular factors that are required for viral capsid stability is still unclear. 
 
1.5.6 HIV-1 Nef 
When a full length sequence for the HIV-1 genome became first available it was discovered 
that an additional unknown open reading frame existed close to the 3’ end of the viral genome, 
partially overlapping with the U3 region (Ratner et al. 1985; Wain-Hobson et al. 1985; Muesing et 
al. 1985). This open reading frame was shown to encode the 27-32 kDa viral protein Nef (for 
negative factor) that is common to all primate lentiviruses. Its name originates from reports that it 
suppresses viral transcription and replication upon overexpression in cell culture (Luciw et al. 1987; 
Ahmad & Venkatesan 1988; Niederman et al. 1989). This was, however, contradicted by later 
reports (Hammes et al. 1989; Kim et al. 1989). Nef seems to play an essential role in vivo for the 
maintenance of high viral loads as well as the development of AIDS. This became apparent in 
rhesus macaques infected with a Nef deficient SIVmac239 or patients infected with a Nef-deleted 
version of HIV-1, which was characterized by the absence of disease progression (Kestler et al. 
1991; Deacon et al. 1995; Kirchhoff et al. 1995).  
Nef comprises a structured, globular core domain that is flanked by a flexible N-terminal arm 
and a C-terminal disordered loop. All of those regions contain important motifs for protein-protein 
interactions or protein trafficking. Nef predominantly localises to perinuclear regions and associates 
with cellular membranes due to its myristoylation, but this also requires two basic leucine and 
arginine clusters close to its N-terminus (Greenberg et al. 1997; Bentham et al. 2006). It is 
incorporated into assembling virions, probably due to its association with cellular membranes, and 
gets cleaved by the viral protease, but the role of these events remains unclear (Pandori et al. 1996; 
Welker et al. 1996; Bukovsky et al. 1997; Chen et al. 1998). Nef interacts with numerous host factors 
and various roles have been ascribed to this accessory protein including downregulation of host 
cell molecules such as CD4, MHC-I and tetherin from the plasma membrane, modification of T cell 
signalling and activation, and enhancement of viral infectivity.  
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Nef achieves the downregulation of CD4 from the surface of infected cells by direct binding to 
CD4 and recruitment of clathrin adaptor protein 2 (AP-2) via its canonical dileucine 160ExxxLL165 
motif and additional stabilizing acidic residues 174(E/D)D175 (Lindwasser et al. 2008; Ren et al. 2014). 
This induces the endocytosis of surface CD4, followed by lysosomal degradation of the protein. Nef 
binds to the membrane proximal region of CD4’s cytoplasmic tail, which involves W57 and L58 
residues in Nef (Anderson et al. 1994; Grzesiek et al. 1996). However, this function of Nef is 
independent of serine phosphorylation in the CD4 cytoplasmic tail (Garcia & Miller 1991). Nef is not 
the only HIV-1 protein that affects CD4. In addition, HIV-1 Vpu is able to mediate the lysosomal 
degradation of newly synthesized CD4, which it encounters in the ER. There have been numerous  
explanations suggested for the benefits of CD4 downmodulation by HIV-1. It increases virion 
release and infectivity of viral particles, enhances viral replication and prevents cytotoxic 
superinfection (Argañaraz et al. 2003; Wildum et al. 2006). Furthermore, binding of CD4 to Env 
gp120 leads to conformational changes that result in the interaction with the co-receptor and in the 
exposure of the helical heptad repeat (HR1) of the gp41 ectodomain, which can serve as an epitope 
for antibody-dependent cell-mediated cytotoxicity (ADCC). Downmodulation of CD4 by HIV-1 Nef 
and Vpu has been reported to prevent this (Veillette et al. 2014; Pham et al. 2014). The 
downregulation of CD4 by Nef seems to be a crucial function as it is highly conserved among Nef 
proteins and also maintained throughout disease progression (Basmaciogullari & Pizzato 2014).  
Another surface molecule that is modulated by Nef is the major histocompatibility complex I 
(MHC-I). This Nef function is only maintained under strong selection pressure in the acute phase 
of infection and is supposed to protect the infected cell from killing by cytotoxic T lymphocytes 
(CTLs) at a stage of infection when the host is still immuno-competent (Collins et al. 1998; Carl et 
al. 2001). Two models for Nef-mediated downmodulation of surface MHC-I have been suggested. 
One proposes that Nef enhances the endocytosis of surface MHC-I, whereas the other model states 
that Nef induces the mis-trafficking of newly synthesized MHC-I. In the first model, Nef binds directly 
to the membrane trafficking proteins phosphofurin acidic cluster sorting proteins 1 or 2 (PACS-1/-
2), which mediates trafficking of Nef to the TGN where Nef interacts with Src family kinases (SFK) 
(Atkins et al. 2008). This activates the SFKs Kck, Lyn and c-Src, which trigger a phosphorylation 
cascade and the formation of a protein complex comprised of tyrosine kinase zeta-chain-associated 
protein kinase 70 (ZAP-70) and the signalling kinase phosphoinositide 3-kinase (PI3K). This 
activates PI3K, which leads to the production of phosphatidylinositol (3,4,5)-triphosphate (PIP3) on 
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the inner leaflet of the membrane. How this process mediates the internalization of MHC-I is so far 
unclear (Reviewed by Pawlak & Dikeakos 2015). Internalized MHC-I is also inhibited from recycling 
back to the PM. This is achieved by the formation of a ternary complex between Nef, the 
cytoplasmic tail of MHC-I and the µ1 subunit of AP-1 (Figure 1.11) (Jia et al. 2012). The second 
model proposes that Nef blocks the trafficking of newly synthesized MHC-I from the TGN to the 
PM. Nef binds to immature, hyperphosphorylated MHC-I in the TGN and sequesters it, thereby 
inhibiting trafficking to the PM (Kasper et al. 2005). This also requires a ternary complex between 
Nef, MHC-I and AP-1, and the sorting into coatomer protein complex subunit beta (β-COPI) coated 
vesicles followed by lysosomal degradation (Schaefer et al. 2008). Both models are not mutually 
exclusive and may occur at different time points and further depend on the cell type. The importance 
of downmodulating MHC-I from the cell surface may be explained by its function in presenting viral 
peptides to CD8+ cytotoxic T lymphocytes (CTLs). Consistent with this hypothesis, cells that are 
infected with a virus bearing a functional Nef are less efficiently killed by CTLs (Collins et al. 1998; 
Yang et al. 2002). On the other hand, cells lacking any MHC-I are targeted by natural killer (NK) 
cells for destruction (Kusunoki et al. 2000). To avoid this, Nef primarily targets MHC-I classes HLA-
A and HLA-B, while leaving HLA-C, HLA-E and HLA-G unaffected (Cohen et al. 1999; Pizzato et 
al. 2004; Specht et al. 2008).  
Apart from CD4 and MHC-I, some SIV and HIV Nefs also downregulate tetherin to enhance 











Figure 1.11 Model of Nef binding to MHC-I and AP-1 at a lipid membrane. Circled crosses represent PIP2-
binding sites and arrows indicate membrane-anchoring sites. (From Jia et al. 2012). 
 
Nef proteins from SIVs that are non-pathogenic in their natural host as well as the Nef encoded 
by HIV-2 have the ability to efficiently downmodulate the TCR-CD3 complex from infected cells. 
This results in the suppression of T cell activation and inhibits activation-induced cell death (AICD). 
This correlates with the lower pathogenicity of these viruses in their natural host and was suggested 
to allow them to persist in the presence of an intact immune system. This activity of Nef was lost in 
SIVcpz prior to transmission to humans and the emergence of HIV-1 and it has been proposed that 
this is a determinant of the higher pathogenicity of HIV-1 in humans (Schindler et al. 2006).  
In addition to influencing the surface levels of certain cellular proteins, Nef also modulates the 
activation threshold of T lymphocytes (Schrager & Marsh 1999; Simmons et al. 2001). It does so 
by hijacking signalling pathways and interacting with Src family tyrosine kinases, p21-activated 
serine/threonine kinases and Vav (Saksela et al. 1995; Fackler et al. 1999). This alters the 
transcriptional program in infected T cells, potentially creating a favourable environment for HIV 
replication. Moreover, this interference with signalling pathways also mediates the inactivation of 
cofilin, an actin depolymerizing factor, which leads to restriction of cell motility and migration of 
59 
 
infected cells (Stolp et al. 2009). Residues in Nef required for these activities are a proline-rich motif 
PxxP, an amphiphatic ɑ-helix in the N-terminal region and a hydrophobic surface in the C-terminal 
loop (Saksela et al. 1995; Baur et al. 1997; Agopian et al. 2006).  
Another important function of Nef is its positive effect on the infectivity of virions independent 
of its function of increasing infectivity by inducing the degradation of CD4 (Chowers et al. 1994; 
Miller et al. 1995; Goldsmith et al. 1995). This activity of Nef is highly conserved among various Nef 
proteins from HIV and SIV and is maintained during disease progression by strong selective 
pressure, but the precise role and mechanism were not understood until recently (Carl et al. 2001; 
Münch et al. 2007).  
Infectivity enhancement by Nef requires AP-2 interaction via the ExxxLL or YxxL motif in HIV 
or SIV Nef, respectively (Chowers et al. 1994; Lock et al. 1999). Furthermore, dynamin 2 interaction 
and clathrin-mediated endocytosis are crucial for this function and it was suggested that it induces 
the endocytosis of a cellular factor (Pizzato et al. 2007). Comparative analysis of the protein 
composition of Nef-positive and Nef-deficient virus revealed that the cellular proteins Ezrin and 
EHD4 were more abundant in nascent virions produced in the absence of Nef (Bregnard et al. 
2013). Although no direct inhibitory effect of these proteins was shown they were suggested to be 
co-factors for the infectivity enhancement by Nef. In addition, the lipid composition of viral particles 
did not correlate with virion infectivity (Brügger et al. 2007). 
It was clear that Nef needed to be expressed in producer cells to overcome the restriction. 
However, it does not alter the incorporation of viral Env into budding virions (Aiken & Trono 1995; 
Miller et al. 1995; Lai et al. 2011). Nevertheless, the requirement for Nef to enhance infectivity 
depends on the envelope used to pseudotype the HIV particle. Env from viruses that require 
endocytosis and endosome acidification for fusion, such as VSV,  are not responsive to Nef 
expression, i.e. Nef does not enhance the infectivity of HIV bearing these envelopes (Miller et al. 
1995; Aiken 1997; Luo et al. 1998; Pizzato et al. 2008). In contrast, envelopes from viruses that 
fuse at neutral pH at the plasma membrane, such as HIV, require Nef for infectivity enhancement. 
Although, this has been a matter of debate, as HIV has been shown to also be able to fuse in early 
endosomes after endocytosis, but before acidification (Miyauchi et al. 2009; van Wilgenburg et al. 
2014). Some HIV envelopes are more responsive to Nef’s action than others and co-receptor usage 
does not seem to determine this requirement (Papkalla et al. 2002; Lai et al. 2011; Usami & 
60 
 
Göttlinger 2013). The differences in Nef responsiveness were mapped to a variable region of 
gp120, V2, that is also involved in neutralization sensitivity and trimer association. In fact, Nef has 
been shown to decrease the sensitivity to neutralizing antibodies that are directed against the 
membrane-proximal extracellular region of gp41 (Lai et al. 2011).  
Reports about a possible Nef interference with the process of fusion of the the viral particle 
with the host cell membrane are conflicting, but it was suggested that Nef may interfere with the 
enlargement of the fusion pore that is required for efficient translocation of the viral core (Zhou & 
Aiken 2001; Tobiume et al. 2003; Cavrois et al. 2004). Differential results have been ascribed to 
different experimental set ups and the potentially easier diffusion of small molecules through the 
fusion pore compared to the large viral core.  
Interestingly, an unrelated protein to Nef that is expressed by MLV, glycoGag, has been shown 
to have identical effects on HIV infectivity. GlycoGag is expressed from an unspliced MLV RNA that 
is translated from a CUG initiation codon upstream from the Gag initiation codon, resulting in a 
chimeric protein where the N-terminus constitutes a transmembrane domain (Pizzato 2010; Usami 
& Göttlinger 2013; Usami et al. 2014). It similarly increased infectivity of Nef-deficient virus and as 
for Nef, the V2 region of gp120 dictates the responsiveness to glycoGag. Envelopes such as VSV-
G are, however, not affected. Importantly, the effect of Nef and glycoGag on infectivity are not 
additive.  
Recently, it was found that Nef’s enhancement of particle infectivity was due to its counteraction 
of the cellular membrane proteins serine incorporator 3 and 5 (SERINC3/5) (Usami et al. 2015; 
Rosa et al. 2015; Matheson et al. 2015). SERINC’s mechanism of action in reducing infectivity of 
nascent virions  is still unclear and several questions remain. The antiviral function of SERINC 
proteins and counteraction by HIV-1 Nef will be further addressed in chapter 5.   
 
1.5.7 HIV-1 Vpu 
The viral protein unique (Vpu) was identified in 1988 when an additional HIV-1 open reading 
frame, overlapping with the tat and env genes, was identified (Cohen et al. 1988; Strebel et al. 
1988). Vpu is expressed by HIV-1, SIVgor and their precursor SIVcpz. Furthermore, SIVgsn, 
SIVmon, SIVmus and Dent’s monkey SIV (SIVden) also express a Vpu protein. SIVcpz originates 
from successive cross-species transmission and recombination events involving the precursors of 
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SIVgsn/mon/mus/den and SIVrcm (Bailes et al. 2003). Therefore, it is likely that all Vpu proteins 
originate from the SIVgsn/mon/mus/den lineage of lentiviruses.  
It was clear early on that Vpu was essential for the efficient release of virions from infected 
cells and it was reported later that this was due to the counteraction of tetherin (Terwilliger et al. 
1989; Klimkait et al. 1990; Neil et al. 2008). This Vpu function will be discussed in more detail in 
section 1.6.4.1. Importantly, Vpu also induces the downregulation of CD4, and other surface 
molecules such as CD1d, NTB-A and SNAT1 (Klimkait et al. 1990; Willey et al. 1992; Shah et al. 
2010; Moll et al. 2010; Matheson et al. 2015). 
The 16 kDa phosphoprotein Vpu is translated from a bicistronic mRNA that also encodes for 
the HIV-1 envelope glycoprotein (Schwartz et al. 1990). It contains a short N-terminal domain, a 
transmembrane domain and C-terminal cytoplasmic tail (Figure 1.12) (Maldarelli et al. 1993; Bour 
& Strebel 2003). NMR data indicates that the transmembrane domain of Vpu is tilted between 15° 
and 30° in a lipid environment and is required for oligomerization of Vpu and ion-channel formation 
(Park et al. 2003; Park & Opella 2005; Schubert et al. 1996; Lopez et al. 2002). However, ion 
channel activity does not appear to be required for tetherin counteraction and virus release (Skasko 
et al. 2011; Bolduan et al. 2011). The cytoplasmic portion of Vpu comprises two alpha helices and 
has conformational flexibility. A recent study solved the Vpu full-length structure and showed that 
the two cytoplasmic helices form a U-shape (Zhang et al. 2015). The length of the inter-helical loop 
and the orientation of the third helix depend on the lipid composition. The relative flexibility of the 
C-terminal helix was suggested to support accessibility for the interaction with various proteins.  
Two highly conserved serine residues in the cytoplasmic tail (S52 and S56) are constitutively 
phosphorylated by casein kinase II (CKII) (Schubert et al. 1992; Schubert & Strebel 1994; Friborg 
et al. 1995). This serine modification is required for the direct interaction with β-TrCP and the 
recruitment of the E3 ubiquitin ligase SCF complex (SCFTrCP), which mediates CD4 and tetherin 








Figure 1.12 The topology of HIV-1 Vpu. (A) secondary structure of NL4.3 Vpu. The N-terminal 
transmembrane domain is predicted to be tilted by 13°. The cytoplasmic tail contains two alpha helices and is 
phosphorylated (P) at two serines at position 52 and 56. (B) Amino acid sequence of HIV-1 NL4.3 Vpu. 
Domains are indicated. Important residues are highlighted. Green: alanine face in the TM domain, required for 
direct interaction with tetherin. Blue: phosphorylated serine residues required for β-TrCP interaction. Pink: 
ExxxLV trafficking motif.  
 
Vpu predominantly localizes to the TGN, endosomes and the ER (Varthakavi et al. 2003; Dubé 
et al. 2009). A dileucine-based sorting motif, ExxxLV, in the second alpha helix of the cytoplasmic 
tail of Vpu has been shown to be essential for this localization (Dubé et al. 2009; Kueck & Neil 
2012). HIV-1 subtype C Vpus have a dileucine-based motif proximal to the transmembrane domain. 
These Vpus, however, localize mainly to the plasma membrane (Ruiz et al. 2008).  
 
1.5.7.1 Vpu and CD4 Degradation  
HIV-1 encodes two accessory proteins that are able to induce the degradation of CD4: Nef and 
Vpu. This indicates that removal of CD4 plays a crucial role in HIV-1 replication. CD4 can reduce 
the infectivity of viral particles by binding to the envelope precursor gp160 in the ER and preventing 
it from being processed and reaching the cell surface (Willey et al. 1992). This results in reduced 
Env-incorporation and infectivity of the budding particles. Additionally, CD4 surface expression can 
lead to super-infection of the cell, which is associated with increased cytotoxicity and reduced viral 
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spread (Wildum et al. 2006). Furthermore, binding of HIV-1 Env to CD4 exposes epitopes that are 
targeted by ADCC-mediating antibodies (Veillette et al. 2014). Nef and Vpu do not share the same 
anti-CD4 mechanism. Whilst Nef is expressed early in the viral life cycle and induces the enhanced 
AP-2 dependent endocytosis of surface CD4 followed by lysosomal degradation, Vpu is expressed 
at the same time as Env and induces the degradation of newly synthesized CD4 in the ER 
(Reviewed by Dubé et al. 2010).  
Vpu and CD4 interact directly via their cytoplasmic tails and the hydrophobic transmembrane 
domains were suggested to stabilize the contact (Bour et al. 1995; Magadán et al. 2010). Residues 
in the cytoplasmic tail of CD4, 414LSEKKT419, and a membrane proximal ɑ-helix are sufficient to 
confer sensitivity to Vpu. Both cytoplasmic ɑ-helices in Vpu have been found to be important for 
CD4 binding (Tiganos et al. 1997; Schubert et al. 2010; Singh et al. 2012). The phosphorylated 
serine motif is required for direct interaction with a WD-repeat in β-TrCP and formation of a ternary 
complex consisting of Vpu, CD4 and β-TrCP, which recruits the SCF E3 ubiquitin ligase (Margottin 
et al. 1998). This induces the ubiquitination of CD4 lysine, serine and threonine residues, which is 
followed by extraction from the ER and a form of endoplasmic reticulum-associated protein 
degradation (ERAD) (Binette et al. 2007; Magadán et al. 2010). This Vpu-mediated ERAD of CD4 
differs from the classical process, because it does not use the ER membrane-associated E3 
ubiquitin ligases. The VCP-UFD1L-NPL4 complex, including AAA-ATPase p97/VCP, that is 
involved in extraction of ERAD substrates from the ER, however, is required for Vpu-induced CD4 
degradation (Binette et al. 2007).  
 
1.5.7.2 Vpu and the Innate Immune Response 
NK cells play a major role in the innate immune response to HIV-1 infection as discussed in 
section 1.4. The activation of NK cells is achieved by recognition of stress-induced molecules 
through the NK cell receptor NKG2D, but further signals are required to induce degranulation of NK 
cells (Cerwenka & Lanier 2001). One such signal can be the activation of co-receptors like the NK-
T and B cell antigen (NTB-A), which belongs to the signalling lymphocytic activation molecule 
(SLAM) family and is found on blood-derived NK, T and B cells. Interestingly, HIV-1 Vpr was shown 
to increase NKG2D ligand expression levels (Ward et al. 2009). Also, HIV-1 Nef induces the 
downmodulation of MHC-I molecules from the surface of infected cells, which could potentially 
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enhance NK cell response (Cohen et al. 1999). In contrast, Vpu was shown to inhibit NK cell 
activation by downregulating surface levels of NTB-A in infected T cells (Shah et al. 2010). This 
Vpu function appears to be mechanistically different to its anti-tetherin and anti-CD4 function. Direct 
binding to NTB-A involves the transmembrane domain of Vpu. However, Vpu does not enhance the 
endocytosis of surface NTB-A and it was proposed that Vpu induces differential trafficking and 
sequestration of NTB-A. Counteraction is not dependent on β-TrCP recruitment and Vpu does not 
induce the degradation of NTB-A. Rather, Vpu interferes with the glycosylation pattern of newly 
synthesized NTB-A , which results in aberrant transport (Bolduan et al. 2013). Whether this Vpu 
function is essential in vivo is, however, unclear. In humanized, infected mice NTB-A was not found 
to be downregulated in a Vpu-dependent manner (Sato et al. 2012; Dave et al. 2013). While NK 
cell activation may be highly regulated by different HIV-1 proteins, further investigation is needed 
to understand the interference with NK cell activation by HIV-1. 
Another surface molecule that has been shown to be downmodulated from HIV-1 infected 
dendritic cells is CD1d (Moll et al. 2010). As an MHC-I-like protein, CD1d presents antigens to 
natural killer T (NKT) cells. This results in the activation of immune cells and cytokine secretion, 
which further stimulates the antiviral immune response. Vpu does not induce enhanced endocytosis 
or degradation of CD1d, but rather sequesters it in early endosomes and prevents it from recycling 
back to the cell surface. As a result, CD1d is unable to present antigens to the immune system. 
Recently, Vpu was found to downregulate the amino acid transporter SNAT1 from the cell 
surface of infected cells and to induce its ESCRT-dependent endolysosomal degradation via 
recruitment of β-TrCP (Matheson et al. 2015). This requires the phospho-serines in the Vpu 
cytoplasmic tail, but also W22 in the Vpu TM has been shown to be required. SNAT1 regulates the 
uptake of alanine into primary human CD4+ T cells and alanine has been shown to be essential for 
T cell mitogenesis. Therefore, Vpu-mediated SNAT1 downregulation may represent a strategy to 
regulate immune cell activation (Matheson et al. 2015).  
Recent data suggest that Vpu plays an additional important role in regulating the 
proinflammatory immune response. Vpu was shown to limit immune activation by NF-κB by 
antagonising tetherin-mediated signalling as discussed in section 1.6.8, but also by directly 
interfering with downstream NF-κB activation (Bour et al. 2001; Sauter et al. 2015). Whilst not all 
Vpu proteins antagonise tetherin, direct NF-κB inhibition is a conserved function among various 
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primate Vpus. Interestingly, primary Vpus from patient isolates were highly efficient in inhibiting NF-
κB activation, compared to the lab-adapted strain NL4.3 Vpu (Pickering et al. 2014). It was 
suggested that Vpu achieves the direct inhibition of signalling by sequestration of β-TrCP and 
thereby stabilization of the NF-κB inhibitor IκB, which is a target of the SCF-β–TrCP ligase 
(Besnard-Guerin et al. 2004; Hotter et al. 2013). Interestingly, HIV-1 Nef induces NF-κB early in 
infection, presumably to promote viral replication. NF-κB inhibition by late expression of Vpu is 
dominant over the stimulating effects mediated by Nef, at a stage of infection when viral replication 
is efficiently driven by Tat, thereby independent of NF-κB (Sauter et al. 2015).  
In addition, Vpu has been implicated in reducing TLR7-mediated type-I IFN production by pDCs 
(Bego et al. 2015). Through downmodulation and relocation of surface tetherin, it was suggested 
to promote tetherin/ILT-7 interaction upon cell-to-cell contact, which then results in the suppression 
of type-I IFN production by pDCs.  
 
1.6 Tetherin and its Counteraction by Viruses 
Tetherin, also known as CD317, HM1.24 or bone marrow stromal cell antigen 2 (BST-2), was 
discovered in a proteomic screen as a plasma membrane protein that was downregulated from the 
surface of cells expressing K5, a membrane-associated RING CH ubiquitin ligase encoded by 
Kaposi’s sarcoma-associated herpesvirus (KSHV; also human herpesvirus 8 (HHV8)) (Bartee et al. 
2006). Shortly after, tetherin was shown to be the target of HIV-1 Vpu (Neil et al. 2008; Van Damme 
et al. 2008).  
It was long known that Vpu was able to enhance the release of virions from the plasma 
membrane of infected cells and that in the absence of Vpu virions would accumulate at the cell 
surface and in endosomes (Klimkait et al. 1990; Göttlinger et al. 1993). This requirement for Vpu 
was cell type dependent and species-specific (Varthakavi et al. 2003; Neil et al. 2006; Neil et al. 
2007). Efficient HIV-1 release from permissive cell lines such as 293T, HT1080 or HOS cells did 
not require Vpu expression. In non-permissive cell lines such as Hela cells, HIV-1 release was 
restricted in the absence of Vpu. Heterokaryon experiments between permissive and non-
permissive cells suggested a dominantly acting cellular factor was inhibiting the release of HIV-1 
particles in the absence of Vpu (Varthakavi et al. 2003; Neil et al. 2006). Vpu was also able to 
rescue the release of a range of retroviral and filovirus-like particles and the restrictive phenotype 
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could be induced in permissive cells by type-I interferon treatment (Göttlinger et al. 1993; Neil et al. 
2007). Fully mature virions were retained at the cell surface of Vpu-deficient HIV-1 infected cells. 
These virions could be released by protease treatment, in particular, when endocytosis was blocked 
using a Rab5 dominant negative mutant (Neil et al. 2006; Neil et al. 2007). Therefore, it was 
concluded that the inhibitor was a cellular, IFN-inducible protein that retained virions on the cell 
surface. It was constitutively expressed in some cell types such as Hela cells and was antagonised 
by HIV-1 Vpu. 
BST-2 was identified as this restriction factor in 2008 (Neil et al. 2008; Van Damme et al. 2008). 
It was first described to be expressed on bone marrow stromal cells (hence the name), terminally 
differentiated B cells and plasmacytoid dendritic cells, and it was suggested to be involved in B cell 
growth (Goto et al. 1994; Ishikawa et al. 1995; Blasius et al. 2006). Comparing gene arrays from 
cell types that require Vpu expression for HIV-1 release or not revealed that BST-2 was expressed 
at levels 20-fold higher in Hela cells compared to HOS cells and it was upregulated to the same 
level by IFN-ɑ treatment in permissive cell types such as 293T or HT1080 cells. It was subsequently 
called tetherin due to its ‘tethering’ mechanism of action (Neil et al. 2008).  
It was soon clear that tetherin was capable of inhibiting diverse enveloped DNA and RNA 
viruses and that viruses had co-evolved to encode species-specific countermeasures, such as Vpu 
or K5. The anti-tetherin activity of a virus was suggested to play a crucial role in cross-species 
transmission of HIV-1 and HIV-2 (Sharp & Hahn 2011a). Importantly, tetherin was also suggested 
to play a role in retroviral pathogenesis and the anti-viral immune response in vivo (Liberatore & 
Bieniasz 2011; Barrett et al. 2012; Swiecki et al. 2012). Additionally, it is now clear that tetherin 
possesses antiviral function in addition to its physical function of virion retention. The following 
sections will describe the role of tetherin and its viral antagonism in more detail.  
 
1.6.1 Tetherin Topology and Subcellular Localization  
Tetherin is a type-II transmembrane protein with an unusual topology. It comprises a short N-
terminal cytoplasmic tail, a transmembrane domain and an extracellular domain with a 
glycosylphosphatidylinositol (GPI)-anchor that covalently anchors the C-terminus to the outer leaflet 
of the PM (Figure 1.13) (Kupzig et al. 2003; Hinz et al. 2010; Schubert et al. 2010; H. Yang et al. 
2010; Swiecki et al. 2011). Thus, tetherin is anchored to the PM at both ends, which is essential for 
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its anti-viral function. The GPI anchor is added to the protein posttranslationally in the ER through 
the enzymatic activity of PIG-L (Nakamura et al. 1997). In cells that lack PIG-L, no GPI anchor is 
added to proteins, resulting in their ER retention and failure to enter the secretory pathway. In the 
case of tetherin, this leads to a loss of antiviral function (Perez-Caballero et al. 2009). In addition, 
the GPI anchor is responsible for the association with lipid rafts (Kupzig et al. 2003). Two conserved 
asparagine residues in the ectodomain of tetherin (N-65 and N-92) are glycosylated, which explains 
the variable running size of 30-40 kDa of the mature protein in Western blots. While glycosylation 
has been shown to contribute to the transport and folding of tetherin, it is dispensable for antiviral 
function (Andrew et al. 2009; Perez-Caballero et al. 2009).Three cysteine residues in the 
ectodomain (C-53, C-63 and C-91) are required for the formation of a disulphide-linked tetherin 
dimer. The extracellular helix forms a parallel, dimeric, disulphide-linked coiled coil domain 
(residues 47 to 152), resulting in a 17nm alpha-helical rod-like structure. The dimer is hinged at two 
positions (A88 and G109 in human tetherin) that provides it with rotational flexibility and allows it to 
accommodate membrane curvature (Schubert et al. 2010; H. Yang et al. 2010). Although two 
tetherin dimers can form head-to-head tetramers under reducing conditions, this does not seem to 
be relevant for tetherin’s anti-viral function and are unlikely to form in vivo due to steric hindrance 
of the disulphide bonds (Schubert et al. 2010). However, tetrameric structures of murine tetherin 
have been reported to resemble BAR domains that are involved in generation or stabilization of 














Figure 1.13 Tetherin topology. (A) Schematic representation of a tetherin monomer at the plasma 
membrane. The major domains are indicated: the N-terminal cytoplasmic tail, the transmembrane domain, the 
long α-helical extracellular coiled-coil domain, and the C-terminal GPI anchor. Important residues are marked. 
The dual-tyrosine motif (YDYCRV) required for endocytosis and signaling. Potential ubiquitin-acceptor 
residues include two lysines (K18 and K21) and an STS motif at the N-terminus. An additional M at position 
13 can serve as an alternative translation start site. Three cysteine residues (C53, C63 and C91) are involved 
in dimerization and two glycosylation sites (N65 and N92) are indicated in the extracellular domain. (B) The 
amino acid sequence of human tetherin with the molecular features described in (A). Additionally, residues in 
the transmembrane domain that are required for Vpu binding are highlighted.  
 
Tetherin predominantly localises to the PM, but also to the TGN and early/recycling endosomes 
(Kupzig et al. 2003). It is endocytosed from the PM in a clathrin-dependent manner that involves 
binding of clathrin adaptor AP-2 via the highly conserved, non-canonical dual-tyrosine motif YxYxxΦ 
in the cytoplasmic tail of tetherin (Figure 1.14) (Rollason et al. 2007; Masuyama et al. 2009). It then 
recycles from endosomes to the TGN, which requires interaction with the clathrin adaptor AP-1, 
before it is transported back to the PM. Clathrin-mediated, cellular transport pathways will be 








Figure 1.14 Model of tetherin recycling. Tetherin trafficking in the absence of Vpu. Newly synthesized 
tetherin traffics to the plasma membrane. AP-2 mediates the endocytosis of tetherin in clathrin-coated pits. It 
then traffics to the TGN, mediated by AP-1, and recycles back to the plasma membrane.  
 
At the PM, tetherin associates with cholesterol-rich lipid rafts via its GPI anchor and it has been 
suggested that tetherin may regulate membrane protein distribution in these micro-domains (Kupzig 
et al. 2003; Billcliff et al. 2013). In addition, tetherin is involved in the polarization of epithelial cells 
where it interacts with the subapical actin cytoskeleton (Rollason et al. 2009). This is mediated 
through interaction with RICH2, EBP50 and ezrin. Interestingly, tetherin knock-out mice do not show 
developmental defects and the role of this tetherin function in vivo is unclear (Rollason et al. 2009; 
Liberatore & Bieniasz 2011). Interaction of tetherin with RICH2 also has implications for the 
signalling capacity of tetherin upon virion restriction, which will be explained in more detail in section 
1.6.8. 
Tetherin is constitutively expressed in many tissues and cell types including vascular 
endothelium, hepatocytes, monocytes, plasma cells and epithelia (Erikson et al. 2011). Tetherin 
expression can be induced by IFN-I treatment, but also by IFN-II and other proinflammatory 
cytokines to varying degrees in different cell types (Blasius et al. 2006; Neil et al. 2008; Van Damme 
et al. 2008; Homann et al. 2011; Bego et al. 2012). The tetherin promoter harbours several putative 
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NFAT, STAT and NF-κB binding sites 1.5 kb upstream of the transcriptional start site. An 
overlapping sequence containing an interferon-stimulated response element (ISRE), gamma-
interferon activation site (GAS) and interferon regulatory factor (IRF) binding site is also present in 
the promoter region that is conserved across species (Bego et al. 2012). Tetherin expression can 
be directly induced by IRF 1, 3 and 7 independently of autocrine IFN-I, suggesting that tetherin can 
be induced by PRR signalling, as has been shown for TLR3 and TLR8 in human lymphoid and 
myeloid cells, respectively (Homann et al. 2011; Bego et al. 2012).  
 
1.6.2 Genetic Diversity of Tetherin  
Orthologues of tetherin exist in vertebrates including fish, birds, reptiles and mammals 
(Heusinger et al. 2015). Two unrelated proteins of the slime mold Dictyostelium discoideum have 
an organization similar to tetherin, but no evidence for convergent evolution or antiviral activity was 
detected. Human tetherin is encoded on chromosome 19 and can be expressed as two isoforms 
(Ishikawa et al. 1995; Cocka & Bates 2012). Like all mammalian tetherins that have been 
sequenced to date, human tetherin contains a second methionine in the cytoplasmic tail. In human 
tetherin it is located at position 13 and has, like the methionine at position 1, a weak Kozak 
consensus sequence in front of it. This results in leaky ribosomal scanning during translation and 
the expression of both a long and short isoform (Cocka & Bates 2012). The twelve amino acids that 
are missing in the short isoform contain important motifs for trafficking, but also ubiquitination and 
tetherin signalling. The latter will be explained in more detail in section 1.6.8. Whilst both human 
isoforms restrict HIV-1 release they are differentially sensitive to HIV-1 Vpu. Data presented in 
chapter 3 of this thesis addresses the differential role of human tetherin isoforms in the context of 
viral antagonism.  
Polymorphic initiation codons for the long tetherin isoform have been described in domestic 
cats and NZW mice (Celestino et al. 2012; Barrett et al. 2012). Both lack the first AUG start codon 
in the bst-2 gene and only express the shorter version of tetherin. In the case of NZW mice this has 
been associated with decreased pathogenesis of Friend virus infection in vivo. During the evolution 
of ruminants and before sheep, goats and cows diverged, their bst2 gene was duplicated, which 
resulted in the expression of two tetherin isoforms. Both sheep tetherins, oBST2A and oBST2B, 
have antiviral activity with varying efficiency and potentially cell type specificity (Arnaud et al. 2010). 
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1.6.3 Tetherin’s Antiviral Activity  
Tetherin restricts the release of enveloped viruses by physically cross-linking budding virions 
to the plasma membrane (Figure 1.15 A-B). This non-specific mechanism of inhibition allows it to 
prevent the release of a broad range of viruses including all members of the Retroviridae family, 
Paramyxoviruses (Nipah, Hendra), Filoviruses (Ebola virua, Marburg virus), Rhabdoviruses (VSV), 
Arenaviruses (Lassa), Flaviviruses (Dengue virus) and some Herpesviruses (Herpes simplex virus 
1 and 2, Human herpes virus 8). This also indicates that it is unlikely that tetherin executes its 
function through direct specific interaction with viral proteins. There are several lines of evidence 
supporting the role of tetherin in cross-linking virions to the PM. Restricted virions can be released 
by protease treatment and tetherin fragments can be detected in the liberated particle (Neil et al. 
2008; Perez-Caballero et al. 2009; Venkatesh & Bieniasz 2013). Furthermore, tetherin colocalizes 
with HIV-1 Gag in immunofluorescence assays and immunoelectron micrographs show tetherin 
between budding virions and the PM (Figure 1.15 A and B) (Neil et al. 2008; Jolly et al. 2010; 
Fitzpatrick et al. 2010; Hammonds et al. 2010).  
The topology of tetherin is essential for its antiviral function. However, it is not the specific 
sequence of tetherin, but rather the overall structure that is required. An artificial molecule mimicking 
the topology of tetherin was almost as potent in inhibiting virus release as tetherin (Perez-Caballero 
et al. 2009). This suggests that tetherin does not require a co-factor for its antiviral activity. 
Theoretically, several models of tetherin cross-links between virion and PM are possible. An 
equatorial model was proposed, where both ends of one tetherin molecule are inserted into the 
same lipid membrane and virion tethering would occur through dimer formation. Another model is 
the axial model, where both N-termini or C-termini of the dimer are either inserted together in the 
PM or the virion (Figure 1.15 C). Accumulating evidence supports the axial model of tetherin 
insertion (Perez-Caballero et al. 2009; Venkatesh & Bieniasz 2013). Site specific proteolytic 
cleavage and quantification of tethered virions showed that the C-termini of tetherin dimers were 
incorporated into budding virions three to five times more often than the N-termini (Venkatesh & 
Bieniasz 2013). One study suggested that 4-7 tetherin dimers are inserted per virion, while another 
study proposed that each particle was associated with 80-400 dimers (Lehmann et al. 2011; 
Venkatesh & Bieniasz 2013). The distinct experimental setup of these two studies may explain 
these differences and the number of tetherin dimers inserted into budding virions for restriction is 





Figure 1.15 Restriction of viral particles by tetherin. (A) Electron micrographs: Vpu-deficient HIV-1 
accumulate at the cell surface of infected HT1080 cells expressing tetherin. (From Neil et al. 2008) (B) Jurkat 
cells infected with HIV-1 NL4.3 ΔVpu were fixed and prepared for TEM. Virions tethered to the PM are indicated 
with an arrow. Scale bar, 100 nm. (From (Jolly et al. 2010) (C) Schematic representation virion restriction by 
tetherin. Tetherin monomers are in parallel orientation. Either the GPI anchors or the N-terminal 
transmembrane domains are inserted into the virion. (From Venkatesh & Bieniasz 2013).  
 
Virion retention is followed by endocytosis of the particles that then accumulate in endosomal 
compartments. Potentially, this can lead to the degradation of the virions and release of viral 
antigens for presentation to the immune system. This would have implications for an augmented 
antiviral immune response induced by tetherin-mediated virion restriction. The process of 
endocytosis and endosomal accumulation is dependent on the dual-tyrosine motif in the 
cytoplasmic tail of tetherin and the cellular GTPase Rab5 and E3 ubiquitin ligase Rabring7 (BCA-
2) (Neil et al. 2006; Miyakawa et al. 2009). Whether the association of tetherin with the cortical actin 
network via RICH2 plays a role in virion internalization is unclear.  
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1.6.4 Viral Antagonists 
As mentioned previously, tetherin restricts a broad range of viruses. To overcome this 
restriction, several viruses have evolved antagonists. These virally encoded proteins remove 
tetherin from its site of viral budding, thereby preventing its insertion and virion retention. 
Antagonism often involves the mis-trafficking of tetherin, either preventing it from reaching the 
plasma membrane or inducing its endocytosis (Le Tortorec et al. 2011). Tetherin counteraction is 
species-specific and different viruses evolved different countermeasures and mechanisms that will 
be discussed in the following section. Examples of tetherin antagonists and a short description of 
their mechanism is depicted in Figure 1.16.  
 
 
Figure 1.16 Viral tetherin antagonists. Schematic representation of well characterized tetherin antagonists 
HIV-1 Vpu, SIV/HIV-1 Nef, HIV-SIV Env, KSHV K5 and Ebola GP with a short summary of their mechanism of 
action. 
 
1.6.4.1 HIV-1 Vpu 
HIV-1 Vpu is the prototypic tetherin antagonist and has been studied extensively. It induces 
the downmodulation of tetherin from the surface, which is achieved by re-routing newly synthesized 
and recycling tetherin and preventing it from reaching the cell surface. It also reduces total cellular 
levels of tetherin by inducing its ESCRT-dependent lysosomal degradation. This process is 
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mechanistically different to Vpu-mediated CD4 degradation (Van Damme et al. 2008; Douglas et 
al. 2009; Iwabu et al. 2009; Mitchell et al. 2009).  
Tetherin and Vpu interact directly via their transmembrane domains and this is essential for 
counteraction and determines species-specificity (Figure 1.17) (Iwabu et al. 2009; Mangeat et al. 
2009; Perez-Caballero et al. 2009; Dubé, Roy, et al. 2010; Vigan & Neil 2010; McNatt et al. 2013). 
Whilst HIV-1 Vpu efficiently antagonises human tetherin it is inactive against non-human primate 
tetherins other than chimpanzee or gorilla (McNatt et al. 2009). Residues that are essential for Vpu-
sensitivity lie along one face in the transmembrane ɑ-helix and include I34, L37 and L41. 
Additionally, a threonine at position 45 has been implicated. In Vpu, a conserved alanine face, 
A10xxx(A/V)14xxxA18xxxW22, was found to be crucial for direct interaction with tetherin (Gupta et al. 
2009; Vigan & Neil 2010; Kobayashi et al. 2011; Skasko et al. 2011; Matthew W. McNatt et al. 
2013). Interestingly, these residues are conserved in the Vpu proteins from HIV-1 groups M and N, 
but not in the Vpu proteins of group O that have no anti-tetherin activity (Sauter et al. 2009; Vigan 
& Neil 2010). The requirements for tetherin/Vpu interaction furthermore suggest that Vpu binds 
tetherin as a monomer, as a Vpu multimer would not allow binding via this face (Park et al. 2003; 
Vigan & Neil 2010). Tryptophan 22 in Vpu’s transmembrane domain has also been suggested to 











Figure 1.17 Interaction between tetherin and Vpu. (A) Vpu and tetherin interact via their transmembrane 
domains. (B) NMR structural model of Vpu and tetherin transmembrane domains interacting. Important 
residues for interaction are annotated for Vpu (red) and tetherin (blue) (from Skasko et al. 2012).  
 
To antagonise restriction, Vpu removes tetherin from the cell surface, the site of its action. 
However, Vpu does not induce enhanced endocytosis of tetherin or its removal from lipid rafts 
(Mitchell et al. 2009; Miyagi et al. 2009; Dubé et al. 2010; Schmidt et al. 2011). Rather, Vpu prevents 
the trafficking of tetherin to the plasma membrane and mediates its sequestration in TGN-
associated and/or endosomal compartments, which is followed by lysosomal degradation (Van 
Damme et al. 2008; Douglas et al. 2009; Iwabu et al. 2009; Mitchell et al. 2009) (Figure 1.18). 
Whether the final degradation step is required for tetherin antagonism by Vpu is a matter of debate 
and it has been further proposed that the mis-trafficking of tetherin may be sufficient for 
counteraction (Schubert & Strebel 1994; Mangeat et al. 2009; Mitchell et al. 2009). In agreement 
with tetherin sequestration, Vpu and tetherin co-localize predominantly to the TGN and endosomal 
compartments. Moreover, mutations in Vpu that inhibit its TGN localization also confer a defect in 





Figure 1.18 Model of Vpu-mediated mis-trafficking of tetherin. In an uninfected cell, newly synthesized 
tetherin traffics to the plasma membrane. AP-2 mediates the endocytosis of tetherin in clathrin-coated pits. It 
then traffics to the TGN, mediated by AP-1, and recycles back to the plasma membrane. In HIV-1 infected 
cells, Vpu interacts with newly synthesized or recycling tetherin in the endoplasmic reticulum (ER) or the Golgi 
apparatus. Instead of reaching the plasma membrane, the Vpu/tetherin complexes are sorted into endosomal 
compartments. Furthermore, Vpu recruits SCF-β-TrCP, which ubiquitinates tetherin’s cytoplasmic tail. 
Ubiquitin-dependent recruitment of HRS then induces ESCRT-dependent degradation in lysosomes.   
 
Inhibition of the fast recycling pathway through monensin had no effect on tetherin surface 
levels and revealed that tetherin recycles through a slow pathway (Dubé et al. 2011). Thus, it was 
suggested that Vpu has to counteract both newly synthesized and slow-recycling tetherin to 
promote virus release. Interestingly, the anti-malaria drug primaquine was shown to mimic Vpu’s 
anti-tetherin function. Whilst not inducing tetherin endocytosis, it interferes with cellular transport 
pathways and is able to overcome tetherin restriction, further indicating that mis-trafficking of 
tetherin may be sufficient for antagonism (Schmidt et al. 2011). Additionally, evidence for 
antagonism of recycling tetherin by Vpu comes from a study using brefeldin A (BFA), which inhibits 
protein transport from the ER to the Golgi apparatus. BFA treatment did not affect tetherin 
downmodulation in the presence of Vpu, contributing to the evidence that Vpu inhibits the 
endosomal recycling of tetherin in addition (Lau et al. 2011).  
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Tetherin antagonism by Vpu is dependent on clathrin, which was demonstrated by 
overexpression of the C-terminal fragment of AP180 that disrupts clathrin-mediated endocytosis 
(Lau et al. 2011; Kueck & Neil 2012).  This is determined by an acidic dileucine sorting motif, 
ExxxLV, in the second alpha helix of the Vpu cytoplasmic tail. The subcellular localization of Vpu 
suggested that the mis-trafficking of tetherin may involve the clathrin adaptor AP-1. However, 
individual knockdown of clathrin adaptors AP-1, AP-2 or AP-3 did not lead to reduced counteraction 
of tetherin by Vpu and it was suggested that this may be due to redundancy in clathrin adaptor 
usage (Mitchell et al. 2009; Kueck & Neil 2012). Recently, binding of a Vpu-tetherin fusion protein 
to AP-1 has been demonstrated structurally (Jia et al. 2014). While tetherin binds to the µ subunit 
of AP-1 via its dual-tyrosine motif, Vpu binds the σ subunit via the ExxxLV trafficking motif. The 
ExxxLV motif in Vpu is required for correct subcellular localization of Vpu and also tetherin 
counteraction. Mutation of these residues leads to increased tetherin surface levels and inhibits 
tetherin degradation (Kueck & Neil 2012). Interestingly, this trafficking motif is absent in the Vpu 
proteins of HIV-1 group M subtype C. However, they contain a di-leucine motif, ExxxLL, in the first 
cytoplasmic alpha-helix (Ruiz et al. 2008). Whether this motif plays a role in trafficking and tetherin 
antagonism remains to be determined. In chapter 4 of this thesis, Vpu trafficking, the role of the 
phospho-serines in tetherin antagonism and clathrin adaptor binding will be analysed further.  
Vpu mediates the degradation of tetherin by sorting it into an endo-lysosomal pathway, which 
involves Rab GTPases that mediate intracellular membrane trafficking. The late endosome-
associated Rab7a is involved in fusion of endosomal and lysosomal compartments and was also 
shown to be required for the processing of HIV-1 Env and Env incorporation into assembling virions, 
which is important for virion infectivity (Caillet et al. 2011). In addition, knockdown of this GTPase 
resulted in a release defect of HIV-1 in tetherin expressing cells. It was suggested that Rab7a-
mediated trafficking processes are essential for the activity of Vpu to overcome tetherin restriction.  
Tetherin degradation is dependent on ubiquitination and several residues in tetherin have been 
proposed to be ubiquitin acceptor sites. Lysine 18 and/or 21 were shown to be mono-ubiquitinated 
and their mutation blocks tetherin degradation (Pardieu et al. 2010; Goffinet et al. 2010). 
Furthermore, serine and threonine residues were reported to be poly-ubiquitinated and implicated 
in Vpu-mediated antagonism (Tokarev et al. 2011). In contrast, another study indicated that none 
of theses residues were required and a mutated tetherin was still ubiquitinated and antagonised 
(Gustin et al. 2012). In this study, it was suggested that tetherin may be ubiquitinated at the 
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cytoplasmic tyrosine residues or the NH2 terminus of tetherin. The ubiquitination of tetherin depends 
on the phosphorylation of the two serine residues in the DSGNES motif in Vpu’s cytoplasmic tail 
that are required for the recruitment of the E3 ubiquitin ligase complex SCFTrCP (Margottin et al. 
1998; Mangeat et al. 2009; Douglas et al. 2009; Mitchell et al. 2009; Iwabu et al. 2009; Goffinet et 
al. 2009). Mutation of the two serines completely abrogates the interaction between Vpu and β-
TrCP, but only partially reduces virus release from tetherin expressing cells (Van Damme et al. 
2008; Mitchell et al. 2009). This indicates that the β-TrCP-mediated degradation of tetherin may not 
be solely responsible for the anti-tetherin activity of Vpu. However, there are discrepant data on the 
role of tetherin degradation in Vpu-mediated antagonism and it is still unclear whether this last step 
is essential for promoting virus release from infected cells. The role of tetherin degradation in 
tetherin antagonism by HIV-1 Vpu is re-evaluated in chapter 4 of this thesis.  
The ESCRT machinery is involved in the natural turnover of tetherin. ESCRT-0 component 
HRS binds to ubiquitinated cargo and induces its sorting for lysosomal degradation. It was reported 
that HRS was required for the downregulation and degradation of tetherin by Vpu and efficient 
particle release (Janvier et al. 2011). Moreover, ESCRT-I subunit UBAP1 was shown to be essential 
for tetherin degradation (Agromayor et al. 2012). UBAP1 knockdown resulted in the accumulation 
of ubiquitinated tetherin, which suggests that Vpu-mediated sorting of tetherin for degradation 
requires the ubiquitin-dependent multivesicular body pathway. However, UBAP1 depletion had no 
effect on virus release, further indicating that the trafficking of tetherin to endosomal compartments 
from which it cannot escape is required for virus release, but tetherin degradation may be 
dispensable.  
As mentioned earlier, Vpu proteins are also expressed by the SIVgsn/mon/mus/den lineage 
and SIVcpz and SIVgor. While SIVcpz and SIVgor Vpus have no anti-tetherin activity, the Vpu 
proteins from SIVgsn/mon/mus/den have activity against their host species tetherin (Sauter et al. 
2009). SIV cross-species transmission resulted in the emergence of HIV-1 groups M, N, O and P. 
While group M Vpu is an efficient tetherin antagonist, the Vpu proteins encoded by group N have 
moderate, if any activity, while group O and P encoded Vpus are completely inactive. In the case 
of group O, Vpu lacks the important transmembrane residues required for interaction with tetherin, 
which is essential for antagonism (Yang et al. 2011; Vigan & Neil 2011). However, its Nef protein 
has adapted to moderately counteract human tetherin (Kluge et al. 2014). While group N Vpus are 
still able to interact with tetherin, most of them lack the crucial phospho-serine and ExxxLV motifs 
79 
 
in the cytoplasmic tail, which also inhibits their anti-CD4 function (Sauter et al. 2012). One exception 
is a highly pathogenic variant of HIV-1 group N that was isolated from an individual returning to 
France from Togo. The Vpu from this isolate shows an intact phospho-serine and ExxxLV motif and 
is able to efficiently counteract tetherin. Only two isolates of group P have been identified to date. 
Vpu, Nef and Env proteins from these viruses do not counteract tetherin (Yang et al. 2011; Sauter 
et al. 2011).  
 
1.6.4.2 SIV Nef and HIV-1 Group O Nef 
Most SIVs do not encode a Vpu and instead use their Nef protein to counteract the tetherin of 
their host species (Jia et al. 2009; Sauter et al. 2009; Zhang et al. 2009). These include SIVmac 
(rhesus macaque), SIVagm (African green monkey), SIVsmm (sooty mangabey), and SIVrcm (red 
capped mangabey). To evade tetherin restriction, SIV Nef induces the enhanced internalization of 
tetherin from the cell surface, which is dependent on interaction with AP-2, but, of note, does not 
induce the degradation of tetherin (Zhang et al. 2011a). Depletion of AP-2 by RNAi or mutation of 
the AP-2 binding site in Nef abrogates its anti-tetherin function. Furthermore, myristoylation and 
membrane association of Nef is required for this function.  
SIV Nef counteracts tetherin in a species-specific manner and human tetherin is resistant to its 
antagonism. This maps to a five amino acid deletion in (G/DIWKK) in the cytoplasmic tail of human 
tetherin. Insertion of these residues into human tetherin renders it sensitive to SIV Nef antagonism 
(Zhang et al. 2009). It was suggested that Nef-like activity may have exerted strong selective 
pressure on tetherin, which resulted in the loss of this motif on human tetherin (Lim et al. 2010). 
SIVcpz and SIVgor encode a Vpu protein, but they do not possess anti-tetherin activity. Instead 
they use their Nef protein for antagonism (Yang et al. 2010; Sauter & Kirchhoff 2011). This may be 
explained by the fact that SIVcpz is the product of cross-species transmission and recombination 
events that involves precursors of the SIVgsn/mus/mon/den lineage and SIVrcm (Bailes et al. 
2003). The 5’ portion of the SIVcpz genome, including vpu, originates from an SIV infecting guenons 
and the 3’ portion, including nef, from an SIV most similar to SIVrcm, which lacks vpu (Sharp & 
Hahn 2011a). As two different tetherin antagonists were present in SIVcpz, this function may have 
been lost in Vpu, but preserved in Nef (Sauter et al. 2010).  
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There are several examples that provide evidence that tetherin exerts high selective pressure 
on SIV replication in vivo. When a chimpanzee experimentally infected with HIV-1 developed 
disease, it was found that the Vpu-deficient virus re-acquired anti-tetherin function in Nef (Götz et 
al. 2012). In a separate study, attenuated Nef-deficient SIVmac was shown to regain pathogenesis 
by adapting its Env protein to counteract rhesus tetherin (Serra-Moreno et al. 2011).  
Similarly to SIVcpz and SIVgor, HIV-1 group O encodes a Vpu that does not exhibit anti-tetherin 
function. Recently, it was shown that the Nef protein of HIV-1 group O has some capacity to 
counteract human tetherin (Kluge et al. 2014). Due to the five amino acid deletion in human tetherin, 
group O Nef seems to have adapted to target adjacent residues and was suggested to prevent the 
transport of long tetherin to the cell surface instead of enhancing endocytosis.  
 
1.6.4.3 Retroviral Envelope Proteins 
While HIV-1 Vpu readapted to compensate for the lack of Nef activity against human tetherin, 
HIV-2, which does not encode a Vpu, uses its Env to remove tetherin from its site of action (Sharp 
& Hahn 2011a). Interaction between Env and tetherin is essential for the downregulation of tetherin 
and this is determined by the Env ectodomain (Le Tortorec & Neil 2009). Differences in these 
regions account for the lack of anti-tetherin activity of HIV-1 ROD14, compared to HIV-2 ROD10 or 
HIV-2 ST (Jia et al. 2009; Le Tortorec & Neil 2009; Hauser et al. 2010; Exline et al. 2015). In the 
case of tetherin, an alanine face in the coiled-coil ectodomain was found to confer sensitivity to HIV-
2 Env (Exline et al. 2015). In addition, proteolytic processing of the Env gp140 precursor to gp105 
and gp41 is essential for tetherin counteractivity, as well as AP-2 binding via a GYxxΦ motif in the 
cytoplasmic tail that is common to all HIV and SIV Envs (Abada et al. 2005; Noble et al. 2006; Le 
Tortorec & Neil 2009). There is no evidence of Env-induced tetherin degradation, but tetherin is 
sequestered away from the PM and accumulates in TGN-associated compartments. HIV-2 Env is 
a less efficient tetherin antagonist than HIV-1 Vpu or SIV Nef, but shows a broader species-
specificity (Hauser et al. 2010). As Env is a major determinant of viral infectivity, it is possible that 
adaption of Env to tetherin antagonism may come with a fitness cost (Evans et al. 2010).  
Several other lentiviral envelopes have been described to have anti-tetherin activity. There is 
the Env from tantalus monkey SIV (SIVtan) that is able to counteract several primate tetherins. 
Again, the AP-2 binding site as well as interaction with tetherin via its ectodomain are required for 
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its function (Gupta et al. 2009). However, as the infectious molecular clone of SIVtan has been 
passaged in human T cells it is unclear what role SIVtan Env or Nef may play in infection of the 
natural host. A further example of a primate lentivirus using Env to counteract tetherin is a Nef-
deleted SIVmac that reverted back to its pathogenicity in infected Rhesus macaques (Serra-Moreno 
et al. 2011). Interestingly, in this virus amino acid changes in the cytoplasmic tail of gp41 confer 
tetherin-counteractivity. Antagonism is also determined by species-specific differences in the 
cytoplasmic tail of tetherin surrounding the dual-tyrosine motif (PILYDY(R/C)KM versus 
STSYDYCRV in Rhesus macaque and human tetherin, respectively). Another virus that uses Env 
to counteract tetherin is FIV against feline tetherin (Dietrich, McMonagle, et al. 2011; Celestino et 
al. 2012; Morrison et al. 2014). Interestingly, it does not induce downmodulation of tetherin from the 
cell surface, yet is required for optimal release. Furthermore, FIV Env only rescues the release of 
FIV, but not other viral particles (Morrison et al. 2014). Therefore, FIV Env seems to employ a so 
far unknown mechanism of tetherin antagonism.  
The human endogenous retrovirus K (HERV-K) has recently been described to possess anti-
tetherin activity, mediated by its envelope protein (Lemaître et al. 2014). Two out of six HERV-K 
Envs tested exhibited tetherin counteractivity, but due to the extremely polymorphic nature of these 
elements in humans, variability in antagonistic activity is likely. HERV-K Env does not induce the 
removal of tetherin from the cell surface or its degradation and the mechanism of counteraction is 
so far unknown.  
 
1.6.4.4 Herpesviruses 
Kaposi’s sarcoma-associated herpesvirus (KSHV; also human herpesvirus 8, HHV8) encodes 
two MARCH E3 ubiquitin ligases, K3 and K5 (Boname & Lehner 2011). Both contain two 
transmembrane domains that are linked by a short extra-cellular loop, a C-terminal cytoplasmic tail 
that contains residues required for subcellular trafficking and endosomal targeting, and an N-
terminal cytoplasmic tail that contains the RING-CH domain that is crucial for the protein’s function. 
K5 induces the ubiquitination and endosomal degradation of a range of cellular membrane proteins 
such as MHC-I, NK-receptor ligands, adhesion molecules and cytokine receptors. Tetherin was 
identified as a target of K5 in a mass-spectrometry-based proteomic screen and it was shown that 
K5 was required to enhance KSHV, but also Vpu-deficient HIV-1 release from tetherin expressing 
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cells (Bartee et al. 2006; Mansouri et al. 2009; Pardieu et al. 2010). The assembly process of 
herpesviruses differs from HIV in that there are several envelopment phases that eventually lead 
to the release of virions through the secretory pathway. It is still unclear at which step tetherin 
inhibits K5-deficient KSHV release (Pardieu et al. 2010). 
The substrate specificity of K3 and K5 is determined by their transmembrane domains, but no 
direct interaction with target molecules has so far been demonstrated (Ishido et al. 2000). Rhesus 
and murine tetherin are insensitive to K5. Human tetherin that contains macaque-specific mutations 
in the transmembrane domain that render it insensitive to HIV-1 Vpu is still downregulated. This 
implies different determinants of species-specificity for both antagonists (Pardieu et al. 2010). K5 
induces the ubiquitination of its target molecules on membrane-proximal lysine residues, which in 
the case of tetherin is lysine 18, whereas lysine 21 seems to be dispensable (Mansouri et al. 2009; 
Pardieu et al. 2010). This is followed by ESCRT-dependent lysosomal degradation. K5 was 
suggested to mediate tetherin degradation similarly to MHC-I degradation. This involves 
ubiquitination during transport to the PM, which then induces enhanced uptake and endosomal 
targeting. The addition of ubiquitin is mediated by E2-ligases of the UbcH5 family and Ubc13 then 
promotes poly-Ub chain formation (Duncan et al. 2006). For K5 activity it was suggested that K63 
ubiquitin linkages, but also branched poly-Ub chains with K11 linkages are important (Boname et 
al. 2010).  
K3 or K5 homologues can be found in other mammalian ɣ2-herpesviruses and MARCH-ligases 
are also encoded by mammalian poxviruses. Although, whether they have anti-tetherin function is 
unclear (Lehner et al. 2005). The cellular K5 homologue MARCH-VIII is able to promote tetherin 
degradation and it is possible that this may regulate cellular tetherin expression in an ESCRT-
dependent manner (Bartee et al. 2006).  
Other herpesviruses that were reported to be restricted by tetherin are herpes simplex virus 1 
and 2 (HSV-1, HSV-2) (Zenner et al. 2013; Blondeau et al. 2013; Liu et al. 2014). While HSV-1 
glycoprotein M (gM) has been demonstrated to have moderate anti-tetherin activity, HSV-1 gB or 
gD do not. gM induces tetherin accumulation in TGN46-positive compartments, but tetherin 
degradation seems to be independent of gM (Blondeau et al. 2013). Another group identified the 
virion host shut-off (Vhs) protein, an endoribonuclease, as a tetherin antagonist and suggested it 
reduces mRNA levels of a range of transcripts, including that of tetherin (Zenner et al. 2013). For 
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HSV-2 it was suggested that gB, gD, gH and gL exhibited anti-tetherin activity and they were able 
to downregulate tetherin to a certain extent (Liu et al. 2014).  
One interesting example is the β-herpesvirus human cytomegalovirus (HCMV). Not only does 
it seem to be resistant to tetherin restriction in infected cells, but tetherin was reported to enhance 
entry of HCMV into cells expressing high levels of tetherin (Viswanathan et al. 2011). As tetherin is 
incorporated into released HCMV it was proposed that tetherin facilitates the interaction with other 
tetherin molecules in the target cell membrane.  
 
1.6.4.5 Ebolavirus GP 
Filoviruses, such as Eboalvirus (EBOV) and Marburg virus (MARV) are sensitive to tetherin 
restriction and the glycoproteins (GPs) encoded by both viruses have been implicated in tetherin 
antagonism (Kaletsky et al. 2009; Lopez et al. 2010; Kühl et al. 2011). Another report however, 
suggests that infectious EBOV replication is not negatively affected by tetherin and it was suggested 
that the role of GP may be cell-type specific (Radoshitzky et al. 2010; Kühl et al. 2011). Despite this 
discrepancy, GP is able to enhance the release of Vpu-defective HIV-1 from tetherin expressing 
cells. In addition to human tetherin, it also antagonises primate and murine tetherins. However, it is 
still unclear how, or even if GP mediates the exclusion of tetherin from assembling virions. It does 
not appear to induce the downmodulation of tetherin from the cell surface or its association with 
lipid rafts (Lopez et al. 2012). Sequences in the membrane spanning domain (msd) of GP as well 
as its glycan cap and mucin domain have been shown to be crucial for anti-tetherin function (Vande 
Burgt et al. 2015).  
 
1.6.4.6 Other Viral Tetherin Antagonists 
Tetherin restricts a broad range of viruses due to its ability to target the lipid membrane. Some 
viruses may be sensitive to tetherin restriction, but do not encode a countermeasure. This may not 
be required if tetherin is not expressed in the tissue that is infected or if the virus is capable of 
interfering with the host immune response and interferon-induced gene expression. Depending on 
the mode of assembly, some viruses may also be intrinsically insensitive. In addition to the viruses 
and viral antagonists described above, tetherin restriction has also been investigated in the context 
of other viruses.  
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Influenza A virus (FLUAV) is released from the plasma membrane of infected cells. However, 
the role of tetherin restriction is a matter of debate. Whilst earlier studies suggest FLUAV is only 
modestly restricted by tetherin, the release of FLUAV VLPs produced by expressing virion 
components in trans is markedly inhibited (Watanabe et al. 2011; Bruce et al. 2012; Winkler et al. 
2012). Additionally, no effect of tetherin on viral replication was found in FLUAV infected mice 
(Londrigan et al.). In contrast, other studies demonstrated that FLUAV release is inhibited by 
tetherin (Mangeat et al. 2012; Leyva-Grado et al. 2014; Dittmann et al. 2015). The viral 
neuraminidase (NA) has been implicated in tetherin antagonism and a recent study suggests that 
tetherin sensitivity depends on the FLUAV strain used and that both NA and hemagglutinin (HA) 
are required for tetherin antagonism (Yondola et al. 2011; Gnirß et al. 2015).  
Hepatitis B virus (HBV) is a member of the Hepadnaviridae family of enveloped DNA viruses. 
Tetherin seems to only have a minimal effect on HBV release, although it was suggested that this 
is cell type dependent (Miyakawa et al. 2015; Lv et al. 2015). The HBV surface protein (HBs) was 
implicated in tetherin antagonism. It can interact with tetherin via its fourth transmembrane domain 
and is supposed to inhibit tetherin dimerization, which is essential for its restrictive activity.  
 Alphaviruses are small enveloped RNA viruses that bud from the plasma membrane and 
include Chikungunya virus (CHIKV) and Semliki Forest virus (SFV). Both are restricted by tetherin 
and CHIKV was reported to counteract this restriction via its nsP1 protein that induces the 
downregulation of tetherin from the cell surface (Jones et al. 2013; Mahauad-Fernandez et al. 2014; 
Ooi et al. 2015). Interestingly, SFV seems to be restricted by long tetherin only, but not by short 
tetherin (Ooi et al. 2015).  
Tetherin can also restrict coronaviruses, including the severe acute respiratory coronavirus 
(SARS-CoV), that does not bud from the plasma membrane, but in the ER-Golgi apparatus 
intermediate compartment and reaches the cell surface in vesicles (Wang et al. 2014; Taylor et al. 
2015). A novel mechanism of tetherin counteraction was suggested to be employed by SARS-CoV. 
Its ORF7a was proposed to interfere with tetherin glycosylation to overcome restriction (Taylor et 




1.6.5 Tetherin in the Context of Primate Lentiviral Evolution  
As described above, tetherin counteraction by primate lentiviruses is not mediated by the same 
protein for each virus (Sauter et al. 2009). Whilst encoding both Vpu and Nef, SIVcpz Nef has anti-
tetherin activity, but Vpu has not. Evolutionary analyses suggested that SIVcpz is the result from 
cross-species transmission and recombination events (Figure 1.19 B). The 5’ region of its genome 
including the vpu gene originates from the SIVgsn/mus/mon lineage. The 3’ region including the 
nef gene from SIVrcm (Bailes et al. 2003). Both Vpu and Nef were functional against the original 
host and related monkey tetherins. In SIVcpz, only the Nef gene adapted to counteract tetherin, 
while both Vpu and Nef are able to downregulate CD4 (Sauter et al. 2009).  
Upon cross-species transmission to humans Nef was unable to antagonise human tetherin, 
due to a five amino acid deletion in the cytoplasmic tail of human tetherin (Figure 1.19 A). This 
deletion occurred before the separation of Neanderthal, Denisovian and homo sapiens, 
approximately 1 Mya (Sauter et al. 2011). However, in the case of pandemic HIV-1 group M, Vpu 
readapted to efficiently counteract human tetherin. The other three independent cross-species 
transmissions to humans resulting in HIV-1 groups N, O and P did not lead to successful readaption 
of this function in Vpu. Group N Vpus have moderate anti-tetherin activity, but group O and P lack 
it completely (Sauter et al. 2009). Instead, group O adapted its Nef protein to counteract tetherin by 
targeting residues in the cytoplasmic tail adjacent to the deletion (Kluge et al. 2014).  
The species-specificity of tetherin counteraction maps to residues in the TM domain of the 
protein. One amino acid change is sufficient to render it resistant to HIV-1 Vpu (Gupta et al. 2009). 
It can counteract human and also great ape tetherins including chimpanzee and gorilla proteins, 
but is inefficient against the monkey variant (Jia et al. 2009; Sauter et al. 2009). Switching the 
African green monkey or rhesus macaque tetherin TM with that of the human protein, however, 
restores counteractivity by HIV-1 Vpu (McNatt et al. 2009).  
HIV-2 does not encode a Vpu protein due to its origin from the SIVsmm lineage that also does 
not encode it. Whilst SIVsmm has a Nef that counteracts its host species tetherin, again, this protein 
was inefficient against human tetherin due to the five amino acid deletion (Figure 1.19). Therefore, 







Figure 1.19 Co-evolution of tetherin and its primate lentiviral antagonists. (A) Amino acid alignment of 
the cytoplasmic tail of primate tetherins. Identical amino acids between all four sequences are indicated by an 
asterisk. The dual-tyrosine motif important for endocytosis and signaling is marked green. The five amino acid 
stretch that was deleted in human tetherin and is supposed to be targetted by SIV Nef is marked in blue. (B) 
SIVcpz acquired vpu and nef from two different monkey SIV lineages, SIVgsn/mus/mon and SIVrcm, 
respectively, and SIVcpz Nef adapted to counteract chimpanzee tetherin SIVgor and SIVsmm also use Nef to 
counteract tetherin. Upon cross-species SIV Nefs were unable to antagonise human tetherin, because of the 





There is evidence that tetherin exerts strong selective pressure on viruses and that changes in 
the protein sequence have driven the evolution of Nef, Env and Vpu to adapt to counteraction. 
Being able to switch between these accessory proteins to fulfil this function may have been a key 
to cross-species transmission to humans (Sharp & Hahn 2011b). Further examples indicating the 
selective pressure of tetherin in vivo come from a Nef-deleted SIVmac that regained pathogenicity 
and was show to have readapted to tetherin antagonism using its Env protein (Serra-Moreno et al. 
2011). Furthermore, Nef reacquired anti-tetherin function in HIV-1 passaged in a chimpanzee (Götz 
et al. 2012). Also, a highly pathogenic HIV-1 group N virus was isolated that harboured a Vpu 
protein with enhanced anti-tetherin activity (Sauter et al. 2012).  
While efficient tetherin antagonism is clearly not the only determinant of enhanced 
pathogenicity and viral spread, it can be speculated that this function contributes to it. Importantly, 
the pandemic HIV-1 group M encodes the most efficient antagonists for human tetherin, while other 
HIV-1 groups N, O and P, and HIV-2 remain largely geographically restricted.  
 
1.6.6 Tetherin and Cell-to-Cell Transmission 
Replication of HIV-1 is more rapid when infected cells are co-cultured with target cells as 
compared to when infection occurs through cell-free virus and it has been suggested that cell-to-
cell transmission may be the major route of HIV-1 dissemination in vivo (Sattentau 2008). Cell-to-
cell transfer of virus occurs through a polarized physical interaction between a donor and a target 
cell that is known as the virological synapse (VS). This cell contact does not only promote HIV-1, 
but also human T-lymphotropic virus type 1 (HTLV-1) transmission, the latter spreading almost 
exclusively via this mode (Igakura et al. 2003; Jolly et al. 2004). The VS is formed by viral envelope 
and receptor interactions and is stabilized by cytoskeletal rearrangements and adhesion molecules. 
Before the discovery of tetherin as the cellular target of Vpu, it was clear that Vpu-deficient HIV-1 
was able to replicate efficiently in T cells without being released into the supernatant from the 
infected cell (Strebel et al. 1989; Terwilliger et al. 1989; Klimkait et al. 1990; Yao et al. 1992; 
Schubert et al. 1995). In fact, HIV-1 was shown to lose its functional Vpu when selected for variants 
that exhibit enhanced cell-to-cell transmission efficiency (Gummuluru et al. 2000). Furthermore, 
more synaptic contacts can be observed in T cells infected with a Vpu-deficient HIV-1. However, 
the role of tetherin in cell-to-cell transmission remains unclear. Correlating with the earlier data, 
88 
 
Vpu-deficient virus spreads more efficiently via the VS between Jurkat cells and primary CD4+ T 
cells and siRNA knockdown of tetherin reduces this spread (Jolly et al. 2010). In contrast, other 
studies using co-culture assays and various cell types found that tetherin inhibits the efficient spread 
via the VS (Casartelli et al. 2010; Kuhl et al. 2010; Giese & Marsh 2014). Interestingly, HTLV-1 cell-
to-cell transmission is not sensitive to tetherin (Ilinskaya et al. 2013). Discrepant results on the role 
of tetherin in cell-to-cell transfer of HIV-1 may be explained by cell type-specific differences in 
tetherin expression levels, but also by differences in the speed of tethered virion endocytosis, which 
removes viruses from the site of transfer (Zhong et al. 2013). Altogether, where an effect of tetherin 
expression on cell-to-cell transmission was observed, it was weak and the role of tetherin in this 
process remains elusive.  
  
1.6.7 Tetherin and Viral Pathogenesis  
Various examples indicate that tetherin is a potent anti-viral factor in vivo. Homozygous tetherin 
knockout mice show no developmental defects or abnormalities in the lymphoid and myeloid cell 
population. However, when fibroblasts from these mice were infected with Moloney MLV (Mo-MLV) 
the virus was less sensitive to inhibition by type-I IFN. When the tetherin knockout mice were 
infected with the IFN inducing MLV variant LP-BM5 viral loads were increased and pathogenesis 
was more severe, pointing to an important anti-viral role of tetherin in vivo (Liberatore & Bieniasz 
2011). Another example comes from NZW mice that only harbour a truncated version of tetherin, 
similar to short human tetherin. Lymphoid and myeloid cells from these mice show increased 
tetherin surface levels and Friend MLV infection was characterized by reduced viral loads and 
pathogenesis (Barrett et al. 2012). Accordingly, in vivo RNAi knockdown of tetherin in mice infected 
with mouse mammary tumor virus (MMTV) resulted in increased viral loads (Jones et al. 2012). In 
contrast, when tetherin knockout mice were infected with influenza virus, viral titers were reduced 
and CD8+ T cell response increased (Swiecki et al. 2013). The role of tetherin in influenza infection 
is still unclear and these results may indicate that the role of tetherin in vivo is more complex.  
The adaptation of HIV-1 group M Vpu to efficiently counteract tetherin is an indicator that 
tetherin plays an essential anti-viral role in vivo, considering that HIV-1 group M is primarily 
responsible for the HIV pandemic (Sauter et al. 2009). Furthermore, there is evidence that anti-
tetherin function is selected for in HIV-1 infected individuals even many years after initial infection 
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(Pickering et al. 2014). Pegylated-IFNɑ treatment of HIV-1/HCV co-infected individuals leads to an 
increase in tetherin and APOBEC3G, correlating with reduction of HIV-1 viral loads, and emergence 
of Vpu sequence changes that confer enhanced tetherin antagonism (Pillai et al. 2012). Moreover, 
polymorphisms in the promoter region of tetherin have been correlated with disease progression 
(Laplana et al. 2013). 
 
1.6.8 Tetherin and Anti-Viral Innate Immunity 
The restriction of cell-free virus release by tetherin is not the only anti-viral function of tetherin. 
It has been suggested that it plays a broader role in the antiviral immune response in vivo. Tetherin-
mediated virion retention may have several consequences that are summarized in Figure 1.20. 
Restricted virions accumulate on the cell surface and may trigger an antiviral immune response due 
to antibody opsonisation and complement- or phagocyte-mediated destruction through Fc-receptor 
recognition. Antibody-dependent cell-mediated cytotoxicity (ADCC) has been shown to be 
enhanced by tetherin-restricted virions. Binding of gp120 to CD4 exposes epitopes in gp120 that 
are targeted by ADCC. Increased abundance of HIV-1 Env at the surface through tetherin restriction 
may therefore enhance the exposure of these epitopes upon CD4 binding. Importantly, HIV-1 Vpu 
and Nef antagonism of tetherin inhibit the ADCC response (Veillette et al. 2014; Arias et al. 2014; 
Alvarez et al. 2014a; Pham et al. 2014). Tetherin also mediates the endocytosis of restricted virions 
that accumulate in endosomes. These may then be subject to endosomal processing and 
generation of viral PAMPs that can be recognised by endosomal PRRs such as TLRs. Furthermore, 
in antigen-presenting cells virion degradation may lead to the liberation of antigens that can be 
presented via MHC-II to further stimulate an antiviral T cell response.   
Tetherin can also directly induce NF-κB activation (Matsuda et al. 2003; Galão et al. 2012; 
Cocka & Bates 2012; Tokarev et al. 2013). This can be achieved by overexpression of tetherin, 
antibody crosslinking of surface tetherin and, importantly, via the retention of tetherin-sensitive 
retroviral and filoviral particles on tetherin-expressing cells, which also induces cross-linking. 
Therefore, tetherin can be seen as an innate sensor of budding virions. NF-κB activation results in 
increased proinflammatory gene expression and promotes an antiviral state. Primary human CD4+ 
T cells infected with tetherin-sensitive HIV-1 produce higher levels of the chemokines/cytokines 
CXCL10, IL-6 and also type-I IFN in a tetherin-dependent manner (Galão et al. 2012). This function 
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requires the structural determinants in tetherin that are also essential for virion restriction, but 
additionally the tyrosine-based motif in the cytoplasmic tail of long tetherin has been found to be 
crucial. While this motif is also responsible for endocytosis, virion internalization is not required for 
tetherin to induce NF-κB signalling. The YDYCRV motifs of a long tetherin homodimer have been 
described to act as a hemITAM that can be found in C-type lectins (Galão et al. 2014). 
Phosphorylation of the tyrosines by Src family kinases allows the recruitment of Syk, which then 
promotes NF-κB activation dependent on TRAF2 and 6 and TAK1. Interaction with RICH2 and 
indirect connection of tetherin to the cortical actin cytoskeleton is also essential for induction of 
signalling, even though it is not required for inhibition of virus release. Whether RICH2 is required 
for the internalization of restricted virions for endosomal degradation is so far unclear.  
 
Figure 1.20 Potential tetherin-mediated immunological consequences of virion retention. Tetherin 
physically blocks cell-free virion release. Accumulations of virus may promote opsonisation by specific antiviral 
antibodies and results in clearance of the virus infected cell by complement deposition and/or killing by 
phagocytes expressing Fc receptors. In addition, tetherin induces NF-κB activation upon aggregation and 
synthesis of proinflammatory cytokines. Internalization of tetherin-retained virions into late endosomes may 
further lead to degradation of the particle, potentially releasing PAMPs for recognition by other endosomal 
PRRs, promoting type 1 IFN expression. Endosomal processing of viral proteins in myeloid cells may also lead 
to enhanced presentation of viral antigens on class II MHC molecules to CD4+ T cells. Moreover, increased 





While chimpanzee tetherin is able to induce NF-κB moderately, tetherin proteins from rhesus 
macaques, African green monkeys or gorillas are not able to induce signalling at all. These 
differences are determined by amino acid residues in the cytoplasmic tail, specifically the RV in the 
YDYCRV motif and also the five amino acid deletion (G/DIWKK) in human tetherin (Galão et al. 
2012). While the tyrosines are conserved across species, monkey tetherins are not phosphorylated 
at these positions and fail to recruit Syk. This may be due to structural differences and lack of 
accessibility to Src family kinases (Galão et al. 2014). Importantly, human tetherin seems to have 
evolved this function specifically. Due to the lack of required residues in the cytoplasmic tail of short 
human tetherin, this isoform does not induce NF-κB signalling, but rather dominantly interferes with 
it (Cocka & Bates 2012; Galão et al. 2012). As HIV-1 group M efficiently antagonises and degrades 
the human long, but not short, isoform, it was speculated that tetherin signalling affected the 
adaptation of Vpu during zoonotic transmission of this group, perhaps influencing the ability of HIV 
to become pandemic (Weinelt & Neil 2014). Whether tetherin signalling is regulated at the level of 
differential isoform expression remains to be determined. 
Tetherin also induces type-I IFN production in primary CD4+ T cells. However, this process 
may be indirect. It involves IRF3 activation and can be blocked by inhibition of the TLR3 adaptor 
TRIF (Galão et al. 2012). These findings suggest that restricted and endocytosed virions may 
become available to PRR sensing.  
Additionally, tetherin has been shown to interact with the immunoglobulin-like transcript 7 (ILT-
7) (Cao et al. 2009). ILT-7 is a leukocyte inhibitory receptor that is expressed on pDCs and 
suppresses TLR7- and TLR9-induced type-I IFN production upon cross-linking. pDCs sense HIV 
infected cells mainly through TLR7 and this involves Env-dependent transfer of virus across cells 
(Lepelley et al. 2011; Beignon et al. 2005). It was suggested that binding of tetherin to ILT-7 would 
induce this inhibitory effect on TLR signalling (Cao et al. 2009). However, another study 
contradicted these findings (Tavano et al. 2013). A recently published report may have elucidated 
this discrepancy (Bego et al. 2015). It confirms that the tetherin and ILT-7 interaction induces an 
inhibitory effect on type-I IFN production in pDCs. Tetherin-restricted virions are efficiently sensed 
by pDCs and it was suggested that this was due to inefficient interaction between tetherin and ILT-
7 in this scenario. Vpu reduces tetherin surface expression. However, it was shown that some pools 
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of tetherin remain on the surface and are sequestered away from the site of viral budding. Thereby, 
Vpu promotes virus release from infected cells and enables the remaining surface tetherin to 
interact with ILT-7, which then results in reduced levels of type-I IFN (Bego et al. 2015). Whether 
the remaining tetherin on the surface is comprised of the short isoform that cannot be 
downregulated by Vpu remains to be confirmed. However, it may explain the benefit of preferentially 
targeting the long, signalling isoform and leaving the short one on the surface.   
 
1.7 The Clathrin Machinery and Vesicle Trafficking  
Vesicular transport in the cell mediates the trafficking of cargo between different subcellular 
compartments. Vesicles bud from specialized coated regions. This coat is required for directing 
specific membrane proteins to the membrane patch from which the vesicle will bud, but is also 
required to form the curved basket-like lattice that shapes the vesicle. There are clathrin-, COPI- 
and COPII-coated vesicles. While COPI/COPII coated vesicles mediate the transport from the ER 
and the Golgi cisternae, clathrin mediates the transport between the Golgi apparatus, the plasma 
membrane and endosomes. Viruses have been shown to hijack clathrin-mediated trafficking to 
induce the mis-localization and sometimes degradation of cellular proteins. Clathrin forms 
triskelions that contain three heavy chains that assemble at their C-termini and each bind a clathrin 
light chain. The triskelions then form the basket-like structure made up of pentagonal and hexagonal 
faces. Spherical clathrin-coated vesicles then bud from membranes and the GTPase dynamin 2 
pinches the vesicle off by forming a spiral around the neck of the vesicle and restraining it through 
GTP hydrolysis (Bonifacino & Traub 2003).  
Membrane sites where clathrin assembles are characterized by phosphoinositides and Arf 
GTPases. These recruit clathrin adaptor proteins, which are responsible for cargo protein binding, 
to the site of vesicle formation. Several clathrin binding proteins have been described, including 
clathrin adaptor proteins (APs), HRS, AP180 and gamma adaptin ear-containing ARF-binding 
(GGA) proteins. All contain a long unstructured region that is able to interact with the β-propeller 
head of clathrin located at the N-terminus of the heavy chain. This unstructured region contains a 
peptide called clathrin box with a consensus sequence of ρLφρφρ (ρ=polar residue, φ=aliphatic 
hydrophobic residue) (Lafer 2002).  
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APs are a family of heterotetrameric proteins that comprises AP-1, AP-2, AP-3, AP-4 and AP-
5 and are components of clathrin coats. They consist of a globular core formed by two large subunits 
(ɑ and β2 in AP-2, ɣ and β1 in AP-1), a medium-sized subunit (µ2 in AP-2, µ1 in AP-1) and one 
small subunit (σ2 in AP-2, σ1 in AP-1). The C-terminal region of the large subunits projects from 
the core and contains a disordered “hinge” and a globular “ear” or “appendage” domain. While the 
core is responsible for the recognition of sorting signals in cargo proteins and recruitment to 
membranes, the hinge/appendage region interacts with clathrin or other adaptor proteins. Each 
adaptor protein mediates the transport between different cellular compartments. AP-1 mainly 
mediates the bi-directional transport between the TGN and endosomes and AP-2 induces the 
endocytosis of transmembrane proteins from the plasma membrane for sorting into endosomes 
(Figure 1.21). The roles of AP-3, AP-4 and AP-5 are less clear. AP-4 and AP-5 have been proposed 
to be components of non-clathrin coats mediating TGN/endosomal and endosomal sorting, 
respectively. The function of AP-3 and whether it is clathrin-dependent is unclear, but it has been 
suggested to play a role in sorting between endosomes and lysosomes (Lafer 2002; Hirst et al. 
2011; Canagarajah et al. 2013). 
 
 
Figure 1.21 Clathrin adaptor proteins and membrane trafficking. Schematic representation of sorting 
pathways between TGN, plasma membrane and endosomal compartments. AP-1 mainly mediates sorting 
between the TGN and endosomes, while AP-2 exclusively induces the endocytosis of membrane proteins from 
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the plasma membrane. AP-3 is thought to be involved in sorting between endosomes and lysosomes. AP-4 
and AP-5 are not associated with clathrin coats, but have been implicated in TGN to endosome and late 
endosomal sorting, respectively.  
 
Clathrin adapter proteins AP-1 and AP-2 are able to recognize their cargo proteins through 
specific linear sequences that are present in cytoplasmic regions. These are either tyrosine-based 
motifs Yxxφ or dileucine-based motifs (D/E)xxxL(L/I) (Bonifacino & Traub 2003). In the case of 
tyrosine-based motifs, the Y is indispensable and the φ represents a bulky hydrophobic residue. 
Residues 2 and 3 are variable, but tend to be hydrophilic. Flanking residues can also influence the 
strength and specificity of binding. These motifs bind to the core µ subunit of adaptor proteins and 
induce rapid endocytosis from the PM as well as targeting to lysosomes and sorting between TGN 
and endosomes. Tetherin comprises a variant of this motif with its sequence YxYxxφ that interacts 
with the AP-2 ɑ subunit and can also bind the µ subunits of AP-1 and AP-2 (Masuyama et al. 2009; 
Rollason et al. 2007). For the dileucine motif (D/E)xxxL(L/I), the first leucine is essential, while the 
second leucine can also be replaced by an isoleucine. An acidic residue is placed at position one 
and is required for targeting the cargo to late endosomes and lysosomes. Dileucine motifs can be 
recognized by core small σ and the large γ subunit interface of AP-1 or the large ɑ subunit of AP-
2, but also by µ subunits of AP-1 and AP-2 at different sites than tyrosine-based signals. These 
motifs mediate rapid endocytosis and transport to endosomal and lysosomal compartments. HIV-1 
Nef has been demonstrated to contain two dileucine motifs that interact with the µ subunit of AP-1 
and -2 and the σ- α hemi-complex of AP-2. Interaction of Nef with AP-1 and -2 is required for the 
downregulation of cellular proteins CD4 and MHC-I (Janvier et al. 2003; Chaudhuri et al. 2007; 
Lindwasser et al. 2008; Ren et al. 2014). HIV-1 Vpu also contains a variant of a dileucine motif in 
its cytoplasmic tail, ExxxLV, that has been demonstrated to be essential for the correct localisation 
and anti-tetherin function of Vpu, and for interaction with the σ-subunit of AP-1 (Kueck & Neil 2012; 
Jia et al. 2014).  
 
1.8 The ESCRT Pathway  
The endosomal sorting complex required for transport (ESCRT) system is involved in 
remodelling and scission of membranes. The initial function was described to be the sorting of 
membrane proteins from endosomes to lysosomes via the formation of multivesicular bodies 
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(MVBs) (Katzmann et al. 2001). Biogenesis of MVBs are formed from endosomes when the 
membrane buds into the lumen. Ubiquitinated membrane proteins can be sorted into these budding 
vesicles by ESCRT proteins. In addition to this role, two more functions of ESCRT have been 
investigated extensively. These are the budding off of HIV-1 and other enveloped viruses from the 
infected cell and membrane abscission during cytokinesis (Figure 1.22). All these functions involve 
invaginations that bud off, away from the cytoplasm (Henne et al. 2011). 
 
 
Figure 1.22 Roles of the ECSRT machinery. Main functions of ESCRT include 1. MVB biogenesis, 2. viral 
budding and 3. abscission.  
 
There are five ESCRT complexes that comprise different proteins that are recruited in a 
sequential manner. The ESCRT-0 complex contains the hepatocyte growth factor-regulated 
tyrosine kinase substrate (HRS) and the signal transducing adaptor molecule 1/2 (STAM1/2) and 
both interact via their coiled coil domains in a 1:1 ratio. HRS has a zinc finger domain, FYVE (Fab-
1, YGL023, VPS27 and EEA1), that binds to the endosomal lipid phosphatidylinositol 3-phosphate 
(PtdIn(3)P) and is important for specificity and membrane recruitment. Both HRS and STAM1/2 
contain several ubiquitin binding motifs. HRS, for example, is supposed to bind to mono- and lysine 
63-linked ubiquitinated proteins via its double-sided ubiquitin-interacting motif (DUIM) and the N-
terminal VHS domain (VPS27, HRS, STAM). Several ubiquitin binding domains have been 
suggested to allow the sequestration of multiple proteins simultaneously. Additionally, both HRS 
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and STAM1/2 have clathrin binding regions. HRS interacts with clathrin’s heavy chain at endosomal 
membranes and recruits cargo into flat clathrin lattice microdomains (Raiborg et al. 2006). It is 
unclear whether HRS and STAM1/2 are the only ESCRT-0 components and other proteins such as 
GGA proteins have been suggested due to similar domain organization.  
The ESCRT-I complex consists of TSG101, VPS28, VPS37 and either MVB12 or UBAP1 that 
assemble in a 1:1:1:1 ratio. This complex is recruited to endosomes by HRS, which is essential for 
the sorting of cargo proteins for lysosomal degradation as ESCRT-I cannot bind to membrane lipids 
directly. Specifically, the HRS PSAP motif binds to the ubiquitin E2 variant domain (UEV) of 
TSG101. The ESCRT-I proteins TSG101, MVB12 and UBAP1 are able to bind to ubiquitin through 
hydrophobic isoleucine 44. However, unlike ESCRT-0, they are not involved in capturing the 
ubiquitinated cargo.  
The ESCRT-II complex consists of EAP45, EAP30 and EAP20, that assemble in a 1:1:2 ratio. 
The recruitment of ESCRT-II depends on VPS28. The GRAM-like ubiquitin binding in EAP45 
(GLUE) domain in EAP45 is able to bind to ubiquitin and also PtdIn(3)P, which mediates localization 
to cellular membranes.  
The ESCRT-III complex consist of four major subunits termed charged multivesicular body 
proteins, CHMP2, 3, 4 and 6 and their isoforms and also ALIX (apoptosis-linked gene-2 interacting 
protein X), CHMP1, and IST1 (increased salt tolerance-1). When membranes sculpt for budding, 
the components of this complex recruit each other to endosomes transiently and the physical 
contact between the components induces conformational changes that activate the subunits that 
are usually auto-inhibited. Apart from ALIX, none of the ESCRT-III components has been shown to 
interact with ubiquitin. ALIX and CHMP1 are also required for MVB sorting and cytokinesis, whereas 
IST1 is only implicated in cytokinesis. When the ESCRT-III complex assembles at the endosomal 
membrane, the energy to separate the membranes is delivered by the AAA ATPase VPS4 that 
binds to ESCRT-III via its microtubule-interacting and trafficking (MIT) domain. VPS4 was also 
proposed to be involved in the recycling of ESCRT-III subunits after completion of abscission or 
possibly the removal of ESCRT-III to generate constrictive forces that may be required for 
abscission. During the final steps of abscission the centrosomal protein 55 (CEP55) is recruited to 
the midbody, which then leads to the recruitment of ESCRT-I and ALIX and subsequently ESCRT-
II for abscission.  
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HIV-1 has hijacked the cellular ESCRT pathways to mediate budding from the plasma 
membrane. As mentioned earlier, Gag recruits ESCRT-I and –III complexes via its P(S/T)AP motif 
in the p6 domain that specifically interacts with TSG101 and recruits further ESCRT-III components. 
Additionally, the (L)YPXnL motif in p6 is able to bind ALIX and recruit ESCRT components.     
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1.9 Aim of Thesis 
HIV-1 interferes with host cellular processes to promote an optimal environment for virus 
replication. Virally encoded proteins have a broad range of functions to overcome restrictions 
imposed by the host. The counteraction of so-called cellular restriction factors by HIV-1 accessory 
proteins plays a crucial role in the fitness of a virus and is a major field of scientific investigation. 
Understanding these host-virus interactions may provide us with new strategies in antiviral therapy 
in the future.  
The data presented in this thesis aims to clarify aspects of restriction factor antagonism by HIV-
1 and other primate lentiviruses. In particular, this work focuses on the antiviral function of two 
cellular transmembrane proteins, tetherin and SERINC3/5. The results section of this thesis is 
divided into three chapters:   
1. The cellular restriction factor tetherin is expressed as two isoforms in humans, which 
exhibit differential sensitivity to HIV-1 group M Vpu proteins, but not other tetherin 
antagonists.  
2. Mis-trafficking of tetherin is sufficient for Vpu to overcome release restriction. Motifs in 
Vpu’s cytoplasmic tail and serine phosphorylation are required for this function and 
mediate clathrin adaptor interaction. 
3. HIV-1 Nef enhances virion infectivity by counteraction of the recently identified restriction 





Chapter 2 Materials and Methods 
 
2.1 Polymerase Chain Reaction (PCR) 
Primers for all PCR reactions were synthesized by MWG Eurofins. Primers were designed to 
contain EcoRI, NotI or XhoI restriction enzyme cleavage sites. A Kozak consensus sequence was 
also included in the forward primers and a TAG or TGA stop codon was included in the reverse 
primer or not, depending on whether a C-terminal HA-tag was added.  
The standard PCR was used for subcloning of DNA fragments into vectors with different 
multiple cloning sites. All tetherin constructs were generated with the natural Kozak consensus 
sequence (ATC TGG or GTG CCC), all other proteins were generated to contain an optimal Kozak 
consensus sequence (GCC ACC) immediately upstream of the ATG start codon. The PCR mix was 
prepared as described in table 1 and the thermo cycler (Eppendorf Mastercycler) was programmed 
as shown in table 2.  
Overlapping PCR was used to generate Vpu mutants in pCRV1 and mutants in the NL4.3 
proviral plasmid. Two reverse complementary primers were designed containing the desired 
mutation and two separate PCR reactions were conducted all using the standard PCR conditions. 
The mutation-containing primers (primer 1, forward, and 2, reverse) were used in combination with 
full-length outer Vpu primers or, in the case of NL4.3 provirus, a forward primer annealing upstream 
of the vpr gene (CAT AAT AAG AAT TCT GCA ACA ACT GC) and a reverse primer annealing in 
the env gene (CTT AAT TTG CTA GCT ATC TGT TTT AAA GTG). The forward primer and primer 
2, and the reverse primer and primer 1 were used in separate reactions. Amplified products were 
purified and both combined in a third PCR mix using the outer forward and reverse primer only to 
generate a full-length construct.  
Site directed mutagenesis (QuickChange) was used to generate Vpu mutants in pCR3.1. 
Reverse complementary primers containing the desired mutation in the middle were designed. 125 
ng of each primer and 20 ng of template PCR were mixed in the otherwise standard PCR mix and 
the cycler was programmed as described in table 2. The PCR product was then treated with the 
DpnI restriction enzyme to digest the methylated template DNA, before being transformed. 
For construct synthesis, overlapping primers for the full coding sequence were designed for 
greater spot-nosed and mona monkey tetherin as well as N1.FR.2011 Vpu. The outer primers 
contained the desired restriction sites. All primers were added to the same standard PCR mix and 
PCR conditions were the same as for the standard PCR, however, with only 10 cycle repeats. 1 µl 
from this reaction was then added to another standard PCR mix containing only the outer primers 






Table 1. PCR mix 
Reagent  Final concentration 
Phusion® High-Fidelity DNA Polymerase 
(NEB) 0.5 µl (1 unit) 
Phusion®  HF buffer (NEB) 1 x  
dNTPs (Sigma) 500 µM 
DNA template  200 ng (standard PCR) 
20 ng (QuickChange) 
Primer (reverse and forward) 0.5 µM each 
ddH2O x µl 
Total 20 µl (standard PCR) 50 µl (QuickChange) 
 
Table 2. PCR conditions 
Step Temperature Time Cycle repeats 
Denaturation 95°C 30 sec 1 x 
Denaturation 95°C 30 sec  
 
30 x (standard PCR) 
16 x (QuickChange) 
Primer annealing 58°C 30 sec (standard PCR) 
60 sec (QuickChange) 
Extension  72°C 60 sec (standard PCR) 
1 min per kb (QuickChange) 
Extension  72°C 10 min 1 x 
Cooling 4°C Until stopped  
 
2.2 Extraction and Purification of DNA 
The PCR products were separated using agarose gel electrophoresis. For a 1% agarose gel, 
1 g electrophoresis grade agarose (Invitrogen) was dissolved while heating in 100 ml 1 x TAE buffer 
(1x TAE: 40 mM Tris-acetate, 1 mM EDTA, 0.114% glacial acetic acid, pH 8.2-8.3). After cooling, 
2 µl ethidium bromide (Sigma) was added and the gel was poured into a gel cast. Once the gel set, 
the samples were loaded next to a 2-log DNA ladder (NEB). Samples were separated in the electric 
field at 100 V for around 30 min. To visualize the bands, the Chemi Doc UV system (Bio-Rad) was 
used. DNA fragments of the right size were cut out of the agarose gel and DNA was extracted using 
the QIAquick Gel Extraction Kit (QIAGEN) following the manufacturers instructions.  
2.3 Restriction Endonuclease Digestion 
To clone DNA fragments into vectors, the DNA fragment and vector backbone were cleaved 
using restriction endonucleases. Restriction enzymes commonly used in these studies include 
EcoRI, NotI, XhoI, NheI and DpnI (all NEB). The digestion mix was prepared as shown in table 3 
and incubated at 37°C for 2 h. If required, self-ligation was prevented using Antarctic 
Phosphatase (NEB), which removes the 5’ phosphate group of the linearized vector. Antarctic 
Phosphatase reaction buffer (1 x final concentration) was mixed with 5 units of the enzyme, 




Table 3. Restriction endonuclease digestion 
Reagent Final volume 
Buffer (depending on enzyme, e.g. 
CutSmart) 
2 µl  
BSA (not with CutSmart buffer) 1 x  
Restriction enzyme(s) 20 units  
DNA (1-2 µg)  x µl  
ddH2O x µl  
Total  Up to 20 µl  
 
2.4 Ligation and Transformation of Plasmid DNA into Competent Cells 
A ligation reaction mix was prepared as shown in table 4 using T4 DNA ligase (NEB). The mix 
was then incubated for 30 min at room temperature or at 16°C overnight. A negative control was 
treated the same way, but sterile water instead of the DNA insert was added to the mix. This was 
done to check the background level of vector self-ligation.  
Table 4. DNA ligation 
Reagent Final volume 
Vector x µl 
DNA Insert  x µl (3 x of vector) 
T4 ligase buffer 10 x 1 µl  
T4 DNA ligase  1 µl  
ddH2O x µl 
Total  10 µl 
 
The ligation mix was then added to 50 µl of chemically competent DH10 Escherichia coli (E.coli) 
cells and incubated for 20 min on ice. The cells were then heat-shocked for 45 sec at 42°C before 
going back on ice. Then 750 µl fresh Luria-Bertani (LB) broth without antibiotics was added to the 
cells and they were incubate in a shaker at 30°C or 37°C for 1 h. Cells were then spread on LB 
agar plates containing ampicillin (100 µg/ml) and incubated at 30°C or 37°C overnight. All retroviral 
vectors were grown at 30°C to avoid recombination. Single colonies were picked and grown 
overnight in 3 ml LB broth containing ampicillin. The culture was then used to purify plasmid DNA 
for restriction enzyme digest or sequencing, or to inoculate a bigger culture (100 ml) for incubation 
overnight.  
2.5 Preparation of Chemically Competent Cells 
DH10 E.coli cells (Invitrogen) were grown in LB broth in a shaker (220rpm) at 37°C for 16 h. 
Then 500 µl of the overnight culture were added to 50 ml LB broth and incubated at 37°C in a 
shaker until the OD550 reached 0.45. Cells were put on ice for 10 min and pelleted in a pre-chilled 
bench top centrifuge at 3000 x g. the pellet was resuspended in 20 ml buffer 1 (table 5) and 
incubated for 5 min on ice. Cells were pelleted again and resuspended in buffer 2. After 10 min on 
ice cells were snap-frozen on dry ice in aliquots and stored at -80°C until used further.  
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Table 5. Buffers used for making chemically competent cells. All filter-sterilized.  
Buffer 1 Buffer 2 
30 mM KAc 10 mM PIPES 
100 mM RbCl 75 mM CaCl2 
10 mM CaCl2 10 mM RbCl 
50 mM MnCl2 15% glycerol  
15% glycerol  
 
2.6 Plasmid Amplification and Purification  
From a 3 ml bacterial overnight mini-culture, 100 µl were added to 100 ml LB broth containing 
ampicillin and incubated overnight at 30°C or 37°C in a shaker. Cells were pelleted at 6000 x g for 
15 min at 4°C. Plasmid DNA was extracted using the endotoxin free NucleoBond® Xtra Midi kit 
(Macherey-Nagel). Bacterial cells were lysed and the lysate was cleared and loaded onto an 
equilibrated column where the DNA binds to the silica-based membrane. The membrane was 
washed twice and the DNA was eluted in a high salt buffer and precipitated by centrifugation using 
isopropanol. The precipitated DNA was washed again in 70% ethanol before being eluted in 
endotoxin free water.  
Plasmids from a 3 ml bacterial mini-cultures were purified by the same principle using the 
QIAprep Spin Miniprep Kit (QIAGEN) and following the manufacturer’s instructions.  
2.7 DNA Sequencing and Vectors 
The Nanodrop ND-100 Spectrophotometer (Labtech International) was used to determine the 
DNA concentrations of purified plasmid DNA before being sent off for sequencing to Eurofins MWG 
Operon. For sequencing of pCR3.1 the T7 forward primer or BGH reverse primer were used. For 
the other vectors, primers directed to down- or upstream sequences of the multiple cloning site 
were used. A list of plasmids used in these studies is shown in table 6 and 7 and important features 












Table 6. Vectors and proviruses 
Vector Source Description 
pCR3.1  Invitrogen Mammalian expression vector, cytomegalovirus 
(CMV) promoter 
pCRV1  Paul Bieniasz HIV-based, Rev-dependent expression vector 
(Zennou et al. 2004) 
pLHCX Clontech Retroviral vector derived from moloney murine 
leukemia virus (MMLV), hygromycin resistance, CMV 
promoter 
pCMS28 Michael Malim Retroviral vector derived from pMigR1, puromycin 
resistance via IRES 
HIV-1 NL4.3 NIH AIDS Reagent Program  Full length, replication competent HIV-1 molecular 
clone 
HIV-1 NL4.3 ΔVpu Stuart Neil As WT NL4.3, but ATG start codon of vpu ORF 
replaced with BamHI restriction site that introduces 
frameshift (Neil et al. 2006) 
HIV-1 NL4.3 ΔNef and 
ΔNefΔVpu 
Anna Le Tortorec ATG of Nef mutated or both Nef and Vpu ATG 
mutated 
HIV-1 NL4.3 Vpu 2/6, 
ELV, LILI mutants 
Tonya Kueck  
Other HIV-1 NL4.3 
Vpu mutants 
Generated using overlapping PCR  
HIV-2 pRod10 Centre for AIDS Research (NIBSC, 
Potters Bar, UK) 
Full length, replication competent HIV-2 molecular 
clone 
SIVmac239 Theodora Hatziioannou Assembled from plasmids p239SpSp5′ and 
p239SpE3′ (Kestler et al. 1990) (NIH AIDS Reagent 
Program) into a low copy number (pXF3) backbone 
(Zhang et al. 2009) 
SIVmac239 ΔNef Theodora Hatziioannou Premature stop codon at codons 58 and 59 of Nef 3’ 














Table 7. List of plasmids 
Gene Vector Restriction 
sites 



































































HIV-1 NL4.3 Vpu pCR3.1 
pCRV1 
pCMS28 











 - - Suzy Pickering 
 
HIV-1 group M 
Vpus (clades) 
pCG  - - Michael Schindler 
















pCG  - - Michael Schindler 
HIV-2 Env IRES 
GFP or mutant 
pCRV1  - - Anna LeTortorec 
K5 or mutant pCMS28 EcoRI/XhoI - HT1080 Rafael Vigan 
HIV-1 NL4.3 Vpu 
and mutants 
pCR3.1 EcoRI/NotI +/- HA - Klaus Strebel, 
Tonya Kueck, 
subcloning 
HIV-1 NL4.3 Vpu 
and mutants 
+CB/CBmut 
pCR3.1 EcoRI/NotI +/- HA - Tonya Kueck, 
QuickChange, 
Overlapping PCR 
HIV-1 2_87 Vpu and 
mutants  
pCR3.1 EcoRI/NotI +/- HA - synthesized, 
Overlapping PCR 
SERINC3/5 pCR3.1 XhoI/NotI HA - Toshana Foster, 
Amplified from 
CD4+ T cells 
SERINC3/5 
isoforms 
pCR3.1  XhoI/NotI HA - Standard PCR 
VSV-G pMDG  - - Stuart Neil 
Ebola GP pCAGGS  - - Ed Wright 
XMRV Env pCRV1  - - Rui Galao 
Measles Env   - - Michael Malim 
MLV Gag-Pol pCRV1  - - Stuart Neil 
HIV Gag-Pol pCRV1  - - Paul Bieniasz 
LentiCRISPRv2   - - Zhang lab 
YFP pCR3.1  - - Paul Bieniasz 
GFP pCR3.1  - - Paul Bieniasz 
 
2.8 Cell Culture 
Adherent cells were incubated at 37°C and 5% CO2 in Dulbecco’s Modified Eagle Medium 
(DMEM; Invitrogen) that was supplemented with 10% heat-inactivated fetal calf serum (FCS; 
Invitrogen) and 0.02 mg/ml gentamycin (Invitrogen). Suspension cells were maintained at 37°C and 
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5% CO2 in Roswell Park Memorial Institute (RPMI) medium (Invitrogen) supplemented with 10% 
FCS and 0.02 mg/ml gentamycin. Cells were passaged every two days or when required. Adherent 
cells were detached from the tissue culture plate using Trypsin (TrpLE Expres + phenol red, 
Invitrogen), resuspended in pre-warmed DMEM and added to a fresh tissue culture plate. 
Suspension cells were aspirated and fresh RPMI medium was added to the tissue culture flask. A 
list of cells used in these studies can be found in table 8.  
To generate frozen stocks of cell lines, cells were pelleted by centrifugation at 3000 x g and 
resuspended in 90% FCS supplemented with 10% DMSO (Sigma). Cells were then placed at -80°C 
before transferring them to liquid nitrogen.  
Table 8. Cell lines used in this study 















DMEM Endogenous tetherin expression; 
expression of CD4 and CCR5; β-













ATCC DMEM No tetherin 
Jurkat CD4+ T 
lymphocyte 
(leukemia) 
ATCC RPMI Endogenous tetherin expression 





RPMI Tetherin expression is IFN-inducible 
 
2.9 Transient Transfection 
Cells were plated the day before at a density of 1.2 x 105 cells per well of a 24 well plate or 3 x 
105 cells per well of a 6 well plate. The right amount of pCR3.1 or pCRV1 expression vector was 
diluted in serum free medium. The transfection reagent was mixed with with serum free medium 
and incubated for 5 min at room temperature before being added to the DNA and gently mixed. 
Either polyethylenimine (PEI; 1 mg/ml in ddH2O, filtered, pH 7.0; Polyscience) or, for Hela cells, 
Lipofectamine 2000 (2 mg/ml; Invitrogen) was used as a transfection reagent. The mix was 
incubated for 20 min and then added onto the cells. Six hours post transfection the medium was 
changed. 48 h post transfection cells and supernatants were analysed for protein expression or 
infectious virus release. In the case of transfection for microscopy, cells were fixed 16 h post 
transfection.   
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2.10 Generation of Stable Cell Lines 
To produce virus-like particles, 293T packaging cells in a 6 well plate were transfected with 
600 ng MLV Gag-Pol expression vector, 300 ng VSV-G expression vector and 1 µg of a MLV-based 
retroviral vector, pLHCX or pCMS28 (containing selection markers for hygromycin or puromycin, 
respectively), encoding the gene of interest such as tetherin, K5 or Vpu. The 293T cells then 
produce replication-incompetent retroviral particles, so called virus-like particles (VLPs). The 
retroviral vector containing the gene of interest is packaged into the particle comprised of MLV 
structural proteins and the VSV-G envelope. When tetherin stable cell lines were produced, 200 ng 
of Vpu expression vector were co-transfected to enable VLP release. 48 h post transfection the 
VLPs were harvested and filtered through a 0.45 µm filter. This supernatant was then added to 
293T, HT1080 or Jurkat cells for transduction. Target cells were spinoculated with VLP supernatant 
for 1 h at 3000 g to increase delivery of viral particles to target cells. The cells were then incubated 
at 37°C for 48 hours before they were split into 10 cm tissue culture plates. Antibiotic selection was 
added to the cells (100 µg/ml hygromycin B or 1 µg/ml puromycin) and they were incubated at 37°C 
until non-transduced cells had died and stably expressing cells were selected for.  
2.11 Generating Stable Knockout Cell Lines Using the CRISPR-Cas9 
System 
Three sets of guide RNAs targeting the SERINC3 or SERINC5 locus were designed using the 
Zhang lab website (http://crispr.mit.edu) and cloned into a lentiCRISPRv2 plasmid (AddGene, 
Cambridge, MA) (Shalem et al. 2014). Guide sequences for SERINC3 (Genbank accession number 
NM_006811.2): 1. GTG TCT TCT CCC TCG CCA GC, 2. ATA AAT GAG GCG AGT CAC CG and 
3. AAC ATG AGG CAC CGC TGC AG, targeting exon 1 or 2. Guide sequences for SERINC5 
(Genbank accession number NM_001174072.2): 1. ATG TCA GCT CAG TGC TGT GC, 2. GCT 
GAG GGA CTG CCG AAT CC and 3. CTG AGG GAC TGC CGA ATC CT, targeting exon 1 or 2. 
Guide sequences targeting Luciferase were used as a non-target control. 293T cells in a 6 well 
plate were transfected with 600 ng HIV Gag-pol, 300 ng VSV-G and 1 µg lentiCRISPRv2 carrying 
the guide sequence per well to generate VLPs. 48 post transfection VLPs were harvested. 293T 
cells (4 x 105 per well) or Jurkat Tag cells (4 x 106 per well) were split into a 6 well plate and 
spinoculated with the VLP supernatants for 1 hour at 3000 x g. Puromycin selection (1 µg/ml) was 
added two days post transduction and was maintained until single cell clones had been obtained 
by limiting dilution (for 293T cells) or fluorescence activated cell sorting (FACS; for Jurkat TAg cells). 
The SERINC knockout was confirmed by sequencing.  
2.12 Isolation of CD4+ T Lymphocytes From Blood 
Total peripheral blood mononuclear cells (PBMCs) were isolated from the blood of healthy 
individuals using density gradient centrifugation. Blood was collected in heparin-coated tubes (BD 
Bioscience) and diluted with an equal amount of 1 x PBS. 30 ml of blood were then layered onto 15 
ml of Lymphoprep (Axis-Shield) in a 50 ml falcon tube and centrifuged at 1000 x g at room 
temperature for 30 min without brakes. PBMCs form a separate layer, the buffy coat, at the border 
between blood and lymphoprep and can be aspirated using a Pasteur pipette. PBMCs were then 
diluted in 40 ml of 1 x PBS and pelleted at 300 x g for 10 min. This was repeated three times. The 
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CD4+ T cells were isolated from the total PBMCs by negative isolation using the Dynabeads 
Untouched Human CD4 T Cells kit (Invitrogen) following the manufacturer’s instructions. Total CD8+ 
T cells, B cells, NK cells, monocytes, platelets, dendritic cells granulocytes and erythrocytes were 
depleted from total PBMCs using a mixture if mouse IgG antibodies directed against non-CD4+ T 
cells that were captured by magnetic Dynabeads. The remaining CD4+ T cells were then activated 
using Dynabeads Human T-Activator CD3/CD28 for T cell expansion and activiation (Invitrogen) 
following the manufacturer’s instructions. The Dynabeads provide both TCR and co-stimulating 
signals for T cell activation. The beads were then removed and the cells were kept in rhIL-2 (30 
U/ml; Roche) before they were infected with VSV-G pseudotyped HIV-1.  
2.13 SDS-PAGE and Western Blotting 
For the detection of proteins in cell lysates and culture supernatants from experimental assays 
were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blotting.  
The resolving gel was mixed containing all the ingredients shown in table 9 and poured into a 
glass plate sandwich and casting frame. Where indicated, 25 µM Phos-tag (Wako Chemicals, 
Japan) and 50 µM MnCl2 (Sigma) were added to an 8% polyacrylamide gel to induce a mobility 
shift of phosphorylated proteins. The gel was then topped with isopropanol and allowed to set before 
it was rinsed with ddH2O. The stacking gel was mixed as mentioned in table 9 and poured on top 
of the resolving gel. A plastic comb was inserted and the gel was allowed to set. The gel was then 
placed into a Mini-PROTEAN Tetra Cell electrophoresis system (Bio-Rad) and filled with running 
buffer (0.1% SDS, 25 mM Tris-Base, 200 mM glycine pH 8.8). Samples were diluted with 2 x 
Laemmli buffer (LB; 20% glycerol, 4% SDS, 100 mM Tris-HCL pH 6.8, 200 mM β-mercaptoethanol, 
0.2% bromophenol blue) and boiled for 10 min at 100°C for denaturation before being loaded onto 
the gel, next to a protein marker (Prestained Protein marker, broad range 7-175 kDa; NEB). The 
gel was then run for about 2 h at 80 V.  
The separated proteins were transferred onto a nitrocellulose membrane (Amersham Protran 
0.45 NC) in a Criterion Blotter (Bio-Rad) in transfer buffer (20% ethanol, 25 mM Tris-base, 200 mM 
glycine pH 8.8) for 1 h at 100 V or 16 h at 18 V. The membrane was then blocked using 5% Marvel 
milk dissolved in 1 x PBS/0.1% Tween 20. The primary antibody in 5% milk was incubated with the 
membrane for 1 h at room temperature, followed by three 10 min washing steps in 1 x PBS/0.1% 
Tween 20. The membrane was then incubated with the secondary antibody for 1 hour, followed by 
three wash steps. Membranes incubated with a IRDye conjugated secondary antibody were 
analysed on the LI-COR Odyssey infrared imaging system (LI-COR Bioscience). Membranes that 
were incubated with a horseradish peroxidase (HRP) conjugated secondary antibody were 
additionally incubated with SuperSignal West Pico Chemiluminescent solutions (Thermo Scientific) 






Table 9. SDS-PAGE gel ingredients 
Separating gel 8% 10% 12% Stacking gel  
ddH2O  5.5 ml 5 ml  4.5 ml  ddH2O  3.25 ml 
1.5 M Tris pH 8.8 2.5 ml 2.5 ml 2.5 ml 0.5 M Tris pH 6.8 1.25 ml 
Acrylamide (40%)  2 ml 2.5 ml 3 ml Acrylamide (40%)  465 µl 
APS (10%) 50 µl 50 µl 50 µl  APS (10%) 25 µl 
TEMED 10 µl 10 µl 10 µl  TEMED 5 µl 
SDS (10%) 100 µl 100 µl  100 µl SDS (10%) 50 µl 
 
Table 10. Primary antibodies used for Western blotting 
Antibody Species Antigen Source Dilution 





ɑ-Vpu Rabbit NL4.3 Vpu (amino 
acids 33-81); 
polyclonal 
NIH AIDS Reagent 
Program 
1:5000 




NIH AIDS Reagent 
Program  
1:75 
ɑ-HA Rabbit HA epitope tag; 
polyclonal 
Rockland 1:5000 
ɑ-HA Mouse CYPYDVPDYASL 
HA.11 clone 16B12; 
monoclonal 
Covance 1:5000 
ɑ-BST2 Rabbit Human tetherin; 
polyclonal 
NIH AIDS Reagent 
Program 
1:1000 
ɑ-βTrCP Rabbit Residues 







ɑ-myc Mouse Clone 9E10; 
monoclonal 
Covance  1:1000 
ɑ-AP-1 ɣ1 Mouse Derived from 100/3 
hybridoma, AP-1 
adaptor from bovine 










Table 11. Secondary antibodies used for Western blotting 
Antibody Conjugate Source Dilution 
Goat ɑ-mouse IRDye 680 LI-COR Bioscience 1:5000 
Goat ɑ-rabbit IRDye 800 LI-COR Bioscience 1:5000 
Goat ɑ-mouse HRP Cell signalling 1:5000 
Goat ɑ-rabbit HRP Cell signalling 1:5000 
 
2.14 Gene Knockdown Using siRNA 
293T or 293T tetherin cells were plated at 2 x 105 cells per well of a 12 well plate. For each 
well, 2 µl Dharmafect (Thermo Scientific) was mixed with 98 µl Opti-MEM (Life Technologies) and 
added to 5 µl of the 20 µM siRNA oligonucleotide mixed with 95 µl Opti-MEM. Both β-TrCP1 and 2 
were knocked down using the SMARTpool siRNA against human BTRC and FBXW11 (Thermo 
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Scientific). Non-targeting siRNA was used as a control (Thermo Scientific). Two days post 
transfection cells were reseeded into 24 well plates and a second siRNA transfection was performed 
following manufacturers instructions. 4 h post transfection cells were infected with VSV-G 
pseudotyped HIV-1 or mutants thereof at an MOI of 0.8. Supernatants and cell lysates were 
harvested 48 h later and infectivity of viral supernatants was determined on Hela TZMbl cells as 
described in 2.23. Cell lysates and pelleted viral supernatants were subjected to SDS-PAGE and 
Western blotting for analysis of β-TrCP, Hsp90, Pr55 and p24CA expression as described in 2.13.  
2.15 NF-κB Reporter Assay  
For the transient reporter gene assay, 293 cells were plated into a 24 well plate at a density of 
105 cells per well. They were transfected with 50 ng of pCR3.1 tetherin plasmid or control pCR3.1 
YFP in combination with 10 ng of 3xκB-pCONA-FLuc reporter (NF-κB-dependent firefly luciferase 
reporter construct) and 5 ng pCMV-RLuc (for determination of the background signal). 48 h post 
transfection, firefly and renilla luciferase activity in cell lysates was assayed using the Dual-
Luciferase Reporter Assay System (Promega). Cells were first lysed in 100 µl 1 x passive lysis 
buffer for 10 min. Lysates were transferred into Eppendorf tubes and cleared for 10 min at high 
speed. 10 µl of the cleared lysate were added to a white luminescence 96 well plate and 50 µl 
luciferase assay reagent II. The signal was measured immediately in a luminescence counter 
(Victor Light 1420-Perkin Elmer; Wallac software). Then, 50 µl of the Stop&Glo substrate diluted in 
Stop&Glo buffer 1:50 was added to each well and the signal was measured in the same 
luminescence counter. Values of the luciferase reading were then normalized to the Stop&Glo 
Renilla read-out. 
2.16 Immunoprecipitation (IP) 
Jurkat cells were treated with IFN (1,000 U/ml) or left untreated, Jurkat-TAg L-tetherin, Jurkat-
TAg S-tetherin, and Jurkat- TAg empty-vector control cells were lysed on ice for 20 min in buffer 
containing 50 mM Tris (pH 7.4), 150 mM NaCl, 200 µM sodium orthovanadate, 1% NP-40, 0.5% 
sodium deoxycholate, 5 mM N-ethylmaleimide, and complete protease inhibitors (Roche). Lysates 
were cleared by centrifugation, and supernatants were incubated with 5 µg/ml mouse ɑ-BST2 
monoclonal antibody (eBioscience) for 1.5 h at 4°C. Sepharose-protein G beads were washed in 
lysis buffer before they were added to the samples and incubated for another 3 h. Beads were 
washed five times in lysis buffer before the peptide–N-glycosidase mixture for deglycosylation was 
added (New England BioLabs). Samples were incubated at 37°C overnight and resuspended in 
SDS-PAGE loading buffer. Cell lysates and immunoprecipitates were subjected to SDS-PAGE and 
Western blotting for tetherin and Hsp90 as described in 2.13.  
2.17 Cross-Linking IP 
293T tetherin, 293T tetherin Y6,8A or 293 Rhesus tetherin cells were transfected with 8 μg 
GFP expression construct, pCR3.1 Vpu-HA or mutant thereof. Transfection media was changed 6 
hours post transfection and cells incubated with 50 nM concanamycin. In the case of CKII inhibitor 
treatment, cells were treated with 50 μM final Tyrphostin 24 hours prior to harvesting. 48 hours post 
transfection, cells were trypsinised and washed in PBS. Cells were cross-linked with 0.05% 
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HCHO/PBS for 10 min at 37°C. The cross-linking reaction was then quenched by incubating cells 
in 0.25M glycine for 5 min. Cells were washed once in PBS before resuspension in lysis buffer 
(10mMHepes pH 7, 150mMNaCl, 6mMMgCl2, 2mMDTT, 10% glycerol, 0.5% NP40, 200 μM 
sodium orthvanadate and 1x Complete protease inhibitors (Roche)). Cells were lysed on ice for 10 
min followed by repeated sonication (3 x 10 s cycles with 20 s rests). The cell lysates were clarified 
by centrifugation at 1000 x g for 10 min and supernatants were immunoprecipitated with 5 μg/ml 
mouse monoclonal anti-HA.11 antibody (Covance) or rabbit polyclonal anti-HA antibody (Rockland) 
on Dynabeads protein G beads (Life Technologies) for 4 hours at 4°C. Beads were collected post 
incubation and washed 5 times in lysis buffer before cross-links were reversed in 1% SDS, 10mM 
EDTA and 5mm DTT at 65°C for 45 min. Samples were then analysed for HA, AP-1 and AP-2 by 
SDS-PAGE and Western blotting as described in 2.13. 
For the β-TrCP IP, 293T cells were co-transfected with 700 ng of pCR3.1 myc β-TrCP 2 and 
pCR3.1 Vpu-HA/mutant or pCR3.1 YFP expression plasmids. 48 h post transfection, Crosslinking 
Immunoprecipitation was performed as previously described above. Cell lysates and 
immunoprecipitates were analysed for Vpu and myc by SDS-PAGE and Western blotting assays 
as described in 2.13. 
2.18 Immunofluorescence Microscopy 
Cells were plated on poly-L-lysine (Sigma) treated coverslips and transfected with 100 ng of a 
tetherin, Vpu or 500 ng Gag-GFP expression vector. 16 h post transfection cells were fixed in 4% 
paraformaldehyde for 15 min and washed with 10 mM glycine. Cells were permeabilized in 1% 
BSA/0.1% Triton-X100 for 15 min. Then the primary antibodies (table 12) diluted in 1% 
BSA/0.01%Triton-X100 were added and incubated for 45 min at room temperature. Cells were 
washed twice and the secondary antibodies (table 13) were added and incubated for 45 min. After 
two more wash steps, the coverslips were mounted onto glass slides using ProLong AntiFace-49,6-
diamidino-2-phenylindole (DAPI; Molecular Probes, Invitrogen). The cells were then visualised 
either on a Leica DM-IRE2 confocal microscope (63 x oil immersion lens) and images analysed 
using the Leica Confocal Software and ImageJ; or Z stacks were taken on a Nikon ECLIPSE Ti 
inverted microscope (100 x oil immersion lens) and images were deconvolved using AutoQuant X3 
and analysed using ImageJ software.  
Table 12. Primary antibodies used for immunofluorescence microscopy 
Antibody Species Antigen Source Dilution 
ɑ-HA Mouse CYPYDVPDYASL 
HA.11 clone 16B12 
Covance 1:1000 
ɑ-HA Rabbit HA epitope tag Rockland 1:1000 
ɑ-BST2 Mouse  Human tetherin, 
residues 40-181 
Abnova  1:200 
ɑ-TGN46 Sheep Human TGN46 AbD Serotec 1:100 












Table 13. Secondary antibodies used for immunofluorescence microscopy 
Antibody Conjugation Source Dilution 
Donkey ɑ-mouse Alexa Fluor 488 
Alexa Fluor 594 
Alexa Fluor 630 
Molecular Probes (Invitrogen) 1:500 
Donnkey ɑ-rabbit Alexa Fluor 488 
Alexa Fluor 594 
Alexa Fluor 630 
Molecular Probes (Invitrogen) 1:500 
Donkey ɑ-sheep Alexa Fluor 488 
Alexa Fluor 594 
Alexa Fluor 630 
Molecular Probes (Invitrogen) 1:500 
 
2.19 Detection of Surface Proteins by Flow Cytometry  
293 cells stably expressing tetherin isoforms were transfected with 500 ng pCRV1 HIV-2 Env-
IRES-GFP or the indicated mutant. 48 h post transfection cells were stained for surface tetherin 
using a monoclonal ɑ-BST IgG2a antibody (Abnova) and a goat ɑ-mouse IgG2a-Alexa 633 
conjugated secondary antibody (Molecular Probes, Invitrogen). Alternatively, a PE conjugated 
monoclonal ɑ-BST2 antibody (eBioscience) was used to stain untransfected stably tetherin 
expressing 293 cells. The cells were detached from the tissue culture plate using 5 mM EDTA and 
washed in ice cold FACS buffer (1% BSA, 0.1% sodium azide in 1 x PBS). The primary antibody 
was diluted in FACS buffer and added to the cells for 1 hour on ice. Cells were then washed three 
times with FACS buffer, before the secondary antibody was added for 1 hour on ice. Cells were 
then washed three times in FACS buffer and resuspended in 1 x PBS. Tetherin and GFP expression 
were then assessed on a FACSCanto II flow-cytometer (Becton Dickinson) and results were 
analysed using the FlowJo software.  
2.20 Generating Infectious Virus Stocks and Virus Stock Titration on 
Hela-TZMbl Cells 
293T cells in a 6 well plate were transfected using PEI with 2 µg of a provirus and 200 ng 
pCMV-VSV-G, if pseudotyped. This allows the additional expression of VSV-G on the virus particle 
and infection of CD4 negative cells. 6 h post transfection the medium was replaced and 48 h post 
transfection the culture supernatant containing the viral particles was filtered through a 0.45 µm 
filter, aliquoted and stored at -80°C.  
To determine the infectious titer of the virus stock, Hela TZMbl cells were plated in a 96 well 
plate (104 cells per well) and infected with 25 µl of a serial dilution of the virus stock (100 to 10-6). 
48 h later cells were fixed in 0.5% glutaraldehyde for 15 min and washed in 1 x PBS. Then the X-
Gal substrate solution (1 mg/ml X-gal-dimethylformamide, 5 mM K ferrocyanide, 5 mM ferricyanide, 
2 mM MgCl2, 0.02% NP40 and 0.015 Triton-X100 in 1 x PBS) was added and the fixed cells were 
incubated at 37°C for 2 hours or overnight. Infected cells will turn blue due to Tat-activated β-
galactosidase expression and X-Gal cleavage, which then forms an intense blue product. The blue 
colonies were counted with a light microscope and the end point titer was determined as infectious 
units per ml.  
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Cells were then infected at different multiplicities of infection (MOI) depending on the assay. A 
MOI of 1 means that the amount of infectious particles is the same as the amount of cells infected. 
However, the amount of cells that are infected is defined by the Poisson distribution: 
! " = $%×'()"!  
Where P(n) is the probability that a cell will be infected by n viruses and m being the MOI. That 
means that the probability for a cell to be infected at an MOI of 1 is around 63% and at an MOI of 
2 around 87%. An MOI of 2 was used in assays looking at the degradation of tetherin. A lower MOI 
of 0.5-1 was used in single round infection assays. 
2.21 Virus Release Assay  
293T cells were plated in a 24 well plate at a density of 1.2 x 105 cells per well. Cells were 
transfected with 500 ng proviral plasmid and increasing concentrations of tetherin or SERINC 
expression vector using PEI. Alternatively, 293T cells transfected with 50 ng of tetherin or 293T 
tetherin cells were transfected with increasing amounts of Vpu or mutants in addition to 500 ng 
proviral plasmid.  
For infection assays, adherent cells were plated in a 24 well plate at a density of 1.2 x 105 cells 
per well or 1 x 106 suspension cells were infected at an MOI of 0.8-1 with VSV-G pseudotyped 
virus. In the case of CKII inhibitor treatment, cells were treated with 50 μM final Tyrphostin or DMSO 
24 h prior to harvesting. 
The medium was changed 6 h later and cells and supernatants were harvested 48 h post 
transfection/infection. The supernatant was analysed for infectious virus release as described in 
2.23 and for physical virus particle release as described in 2.22. Cell lysates were analysed by 
Western blotting as described in 2.13.  
2.22 Determining Physical Virus Release 
The supernatant was harvested from each well and filtered through a 0.22 µm filter (Millipore) 
into a fresh plate. 700 µl of the filtered supernatant was layered on top of 500 µl cold 20% sucrose 
in 1 x PBS in a microfuge tube. The tubes were then centrifuged for 1 h at 4°C and 17,900 x g. 
Then the supernatant was aspirated and the invisible pellet was resuspended in 20 µl 2 x loading 
buffer. Samples were then boiled for 10 min and analysed by Western blotting for p24CA as 
described in 2.13. 
2.23 Determining Infectious Virus Release  
The infectious virus release in supernatants was determined using Hela-TZMbl cells that were 
plated in a 96 well plate (104 cells per well). 25 µl of the supernatant was added to one well of Hela-
TZMbl cells and the plate was incubated for 48 h at 37°C. Cells were then lysed using 50 µl Tropix 
Galacto-Star Lysis solution (Applied Biosystems) for at least 15 min at room temperature. 10 µl of 
the lysate was transferred into a white luminescence 96 well plate and incubated for 15 min with 45 
µl Tropix Galacto-Star substrate diluted in Reaction Buffer Diluent 1:50 (Applied Biosystems). β-
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galactosidase activity was then measured in a luminescence counter (Victor Light 1420-Perkin 
Elmer; Wallac software).  
2.24 Tetherin Degradation Assay 
To assess tetherin degradation, 293T tetherin cells or Jurkat TAg cells were infected with the 
indicated VSV-G pseudotyped virus at an MOI of 2. The medium was replaced 6 h later and cells 
were harvested 48 h post infection and analysed for total tetherin expression by Western blotting 
as described in 2.13. 
Alternatively, stably tetherin expressing cells were transfected with a Vpu expression construct 
and harvested 48 h later or transduced with VLPs containing Vpu or K5 and harvested after 
selection. Total tetherin in cell lysates was then determined by Western blotting as described in 
2.13. 
2.25 Intracellular p24 Staining for FACS 
Cells were infected with a VSV-G pseudotyped virus at an MOI of 1 and stained 48 h later. 
Cells were first stained for tetherin as described in 2.19. Then they were fixed and permeabilized 
for 20 min using Fixation/Permeabilization solution (Cytofix/cytoperm Fixation/Permeabilization kit, 
BD Bioscience) and stained for intracellular HIV-1 p24CA using the KC57 PE-conjugated antibody 
(Beckman-Coulter) diluted in Perm/Wash buffer (Cytofix/cytoperm Fixation/Permeabilization kit, BD 
Bioscience). Cells were then washed in Perm/Wash buffer and analysed on a FACSCalibur flow-




Chapter 3 Differential Sensitivities of Tetherin Isoforms to 
Counteraction by Primate Lentiviruses  
The data presented in this chapter have been published as “Differential sensitivities of tetherin 
isoforms to counteraction by primate lentiviruses” (Weinelt & Neil 2014). 
3.1 Introduction 
Tetherin (BST-2/CD317) is an interferon-induced transmembrane protein that has antiviral 
activity against a broad range of enveloped viruses including members of the families Retroviridae 
(Neil et al. 2008; Jouvenet et al. 2009) and Herpesviridae (Zenner et al. 2013; Pardieu et al. 2010; 
Mansouri et al. 2009; Blondeau et al. 2013) and negative-strand RNA viruses (Sakuma et al. 2009). 
It crosslinks budding virions to the plasma membrane and thereby restricts virus release from the 
infected cells, facilitated by its unique topology that is crucial for its function (Perez-Caballero et al. 
2009). Tetherin is a dimeric glycoprotein with an N-terminal cytoplasmic tail (CT), a transmembrane 
domain, a coiled-coil extracellular domain and a C-terminal glycosylphosphatidylinositol (GPI) 
anchor (Neil 2013). The GPI anchor is inserted into budding virions and parallel tetherin dimers 
physically restrict their release (Venkatesh & Bieniasz 2013). Tetherin targets a viral determinant, 
the host-derived viral envelope, which the virus cannot mutate and it also explains tetherin’s wide 
activity against various virus families. Tethered virus is eventually endocytosed and trafficked to 
late endosomes (Neil et al. 2008), possibly for degradation. Recently, human tetherin has also been 
shown to induce NF-κB signalling upon virus retention, acting as an innate sensor of viral release 
(Cocka & Bates 2012; Galão et al. 2012; Tokarev et al. 2013). There is genetic evidence from 
primate lentiviruses that the ability of a virus to overcome tetherin is essential for its in vivo spread. 
Tetherin exerts a high evolutionary pressure on enveloped viruses. This is highlighted by the fact 
that various viruses have evolved diverse proteins with anti-tetherin activity that often act in a 
species-specific manner (Neil 2013). Examples include HIV-1 Vpu (Neil et al. 2008; Van Damme et 
al. 2008), SIV Nef (Jia et al. 2009; Zhang et al. 2009), HIV-2 Env (Le Tortorec & Neil 2009), Ebola 
GP (Kaletsky et al. 2009), Herpes gM (Blondeau et al. 2013) and KSHV K5 (Pardieu et al. 2010; 
Mansouri et al. 2009). It has been suggested that efficient tetherin counteraction by the Vpu protein 
of the major HIV-1 group M is a reason for its pandemic spread compared to other HIV-1 groups 
with less efficient antagonists (Sauter et al. 2009).  
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HIV-1 Vpu is a membrane phosphoprotein that interacts with human and chimpanzee tetherin 
(Dubé, Roy, et al. 2010; Skasko et al. 2012; Vigan & Neil 2010; Matthew W McNatt et al. 2013). It 
antagonises tetherin by rerouting the newly synthesized and recycling protein, eventually leading 
to its endosomal degradation (Dubé et al. 2011; Schmidt et al. 2011; Kueck & Neil 2012). This 
trafficking event is dependent on clathrin and requires an acidic dileucine motif (ExxxLV) in Vpu’s 
CT as well as a tyrosine based sorting motif (YDY) in tetherin’s CT (Kueck & Neil 2012). The 
requirements in tetherin for counteraction and degradation are still not completely clear. 
Degradation is dependent on ubiquitination of potentially multiple residues in tetherin’s CT, 
including an STS motif (Tokarev et al. 2011). This process also requires the ESCRT machinery, as 
well as the recruitment of the SCFβTrCP1/2 E3 ligase by a phosphoserine motif (DSGNES) in Vpu 
(Agromayor et al. 2012; Janvier et al. 2011; Tokarev et al. 2011; Gustin et al. 2012; Mitchell et al. 
2009; Douglas et al. 2009). Tetherin antagonists other than HIV-1 Vpu do not mediate degradation, 
but induce endocytosis of tetherin from the cell surface and lead to its sequestration (Jia et al. 2009; 
Le Tortorec & Neil 2009; Zhang et al. 2011b; Serra-Moreno et al. 2013a; Lau et al. 2011).  
Recently, it has been shown that two isoforms of human tetherin can be expressed (Cocka & 
Bates 2012). They differ in the length of their cytoplasmic tail, with the shorter isoform lacking the 
first twelve amino acids compared to the long isoform. Those residues include the tyrosine based 
(YDY) sorting motif that is also important for induction of signalling as well as the STS motif that is 
potentially ubiquitinated. Both isoforms are thought to be expressed due to leaky ribosomal 
scanning, which results from suboptimal Kozak sequences flanking two AUGs. The presence of 
these two start codons is highly conserved among tetherin sequences from different species (Figure 
3.1 A and B). It has been reported that short human tetherin (S-tetherin) is less sensitive to HIV-1 
NL4.3 Vpu than long tetherin (L-tetherin) (Cocka & Bates 2012).  
In this chapter the findings of Cocka and Bates are extended, with further investigation into the 
differences in antagonism of short and long primate tetherins by various viral countermeasures. It 
is confirmed that short human tetherin is less efficiently counteracted, downregulated and degraded 
by HIV-1 Vpu at physiological tetherin expression levels. This is dependent on the tyrosine and 
serine based motifs in tetherin’s CT. Furthermore, the data show that S-tetherin is less sensitive to 
a range of HIV-1 group M Vpus. In contrast, Vpu proteins from a highly pathogenic HIV-1 group N 
virus as well as from greater spot-nosed monkey or mona monkey SIV antagonised both isoforms 
of their respective hosts with equivalent efficiency. Additionally, tetherin isoforms did not exhibit 
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differential sensitivity to other tetherin countermeasures such as SIVmac Nef, HIV-2 Env or KSHV 
K5. These data suggest that the differential sensitivity of tetherin isoforms is a conserved feature of 
HIV-1 group M Vpus only.  
 
 
Figure 3.1 The tetherin cytoplasmic tail amino acid sequence is highly conserved among species. (A) 
Alignment of the amino acid sequences of the cytoplasmic tail of tetherin of different mammalian species. 
Methionines M1 and M13 are highly conserved. Accession numbers: Homo sapiens (NP_004326); Pan 
troglodytes (NP_001177409); Macaca mulatta (ACV96781); Mus musculus (NP_932763). (B) Nucleotide 
sequences in front of the M1 and M13 AUGs in human tetherin mRNA differ from the consensus Kozak 
translation initiation sequence. Positions -3 and +1 to +4 are highlighted and particularly important for 
translation initiation. L-THN and S-THN refer to proteins initiated at M1 or M13 respectively. R=Purine. 







3.2.1 Long and Short Tetherin Isoforms are Differentially Sensitive to HIV-1 Vpu 
To further investigate the differences in counteraction of the two tetherin isoforms, constructs 
were generated encoding human tetherin containing the naturally occurring Kozak sequence (WT 
tetherin) and either the first (M1A, S-tetherin) or the methionine at position thirteen (M13I, L-tetherin) 
were mutated (Figure 3.2 A). First, the findings of Cocka and Bates that HIV-1 Vpu was less efficient 
in counteracting short tetherin were confirmed. 293T cells were transiently transfected with WT 
NL4.3 HIV-1 or a Vpu-deficient version (ΔVpu; with a frame shift mutation in the start codon of Vpu; 
Neil et al. 2006) and increasing amounts of the tetherin expression vectors. Increasing amounts of 
all tetherin constructs led to similarly reduced virus release of the Vpu deficient virus (Figure 3.2 B). 
All tetherins were well expressed with the WT construct expressing both isoforms (Figure 3.2 C). 
WT NL4.3 HIV-1 was unaffected by all concentrations of long tetherin. However, above moderate 
expression levels of short tetherin partially restricted WT virus release. The expression of both 
isoforms from the WT tetherin vector had a weaker, but notable effect on WT HIV-1 release. Four 
times more WT tetherin was needed to restrict WT virus release to a similar level as short tetherin. 
Assuming that L- and S-tetherin assort randomly into homo- and heterodimers, this suggests that 
heterodimers are sensitive to counteraction by Vpu and it is the S-tetherin homodimers that are 
responsible for increased restriction.  
Next, it was tested whether there was a difference in Vpu-mediated degradation of the two 
isoforms. For this, 293 cells stably expressing L-tetherin or S-tetherin were infected. Both tetherin 
isoforms were expressed to similar levels at the cell surface of 293 cells as determined by flow 
cytometry (Figure 3.2 D). As 293 cells do not express CD4, they were infected with VSV-G 
pseudotyped HIV-1 NL4.3 WT or ΔVpu HIV-1 at an MOI of 2 for 48 h. Analysis of tetherin expression 
by Western blotting showed that, as expected, WT virus was potently degrading L-tetherin (Figure 
3.2 E). Under the same conditions S-tetherin was not degraded, but infection led to a molecular 
mass shift in tetherin. This could be a Vpu mediated modification of tetherin, potentially 
















Figure 3.2 Tetherin isoforms are differentially sensitive to HIV-1 NL4.3 Vpu. (A) Schematic 
representation of the wild type tetherin amino acid sequence (WT THN) and mutants for long (L-
THN) and short tetherin (S-THN). (B) and (C) 293T cells were transfected with increasing amounts 
of WT THN, L-THN or S-THN and NL4.3 WT or ΔVpu proviral plasmid. (B) 48 h post transfection 
infectious virus release was determined using Hela-TZMbl reporter cells. Error bars represent 
standard deviations of the means of three independent experiments. Asterisks represent the p value 
for the difference in virus release from L-tetherin and S-tetherin expressing cells at 50 ng, 100 ng 
or 200 ng of tetherin expression vector. ns, not significant; **p<0.01, ***p<0.001 as determined by 
two-tailed t test (C) Cell lysates and pelleted viral supernatants from (B) were subjected to SDS-
PAGE and analyzed by Western blotting for Hsp90, tetherin and p-24CA. Percent of p24 release 
into the supernatant indicated below are relative to the release of NL4.3WT or NL4.3ΔVpu in the 
absence of tetherin. (D) 293 cells stably expressing the tetherin isoforms were analyzed for their 
tetherin surface expression (PE conjugated monoclonal ɑ-BST2 antibody (eBioscience)) by flow 
cytometry. (long tetherin, solid black line; short tetherin, solid grey line; empty vector 293 cells, 
dashed grey line No THN). (E) 293 cells stably expressing tetherin isoforms were infected with VSV-
G-pseudotyped NL4.3WT or NL4.3ΔVpu virus at an MOI of 2. 48 h post infection, cells were 
harvested and subjected to SDS-PAGE and analyzed by Western blotting for tetherin and Hsp90, 
and analyzed by LiCor quantitative imager. Percent of tetherin levels indicated below each lane are 
relative to tetherin levels in the corresponding uninfected cell line. 
 
A tyrosine based sorting signal (YDYCRV) as well as a potential ubiquitination motif (STS) in 
tetherin’s CT have been implicated in tetherin antagonism by HIV-1 Vpu (Kueck & Neil 2012; 
Tokarev et al. 2011). Both motifs are absent in S-tetherin and mutation of those residues reduces 
the sensitivity of tetherin to Vpu (Figure 3.3 A and B). Mutation of both motifs simultaneously 
seemed to have a slightly additive effect, which could be the result of reduced natural turnover due 
to the lack of the required sorting motifs (Figure 3.3 B and C). Replacing the tyrosines with 
phenylalanine (YDY à FDF) retains tetherin’s sensitivity to Vpu as this substitution retains the 
endocytic sorting signal to a certain extent (Figure 3.3 B). This reduced sensitivity of the YDY, STS 
or double mutant does not correlate with total cellular expression or surface levels of tetherin (Figure 
3.3 C and D). This was determined by flow cytometry analysis of 293 cells stably expressing the 
different isoforms (Figure 3.3 D). This demonstrates that these residues are required for Vpu’s 










Figure 3.3 The sensitivity of tetherin to Vpu is dependent on serines, a threonine and tyrosines. (A) 
Cytoplasmic tail amino acid sequence of tetherin mutants used to determine required residues for the 
sensitivity to NL4.3 HIV-1 Vpu. (B and C) 293T cells were transfected with increasing amounts of different 
tetherin mutants and NL4.3 WT or ΔVpu proviral plasmid. (B) 48 h post transfection infectious virus release 
was determined using Hela-TZMbl reporter cells. Error bars represent standard deviations of the means of 
three independent experiments. Black: WT tetherin; green: mutant tetherin; solid lines, NL4.3 wild type 
provirus; dashed lines, NL4.3 ΔVpu provirus. Asterisks represent the p value for the difference in virus release 
from WT tetherin and mutant tetherin expressing cells at 50 ng, 100 ng or 200 ng of tetherin expression vector. 
ns, not significant; **p<0.01, ***p<0.001 as determined by two-tailed t test. (C) Cell lysates and pelleted viral 
supernatants from (B) were subjected to SDS-PAGE and analyzed by Western blotting for Hsp90, tetherin and 
p-24CA. Percent of p24 release into the supernatant indicated below are relative to the release of NL4.3WT 
or NL4.3ΔVpu in the absence of tetherin. (D) 293 cells stably expressing the tetherin mutants (solid black line) 
were analyzed for their tetherin surface expression by flow cytometry (PE conjugated monoclonal ɑ-BST2 
antibody (eBioscience)) and are shown in comparison to 293 cells expressing long tetherin (L-THN; solid grey 
line) and empty vector 293 cells (dashed grey line). Numbers indicate the fold median fluorescence intensity 




Next this phenotype was confirmed in a cell type that is more relevant to HIV infection. A CD4+ 
T cell line, Jurkat TAg, was used, which expresses the SV40 large T antigen and no detectable 
levels of tetherin. Bulk populations of Jurkat TAg cells stably expressing L- or S-tetherin had similar 
tetherin surface levels as Jurkat cells treated with interferon for 24 h as determined by flow 
cytometry (Figure 3.4 A). Immunoprecipitation of tetherin from these cell lines showed that Jurkat 
cells express both isoforms and both L- and S-tetherin are induced equally by Interferon treatment. 
Jurkat TAg cells do not express any detectable tetherin, whereas the stable Jurkat TAg cell lines 
only express either L- or S-tetherin, which means that they were useful for further experiments 
(Figure 3.4 B). L- or S-tetherin expressing Jurkat TAg cells were infected with either WT NL4.3 virus 
or the ΔVpu version for 48 h and tetherin surface levels and intracellular p24 expression were 
assessed. As expected, the Vpu deficient virus was unable to downregulate any tetherin isoform 
from the cell surface (Figure 3.4 C and D). Rather, tetherin levels appeared to be enhanced in p24 
positive cells, which could potentially be due to accumulating virions on the cell surface and was 
observed before (Kueck et al. 2012). The WT virus was able to efficiently downregulate L-tetherin 
from infected cells. However, it was much less efficient in similarly downregulating S-tetherin 
(Figure 3.4 C and D). This was in keeping with the infectious virus released from the same cells. 
There was a significant reduction in WT virus release expressing S-tetherin compared to that from 
L-tetherin expressing cells (Figure 3.4 E). The same phenotype could be observed for the physical 
particle release from the same infected cells (Figure 3.4 F). To rule out that WT tetherin was induced 
by infection, immunoprecipitates of infected cells for tetherin were analysed for tetherin expression 
levels. However, WT tetherin expression was not induced upon infection in this system (Figure 3.4 
G).  
These data confirm that S-tetherin is less sensitive to HIV-1 NL4.3 Vpu, possibly because it is 
lacking important sorting motifs in its cytoplasmic tail that are required for HIV-1 Vpu’s ability to 
counteract tetherin potently. S-tetherin is less efficiently downregulated from the cell surface and is 
not degraded. The residual activity that is observed against S-tetherin is consistent with data from 
others showing that Vpu is capable of promoting virus release without downregulating tetherin from 
the cell surface, but rather by excluding it from sites of viral budding (Matthew W McNatt et al. 2013; 






Figure 3.4 Differential sensitivity of tetherin isoforms to Vpu in CD4+ T cell lines. (A) Jurkat TAg cells 
stably expressing long (solid light-grey line) or short (solid dark grey line) tetherin were analyzed for their 
tetherin surface expression compared to Jurkat cells treated with interferon for 24h (solid black line) or left 
untreated (dashed black line) and to Jurkat TAg cells (dashed grey line) not expressing tetherin. (B) Jurkat 
TAg cells expressing tetherin isoforms and Jurkat cells treated with interferon or left untreated were lysed and 
immunoprecipitated with anti-tetherin antibody and deglycosylated. Lysates and precipitates were subjected 
to SDS-PAGE and analyzed by Western blotting for Hsp90 and tetherin. (C) to (D) Jurkat TAg cells expressing 
long or short tetherin were infected with VSV-G pseudotyped HIV-1 NL4.3 WT or ΔVpu at an MOI of 2 for 48 
h. (C) Cells were analyzed by flow cytometry for their intracellular p24 and surface tetherin expression. Median 
fluorescence intensities (MFI) are indicated. (D) Quantification of C. median fluorescent intensities of three 
independent experiments are represented. *p<0.05 as determined by two-tailed t test. (E) Supernatants from 
infected cells were titered for infectious virus on TZMbl cells. Data are from four different experiments and 
error bars show the SEMs. **p<0.01 as determined by two-tailed t test. (F) Cell lysates and pelleted viral 
supernatants from (C) were subjected to SDS-PAGE and analyzed by Western blotting for HIV-1 Hsp90, 
tetherin and p-24CA. Percent p24 release relative to NL4.3WT or NL4.3ΔVpu release in the absence of tetherin 
is indicated below. (G) 293 cells expressing no THN, L-THN or S-THN were infected at an MOI of 2. 48 h post 
infection cells were lysed and immunoprecipitated with anti-tetherin antibody and deglycosylated. Lysates and 







3.2.2 Tetherin Isoforms Show a Similar Subcellular Localization 
To see whether the differential sensitivity of L- and S-tetherin was due to differential distribution 
of the proteins in the cell, the subcellular localization of both isoforms was analysed. It was shown 
that tetherin localizes to the plasma membrane but also to intracellular endocytic compartments 
and the TGN. HT1080 cells do not express tetherin and are flat and easy to image. Therefore, they 
were transduced with L- or S-tetherin, immunostained for tetherin and a TGN marker (TGN46) and 
analysed by confocal microscopy. However, no apparent difference in localization between the long 
and the short isoform of tetherin could be observed and both seemed to be expressed on the cell 
surface and in TGN46 positive intracellular compartments (Figure 3.5 A). In addition, both isoforms 
were expressed to equal levels on the cell surface of the same cells (Figure 3.5 B).  
Even though the isoforms do not show a differential subcellular localization themselves, we 
were wondering whether retained virions would localize distinctly depending on the tetherin isoform 
expressed. Tetherin-restricted virions are endocytosed and accumulate in late endosomal 
compartments (Neil et al. 2006). As S-tetherin lacks an important tyrosine-based sorting signal that 
is required for AP-1 and AP-2 mediated trafficking, endocytosis of virions would be expected to be 
inhibited as well. This has been reported before by our group for the tyrosine mutant of tetherin 
(Galão et al. 2012). To confirm these results for human S-tetherin, 293 cells stably expressing L- 
or S-tetherin were transfected with HIV-1 Gag-GFP, as a surrogate for viral particles, and analysed 
for whether Gag localized to the plasma membrane only or to the plasma membrane as well as 
distinctly to endosomal compartments (Neil et al. 2006). As expected, in cells expressing no tetherin 
Gag localized predominantly to the plasma membrane only (Figure 3.6 A and B). In contrast, cells 
expressing L-tetherin showed distinct accumulation of Gag in intracellular compartments. Cells 
expressing S-tetherin exhibited a lower proportion of cells with this distinct endosomal 
accumulations compared to L-tetherin expressing cells (41% versus 70%). This indicates that 
residues in the cytoplasmic tail of tetherin play a role in endocytosis. This data confirm previous 
findings implicating the dual-tyrosine motif in the cytoplasmic tail of tetherin in this partial phenotype 
(Lau et al. 2011; Galão et al. 2012). Even though enhanced endocytosis of virions by L-tetherin is 
not relevant for L-tetherin’s signalling capacity, this process may have subsequent detrimental 
effects for virus replication (Galão et al. 2012). For example, endocytosed virions may be sorted 
into endosomal pathways for degradation, which can potentially result in increased pattern 
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recognition or antigen presentation, followed by increased proinflammatory signalling. Therefore, 
counteracting L-tetherin more efficiently may be a way to overcome this.  
 
 
Figure 3.5 Subcellular localization of tetherin isoforms. (A) HT1080 cells expressing human L- or S-
tetherin were fixed, stained for tetherin (green) and TGN46 and examined by confocal microscopy. Nuclei 
were counterstained with DAPI (blue). Panels are representative examples. Bars = 10 μm. (B) The same 
cells were cell surface stained for tetherin and analysed by flow cytometry and compared to HT1080 cells not 




Figure 3.6 HIV-1 gag accumulation in endosomes is reduced in S-tetherin expressing cells (A and B) 
Tetherin-expressing 293 cell lines were transfected with an HIV-1 gag-GFP expression vector. 24 h later cells 
were fixed, stained for late endosomal marker CD63 and examined by widefield fluorescent microscopy. (A) 
Random fields were enumerated on the basis of whether transfected cells displayed plasma-membrane only 
Gag-GFP localization or PM and distinct endsomal accumulation of Gag-GFP. (B) Panels are representative 
examples. Bars = 10 μm. Z stacks were taken of all cells (n = 15), images were deconvolved using the 




3.2.3  The Differential Sensitivity of Tetherin Isoforms is a Feature of HIV-1 Group M Vpu 
Proteins 
Another study that has been conducted in our lab analysed the efficiency of primary Vpu 
proteins from HIV-1-infected patients and found that the lab-adapted HIV-1 strain NL4.3 encodes a 
Vpu that is less potent in antagonising tetherin compared to most primary Vpus (Pickering et al. 
2014). This prompted us to look at the ability of other HIV-1 group M Vpus to antagonise tetherin 
isoforms since the differential effect might have been limited to NL4.3 Vpu, and therefore not be 
representative. One patient Vpu from the Pickering et al. study that has been found to be superior 
to NL4.3 Vpu for tetherin counteraction, RP2v16_287i (2_87), and Vpus from several 
transmitted/founder viruses were tested for their isoform antagonism (Figure 3.7 A). Increasing 
amounts of Vpu expression construct were co-transfected with the NL4.3 ΔVpu provirus and a fixed 
dose of tetherin (50 ng). All Vpus were able to potently counteract L-tetherin even at low 
concentrations (Figure 3.7 B). They also counteracted WT tetherin equally well at higher Vpu 
expression levels. In contrast, they were all less efficient in counteracting S-tetherin, independent 
of Vpu concentration. Similar data were obtained for Vpus from other HIV-1 clades A1, A2, C, F 
and H (Figure 3.8 A). Where Vpu was active against tetherin (clade C MJ4 and F seemed to be 
defective for all isoforms), L-tetherin was antagonised efficiently at low Vpu expression levels 
(Figure 3.7 B). As seen with the other Vpus tested, counteraction of S-tetherin was much reduced 
for those Vpus. Altogether, these data show that the differential sensitivity of tetherin isoforms is a 













Figure 3.7 Differential sensitivity of human tetherin isoforms is a feature HIV-1 Group M Vpu proteins. 
(A) Alignment of HIV-1 Vpu amino acid sequences. Vpus used and their GenBank accession numbers: NL4.3 
(KC913697.1), RP2v16_287i (2_87; Pickering et al. 2012), REJO (JN944911.1), WITO (JN944938.1), TRJO 
(JN944936.1), CHO58 (JN944940.1) and CHO77 (JN944941.1). Alignment was generated using 
Clustal Omega. (B) 293T cells were transfected with increasing amounts of Vpu, ΔVpu proviral plasmid and 
50 ng of human WT THN, L-THN or S-THN. 48 h post transfection infectious virus release was determined 
using Hela-TZMbl reporter cells. Error bars represent standard deviations of the means of three independent 
experiments. Asterisks represent the p value for the difference in virus release from L- tetherin and S-tetherin 






Figure 3.8 Differential sensitivity of human tetherin isoforms is a feature HIV-1 Group M Vpu proteins. 
(A) Alignment of HIV-1 Vpu amino acid sequences. Vpus used and their GenBank accession numbers: NL4.3 
(KC913697.1), A1 (AF069673.1), A2 (AF286237.1), MJ4 (C) (AF321523.1), Bro (C) (U52953.1), F 
(AF005494.1) and H (AF005496.1). Alignment was generated using Clustal Omega. (B) 293T cells were 
transfected with increasing amounts of Vpu, ΔVpu proviral plasmid and 50 ng of human WT THN, L-THN or 
S-THN. 48 h post transfection infectious virus release was determined using Hela-TZMbl reporter cells. Error 
bars represent standard deviations of the means of three independent experiments. Asterisks represent the p 
value for the difference in virus release from L- tetherin and S-tetherin expressing cells at 25 ng of Vpu 





3.2.4 An HIV-1 Group N Vpu From Togo is More Efficient in Counteracting Both Isoforms 
Apart from HIV-1 group M, HIV-1 group N as well as some simian immunodeficiency viruses 
(SIVs) also utilise their Vpu proteins to counteract tetherin. Vpus from HIV-1 group N have been 
reported to be very poor tetherin antagonists. However, there is one exception of a highly 
pathogenic group N virus (N1.FR.2011) isolated from a patient who acquired infection in Togo in 
western Africa (Sauter et al. 2012). Compared to other group N Vpus, this Vpu acquired a trafficking 
motif in the second alpha helix (ExxxLV) that can also be found in group M Vpus and has been 
shown to be crucial for promoting tetherin rerouting to endosomes and therefore counteraction 
(Figure 3.9 A). This particular group N Vpu has been reported to be able to induce tetherin surface 
downregulation as well as increase virus release as potently as group M NL4.3 Vpu. Therefore, it 
was tested whether the two human tetherin isoforms were also differentially sensitive to this group 
N Vpu. NL4.3 ΔVpu virus, a fixed dose of human tetherin (50 ng) and increasing amounts of Vpu 
were co-transfected and infectious virus release was assessed 48 h later. As shown before by 
others, the group N YBF30 Vpu was unable to promote virus release from cells expressing any 
isoform (Figure 3.9 B). N1.FR.2011 however, was very potent in counteracting L-tetherin. 
Additionally, it counteracted S-tetherin equally well at higher Vpu expression levels, which could be 
seen both for infectious virus release and physical particle yield (Figure 3.9 B and C). This ability of 
N1.FR.2011 Vpu to promote virus release from S-tetherin-expressing cells led us to investigate 





Figure 3.9 HIV-1 group N Vpu from Togo is more efficient in targeting of both tetherin isoforms. (A) 
Alignment of HIV-1 Vpu amino acid sequences. Vpus used and their GenBank accession numbers: NL4.3 
(KC913697.1), N1.FR.2011 (JN572926.1) and YBF30 (AJ006022.1). Alignment was generated using Clustal 
Omega. (B) 293T cells were transiently transfected with increasing amounts of Vpu, ΔVpu proviral plasmid 
and 50 ng of human WT THN, L-THN or S-THN. 48 h post transfection infectious virus release was determined 
using Hela-TZMbl reporter cells. Error bars represent standard deviations of the means of three independent 
experiments. Asterisks represent the p value for the difference in virus release from L- tetherin and S-tetherin 
expressing cells at 25 ng of Vpu expression vector. ns, not significant; **p<0.01, ***p<0.001 as determined by 
two-tailed t test. (C) Cell lysates and pelleted viral supernatants from (B) were subjected to SDS-PAGE and 
analyzed by Western blotting for Hsp90 and p-24CA. Fold increase of p24 release into the supernatant 
indicated below are relative to the release of NL4.3ΔVpu in the absence of vpu. (D) 293 cells stably expressing 
L- or S-tetherin were transduced with retroviral vectors encoding different Vpus. Cell lysates were analysed 
for their tetherin expression using SDS PAGE and Western blotting. (E) Vpu transduced cells from (D) were 
stained for surface tetherin and analysed by flow cytometry. 293 empty vector cells (not expressing tetherin), 
dashed grey line. (F) Median fluorescence intensity for tetherin of cells from (E) is shown. Asterisks represent 
the p value for the difference in tetherin surface expression (MFI) on non-transduced or Vpu transduced cells. 
ns, not significant; *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed t test.  
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To see whether any of the group N Vpus were able to degrade the tetherin isoforms, stable 
tetherin-expressing 293 cells were transduced with retroviral vectors encoding the Vpus and 
selected for puromycin resistance. Whereas NL4.3 Vpu was able to induce the degradation of L-
tetherin, but not S-tetherin as expected, both N1.FR.2011 and YBF30 Vpus were unable to mediate 
the degradation of either of the two isoforms (Figure 3.9 D). Similarly, N1.FR.2011 was unable to 
induce the more than 2-fold surface downregulation of L-tetherin seen with NL4.3 Vpu in the same 
transduced cells. No downregulation of S-tetherin was seen for any of the group N Vpus either 
(Figure 3.9 E and F). These results suggest that the mechanism of action of the N1.FR.2011 Vpu 
might rather be exclusion of tetherin molecules from budding virions at the cell surface.  
  
3.2.5 Long and Short Monkey Tetherins are Equally Targeted by Vpu Proteins From 
SIVgsn and SIVmon 
As mentioned before, HIV-1 is not the only primate lentivirus that uses its Vpu protein to target 
tetherin. The HIV-1 Vpu originates from the SIVcpz Vpu, which itself has the Vpu proteins of greater 
spot-nosed (gsn) monkey and mona (mon) monkey SIV as ancestors. Both of these viruses use 
their Vpu to counteract their host species’ tetherin as well as other primate tetherins, such as rhesus 
macaque tetherin. To see whether the differential sensitivity of tetherin isoforms was an ancestral 
feature of Vpu, a fixed dose of rhesus macaque tetherin isoforms was co-transfected with NL4.3 
ΔVpu virus and increasing amounts of SIVgsn or SIVmon Vpu. In contrast to HIV-1 group M Vpu, 
both SIV Vpus were able to counteract all rhesus macaque tetherin isoforms with equal efficiency 
(Figure 3.10 A and B). Furthermore, similarly to N1.FR.2011 Vpu, both SIV Vpus were unable to 
mediate degradation of either L- or S-tetherin (Figure 3.10 C). To rule out species-specific effects, 
it was tested whether a different phenotype could be observed when the host species’ tetherins of 
gsn and mon rather than rhesus macaque tetherin were used. Again, all isoforms were antagonised 
with equal efficiency, taking into account that WT and S-tetherin were more highly expressed 
(Figure 3.10 D-G). These data show that the differential sensitivity of tetherin isoforms to Vpu is not 
an ancestral feature of these proteins. Rather, this suggests that when Vpu was readapting to 
counteract human tetherin during zoonotic transmission of SIVcpz to humans to form HIV-1 group 






Figure 3.10 Targeting of both tetherin isoforms by ancestral Vpu proteins from SIVgsn and SIVmon. 
(A) 293T cells were transiently transfected with increasing amounts of Vpu, ΔVpu proviral plasmid and 50 ng 
of rhesus macaque WT THN, L-THN or S-THN. 48 h post transfection infectious virus release was determined 
using Hela-TZMbl reporter cells. Error bars represent standard deviations of the means of three independent 
experiments. (B) Cell lysates and pelleted viral supernatants from (A) were subjected to SDS-PAGE and 
analyzed by Western blotting for Hsp90 and p-24CA. Fold increase of p24 release into the supernatant 
indicated below are relative to the release of NL4.3ΔVpu in the absence of Vpu. (C) 293 cells stably expressing 
L- or S-tetherin were transduced with retroviral vectors encoding different Vpus. Cell lysates were analysed 
for their tetherin expression using SDS PAGE and Western blotting. (D) and (F) 293T cells were transiently 
transfected with increasing amounts of SIVgsn Vpu (D) or SIVmon Vpu (F), ΔVpu proviral plasmid and 50 ng 
of gsn (D) or mon (F) WT THN, L-THN or S-THN. 48 h post transfection infectious virus release was determined 
using Hela-TZMbl reporter cells. Error bars represent standard deviations of the means of three independent 
experiments. (E) and (G) Cell lysates and pelleted viral supernatants from (D) and (F) were subjected to SDS-
PAGE and analyzed by Western blotting for Hsp90, tetherin and p-24CA. Fold increase of p24 release into the 
supernatant indicated below are relative to the release of NL4.3ΔVpu in the absence of Vpu. GenBank 
accession numbers: Vpu gsn (AF468659), Vpu mon (AY340701), Vpu cpz (AY418255), gsn tetherin 




3.2.6 Both Tetherin Isoforms are Equally Targeted by HIV-2 Envelope, SIVmac Nef and 
KSHV K5 
Next, it was further investigated whether tetherin antagonists other than Vpu might show 
differential efficiency against tetherin isoforms. As mentioned before, tetherin exerts high 
evolutionary pressure on enveloped viruses and therefore various viruses have evolved different 
countermeasures. HIV-2 uses its envelope (Env) to counteract tetherin by enhancing its 
endocytosis from the cell surface, dependent on the clathrin adaptor protein complex 2 (AP-2) (Lau 
et al. 2011; Le Tortorec & Neil 2009). HIV-2 Env binds to AP-2 via a GYXXθ motif in Env’s 
cytoplasmic tail. Mutation of the GY to AA renders the already weak tetherin antagonist completely 
non-functional. To see how efficiently HIV-2 Env counteracts the two human tetherin isoforms, we 
co-transfected the HIV-2 ROD10 provirus or the GY-AA Env mutant thereof with increasing 
amounts of WT, L- or S-tetherin and analysed the amount of physical virus particles released into 
the supernatant. Infectious release of the GY-AA mutant was completely abolished by any 
concentration of any of the tetherin isoforms. Even though HIV-2 ROD10 was rather weak in 
promoting virus release, it did not distinguish between L- and S-tetherin (Figure 4.10 A). The same 
was seen when looking at Env’s ability to downregulate tetherin from the cell surface. 293 cells 
stably expressing L- or S-tetherin were transfected with HIV-2 ROD10 Env IRES GFP or the GY-
AA mutant of it. As expected, the GY-AA mutant was unable to downregulate any tetherin from the 
surface. However, the WT Env downregulated both isoforms equally well (Figure 4.10 B). This 
shows that the mechanism HIV-2 Env uses to counteract tetherin is independent of ubiquitination 












Figure 3.11 HIV-2 Envelope targets human tetherin isoforms with equal efficiency. (A) 293T cells were 
transfected with increasing amounts of human WT-, L- or S-THN and HIV-2 ROD10 or the ROD10 GY-AA 
mutant proviral plasmid. Cell lysates and pelleted virions were subjected to SDS-PAGE and analyzed by 
Western blotting for Hsp90, tetherin and p26CA expression. Percent of p26CA in the supernatant are indicated 
below, relative to virus release in the absence of tetherin. This blot is a representative example of three 
independent experiments. (B) 293 cells stably expressing L-THN or S-THN were transfected with HIV-2 
ROD10 Env IRES GFP or HIV-2 ROD10 GY-AA mutant Env IRES GFP. 48 h post transfection cells were 
analyzed by flow cytometry for their GFP and tetherin surface expression. Panels are representative examples 
of three independent experiments.  
 
Most SIVs use their Nef protein to counteract tetherin as they do not encode a Vpu. One 
example is the rhesus macaque SIV. SIVmac Nef binds to the cytoplasmic tail of rhesus macaque 
tetherin and recruits AP-2 to induce tetherin’s endocytosis and intracellular sequestration similarly 
to the effect of HIV-2 Env (Zhang et al. 2011a; Serra-Moreno et al. 2013a). Nef is thought to bind 
to a five amino acid stretch ((G/D)DIWK) in primate tetherin’s cytoplasmic tail that is not present in 
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both human tetherin isoforms. The short isoform of macaque tetherin lacks twelve amino acids of 
its cytoplasmic tail, however, it still contains this five amino acid motif. We tested the ability of 
SIVmac Nef to counteract the macaque tetherin isoforms by co-transfecting SIVmac239 WT virus 
or a Nef deficient version (ΔNef) with increasing amounts of rhesus macaque tetherin isoforms. The 
Nef deficient virus exhibits an infectivity defect in 293T cells. To overcome this we also co-
transfected VSV-G. Like HIV-1 ΔVpu virus, SIVmac ΔNef virus release was restricted with 
increasing amounts of any tetherin isoform (Figure 3.12 A and B). The WT virus was relatively 
insensitive to any of the tetherin isoform and counteracted them with comparable efficiency. These 
data show that the lack of twelve amino acids in macaque tetherin’s cytoplasmic tail does not impact 
on its sensitivity to SIVmac Nef.  
 
Figure 3.12 SIVmac Nef targets rhesus macaque tetherin isoforms with equal efficiency. (A) and (B) 
293T cells were transfected with increasing amounts of rhesus macaque WT-, L- or S-THN and SIVmac or 
SIVmac ΔNef proviral plasmid. (A) Infectious virus release from transfected cells was titered on Hela-TZMbl 
reporter cells. Solid lines, SIVmac; Dashed lines, SIVmac ΔNef. (B) Cell lysates and pelleted supernatant 
virions were subjected to SDS-PAGE and analyzed by Western blotting for Hsp90, rhesus tetherin and p27CA 
expression. Percent of p27CA in the supernatant are indicated below, relative to virus release in the absence 
of tetherin. This is a representative blot of three independent experiments.  
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The next antagonist tested was the Kaposi’s sarcoma-associated herpesvirus (KSHV) encoded 
K5 ubiquitin ligase. K5 targets a lysine residue at position 18 in the cytoplasmic tail of human 
tetherin and induces ESCRT-dependent endosomal degradation of tetherin. This lysine is present 
in both L- and S-tetherin. However, K5 is not able to counteract rhesus macaque tetherin, which 
suggests that residues in the cytoplasmic tail of tetherin might play a role in this specificity. HT1080 
cells were used for the following experiments as 293Ts do not support K5 function efficiently 
(Pardieu et al. 2010). HT1080 cells stably expressing human tetherin isoforms were transduced 
with puromycin-resistant lentiviral vectors encoding K5 or a mutant of K5, K5NTR. This mutant 
harbours a lesion in it’s C-terminal cytoplasmic tail that eliminates its function (Means et al. 2007). 
Resistant cells were selected for and tetherin surface expression was assessed. Transduction with 
the mutant K5NTR protein did not change tetherin surface levels. However, K5 WT transduced cells 
showed potent tetherin downregulation from the cell surface both for L- and S-tetherin (Figure 3.13 
A).  Examining the total tetherin levels in the same cells revealed that both isoforms were also 
















Figure 3.13 KSHV K5 targets human tetherin isoforms with equal efficiency. (A) HT1080 cells stably 
expressing tetherin isoforms were transduced with K5 or a K5 mutant (K5NTR) defective for tetherin 
antagonism and selected. Cells were then analysed by flow cytometry for surface tetherin expression. Dotted 
grey, tetherin negative HT1080 cells; grey, non-transduced tetherin expressing HT1080 cells; black, tetherin 
expressing cells transduced with wt K5 (upper panel) or a mutant (K5NTR; lower panel). Graph indicates the 
tetherin surface expression on transduced cell lines, shown in percent relative to the fluorescence of the 
corresponding non-transduced tetherin expressing cell line. Asterisks represent the p value for the difference 
in tetherin surface expression (MFI) on non-transduced or K5/K5NTR transduced cells. ns, not significant; 
*p<0.05 as determined by two-tailed t test. (B) Cell lysates of transduced and non-transduced cells were 
subjected to SDS-PAGE and analyzed by Western blotting for Hsp90 and tetherin expression. Percentage of 
tetherin expression in lysates compared to non-transduced cells is shown below. 
 
In summary, these data indicate that the first twelve amino acids that are absent in S-tetherin 
are dispensable for its sensitivity to viral antagonists other than HIV-1 group M Vpu. Both isoforms 
are equally counteracted by all other antagonists tested here. This also suggests that the 
mechanisms of counteraction used by those antagonists are independent of the trafficking of 
tetherin itself, which is dependent on residues that are missing from S-tetherin.   
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3.2.7 Human L- Tetherin is Able to Induce NF-κB Signalling Whereas S-Tetherin and Both 
GSN and MON Tetherin Isoforms are Not 
Apart from its function of physically tethering virions to the plasma membrane of infected cells, 
tetherin has recently been shown to be a potent inducer of NF-κB, not only upon virus retention, 
but also following tetherin overexpression (Cocka & Bates 2012; Galão et al. 2012; Tokarev et al. 
2013). Determinants in tetherin’s cytoplasmic tail have been found to be important for its signalling 
capacity including the two tyrosines at position six and eight as well as the adjacent CRV residues 
and mutation of those motifs has been shown to abolish NF-κB induction. All of the aforementioned 
residues are absent in S-tetherin and, therefore, it is not surprising that S-tetherin is unable to 
induce proinflammatory signalling (Cocka & Bates 2012). These data were confirmed by co-
transfecting 293 cells with human tetherin isoforms and an NF-κB-dependent firefly luciferase 
reporter construct. Cells transfected with L-tetherin showed a 24-fold induction of NF-κB whereas 
cells transfected with WT-tetherin showed a 16-fold induction compared to non-tetherin transfected 
cells (Figure 3.14 A). As expected, cells overexpressing S-tetherin did not show any NF-κB 
induction as S-tetherin is lacking essential residues. This is interesting, considering that HIV-1 
group M Vpus seem to have evolved to efficiently counteract the signalling, long form of human 
tetherin.  
Tetherins from other species have been shown to only have limited signalling capacity.  
Whereas chimpanzee tetherin can induce NF-κB to a certain extent, rhesus, African green monkey 
and mouse tetherin are completely non-functional in this respect, even though they potently inhibit 
virus release (Galão et al. 2012). As the Vpu proteins of SIVgsn and SIVmon counteracted both 
isoforms of their host’s tetherin very efficiently we wondered whether those tetherin proteins were 
also able to induce NF-κB signalling. As before, increasing amounts of tetherin were transfected 
with the reporter construct. However, none of the gsn nor the mon tetherin isoforms were able to 









Figure 3.14 NF- κB activation by different primate tetherin isoforms. 293 cells were transfected with 50 
ng of human, gsn or mon tetherin isoforms and a firefly-luciferase NF-κB reporter plasmid. 48 h post 
transfection fold increase of reporter activity relative to non-tetherin transfected cells was determined. Solid 







In this chapter I examined the differential sensitivity of two tetherin isoforms to a range of 
lentiviral antagonists. I was able to show that the Vpu proteins of the pandemic HIV-1 group M were 
the only tetherin antagonists tested here that exhibit a difference in their ability to counteract human 
L- and S-tetherin. They antagonised the long version of tetherin more efficiently than S-tetherin, 
with L-tetherin being downregulated from the cell surface and degraded. All the other 
countermeasures tested in this study were equally efficient against both isoforms of their host 
species. Examples are SIVmac Nef and HIV-2 envelope, which do not induce degradation, but 
rather lead to endocytosis of tetherin and its sequestration, which occurs in an AP-2 dependent 
manner (Le Tortorec & Neil 2009; Zhang et al. 2011b; Serra-Moreno et al. 2013b; Lau et al. 2011; 
Noble et al. 2006). Also, Vpu proteins from HIV-1 group N or SIVgsn and SIVmon were equally 
efficient against their host species tetherin. These proteins, however, were unable to induce either 
downregulation or degradation of the tetherin, suggesting that their mode of action might be 
different to the other antagonists.  
Human tetherin is expressed as two isoforms. Two ATG start codons exist in its coding 
sequence with suboptimal Kozak sequences in front of them, which can potentially lead to leaky 
ribosomal scanning and the expression of both isoforms. These two ATGs are highly conserved 
among mammalian tetherins (Cocka & Bates 2012). According to our data both isoforms are 
expressed and interferon-induced to equal amounts in CD4 positive T cells. Assuming that they 
assemble independently there would be a ratio of homo- to heterodimers of 1:2:1. This is in 
agreement with our data showing that four times as much wild type tetherin (expressing both 
isoforms) is needed to restrict virus to a similar level as S-tetherin expression only and shows that 
only S-tetherin homodimers are less sensitive to HIV-1 Vpu. Whether the expression of the different 
tetherin isoforms is regulated in any way remains an open question. Even though interferon seems 
to be able to induce both human isoforms to comparable levels, differential regulation cannot be 
completely ruled out. There have been several cases reported for different species, which possess 
a polymorphism in the first ATG of tetherin. Similar to a human S-tetherin, domestic cats (Dietrich 
et al. 2011; Celestino et al. 2012), horses (Yin et al. 2014) and at least one inbred mouse strain, 
NZW, express a truncated version of tetherin lacking N-terminal residues (Barrett et al. 2012). In 
the latter case, this has been correlated with decreased Friend retrovirus replication and 
pathogenesis and increased levels of tetherin on CD4+ lymphocytes.  
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The main question that arises is why HIV-1 group M Vpus differentiate between the human 
tetherin isoforms whereas other antagonists do not. This HIV-1 group M emerged from a zoonotic 
transmission of SIVcpz, which itself has its ancestors in guenon SIVs, including SIVgsn and SIVmon 
(Sharp & Hahn 2011). Both those ancestors use their Vpu protein against both host species tetherin 
isoforms, as our data show. SIVcpz, however, uses its Nef protein to counteract chimpanzee 
tetherin. Upon zoonotic transmission of SIVcpz to humans, Vpu readapted to counteract tetherin 
and this was a crucial step in transmission of the virus. As human tetherin has a deletion of five 
amino acids (G/DDIWK) in its cytoplasmic tail it is insensitive to SIVcpz Nef (Sauter et al. 2011; 
Serra-Moreno et al. 2013a). Therefore, Vpu reacquired anti-tetherin function in HIV-1 while still 
maintaining its anti-CD4 function (Sauter et al. 2009). It is important to note that this five amino acid 
deletion in human tetherin is also a determinant of its increased signalling capacity (Galão et al. 
2012). HIV-1 group M is the group that is responsible for the world wide HIV pandemic and its 
success has been partially ascribed to its efficient tetherin-antagonising Vpu protein (Sauter et al. 
2009). There are three key features that make HIV-1 group M Vpu the most efficient at 
downregulating, but also at degrading human tetherin. There is the AxxxAxxxAxxxW 
transmembrane interface that is required for direct tetherin binding (Vigan & Neil 2010; Skasko et 
al. 2012). Furthermore, there are two important motifs in the cytoplasmic tail of Vpu. One acidic 
dileucine trafficking motif (ExxxLV) that has been shown to interact with clathrin adaptor AP-1 in a 
tetherin dependent manner and the E3 ubiquitin ligase binding site, DSGNES, that contains two 
phosphorylated serines (Kueck & Neil 2012; Jia et al. 2014; Kueck et al. 2015; Mitchell et al. 2009; 
Sauter et al. 2012). Vpu proteins from other HIV-1 groups differ from group M in these motifs. HIV-
1 group O Vpus, for example, are unable to bind directly to tetherin via their transmembrane domain 
and are hence non-functional against it (Sauter et al. 2009). However, this group of HIV-1 has 
recently been shown to use its Nef protein to counteract tetherin to some extent (Kluge et al. 2014). 
Group N Vpu proteins are able to bind to tetherin, however, fail to efficiently counteract it or induce 
its downregulation or degradation, with one exception being N1.FR.2011 (Sauter et al. 2009; Sauter 
et al. 2012). Since efficient anti-tetherin function seems to be crucial for successful transmission 
this might explain why those groups of HIV-1 remained geographically restricted. The Vpu protein 
from the pathogenic group N N1.FR.2011 reacquired the essential cytoplasmic tail determinants 
and our data show that it is capable to counteract both human tetherin isoforms equally well, without 
inducing downregulation or degradation of the proteins. This suggests that there must be cell 
biological differences in the mechanism of action. One possibility is that it is excluding tetherin from 
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budding virions, which would require the acidic dileucine motif in Vpu, but not the sorting signal in 
tetherin (McNatt et al. 2013; Sauter et al. 2012). Similarly, SIVgsn and SIVmon Vpus do counteract 
both their host species tetherin isoforms very efficiently without leading to their downregulation or 
degradation, as data presented in this chapter show. In contrast to N1.FR.2011 however, they do 
not have the ExxxLV trafficking motif (Sauter et al. 2009). The mode of action of those proteins still 
needs clarification.  
The question that still remains is: Why do only HIV-1 group M Vpus differentiate between the 
isoforms? In addition to its ability to physically restrict virions, another function of tetherin has 
recently been shown to be the induction of NF-κB and proinflammatory signalling (Galão et al. 2012; 
Tokarev et al. 2013). This function also depends on the YDYCRV motif in tetherin’s cytoplasmic 
tail. Virion retention and clustering of tetherin leads to the phosphorylation of the tyrosines and the 
recruitment of a TRAF2/TRAF6/TAK1 complex that then activates NF-κB in an endocytosis-
independent manner (Galão et al. 2012; Galão et al. 2014). However, only human tetherin and to 
a lesser extent chimpanzee tetherin have been shown to be able to induce robust NF-κB signalling. 
This is due to species-specific changes in tetherin’s cytoplasmic tail, importantly, the deletion of five 
amino acids in human tetherin that also renders it insensitive to SIV Nef (Galão et al. 2012).  
Furthermore, it has been shown that only human L-tetherin is able to induce signalling but not S-
tetherin. S-tetherin even dominantly interferes with signal induction, suggesting that only L-tetherin 
homodimers are able to mediate proinflammatory signalling (Cocka & Bates 2012). This is in 
keeping with the suggestion that the two YDYCRV motifs of a L-tetherin homodimer can act as a 
noncanonical hemi-immunoreceptor tyrosine-based activation motif (hemITAM) (Galão et al. 2014). 
To be able to function, both tyrosine motifs need to be intact. The lack of the YDYCRV signalling 
and sorting motif in S-tetherin also means it is endocytosed and recycled much less than L-tetherin. 
Accordingly, restricted HIV-1 virions are not trafficked to late endosomes as much in the presence 
of S-tetherin or a tetherin YDY mutant (Galão et al. 2012) compared to L-tetherin, as our data 
confirm. The delivery of virions to endosomes by L-tetherin may have, additionally, important 
immunological consequences. Restricted and endocytosed virus is potentially degraded and 
subjected to enhanced antigen presentation or might serve as a pathogen-associated molecular 
pattern (PAMP). This PAMP can be sensed by a pattern recognition receptor (PRR) and would 
induce proinflammatory signalling. The increased accumulation of virions on the cell surface 
possibly mediated by S-tetherin on the other hand, is leading to enhanced opsonisation and 
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antibody-dependent cellular cytotoxicity (ADCC) (Pham et al. 2014; Arias et al. 2014; Alvarez et al. 
2014). Furthermore, tetherin has been reported to regulate PRR function in plasmacytoid dendritic 
cells via the inhibitory leukocyte receptor ILT7. This has been, however, a matter of debate (Cao et 
al. 2009; Tavano et al. 2013; Bego et al. 2015). Moreover, the role of tetherin in restricting cell-to-
cell transfer of virus at the virological synapse (VS) is controversial. Differential representation of 
tetherin isoforms at the VS could potentially explain the different results obtained in those studies 
(Casartelli et al. 2010; Jolly et al. 2010; Kuhl et al. 2010). In both cases, the role of tetherin isoforms 
is unclear and requires further investigation.  
Altogether, the data presented in this chapter show clearly that the differential sensitivity of 
tetherin isoforms is restricted to HIV-1 group M, which is also the only group of tetherin antagonists 
that is able to induce efficient downregulation and degradation of L-tetherin. Considering the 
successful pandemic spread of this group of viruses, being able to specifically target L-tetherin very 
efficiently must have an evolutionary benefit. The proinflammatory signalling capacity of human L-
tetherin upon virus retention is likely to have detrimental effects on a virus in vivo and the ability to 






Chapter 4 Serine Phosphorylation of HIV-1 Vpu and its Binding to 
Tetherin Regulates Interaction with Clathrin Adaptors 
Most of the data presented in this chapter have been published as “Serine Phosphorylation of 
HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors” (Kueck et al. 
2015). This was a co-first authored manuscript by myself, Tonya Kueck and Toshana Foster. Where 
data are presented from others they are referred to appropriately.  
 
4.1 Introduction 
Tetherin physically restricts viral release by cross-linking budding virions to the infected cell, 
which induces proinflammatory signalling (Neil et al. 2008; Van Damme et al. 2008; Galão et al. 
2012). In uninfected cells, endocytosed tetherin is recycled back to the plasma membrane via the 
TGN (Figure 4.1 A). This is dependent on its cytoplasmic dual tyrosine sorting motif (YDYCRV) that 
has been shown to interact with the clathrin adaptor AP-1 (Rollason et al. 2007; Jia et al. 2014). 
Counteraction of tetherin by viral accessory proteins such as Vpu or Nef is a crucial feature of 
successfully transmitted viruses. These antagonists act by removing tetherin from its site of action, 
the plasma membrane (PM). HIV-1 Vpu directly interacts with tetherin via both their transmembrane 
domains and targets it into an ESCRT-dependent endosomal degradation pathway, thereby 
preventing newly synthesized and recycling tetherin from trafficking to the PM (Figure 4.1 B) 
(McNatt et al. 2013; Skasko et al. 2012; Vigan & Neil 2010).  
The degradation of tetherin requires a highly conserved DSGNES motif in Vpu’s cytoplasmic 
tail (Douglas et al. 2009; Mangeat et al. 2009; Mitchell et al. 2009). The two serines in this motif are 
phosphorylated constitutively (S52/53 and S56/57 in subtype B depending on the isolate) by CKII, 
which mediates the recruitment of the β-TrCP 1/2 subunits of the Skp1-Cullin1-F-Box (SCF) E3 
ubiquitin ligase complex (Schubert et al. 1992; Schubert & Strebel 1994; Margottin et al. 1998). 
Tetherin can be ubiquitinated at several cytoplasmic residues including an STS motif (Tokarev et 
al. 2011). However, whether recruitment of β-TrCP and the subsequent degradation of tetherin are 
crucial steps in antagonism by Vpu is a matter of debate and depends on the assay used. Mutation 
of the serines in the conserved DSGNES motif in Vpu (the so-called 2/6A mutant) leads to a partial 
defect in counteraction that cannot be fully explained by the lack of tetherin degradation (Mangeat 
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et al. 2009; Mitchell et al. 2009; Schubert & Strebel 1994). It has been proposed previously that β-
TrCP recruitment is not essential for tetherin counteraction and that the DSGNES motif in Vpu might 
play an additional role (Tervo et al. 2011). This notion is supported by naturally occurring Vpu 
variants that have been examined by our lab. Mutation of the N or the E in the DSGNES motif led 
to reduced anti-tetherin activity without losing anti-CD4 function, which is dependent on the 
recruitment of β-TrCP (Pickering et al. 2014). These data indicate that mis-trafficking of tetherin 
may be sufficient to overcome its restriction. 
Antagonism of tetherin by Vpu has been shown to be clathrin dependent (Lau et al. 2011; 
Kueck & Neil 2012). While AP-1 has been proposed to be the major clathrin adaptor involved in 
Vpu-mediated tetherin mis-trafficking, knock down of AP-1 does not result in loss of Vpu function 
(Kueck & Neil 2012). Recently, it has been reported that tetherin and Vpu can form a ternary 
complex with AP-1 where Vpu’s ExxxLV motif binds the σ-subunit and tetherin’s YXXθ binds the µ-
subunit of AP-1 (Jia et al. 2014). This acidic dileucine variant ExxxLV in the second α-helix of the 
cytoplasmic tail of Vpu has been shown to be required for the mis-trafficking of tetherin (Schmidt et 
al. 2011; Dubé et al. 2011; Kueck & Neil 2012). Mutation of this motif results in aberrant localization 
of Vpu and reduced virus release from tetherin expressing cells. Tetherin degradation by this Vpu 
mutant is completely abolished, without the loss of tetherin-Vpu binding. The residual anti-tetherin 
activity of this mutant is fully dependent on the dual-tyrosine motif in tetherin (Kueck & Neil 2012).  
Two isoleucine residues (I43 and I46 in B Vpu; this mutant is referred to as LILI) and a 
tryptophan residue (W76) have been newly identified as important for Vpu’s anti-tetherin activity 
(Pickering et al. 2014). Whilst the two isoleucine residues are also required for CD4 downregulation, 
the tryptophan is not. Both the LILI and the tryptophan mutant will be further analysed in the 
following chapter.  
Dr Tonya Kueck, a former PhD student in our lab was able to show that the ESCRT 
components UBAP1 and HRS are required for tetherin degradation, but have only little to no effect 
on Vpu’s function to promote virus release (Kueck et al. 2015; see appendix). Dr Kueck along with 
Dr Toshana Foster have been involved in some of the data presented in this chapter and this will 




Figure 4.1 Model of tetherin trafficking and Vpu-mediated mis-trafficking. (A) Tetherin trafficking in the 
absence of Vpu. Newly synthesized tetherin traffics to the plasma membrane. AP-2 mediates the endocytosis 
of tetherin in clathrin-coated pits. It then traffics to the TGN, mediated by AP-1, and recycles back to the plasma 
membrane. (B) Tetherin trafficking in the presence of Vpu. Vpu interacts with newly synthesized or recycling 
tetherin in the endoplasmic reticulum (ER) or the Golgi apparatus. Instead of reaching the plasma membrane, 
the Vpu/tetherin complexes are sorted into endosomal compartments. Vpu recruits SCF-β-TrCP, which 
ubiquitinates tetherin’s cytoplasmic tail. Ubiquitin-dependent recruitment of HRS then induces ESCRT-
dependent degradation in lysosomes.  
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In this chapter the importance of β-TrCP recruitment in tetherin counteraction was re-
evaluated. The data presented here suggest that Vpu phosphorylation is required for counteraction, 
whereas β-TrCP binding is not and they confirm the idea of a dual function of the phosphorylated 
serine motif. The Vpu phospho-mutant 2/6A as well as various other Vpu mutants exhibit defects 
that show similarity to the ExxxLV mutant in terms of virus release and subcellular localization of 
Vpu. This could also be confirmed for the same mutants generated in a primary Vpu. Addition of 
the clathrin binding box of the ESCRT-0 component HRS to the C-terminus of the Vpu mutants 
rescues virus release, tetherin downregulation as well as Vpu localization, but not β-TrCP 
interaction of the 2/6A mutant. For the first time, we are able to demonstrate binding of Vpu to AP-
1 in a tetherin-dependent manner. Altogether, the data support a model where phosphorylation of 
Vpu mediates clathrin adaptor binding and subsequent mis-trafficking of tetherin, which seems to 




4.2 Results  
4.2.1 Recruitment of β-TrCP is Not Required for HIV-1 Release 
Recruitment of the SCFβTRCP1/2 E3 ubiquitin ligase by the phosphorylated DSGNES motif in the 
cytoplasmic tail of Vpu is crucial for the degradation of tetherin. However, whether this degradation 
step is required for counteraction of virus restriction has been a matter of debate. Most of the studies 
in this area have been done under transient transfection conditions. Therefore, this question was 
re-evaluated using viral infection of 293T cells stably expressing tetherin. To ensure these cells 
expressed tetherin at physiological levels, cells stably expressing tetherin were analysed for their 
surface tetherin by flow cytometry and compared to 293T cells that were treated with interferon for 
24 h to induce endogenous tetherin expression. This showed that tetherin was expressed to 
comparable, but slightly higher levels in the stable cell line (Figure 4.2 A). It was previously shown 
that knockdown of UBAP1 (ESCRT-1) resulted in the block of tetherin degradation, but had only an 
insignificant effect on infectious virus release (Agromayor et al. 2012). Similarly, Tonya Kueck 
showed that the ESCRT-0 component HRS was required for tetherin degradation but not virus 
release (Kueck et al. 2015; see appendix). To reinvestigate the role of ubiquitin ligase recruitment, 
β-TrCP 1 and 2 were simultaneously knocked down in 293T or 293T THN cells and infected with 
HIV-1 WT, ΔVpu or the phospho-mutant (2/6A). In Vpu 2/6A two serine residues, 52 and 56, are 
mutated to alanines, which leads to the loss of serine-phosphorylation. This Vpu mutant is unable 
to interact with β-TrCP and has a defect in counteracting tetherin and in inducing its degradation 
(Mitchell et al. 2009; Margottin et al. 1998; Mangeat et al. 2009). Efficient siRNA knock down of β-
TrCP in 293T and 293T tetherin cells had only a minor effect on the release of WT virus and did 
not recapitulate the defect of the 2/6A mutant in tetherin-expressing cells (Figure 4.2 B and C). 
Under the same conditions, the degradation of tetherin was completely abolished in cells infected 
at an MOI of 2. This indicates that not only core ESCRT components are dispensable for tetherin 
counteraction, but also recruitment of the SCFβTRCP1/2 E3 ubiquitin ligase by Vpu is not required for 
promoting virus release from infected cells under conditions where β-TrCP depletion blocks tetherin 









Figure 4.2 Recruitment of β-TrCP is required for tetherin degradation, but not for tetherin 
counteraction. (A) The graph indicates the median fluorescence intensity of tetherin surface expression for 
293T cells, 293T cells treated with 1000 U/ml universal type-I interferon for 24 h or the same cells stably 
expressing tetherin. (B-D) 293T or 293T tetherin cells were transfected with siRNA oligonucleotide directed 
against β-TrCP1 and 2 or non-targeting control. Cells were infected with VSV-G pseudotyped NL4.3 HIV-1 
WT, ΔVpu or Vpu 2/6A mutant at an MOI of 0.8. (B) Infectivity of viral supernatants was assayed on HeLa-
TZMbl reporter cells. Infectious virus release was plotted as β-galactosidase activity in relative light units 
(RLU). Error bars represent the standard deviation of three independent experiments. Asterisks represent the 
p value for the difference in infectious virus release from β-TrCP siRNA or control siRNA transfected cells. ns, 
not significant as determined by two-tailed t test. (C) Cell lysates and sucrose purified viral supernatants from 
(B) were subjected to SDS-PAGE and analyzed by Western blotting for HSP90, β-TrCP and HIV-1 p24CA, 
and analyzed by LiCor quantitative imager. (D) Cells were treated as in (B) but infected at an MOI of 2. Cell 








4.2.2 The 2/6A Phosphorylation Mutant Phenocopies the ExxxLV Trafficking Mutant 
Recently, it has been shown by our group that a conserved ExxxLV sorting signal was required 
for tetherin counteraction and that mutation of this motif to alanines resulted in a virus release and 
Vpu localization defect (Kueck & Neil 2012). Residual activity of the ELV mutant was dependent on 
the presence of the dual tyrosine motif in tetherin (Kueck & Neil 2012). Another study showed that 
Vpu and tetherin form a ternary complex with AP-1, which requires both the ExxxLV in Vpu and the 
YDYCRV in tetherin. Additionally, residues 42 and 43 in Vpu’s first alpha helix were proposed to 
make a non-canonical contact with AP-1µ (Jia et al. 2014). A study conducted in our lab analysing 
patient-derived HIV-1 Vpu sequences also identified similar residues to be important for anti-
tetherin activity (Pickering et al. 2014). Mutation of the conserved L41I42/L45I46 (LILI) residues to 
alanines reduced virus release from infected tetherin-expressing cells to the levels of the ELV 
mutant and also the phospho-mutant 2/6A showed a comparable defect. (Figure 4.3 A-C). Infection 
of 293T cells expressing the tyrosine mutant of tetherin (Y6,8A) resulted in the loss of the residual 
activity of the Vpu mutants. All mutants were also similarly defective for downregulating tetherin 
from the cell surface (Kueck et al. 2015; see appendix). The two serine residues are located in an 
acidic patch between the LILI and the ELV motifs. We therefore hypothesized that the 2/6A mutant 
may be similarly defective for mis-trafficking tetherin like the ELV mutant. WT Vpu predominantly 
associates with the TGN marker TGN46 and it was shown that this localization was significantly 
reduced for the ELV trafficking mutant in tetherin expressing cells (Kueck & Neil 2012). Hela cells 
were transfected with HA-tagged versions of WT Vpu or the 2/6A, ELV and LILI mutants. Like the 
ELV mutant, 2/6A and LILI mainly localized to peripheral endosomal compartments rather than only 
to the TGN (Figure 4.4 A). Quantification of the coincidence of Vpu-HA and TGN46 showed that all 
mutants presented a significantly reduced TGN co-localization compared to WT Vpu (Figure 4.4 B). 
This suggests that the 2/6A and LILI mutants exhibit the same trafficking defect as the ELV mutant 
and that their residual anti-tetherin activity depends on an intact sorting signal in the cytoplasmic 









Figure 4.3 The 2/6 Vpu phospho-mutant phenocopies the Vpu trafficking mutant. (A) Alignment of amino 
acid sequences of HIV-1 NL4.3 Vpu and mutants. Mutations are highlighted in red. Alignment was generated 
using Clustal Omega. (B and C) 293T, 293T tetherin or Y6,8A tetherin cells were infected with VSV-G 
pseudotyped NL4.3 WT or mutant virus at an MOI of 0.8. (B) 48 hours post infection viral supernatants were 
assayed for infectivity using HeLa-TZMbl reporter cells as in Fig 1. Error bars represent the standard deviation 
of three independent experiments. Asterisks represent the p value for the difference in infectious virus release 
from 293T cells and tetherin expressing 293T cells. ns, not significant; *p<0.05, **p<0.01, ***p<0.001 as 
determined by two-tailed t test. (C) Cell lysates and sucrose purified viral supernatants were subjected to SDS-





Figure 4.4 The 2/6 Vpu phospho-mutant has a similar localization defect to the Vpu trafficking mutant. 
(A) Hela-TZMbl cells were transfected with 100 ng of pCR3.1 Vpu-HA or indicated mutants. 16 hours post 
transfection cells were fixed and stained for HA (green) and the TGN marker TGN46 (red) and examined by 
widefield fluorescent microscopy. Panels are of representative examples. Bars = 10 µm. (B) Z stacks were 
taken of all cells (n=15), images were deconvolved using the AutoQuant X3 software and Pearson’s 
correlations were calculated for all Z stacks using ImageJ. Results were analyzed by unpaired 2-tailed t-test - 
**p<0.01, *** p<0.001. 
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If the 2/6A and the ELV mutants are defective for the same reason we might expect that a 
2/6A-ELV double mutant would not have an additive anti-tetherin defect. In keeping with this 
hypothesis, there was no significant additive reduction of virus release in the case of the double-
mutant from infected 293T tetherin cells, even though virus release seemed to be slightly reduced 
in all cell types (Figure 4.5).  Another DSGNES motif mutant, NE, was also examined for its ability 
to counteract tetherin. N54 and E55 are highly conserved and while these residues are not required 
for β-TrCP interaction, patient-derived mutants (N55H/E56G) have been found to have impaired 
anti-tetherin activity (Pickering et al. 2014). Mutation of these residues in NL4.3  led to reduced 
virus release similar to all the other mutants tested (Figure 4.5). Furthermore, all mutants exhibited 
the same phenotype in primary CD4+ T-cells treated with type-I interferon, which induces tetherin 
expression (Figure 4.6). Of note, the apparent molecular weight of the LILI Vpu mutant in figure 4.5 
B and 4.6 does not correlate with the amino acid length of the protein. The anomalous migration 
could be due to amino acid changes resulting in gel shifting.   
These data further indicate that the DSGNES motif plays a role in anti-tetherin activity 
independent of its β-TrCP recruitment function. Altogether, these data suggest that the 2/6A mutant 
is defective in tetherin counteraction, potentially because serine phosphorylation regulates 
















Figure 4.5  Additional Vpu mutants have a similar virus release defect in 293T tetherin cells. (A and B) 
293T, 293T tetherin or Y6,8A tetherin cells were infected with VSV-G pseudotyped NL4.3 WT or mutant virus 
at an MOI of 0.8. (A) 48 hours post infection viral supernatants were assayed for infectivity using HeLa-TZMbl 
reporter cells as in Figure 1. Error bars represent the standard deviation of three independent experiments. 
Asterisks represent the p value for the difference in infectious virus release from 293T cells and tetherin 
expressing 293T cells. ns, not significant; *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed t test.  
(B) Cell lysates and sucrose purified viral supernatants were subjected to SDS-PAGE and analysed by 










Figure 4.6 Additional Vpu mutants have a similar virus release defect in primary CD4+ T cells. (A) 
Primary human CD4+ T cells were infected with the indicated HIV-1 mutant at an MOI of 0.8. 16 h later the 
cells were treated or not with 5000 U/ml universal type-I interferon. Cell lysates and viral supernatants were 
harvested a further 24 h later and analysed cellular viral expression and physical particle yield by quantitative 
Western blotting.  
 
4.2.3 Equivalent Mutants in a Highly Active Primary Vpu Show the Same Phenotypes as 
the NL4.3 Vpu Mutants 
As mentioned before, a previous study conducted by members of our group found that the lab 
strain NL4.3 Vpu is inferior in its anti-tetherin activity to most Vpus isolated from patient samples 
(Pickering et al. 2014). To be sure that the defects seen with the different mutants are not limited 
to NL4.3, the same mutations were introduced in a highly active patient-derived Vpu (Vpu 2_87) 
and tested for their tetherin counteractivity and subcellular localization. The 2/6A phospho-mutant 
is named 3/7A here, because in this isolate the two serines are at positions 53 and 57. 293T cells 
expressing WT tetherin or the tyrosine mutant (Y6,8A) were co-transfected with increasing amounts 
of Vpu and a Vpu-defective NL4.3 provirus. At lower concentrations 2_87 Vpu WT was 
counteracting tetherin more efficiently than NL4.3 Vpu WT (Figure 4.7 A black versus grey lines, all 
panels). Similar to the mutants in NL4.3 Vpu all 2_87 Vpu mutants were partially defective in 
antagonizing WT tetherin compared to 2_87 Vpu WT (Figure 4.7A red triangle) and lost any residual 
activity against the tyrosine mutant of tetherin Y6,8A (Figure 4.7 A red open circle). Also, the 
localization of all mutants was comparable to that of the NL4.3 Vpu mutants with more Vpu being 
present in peripheral endosomal compartments. Quantification revealed that there was a significant 
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reduction in co-localization of Vpu with TGN46 for all the mutants compared to WT 2_87 Vpu (Figure 
4.8 A and B). This demonstrates that the defects of the Vpu mutants are not restricted to the lab 
strain NL4.3 Vpu and shows that these residues are essential for Vpu trafficking and tetherin 
antagonism in a patient-derived Vpu protein.  
 
 
Figure 4.7 Mutants of a primary isolate Vpu exhibit a comparable virus release defect to NL4.3 Vpu 
mutants. (A) 293T tetherin cells were transfected with NL4.3 ΔVpu proviral plasmid in combination with YFP 
expression vector and pCR3.1 2_87 Vpu or mutants thereof. 48 hours post transfection infectivity of viral 
supernatants was determined on HeLa-TZMbl cells as in figure 4.2. Error bars represent standard deviation of 
two independent experiments. Red, 2_87 Vpu mutant; black, 2_87 Vpu WT; grey, NL4.3 Vpu WT; Triangle, 
293T THN cells; open circle, 293T THN Y6,8A. Asterisks represent the p value for the difference in virus 
release from 293T THN cells between 2_87 Vpu WT and Vpu mutant at 25ng of Vpu expression vector. *p > 
0.05, **p > 0.01, as determined by two-tailed t test (B) Cell lysates and pelleted supernatant virions from (A) 
were harvested and subjected to SDS-PAGE and analysed by Western blotting for HIV-1 p24CA, Vpu and 





Figure 4.8 Mutants of a primary isolate Vpu exhibit a comparable localization phenotype to NL4.3 Vpu 
mutants. (A) Hela cells were transfected with 100 ng of pCR3.1 2_87 Vpu-HA or indicated mutants. 16 hours 
post transfection cells were fixed and stained for HA (green) and the TGN marker TGN46 (red) and examined 
by widefield fluorescent microscopy. Panels are of representative examples. Bars = 10 µm. (B) Z stacks were 
taken of all cells (n=15), images were deconvolved using the AutoQuant X3 software and Pearson’s 
correlations were calculated for all Z stacks using ImageJ. Results were analyzed by unpaired 2-tailed t-test - 
*** P = 10-5 or lower. 
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4.2.4 Vpu Phosphorylation is Required for Tetherin Counteraction 
The HIV-1 Vpu 2/6A mutant shows a defect in virus release that cannot be completely attributed 
to its inability to recruit β-TrCP and this suggests that Vpu phosphorylation potentially plays another 
role in tetherin antagonism. Both serines are phosphorylated by casein kinase II (CKII) (Schubert 
et al. 1994). To test the requirement of Vpu serine phosphorylation for tetherin antagonism the CK-
II inhibitor Tyrphostin AG 1112 was used, which has been implicated in inhibition of Vpu-mediated 
tetherin degradation (Schindler et al. 2010). Therefore, WT HIV-1 infected cells were treated with 
Tyrphostin AG 1112 to see whether this would recapitulate the 2/6A defect. The treatment resulted 
in the inhibition of WT HIV-1 release in tetherin-expressing cells, especially in those expressing the 
Y6,8A mutant (Figure 4.9 A). Lysates from cells transfected with HA-tagged Vpu expression vectors 
were run on an 8% PhosTag gel and analysed for Vpu by Western blotting. Phosphorylated WT 
Vpu appeared as a smear in contrast to the unphosphorylated 2/6A Vpu (Figure 4.9 C). WT Vpu 
from cells treated with Tyrphostin, however, appeared as a significantly reduced smear, consistent 
with loss of phosphorylation. These data further demonstrate that phosphorylation of serine 
residues in the cytoplasmic tail of Vpu is required for efficient virus release. Importantly, while these 
data correlate with the previous findings, it needs to be mentioned that Tyrphostin AG 1112 may 
have additional effects on the overall experimental system and is toxic at concentrations higher that 














Figure 4.9 Serine phosphorylation of Vpu is required for tetherin counteraction. (A) 293T, 293T tetherin 
or Y6,8A tetherin cells were infected with VSV-G pseudotyped NL4.3WT at an MOI of 0.8. 6 hours post 
infection DMSO or 50 μM Tyrphostin was added to the medium. 48 hours post infection viral supernatants 
were assayed for infectivity using HeLa-TZMbl reporter cells as in figure 4.2. Error bars represent the standard 
deviation of three independent experiments. Asterisks represent the p value for the difference in virus release 
from 293T or 293T THN cells treated with DMSO or Tyrphostin AG 1112. *p > 0.05, ***p > 0.001, as determined 
by two-tailed t test (B) Cell lysates and sucrose purified viral supernatants were subjected to SDS-PAGE and 
analyzed by Western blotting as in figure 4.2. (C) 293T tetherin cells were transfected with 2 μg pCR3.1Vpu-
HA or 2/6 Vpu-HA and treated with DMSO or 50 μM Tyrphostin for 24 h. Cell lysates were electrophoresed as 
before, or on an 8%, 50 μMPhos-tag gel to separate the phosphorylated species. 
 
 
4.2.5 Addition of the HRS Clathrin Binding Box Rescues Vpu Mutants in Tetherin-
Expressing Cells, Which is Dependent on Tetherin’s YDY Motif 
Vpu counteracts tetherin by preventing it from reaching the cell surface and rerouting it into a 
clathrin-dependent endosomal trafficking pathway. All mutants tested in this study exhibit a defect 
in their anti-tetherin activity and subcellular localization comparable to the ELV trafficking mutant 
that has been suggested to be impaired in its ability to bind AP-1 (Jia et al. 2014). The next question 
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was whether this defect could be rescued when clathrin adaptors were bypassed. To test this, the 
clathrin box (CB) from ESCRT-0 component HRS (AQLISFD) or a clathrin-interaction mutant 
thereof (AQAASFD) was added to the C-terminus of all the Vpu mutants (Figure 4.10 A). All 
constructs were transiently co-transfected with a Vpu-deficient provirus into 293T cells stably 
expressing WT tetherin or Y6,8A tetherin. WT Vpu rescued virus release efficiently with or without 
CB addition in 293T tetherin cells and also remained active in 293T cells expressing the tyrosine 
mutant Y6,8A (Figure 4.10 B and C). As expected, all mutants showed reduced tetherin 
counteractivity in tetherin expressing cells. They were all expressed well, although the molecular 
weight of the chimeras in SDS-PAGE did not reflect their amino acid length (Figure 4.10 C). The 
residual anti-tetherin-activity of all mutants was completely abolished in Y6,8A tetherin cells (Figure 
4.10 B). The addition of the HRS CB rescued virus release efficiently for all mutants in tetherin-
expressing cells (Figure 4.10 B). In contrast, CB addition did not rescue virus release in Y6,8A 
tetherin cells and all chimeras remained defective (Figure 4.11). This shows that addition of a 
clathrin binding box to a Vpu trafficking mutant is not sufficient to reconstitute WT Vpu function in 
Y6,8A tetherin cells. Tetherin sorting into clathrin-rich domains in the recycling compartment is 
crucial for the CB chimera rescue and subsequent anchoring of the Vpu/tetherin complex to clathrin 





Figure 4.10 Functional rescue of Vpu phospho- and trafficking mutants by direct interaction with 
clathrin. (A) Schematic representation of Vpu CB chimera constructs. (B) 293T tetherin cells were transfected 
with NL4.3 ΔVpu proviral plasmid in combination with YFP expression vector and pCR3.1 Vpu, pCR3.1 Vpu 
CB or Vpu CB mut or Vpu mutants thereof. 48 hours post transfection infectivity of viral supernatants was 
determined on HeLa-TZMbl cells as in figure 4.3. Error bars represent standard deviation of three independent 
experiments. Asterisks represent the p value for the difference in virus release from 293T cells between Vpu 
mutants and Vpu mutants with CB at 25ng of Vpu expression vector. *p > 0.05, **p > 0.01, as determined by 
two-tailed t test (C) Cell lysates and pelleted supernatant virions from (B) were harvested and subjected to 






Figure 4.11 The rescue of trafficking mutants by direct clathrin interaction is dependent on tetherin’s 
dual tyrosine motif. 293T Y6,8A tetherin cells were transfected with NL4.3 ΔVpu proviral plasmid in 
combination with YFP expression vector and pCR3.1 Vpu, pCR3.1 Vpu CB or Vpu CBmut or Vpu mutants 
thereof. 48 hours post transfection infectivity of viral supernatants was determined on HeLa-TZMbl cells as in 
figure 4.2. Error bars represent standard deviation of three independent experiments. Asterisks represent the 
p value for the difference in virus release from 293T THN cells between 2_87 Vpu WT and Vpu mutant at 25ng 
of Vpu expression vector. ns, not significant; as determined by two-tailed t test. 
 
As CB addition to the Vpu mutants restored their tetherin counteractivity, Tonya Kueck also 
investigated whether it would also rescue tetherin downregulation from the cell surface. Hela-TZMbl 
cells were therefore transfected with the different Vpu constructs and analysed for their tetherin 
surface expression 48 h later. This revealed that the CB addition enabled the Vpu mutants to 
downregulate tetherin from the surface as efficiently as WT Vpu (Figure 4.12 A). In contrast, tetherin 
degradation was not restored in the same cells when the CB was present (Figure 4.12 B). Moreover, 
it was tested whether direct clathrin linkage would restore binding of the Vpu 2/6A mutant to β-
TrCP. All Vpu mutants with CB or CBmut could be immunoprecipitated with a myc-tagged β-TrCP2, 
except the Vpu 2/6A mutant (Figure 4.13). This further supports the notion that Vpu’s anti-tetherin 






Figure 4.12 Clathrin binding rescues tetherin downregulation, but not tetherin degradation. (A) HeLa-
TZMbl cells were co-transfected with pCR3.1 Vpu or indicated mutant and a GFP expression vector. Cell-
surface tetherin levels were analysed 48 hours post transfection by flow cytometry in the GFP positive cells. 
The percentages of tetherin surface expression levels are calculated from median fluorescence intensities. 
Error bars represent standard deviation of two independent experiments. (B) 293T tetherin cells were 
transfected with pCR3.1 Vpu or indicated mutant. 48 hours post transfection cell lysates were subjected to 
SDS-PAGE and analyzed by Western blotting for HSP90 and tetherin, and analyzed by LiCor quantitative 








Figure 4.13 Clathrin binding does not restore β-TrCP binding. 293T cells were transfected with pCR3.1 
Vpu or indicated mutant in combination with a pCR3.1 myc-β-TrCP2 expression vector. 48 hours post 
transfection cells were lysed and immunoprecipitated with anti-myc antibody, using PFA (0.05% w/v) as a 
cross-linking agent. Total cell lysates and precipitates were subjected to SDS-PAGE and analysed by Western 
blotting for myc-β-TrCP2 and Vpu-HA, and analysed by ImageQuant. All data by Tonya Kueck. 
 
As CB addition to mutant Vpus is able to rescue virus release from transfected cells it was next 
investigated whether there was also a change in subcellular localization of the chimeric Vpus. Hela-
TZMbl cells were transfected with HA-tagged versions of the Vpu mutants and the Vpu-CB chimeric 
constructs. As described before, all mutants showed significantly reduced co-localization to TGN46 
positive compartments (Figure 4.14 A). Adding the CB restored the localization of all mutants to a 
WT Vpu phenotype and peripheral endosomal localization was remarkably reduced. Quantification 
confirmed that there was a significant difference in co-localization of Vpu with TGN46 between 
mutant Vpus and their Vpu-CB chimeras (Figure 4.14 B).  
These data strengthen our hypothesis that the anti-tetherin defect of the 2/6A mutant and all 
the other trafficking mutants is due to a deficiency in clathrin-dependent sorting upstream of 






Figure 4.14 Addition of a clathrin box to Vpu mutants rescues subcellular localization. (A and B) Hela 
cells were transfected with 100 ng of pCR3.1 Vpu-HA or Vpu-HA CB or indicated mutants and processed as 
in Figure 2. Vpu-HA (green); TGN marker TGN46 (red). (A) Bars = 10 µm. (B) Asterisks inside the bars 
represent significant localization differences between the mutant and WT Vpu, those above between mutant 
and mutant clathrin box fusion. 
 
4.2.6 Vpu Interacts with Clathrin Adaptors AP-1 and AP-2 in Tetherin-Expressing Cells in 
a Phosphorylation-Dependent Manner 
Clathrin-dependent sorting of Vpu/tetherin complexes has been proposed to be the first 
essential step in Vpu-mediated tetherin antagonism (Kueck & Neil 2012). Furthermore, it has been 
suggested that Vpu inhibits trafficking of recycling and newly synthesised tetherin to the plasma 
membrane rather than enhancing tetherin endocytosis, which indicates the involvement of AP-1 
(Schmidt et al. 2011; Dubé et al. 2011). This is in keeping with structural data suggesting that 
tetherin and Vpu form a ternary complex with AP-1, wherein Vpu binds the σ-subunit of AP-1 via its 
ExxxLV motif and tetherin the µ-subunit via its YDYCRV motif (Jia et al. 2014). However, neither 
siRNA knockdown of AP-1 nor mouse AP-1ɣ1a -/- fibroblasts have any effect on Vpu-mediated 
antagonism (Kueck & Neil 2012). Due to the relatively weak affinities of clathrin adaptors to their 
cargoes it has been difficult to demonstrate binding by conventional immunoprecipitation in living 
cells. Dr Toshana Foster, a postdoc in our group, performed cross-linking immunoprecipitations in 
293T tetherin cells that were transfected with HA-tagged Vpu or mutants. Results from these 
experiments demonstrated an interaction between AP-1ɣ and WT Vpu-HA (Figure 4.15 A). In 
contrast, AP-1ɣ was not detectable in immunoprecipitates of the A14L/W22A Vpu, a mutant that is 
unable to interact with tetherin’s transmembrane domain (Vigan & Neil 2010). This suggests that 
the interaction of Vpu and tetherin via their transmembrane domains is crucial for AP-1 binding and 
anti-tetherin activity. This idea was further supported by the finding that no AP-1ɣ could be pulled 
down with WT Vpu in 293T cells not expressing tetherin (Kueck et al. 2015; see appendix). For all 
the other Vpu mutants the amount of AP-1 ɣ was reduced in the immunoprecipitates (Figure 4.15 
A). When the same assay was done in 293T cells expressing Y6,8A tetherin all residual AP-1ɣ 
interaction was abolished (Figure 4.15 B). This shows that AP-1/tetherin interaction is important for 
the residual binding of the Vpu mutants. Additionally, there was no binding to AP-1 of any Vpu, 
including WT Vpu, in cells expressing rhesus macaque tetherin (Figure 4.15 C). As HIV-1 Vpu is 
unable to bind to rhesus macaque tetherin, this result confirms that direct interaction of Vpu and 
tetherin is crucial for AP-1 binding. 
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As mentioned before, AP-1 knockdown does not have any effect on tetherin antagonism. 
However, Vpu’s ExxxLV motif could potentially interact with other clathrin adaptors such as AP-2, 
which could serve as an alternative route of clathrin machinery interaction. Therefore, we analysed 
the immunoprecipitates of the 293T tetherin and Y6,8A tetherin cells also for the presence of AP-
2. We found that AP-2 could be pulled down with WT Vpu, but none of the mutants in both cell lines 
(Figure 4.15 A and B). Therefore, the ExxxLV trafficking motif is likely to also mediate AP-2 
interaction. Since WT Vpu can interact with both major clathrin adaptors and knockdown of one 
adaptor has no effect on tetherin antagonism, it might be possible that they compensate for the lack 
of the other.  
We wanted to further investigate the role of serine phosphorylation in clathrin adaptor binding. 
Therefore, immunoprecipitation in 293T Y6,8A tetherin was repeated, but cells were treated with 
the CK-II inhibitor Tyrphostin. Binding of WT Vpu to AP-1 and AP-2 was completely abolished under 
these conditions, supporting the hypothesis that Vpu phosphorylation is required for the interaction 
with the clathrin machinery (Figure 4.15 D).  
Together, these data demonstrate an interaction between Vpu and endogenous AP-1 in living 
cells and transmembrane domain interaction of tetherin and Vpu is essential. Importantly, the 2/6A 
mutant was unable to bind to AP-1, which emphasizes the potential role of serine phosphorylation 





Figure 4.15 Vpu interacts with clathrin adaptors AP-1 and AP-2 in tetherin-expressing cells in a 
phosphorylation dependent manner. (A-C) 293T tetherin (A), 293T tetherin Y6,8A (B) or 293 rhesus tetherin 
(C) cells were transfected with pCR3.1 Vpu-HA, Vpu A14L/W22A-HA, Vpu ELV-HA, Vpu 2/6A-HA, Vpu LILI-
HA or Vpu NE-HA mutants. 48 h post transfection, cells were lysed and cross-linked using PFA (0.05% w/v) 
and immunoprecipitated with anti-HA antibody. Total cell lysates and precipitates were subjected to SDS-
PAGE and analyzed by Western blotting for Vpu-HA, tetherin, AP-1γ or AP-2α. Panels are of representative 
experiments. All data by Toshana Foster. 
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4.2.7 A Highly Conserved C-Terminal Tryptophan in the Cytoplasmic Tail of Vpu Has a 
Context Dependent Phenotype 
A highly conserved tryptophan residue in the C-terminal part of the cytoplasmic tail of Vpu was 
proposed to be important in tetherin antagonism and has been ascribed a role in membrane 
anchoring (Pickering et al. 2014; Lewinski et al. 2015; Jafari et al. 2014; Zhang et al. 2015). A 
naturally occurring polymorphism at position 76 (W76G) was described to reduce viral release from 
tetherin-expressing cells whereas tetherin downregulation and degradation were not affected. 
Therefore, this W76G substitution in NL4.3 Vpu was tested with the addition of the HRS clathrin 
box or mutant as described in Figure 4.10. 293T tetherin or Y6,8A tetherin cells were co-transfected 
with increasing amounts of Vpu or the W mutant and a Vpu deficient NL4.3 provirus. In contrast to 
the previous findings the NL4.3 Vpu W76G mutant was highly active against WT tetherin in this 
assay (Figure 4.16 A and B). However, W76G lost its activity almost completely against the Y6,8A 
mutant of tetherin, similar to the results obtained with the Vpu trafficking mutants.  Interestingly, 
addition of the HRS clathrin box to W76G was able to rescue virus release in Y6,8A tetherin cells. 
It should be noted that the W76G Vpu was not recognized well by the NIH Vpu antibody (Figure 
4.16 B). When HA-tagged Vpu constructs were transfected into 293T cells, the difference in 
detection between the NIH Vpu antibody and an HA antibody was apparent (Figure 4.16 C). Wild 
type Vpu or the W76G Vpu mutant appeared to run at a higher molecular weight then the same 
Vpus with the added clathrin box. These gel shifts could be due to the nature of the amino acids 
added and do not correlate with the amino acid length of the proteins.  
Furthermore, the subcellular localization of this Vpu mutant was investigated by transfecting 
Hela cells with the W76G-HA construct and staining the fixed cells for HA and the TGN marker 
TGN46. This mutant appeared to localize to peripheral compartments to a certain extent, although 
this was less pronounced than the trafficking mutants (Figure 4.16 D). However, no quantification 
of the co-localization of W76G Vpu with TGN46 has been conducted to confirm a difference to WT 
Vpu. These data indicate that the W76G mutant has an intermediate phenotype. While it is not 
acting like WT Vpu it also is not as defective as the trafficking mutants in terms of promoting virus 
release and subcellular localization. Furthermore, the data here presented does not correlated with 
the previous reports. Further investigation is needed to explain the varying and unusual phenotypes 
described. Whether W76 plays a role in tetherin mis-trafficking and clathrin adaptor binding is so 





Figure 4.16 A highly conserved tryptophan in Vpu’s cytoplasmic tail has a context dependent 
phenotype. (A) 293T tetherin cells were transfected with NL4.3 ΔVpu proviral plasmid in combination with 
YFP expression vector and pCR3.1 Vpu, pCR3.1 Vpu CB or Vpu CB mut or the Vpu W76G mutant thereof. 
48 hours post transfection infectivity of viral supernatants was determined on HeLa-TZMbl cells as in Figure 
4.3. Error bars represent standard deviation of three independent experiments. Asterisks represent the p value 
for the difference in virus release from 293T cells between Vpu W76G and Vpu W76G CB transfected cells at 
25ng of Vpu expression vector. ns, not significant; *p > 0.05, as determined by two-tailed t test (B) Cell lysates 
and pelleted supernatant virions from (A) were harvested and subjected to SDS-PAGE and analyzed by 
Western blotting for HIV-1 p24CA, Vpu and HSP90, and analyzed by LiCor quantitative imager. (C) 293T cells 
were transfected with 700 ng pCR3.1 Vpu-HA or the indicated mutant. 48 h later cell lysates were harvested 
and subjected to SDS-PAGE and analysed by Western blotting for Hsp90, HIV-1 Vpu and HA. (D) Hela cells 
were transfected with 100 ng of pCR3.1 2_87 Vpu-HA or indicated mutants. 16 hours post transfection cells 
were fixed and stained for HA (green) and the TGN marker TGN46 (red) and examined by widefield fluorescent 




In this chapter the role of SCFβTrCP1/2 recruitment in Vpu-mediated tetherin antagonism has 
been re-evaluated.  β-TrCP binding to the phosphorylated serines in the cytoplasmic tail of Vpu has 
been shown to be essential for CD4 and tetherin degradation. However, whether this process is 
required for counteraction of the physical restriction imposed by tetherin has been a matter of 
debate. Here, it has been demonstrated that the Vpu phospho-mutant (2/6A) is partially defective 
for tetherin counteraction and that this is likely due to its inability to interact with the clathrin 
trafficking machinery rather than the lack of β-TrCP recruitment. For the first time we were able to 
show that Vpu interacts with AP-1 and AP-2 in cellulo and that this is dependent on transmembrane 
interaction of Vpu and tetherin. The data discussed support recent structural observations showing 
that Vpu and tetherin form a ternary complex with AP-1 (Jia et al. 2014). This is dependent on the 
YDYCRV sorting signal in tetherin and the ExxxLV trafficking motif in Vpu. It was demonstrated that 
the Vpu ELV, 2/6A and other trafficking mutants are unable to bind AP-1 efficiently in the presence 
of tetherin and that direct linkage to the clathrin machinery rescues all Vpu trafficking mutants. This 
is dependent on the intact YDY motif in tetherin, but does not restore β-TrCP interaction of 2/6A. 
The data clarify the role of the DSGNES motif in tetherin antagonism by Vpu and we therefore 
propose that sorting of Vpu/tetherin complexes into clathrin-rich domains is the crucial step in 
tetherin antagonism.  
So far, many studies investigating the mechanism of Vpu-mediated tetherin counteraction have 
been done under conditions wherein tetherin, Vpu and/or provirus have been transiently transfected 
into cells. This, however, can lead to artefacts such as overexpression induced ER-associated 
degradation (Andrew et al. 2011). Furthermore, transfection leads to a high variability in expression 
levels of the transfected constructs between cells. In contrast, under infection conditions tetherin is 
degraded in endosomes. When strong blocks to degradation are imposed, however, tetherin 
accumulates due to potentially overwhelmed endosomes, which can lead to an artificial block to 
counteraction. Performing infection assays at a relevant multiplicity of infection enabled us to 
separate the role of Vpu phosphorylation in  SCFβTrCP1/2 recruitment and counteraction of physical 
tetherin restriction. The biochemical data presented in this chapter confirms recent structural data 
(Jia et al. 2014). The ExxxLV motif in Vpu has been suggested to interact with the acidic dileucine 
binding site in the AP-1 σ-subunit and is essential in AP-1 binding. Additionally, our LILI mutant 
phenotype correlates with a proposed non-canonical interaction of R44/L45 with AP-1 µ. However, 
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the structural data have been obtained using artificial Vpu/tetherin fusions that may not necessarily 
reflect the biological role of clathrin adaptor recruitment. Therefore, our data demonstrate, for the 
first time in living cells, the involvement of the DSGNES motif and Vpu-tetherin transmembrane 
interaction in the recruitment of the clathrin trafficking machinery. We propose a model where 
phosphorylation regulates the interaction of the ExxxLV motif with clathrin adaptors (Figure 4.17). 
Although we cannot exclude the direct binding of the phosphorylated motif to clathrin adaptors, this 
explanation is more consistent with the data presented here, as there is no significant additive effect 




Figure 4.17 A proposed model for Vpu engagement of clathrin adaptors during tetherin counteraction. 
Vpu and tetherin interactions via TM/TM domain interactions and casein kinase II phosphorylation promote 
Vpu recruitment of AP-1 or AP-2. This allows the EXXXLV motif to bind to the σ subunit, and potentially through 
non-canonical interactions between its first alpha helix with the AP-1 or 2 μ subunits. In addition, the YDY motif 
in tetherin binds to the AP1μ. Thus tetherin/Vpu complexes are sorted into clathrin rich domains of the TGN or 
PM for subsequent trafficking and ubiquitination. 
 
 
Phosphorylated motifs upstream of acidic dileucine motifs have been described before to 
regulate interaction with the clathrin machinery. An example is the CK-II-mediated phosphorylation 
upstream of a non-canonical AP-1 binding site in the cation-dependent mannose-6-phosphate 
receptor that regulates their interaction (Mauxion et al. 1996). Additionally, adjacent acidic patches 
have been implicated to be important. Such a patch exists in HIV-1 Vpu between the DSGNES and 
the ExxxLV motif and has been shown to be shorter in the laboratory-adapted strain NL4.3 Vpu 
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compared to patient derived isolates with superior anti-tetherin activity (Pickering et al. 2014). 
Vpu/tetherin interaction  and Vpu phosphorylation could potentially induce conformational changes 
that allow the complex to interact with clathrin adaptors. Whereas clathrin adaptor binding requires 
tetherin to be present, β-TrCP binding does not, which indicates that Vpu phosphorylation is an 
independent event with additional function. SCY1-like protein 2 (SCYL2), a clathrin associated 
protein that modulates protein phosphatase 2A (PP2A), has been reported to induce the de-
phosphorylation of Vpu and thereby inhibit its function (Miyakawa et al. 2012). Regulated 
phosphorylation/de-phosphorylation of Vpu could therefore potentially regulate Vpu activity at the 
level of clathrin-dependent trafficking.  
Partial NMR structures of Vpu in solution or associated with lipid show that the ExxxLV motif is 
embedded within the structure in lipids. However, it adapts an extended conformation when in 
solution (Figure 4.18) (Wittlich et al. 2009; Willbold et al. 1997). Vpu phosphorylation has been 
shown to induce conformational changes in the C-terminal region of Vpu’s cytoplasmic tail that are 
important for β-TrCP binding. However, there is discrepancy in the literature whether these changes 
correlate with an opening up of the ExxxLV site (Coadou et al. 2002; Coadou et al. 2003; Wittlich 
et al. 2008). A full length Vpu NMR structure has recently been reported and confirms the previously 
reported results (Zhang et al. 2015). Importantly, all these studies have been conducted in the 
absence of target binding and therefore it is uncertain how representative they are.  
In lipid-associated structures, a highly conserved tryptophan residue (W76) at the C-terminus 
of Vpu’s cytoplasmic tail has been shown to pack against the DSGNES motif, as if it were locking 
the structure. Alternatively, W76 has been implicated in displacing tetherin from sites of viral 
assembly due to its potential role in membrane anchoring (Lewinski et al. 2015; Zhang et al. 2015). 
However, data presented in this chapter suggest that mutation of this residue to a glycine reduces 
viral release dramatically only in cells expressing the tetherin mutant Y6,8A and this can be rescued 
by direct clathrin linkage. Furthermore, this Vpu mutant does not seem to exhibit a localization 
defect as dramatic as, for example, that of an ExxxLV mutant. The role of this residue in trafficking 
Vpu/tetherin complexes, potentially into clathrin-rich domains, remains therefore elusive due to 
conflicting results. Further investigation is necessary and might show a potential trafficking and/or 






Figure 4.18 Important residues for the anti-tetherin function of Vpu. (A) Amino acid sequence of HIV-1 
NL4.3 Vpu. Conserved residues that are required for tetherin counteraction are highlighted. (B) Structure of 
the cytoplasmic tail of Vpu in the presence of membrane simulating dodecylphosphatidylcholine (DPC) 
micelles obtained by high-resolution liquid state NMR. (C) Structure of the cytoplasmic tail of Vpu in aqueous 
buffer obtained by high-resolution liquid state NMR. (B) and (C) adapted from Wittlich et al., 2009. Highlighted 
motifs are colour-coordinated with (A), (Images were produced by Stuart Neil using PyMol version 1.7). 
 
There is much indirect evidence that AP-1 is the major clathrin adaptor involved in Vpu-
mediated tetherin antagonism. Vpu localizes predominantly to the TGN and blocks the transport of 
recycling tetherin to the plasma membrane (Schmidt et al. 2011; Dubé et al. 2011; Kueck & Neil 
2012). Additionally, recently published structural data suggests that Vpu and tetherin can form a 
ternary complex with AP-1 (Jia et al. 2014). However, knockdown of AP-1 or other clathrin adaptors 
has no effect on Vpu function (Kueck & Neil 2012). Several orthologs exist for some subunits of 
AP-1 and there is potential redundancy in clathrin adaptor usage (Bonifacino & Traub 2003). 
Therefore, our observation that Vpu can also bind to AP-2 in an ExxxLV dependent manner is 
important. It potentially explains why neither of the clathrin adaptors have been identified as being 
essential for tetherin antagonism by Vpu, as lack of one clathrin adaptor might be compensated for 
by another (Mitchell et al. 2009; Kueck & Neil 2012). It also correlates with the weakly enhanced 
endocytosis of tetherin that has been reported (Dubé et al. 2011). Also, Vpu/tetherin chimeric 
proteins have been shown to be excluded from sites of viral budding at the cell surface, which is 
dependent on the ExxxLV motif. This may indicate AP-2-mediated trafficking and anchoring to 
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clathrin-rich domains at the plasma membrane (McNatt et al. 2013). However, tetherin’s YDY motif 
cannot bind the AP-2 µ subunit because of a steric clash of Y6 in the binding pocket  (Jia et al. 
2014). This motif on the other hand has been shown to be essential in AP-1-mediated trafficking to 
the plasma membrane via the TGN and this is where Vpu most likely encounters the majority of the 
tetherin molecules (Rollason et al. 2007; Schmidt et al. 2011). AP-1 also mediates the transport 
between the TGN and endosomes and therefore it is likely to be the major clathrin adaptor involved 
in tetherin antagonism (Bonifacino & Traub 2003). Since the Vpu ExxxLV motif is dominant over 
the YDY tetherin motif it may be possible that Vpu/tetherin complexes that escape the transport 
from the TGN to endosomes and traffic to the plasma membrane would be endocytosed. This could 
be mediated by AP-2 as it has been shown for SIV Nef and HIV-2 Env (Zhang et al. 2011; Lau et 
al. 2011; Serra-Moreno et al. 2013). AP-2 binding can also possibly be the explanation for the 
residual activity of Vpu against short tetherin in the absence of surface downregulation that has 
been discussed in chapter 3 (Cocka & Bates 2012; Weinelt & Neil 2014). A combination of the 
events discussed above may be the reason for variable observations in the importance of surface 
downregulation in tetherin.  
Even though degradation may be decoupled from counteracting tetherin’s physical restriction, 
that does not mean that tetherin degradation does not play an important role for HIV-1 in vivo. Long 
human tetherin is able to induce NF-κB signalling upon virion retention and can lead to endocytosis 
and possibly virion degradation. This is potentially followed by enhanced antigen presentation 
and/or detection by pattern recognition receptors, which could explain the highly efficient 
antagonism of the long tetherin isoform by HIV-1 group M Vpus. Additionally, tetherin has been 
suggested to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) and to be involved in 
modulating immune activation via interaction with the immunoglobulin-like transcript 7 (ILT7), both 
detrimental processes for a virus (Arias et al. 2014; Alvarez et al. 2014; Pham et al. 2014; Cao et 
al. 2009; Tavano et al. 2013; Bego et al. 2015). The LILI and ELV mutants remain able to bind β-
TrCP so that ubiquitination of the STS motif would still occur. However, all Vpu trafficking mutants 
can still be rescued by clathrin box addition in cells expressing the STS tetherin mutant (Kueck et 
al. 2015). This suggests that clathrin-dependent mis-trafficking is the essential antagonistic step 
and is likely to occur before ubiquitination. Tetherin degradation could possibly be essential for HIV-
1 in vivo to prevent recognition by the host, rather than to counteract the physical restriction imposed 
by tetherin.  
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Chapter 5 HIV-1 Nef Counteracts Serine Incorporators 5 and 3 
That Restrict Virion Infectivity 
Selected data presented in this chapter are part of the collaborative publication “Cell Surface 
Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef” 
(Matheson et al. 2015).  
 
5.1 Introduction 
Nef is an accessory protein encoded by all primate lentiviruses including HIV-1. It is a 27 kDa 
protein that is myristoylated at its N-terminus and localizes predominantly to peri-nuclear 
compartments. Whilst it does not seem to be a crucial factor for replication in cell culture, it is 
required in primary cells and plays a fundamental role in vivo as a determinant of viral pathogenicity 
and in the development of AIDS (Kestler et al. 1991; Deacon et al. 1995; Kirchhoff et al. 1995). A 
range of functions have been ascribed to Nef. It is responsible for the downregulation of CD4 from 
the cell surface, which is dependent on clathrin-mediated endocytosis and is followed by its 
lysosomal degradation (Garcia & Miller 1991; Aiken et al. 1994; Rhee & Marsh 1994; Chaudhuri et 
al. 2007). Downregulation of CD4 has been suggested to prevent the exposure of HIV-1 Env 
epitopes and limit their susceptibility to ADCC (Veillette et al. 2014). Furthermore, Nef also induces 
the downregulation of other surface molecules such as HLA-A and HLA–B, but not HLA-C 
(Schwartz et al. 1996; Collins et al. 1998; Cohen et al. 1999). This protects infected cells from being 
targeted by cytotoxic T cells that recognize viral peptides presented by HLA-A or HLA-B. At the 
same time, natural killer (NK) cells are prevented from killing the infected cell due to inhibitory 
signals they receive from HLA-C still being expressed on the surface. Many primate lentiviral Nef 
proteins, including that of HIV-2, are also able to downregulate the T cell receptor complex, which 
protects infected cells from activation-induced cell death and has been correlated with non-
pathogenic natural infections (Schindler et al. 2006). However, this function was lost in HIV-1 Nef, 
which potentially accounts for HIV-1’s increased pathogenicity. Another highly conserved function 
of Nef is its ability to increase the infectivity of virions (Chowers et al. 1995; Münch et al. 2007). This 
function seems to be important as it is highly conserved among lentiviruses and is maintained 
throughout disease progression (Münch et al. 2007; Carl et al. 2001). Similarly, the MLV protein 
glycoGag enhances the infectivity of Nef-deficient HIV-1 virions without any sequence homology to 
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Nef (Pizzato 2010). The requirement for both proteins depends on the cell type in which virus is 
produced (Pizzato 2010). Also, clathrin-mediated endocytosis and dynamin 2 have been shown to 
be essential for the infectivity-enhancing function in the producing cells suggesting a factor is 
removed from the plasma membrane (Craig et al. 1998; Pizzato et al. 2007). Furthermore, the Nef 
effect also depends on the envelope of the virus. Variable regions in HIV-1 Env determine the 
responsiveness to Nef, but it is independent of co-receptor usage and there is no Nef effect on Env 
abundance in virions (Lai et al. 2011; Usami & Göttlinger 2013; Miller et al. 1995). In addition, the 
pathway of virus entry determines the Nef responsiveness. Pseudotyping HIV-1 with envelopes 
from viruses that fuse at low pH, such as vesicular stomatitis virus G protein (VSV-G) or ebola virus 
glycoprotein (EBOV GP), has been reported to overcome the the infectivity block (Pizzato 2010; 
Miller et al. 1995; Aiken 1997; Chazal et al. 2001; Pizzato et al. 2008; Luo et al. 1998). Moreover, 
the effect of Nef on virus-cell fusion is limited and has been a matter of debate  (Cavrois et al. 2004; 
Tobiume et al. 2003; Day et al. 2004).  
Recent reports by two independent groups show that the cellular factor responsible for the 
infectivity block that is counteracted by Nef and glycoGag is SERINC5 (S5), and to a lesser extent 
SERINC3 (S3) (Usami et al. 2015; Rosa et al. 2015). Both proteins were also identified as targets 
of Nef in a SILAC-based plasma membrane profiling study conducted by our collaborators 
(Matheson et al. 2015). The data presented in this chapter were generated before the publication 
of those manuscripts, but after SERINC5/3 were revealed to be targets of HIV-1 Nef at the Cold 
Spring Harbor Laboratory Retroviruses meeting in May 2015. 
SERINC3 and 5 belong to the SERINC family of transmembrane proteins, which is comprised 
of five members. They have been reported to be involved in the incorporation of serine into 
membrane lipids such as phosphatidylserine and sphingolipids (Inuzuka et al. 2005). However, their 
function is still largely unknown. S5 is highly expressed in T cell lines such as Jurkat TAg cells and 
primary CD4+ T cells, which impose an infectivity block on Nef-deficient HIV-1. Nef and glycoGag 
inhibit the incorporation of S5 into budding virions by downregulating it from the cell surface. 
However, the mechanism of S5-induced restriction remains unknown (Usami et al. 2015; Rosa et 
al. 2015).  
In this chapter, the reported inhibitory effect of exogenous and endogenous SERINC5/3 on 
Nef-deficient virus was confirmed and the role of this newly identified antiviral factor was further 
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investigated. Four isoforms of SERINC5 and two isoforms of SERINC3 have been predicted. S5 
isoforms differ at their C-terminus whereas S3 isoform 2 lacks 55 N-terminal residues compared to 
isoform 1. Only S5 isoform 4, however, seems to be able to induce a block to Nef-deficient virus. 
Furthermore, I examined a potential role of interferon-induced transmembrane (IFITM) proteins in 
SERINC function. This group of proteins has recently been shown to also restrict HIV-1 at the level 





5.2.1 Exogenous SERINC5 Potently Reduces the Infectivity of Nef-Deficient Viral Particles 
As mentioned before, our collaborators identified SERINC5 (S5) and 3 (S3) as targets of Nef 
in a stable isotope labelling with amino acids in cell culture (SILAC)-based proteomic screen 
(Matheson et al. 2015). CEM-T4 cells grown in the presence of heavy isotope labelled lysine and 
arginine were infected with WT, ΔVpu or ΔNef HIV-1 or transduced with single genes (Vpu or Nef). 
The peptides obtained from the different conditions were analysed by mass spectrometry and 
compared to mock infected or GFP transduced control cells grown in medium containing medium 
or light isotope labelled lysine or arginine. They found changes in the expression of known and 
unknown proteins on the plasma membrane, including S5 and S3, which are downregulated 
specifically in Nef expressing cells (Figure 5.1A).  
Different assays were used to further investigate the effect of SERINC on HIV-1 infectivity 
(Figure 5.1 B). 293T cells with low endogenous levels of SERINC5/3 were transfected with HIV-1 
NL4.3 proviral plasmid, SERINC5/3 expression vector and, where stated, various Env expression 
vectors. Alternatively, Jurkat TAg cells, which express high levels of SERINC5, were infected with 
infectious VSV-G pseudotyped HIV-1 NL4.3 virus. Cells were then incubated for 48 h before the 
infectivity of the virions in the supernatant was titered on target cells, TZMbl reporter cells. 
Depending on the Env expressed on and the presence of SERINC in the released virions infectivity 






Figure 5.1 Identification of SERINC5/3 as a target of HIV-1 Nef and assay design. (A) Plasma membrane 
proteins in CEM-T4 cells transduced with Vpu (x axis) versus Nef (y axis) as single genes or CEM-T4 cells 
infected with Vpu-deficient versus Nef-deficient HIV-1 viruses (not shown) were quantified in a stable isotope 
labelling with amino acids in cell culture (SILAC)-based screen and compared to GFP-transduced or uninfected 
CEM-T4 cells. Known and novel plasma membrane proteins that are modulated by both HIV-1 Vpu and Nef 
(CD4) or by HIV-1 Vpu (tetherin, SNAT1) or HIV-1 Nef (HLA-A, SERINC3, SERINC5) only were identified 
(Matheson et al. 2015). (B) Design of assays conducted in this chapter. Producer cells, such as 293T or Jurkat 
TAg cells, were either infected with VSV-G pseudotyped HIV-1 NL4.3 or transfected with proviral constructs, 
SERINC expression vector and various envelope expression vectors, where applicable. Cells were then 
incubated for 48 h before the amount of infectious virus in the supernatant was determined using TZMbl 
reporter cells as target cells. Infectivity will be influenced by the Env expressed on the released virions and the 
presence of SERINC in virions.  
 
To test the effect of exogenous S5 expression on infectious particle release of HIV-1, 293T 
cells were transiently transfected with a WT, Nef-deficient (ΔNef, mutation of start codon of Nef 
open reading frame), Vpu-deficient (ΔVpu) or Nef- and Vpu-deficient (ΔNefΔVpu) HIV-1 NL4.3 
proviral construct and increasing amounts of S5 expression vector. The progeny virus from the 
293T producer cells was then titered for infectivity on TZMbl reporter cells. 293T cells have been 
shown to express low levels of S5 and also S3 (Rosa et al. 2015). Even at 0 ng exogenous S5, 
ΔNef and ΔNefΔVpu exhibited reduced infectious virus yield compared to WT HIV-1 or the Vpu-
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deficient virus (Figure 5.2 A and B). When exogenous S5 was expressed, the inhibition of ΔNef 
virus by S5 increased from 5-fold at 0 ng to 23-fold at only 10 ng of S5 expression vector. With 
increasing S5 expression levels the infectivity of WT virus also decreased slightly. There was, 
however, no difference in infectivity when Vpu was or or not expressed. This indicates that the 
SERINC effect is Nef-specific and independent of Vpu. This also suggests that the anti-SERINC 
activity of Nef is saturable, as WT infectivity was also reduced, but not to the same extent as ΔNef. 
S5 expression had no effect on intracellular virus protein production and physical virion release did 
not differ significantly between the different viruses (Figure 5.2 A and C). These results confirm the 
recently published data reporting that SERINC5 reduces viral infectivity, which can be overcome 
by Nef (Usami et al. 2015; Rosa et al. 2015).   
 
Figure 5.2 SERINC5 potently reduces the virion infectivity and is antagonised by Nef. (A-B) 293T 
producer cells were transfected with increasing amounts of SERINC5 and NL4.3WT, ΔVpu, ΔNef or ΔNefΔVpu 
proviral plasmid. (A) At 48 h posttransfection, infectious virus release was determined with TZM-bl HeLa 
reporter cells as target cells. Error bars represent standard deviations of the means of three independent 
experiments. RLU, relative light units. Asterisks represent the p value for the difference in virus infectivity of a 
Nef-deficient HIV-1 (ΔNef; orange) or Vpu-deficient HIV-1 (ΔVpu; red) compared to WT HIV-1 NL4.3 in the 
presence of 10 ng SERINC5 expression vector as titered on TZMbl reporter cells. ns, not significant; 
***p<0.001 as determined by two-tailed t test. (B) Cell lysates and pelleted viral supernatants from panel A 
were subjected to SDS-PAGE and analyzed by Western blotting for Hsp90 and p24 CA.  
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5.2.2 Knockout of Endogenous SERINC3 and SERINC5 Rescues the Infectivity of Nef-
Deficient Virus 
Primary T cells as well as many T cell lines, including Jurkat TAg (JTAg), have been reported 
to express high levels of S5 and also S3. It was next tested whether knockout of S5 or S3 in JTAg 
cells would relieve the inhibiting effect on ΔNef virus. Using the clustered regularly interspaced short 
palindromic repeat (CRISPR)-Cas9 system, JTAg knockout cells for S5 or S3 were generated (Mali 
et al. 2013). The guide RNAs for both S5 and S3 targeted the first exon of the genes (S5 (GenBank 
NM_001174072.2) guide sequence: ATGTCAGCTCAGTGCTGTGC; S3 (GenBank NM_006811.2) 
guide sequence: GTGTCTTCTCCCTCGCCAGC). A guide RNA targeting luciferase (Luc) served 
as a non-targeting control. JTAg cells were transduced with virus-like particles containing the 
lentiCRISPR with expression cassettes for Cas9 and the guide RNAs followed by puromycin 
selection. JTAg parental cells and bulk populations of the surviving Luc, S3 or S5 knockout cells 
were infected with VSV-G pseudotyped HIV-1 NL4.3 WT or a Nef and/or Vpu deficient virus at an 
MOI of 1. Viral supernatants were titered 48 h later on TZMbl reporter cells. A 37-fold reduction in 
infectious virus release of the Nef-deficient virus in parental JTAg and Luc control cells could be 
observed compared to WT virus (Figure 5.3 A). When S5 was knocked out, viral infectivity of ΔNef 
increased 17-fold whereas it only increased 3-fold for WT HIV-1. In keeping with previous reports, 
S3 knockout had a milder 4-fold effect on ΔNef infectious virus release. Again, no difference in 
infectivity was observed between WT and ΔVpu virus in all cell lines, confirming that Vpu has no 
role in S5/3 counteraction. As with the transient expression of S5, S3 and S5 knockout had no effect 













Figure 5.3 Endogenous SERINC5 and SERINC3 restrict viral infectivity in infected CD4+ T cells (A and 
B) Jurkat TAg cells or Jurkat TAg cells stably expressing a lentiviral vector containing CRISPR-Cas9 with a 
guide RNA sequence targeting the SERINC5 or SERINC3 or a control guide RNA (luciferase; Luc) were 
infected with VSV-G pseudotyped HIV-1 NL4.3WT, ΔNef, ΔVpu or ΔNefΔVpu at an MOI of 1 for 48 h. (A) 
Infectious virus release into the supernatant of the JTAg cells was determined using TZM-bl HeLa reporter 
cells as target cells. Error bars represent standard deviations of the means of four independent experiments. 
RLU, relative light units. Asterisks represent the p value for the difference in virus infectivity of a Nef-deficient 
HIV-1 (ΔNef) in the presence or absence of SERINC5/3 as titered on TZMbl cells. ns, not significant; 
***p<0.001 as determined by two-tailed t test. (B) Cell lysates and pelleted viral supernatants from panel A 






Single cell clones were generated from the bulk knockout cell populations by flow cytometry 
single cell sorting. Nine (Luc) or ten (S5 and S3) clones were infected as described for Figure 5.3. 
with VSV-G pseudotyped WT or ΔNef NL4.3 virus and infectious virus release was titered on TZMbl 
cells. As expected, ΔNef infectivity was reduced in all Luc-knockout control JTAg cell clones (Figure 
5.4 A upper panel). This restriction was relieved by knocking out S5 or S3 in all single cell clones 
(Figure 5.4 A middle and lower panel). However, the difference in ΔNef release between parental 
cells and S5/3 knockout cells seemed to be smaller in this experiment. None of the knockouts had 
a significant effect on WT HIV-1. The single cell clones can now be used to verify the CRISPR-
Cas9 knockout on a genomic level.  
Altogether, these data confirm that endogenous SERINC5 and SERINC3 restrict the release 

















Figure 5.4 Infection of single cell clones of SERINC depleted Jurkat TAg cells. Jurkat TAg cells or Jurkat 
TAg cells stably expressing a lentiviral vector containing CRISPR-Cas9 with a guide RNA sequence targeting 
the SERINC5 or SERINC3 or a control guide RNA (luciferase; Luc) and single cell clones thereof were infected 
with VSV-G- pseudotyped HIV-1 NL4.3WT, ΔNef, ΔVpu or ΔNefΔVpu at an MOI of 1 for 48 h. Infectious virus 
release was determined with TZM-bl HeLa reporter cells. Error bars represent standard deviations of the 
means of duplicates from one experiment. RLU, relative light units. 
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5.2.3 Envelopes From Viruses That Fuse at Low pH Are Insensitive to SERINC5 
Envelopes from viruses that fuse at a low pH, such as VSV-G or EBOV GP, have been reported 
to be resistant to the block to infectivity that is relieved by Nef (Aiken 1997; Chazal et al. 2001; Luo 
et al. 1998). To test whether those envelope proteins were also resistant to SERINC5 expression, 
WT and Nef-deficient provirus were transiently co-transfected with increasing amounts of SERINC5 
expression vector. Additionally, VSV-G envelope expression or empty vector were transfected and 
infectious virus was titered on TZMbl cells. Again, viral infectivity of ΔNef decreased considerably 
with increasing amounts of S5, whereas WT NL4.3 was less affected (Figure 5.5 A). Physical 
particle release from 293T cells did not change significantly for any virus (Figure 5.5 B). When VSV-
G was added, the restricting effect of S5 was completely absent at all S5 expression levels (Figure 
5.5 A (dashed lines) and B). Also, for this level of VSV-G expression, no saturation was observed, 
compared to non-pseudotyped WT HIV-1. Similarly to the effect of VSV-G, EBOV GP pseudotyping 
rendered both WT and Nef-defective HIV-1 NL4.3 completely resistant to SERINC5 expression 
(Figure 5.6 A). These findings are in keeping with the recently published results. Nef does not 
provide the same level of resistance  to S5 as VSV-G or EBOV GP pseudotypes. Whether this 
resistance is for example conferred by the route of entry or the amount and property of envelope 















Figure 5.5 VSV-G pseudotyping rescues the infectivity defect of Nef-deficient virus. (A-B) 293T producer 
cells were transfected with increasing amounts of SERINC5 expression vector and NL4.3WT or a ΔNef proviral 
plasmid plus or minus 200 ng VSV-G expression vector. (A) At 48 h post transfection, infectious virus release 
was determined on TZM-bl target cells. Dashed lines, plus VSV-G; solid lines, without VSV-G. Error bars 
represent standard deviations of the means of duplicates from one experiment. RLU, relative light units. 
Asterisks represent the p value for the difference in virus infectivity of WT HIV-1 NL4.3 and the Nef-deficient 
HIV-1 NL4.3 (ΔNef) plus or minus VSV-G pseudotyping at 10 ng SERINC5 expression vector as titered on 
TZMbl target cells. ns, not significant; **p<0.01 as determined by two-tailed t test. (B) Cell lysates and pelleted 
viral supernatants from panel A were subjected to SDS-PAGE and analyzed by Western blotting for Hsp90 











Figure 5.6 EBOV GP pseudotyping rescues the infectivity defect of Nef-deficient virus. 293T cells were 
transfected with increasing amounts of SERINC5 expression vector and NL4.3WT or a ΔNef proviral plasmid 
plus or minus 200 ng EBOV GP expression vector. At 48 h post transfection, infectious virus release was 
determined with TZM-bl HeLa reporter cells. Error bars represent standard deviations of the means of 
duplicates from one experiment. RLU, relative light units. Asterisks represent the p value for the difference in 
virus infectivity of WT HIV-1 NL4.3 and the Nef-deficient HIV-1 NL4.3 (ΔNef) plus or minus EbGP pseudotyping 
at 10 ng SERINC5 expression vector as titered on TZMbl target cells. ns, not significant; **p<0.01 as 
determined by two-tailed t test. 
 
Viruses that fuse with the target cell in a pH-independent manner, such as HIV, have been 
reported to be responsive to Nef expression. Therefore, the effect of SERINC5 on other pH-
independent envelopes was tested using measles virus (MV) and xenotropic murine leukemia virus-
related virus (XMRV) envelopes (Lamb 1993; Côté et al. 2012). XMRV is a recombinant 
gammaretrovirus that was probably generated during passages of human prostate tumors in nude 
mice harbouring endogenous MLV proviruses, and its envelope shares significant sequence 
homology with xenotropic and polytropic MLVs (Paprotka et al. 2011). XMRV envelope expression 
or empty vector were transfected into 293T cells with provirus and increasing amounts of S5, and 
infectious virus release was titered 48 h later on TZMbl reporter cells. Whereas ΔNef HIV-1 
infectivity decreased with increasing amounts of S5, co-expression of XMRV Env seemed to 
counteract this effect to a certain extent and also appeared to increase the infectivity of WT virus. 
However, XMRV Env did not overcome the S5 induced difference in infectivity between WT and 
ΔNef virus (Figure 5.7 A). Potentially, this may be an effect of XMRV Env overexpression rather 
than this Env’s ability to counteract S5 function. Expression of Nef and XMRV Env at the same time 
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abrogated the saturating effect of S5 compared to when WT HIV-1 Nef only was expressed. This 
assay will be repeated, to confirm this result.  
For MV, both the fusion (F) protein and hemagglutinin (H) are required to induce fusion with 
the target cell. Both components were co-transfected to equal amounts into 293T cells along with 
provirus and increasing amounts of S5 expression vector. In contrast to XMRV Env, the expression 
of MV F and H increased the inhibitory effect of S5 even further for both WT and ΔNef HIV-1, 
although, the additional effect on infectious virus release of the ΔNef virus was larger (Figure 5.7 
B).  
These results indicate that the lack of Nef-responsiveness reported for pH-dependent viruses, 
correlates with their envelopes’ resistance to S5. The two other envelope proteins from pH-
independent viruses tested here, seem to be differentially affected by S5. Whereas measles 
envelopes increased the restrictive effect of S5 on infectivity, XMRV Env relieved the inhibitory 
effect to a certain extent. However, it was not able to overcome the difference in infectivity between 

















Figure 5.7 XMRV and MV envelopes do not overcome the S5-imposed restriction on Nef-deficient virus. 
(A) 293T cells were transfected with increasing amounts of SERINC5 expression vector and NL4.3WT or a 
ΔNef proviral plasmid plus or minus 200 ng XMRV Env expression vector. At 48 h post transfection, infectious 
virus release was determined with TZM-bl HeLa reporter cells. RLU, relative light units. (B) 293T cells were 
transfected as in (A) plus or minus 100 ng measles hemagglutinin and 100 ng fusion protein expression vector. 





5.2.4 SERINC3 and SERINC5 Isoforms Have Differential Effects on HIV-1 Infectivity 
Several isoforms of SERINC5 and SERINC3 have been proposed (Gerhard et al. 2004, Ota et 
al. 2004). Four isoforms of S5 are predicted that differ in their C-terminus (Figure 5.8). In all previous 
experiments, isoform 4 has been used. This is the longest of all predicted S5 isoforms and, 
according to Uniprot.org (accession number: Q86VE9), contains an extra transmembrane domain 
culminating in a total of ten. For S3, two isoforms have been predicted that differ in the first 55 N-
terminal amino acids with isoform 2 lacking the first 55 amino acids, compared to isoform 1 (Figure 
5.9). All 55 residues are predicted to be in an extracellular domain (Uniprot.org, accession number: 
Q13530).  
Different isoforms may potentially have different antiviral roles, as observed in Chapter 3 with 
tetherin. Therefore, all SERINC isoforms were tested for their ability to block the infectivity of Nef-



















Figure 5.8 Amino acid sequence alignment of SERINC5 isoforms. Four isoforms have been predicted for 
SERINC5 (GenBank accession numbers for I1: NM_178276.6, I2: NM_001174071.2, I3: BC101281.3, I4: 
NM_001174072.2). They differ in the length and sequence of their C-terminus. Topology indicated according 
to Uniprot.org. Green, extracellular domain; orange, cytoplasmic domain; blue, transmembrane (TM) domain, 









Figure 5.9 Amino acid sequence alignment of SERINC3 isoforms. Two isoforms have been predicted for 
SERINC3 (GenBank accession numbers for I1: NM_006811.2, I2: AK300618.1). They differ in the length of 
their N-terminus. Topology indicated according to Uniprot.org. Green, extracellular domain; orange, 
cytoplasmic domain; blue, transmembrane (TM) domain, number of TM domain is indicated. Numbers indicate 
amino acid position. Asterisks indicate sequence identity. 
 
Similar to the assays performed previously, WT or ΔNef NL4.3 provirus were transiently co-
transfected with increasing amounts of the SERINC isoforms into 293T cells. Infectious virus 
release was then assessed 48 h later on TZMbl cells. As expected, increasing amounts of S5 
isoform 4, which has already been used throughout this chapter, decreased virion infectivity of Nef-
deficient virus in a dose-dependent manner and also had some effect on WT HIV-1 (Figure 5.10 
A). In contrast, all other S5 isoforms seemed to have little to no effect on the infectivity of Nef-
deficient or WT virus. Included in this assay was a mutant of S5 isoform 4, S225G. SERINC5 
proteins are very well conserved among primates including chimpanzees, gorillas, rhesus 
macaques and sooty mangabeys. Amino acid sequence alignment of their S5 proteins showed that 
there is a highly conserved glycine at position 225 in a cytoplasmic domain of all the non-human 
primate sequences mentioned before (Figure 5.11). However, in humans this residue has changed 
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to a serine. To assess whether mutation of this residue to a glycine would alter its antiviral activity, 
this mutant was included in this assay. However, mutation of G225 had no effect on viral infectivity 
(Figure 5.10 A). S3 isoforms were also tested for their effect on infectious virus release. S3 is 
reported to play only a limited role in the infectivity defect of Nef-deficient virus and T cell lines and 
primary T cells express less S3 than S5. 293T cells, on the other hand, intrinsically express more 
S3 than S5. Transient, exogenous expression of S3 isoforms in 293T cells had no effect on WT 
HIV-1 and only limited effect on ΔNef infectivity (Figure 5.10 B). All S5 and S3 isoforms were N-
terminally HA-tagged and were well expressed (Figure 5.10 C). 
These data suggest that there is differential sensitivity of ΔNef virus to the different SERINC 
isoforms. They further indicate that the inhibitory function of S5 isoform 4, that has been used 
throughout this chapter and also in the recent publications, is determined by residues in the C-
terminus of the protein that are absent in all other S5 isoforms. Isoform 4 is predicted to have one 
additional transmembrane domain and a C-terminal extracellular domain. Truncation of these 
domains will aid in finding the determinants of S5 function. Furthermore, it will be interesting to see 
whether the difference in inhibition is perhaps due to differential localization of the proteins or 
















Figure 5.10 SERINC Isoforms have differential effects on virion infectivity. (A and B) 293T producer cells 
were transfected with increasing amounts of S5 isoforms and NL4.3WT or ΔNef proviral plasmid. (A) At 48 h 
post transfection, infectious virus release was determined with TZM-bl HeLa reporter cells as target cells. RLU, 
relative light units. Asterisks represent the p value for the difference in virus infectivity between WT and ΔNef 
virions at 10 ng SERINC expression vector titered on TZMbl cells. *p<0.05, **p<0.01, ***p<0.001 as 
determined by two-tailed t test. (B) Cell lysates from 293T cells transfected with HA-SERINC constructs for 24 








Figure 5.11 Alignment of primate SERINC5 amino acid sequences. Human (NP_001167543.1), 
chimpanzee (XP_001136963.1), gorilla (XP_004058691.1), sooty mangabey (XP_011944576.1) and rhesus 
macaque (XP_001109947.2) SERINC5 amino acid sequences were aligned. Serine/glycine 225 is highlighted 




5.2.5 IFITM Proteins Do Not Influence the SERINC5-Induced Infectivity Defect 
Interferon-induced transmembrane (IFITM) proteins have been shown to inhibit a broad range 
of viruses including influenza A, hepatitis C virus, Ebola virus, Dengue virus, VSV and HIV-1 
(Perreira et al. 2013; Weidner et al. 2010; Lu et al. 2011). Their mechanism of action is still not 
understood. However, it has been suggested that they inhibit virus-cell fusion in target cells 
expressing IFITMs (Lu, 2010, JVI).  Furthermore, it has been shown that IFITMs get incorporated 
into budding HIV-1 virions, which then potentially inhibit the infection of target cells (Compton et al. 
2014; Tartour et al. 2014). In contrast, it was also recently proposed that it is not the incorporation 
that reduces infectivity, but rather the effect of IFITMs on Env processing and the inhibition of cell-
to-cell transmission (Yu et al. 2015). S5 was shown to be incorporated into Nef-deficient virions and 
it was suggested that this incorporation is responsible for the inhibition of infection of target cells at 
early stages (Usami et al. 2015; Rosa et al. 2015). Both protein families have been proposed to 
inhibit viruses at the entry stage, and therefore it seemed reasonable to hypothesize that there was 
a synergistic effect of S5 and IFITMs on viral infectivity. To test this, producer 293T cells were 
transiently transfected as before with different proviral constructs and increasing amounts of S5 
expression vector. 48 h post transfection the infectivity of viral supernatants was determined on 
target cells, TZMbl reporter cells (TZM) or TZMbl reporter cells knocked out for IFITM1, 2 and 3 
(TZM CrIFITM) simultaneously, using the CRISPR-Cas9 system. Infectious virus titers revealed 
that there was no additional effect on viral infectivity when target cells expressed IFITMs or not 
(Figure 5.12 A, solid lines versus dashed lines). Similarly, the SERINC5/3 positive or negative 
Jurkat TAg cells were infected as described in Figure 5.3 and viral titers were analysed for infectivity 
on TZMbl or TZMbl IFITM negative cells. Again, no significant difference in infectivity was seen 
between supernatants titered on TZMbl cells or TZMbl cells containing the IFITM knockout (TZM 
CrIFITM) (Figure 5.12 B).  
These data suggest that there is no synergistic effect on viral infectivity of SERINC5 or 3 and 
IFITMs expressed on target cells. However, these experiments do not rule out that there may be 
an effect of IFITMs expressed in the producer Jurkat TAg cells. Furthermore, the inhibitory effects 
seen for IFITMs are generally not more than 2-fold. Due to the significantly larger SERINC effect 





Figure 5.12 Role of IFITMs in SERINC mediated restriction. (A) 293T cells were transfected with increasing 
amounts of S5 and NL4.3WT, ΔVpu, ΔNef or ΔNefΔVpu proviral plasmid. At 48 h post transfection, infectious 
virus release was determined using TZM-bl reporter cells or the same cells stably expressing lentiviral vectors 
containing CRISPR-Cas9 with a guide RNA sequence targeting IFITM1, 2 and 3. Error bars represent standard 
deviations of the means of four independent experiments. RLU, relative light units. Solid lines, TZMbl (TZM); 
dashed lines, TZMbl CRISPR IFITM (TZM CrIFITM). Asterisks represent the p value for the difference in virus 
infectivity titered on TZMbl cells or TZMbl CrIFITM cells. ns, not significant as determined by two-tailed t test 
(B) Jurkat TAg cells or Jurkat TAg cells stably expressing a lentiviral vector containing CRISPR-Cas9 with a 
guide RNA sequence targeting the SERINC5 or SERINC3 or a control guide RNA (Luciferase; Luc) were 
infected with VSV-G- pseudotyped HIV-1 NL4.3WT, ΔNef, ΔVpu or ΔNefΔVpu at an MOI of 1 for 48 h. 
Infectious virus release into the supernatant of the JTAg cells was determined as in (A). Error bars represent 
standard deviations of the means of four independent experiments. RLU, relative light units. Supernatants 
titered on TZMbl CRISPR IFITM are indicated (TZMCr). Asterisks represent the p value for the difference in 





In this chapter I discuss the antiviral activity of SERINC5 and SERINC3, which have recently 
been identified as targets of HIV-1 Nef (Usami et al. 2015; Rosa et al. 2015; Matheson et al. 2015). 
My data confirm the recent findings and extend the characterization of these newly recognized 
restriction factors. 
SERINC5 and 3 have recently been shown to be targets of HIV-1 and MLV glycoGag and are 
responsible for the decreased infectivity of Nef-deficient HIV-1 (Usami et al. 2015; Rosa et al. 2015; 
Matheson et al. 2015). They belong to a family of transmembrane proteins that contains five 
members and is highly conserved in all eukaryotes. Their function is largely unknown, but they were 
reported to facilitate the incorporation of serine into phophatidylserine and sphingolipids (Inuzuka 
et al. 2005). Therefore, they may potentially be able to alter the lipid composition of the cellular 
plasma membrane domain where the virus assembles, thereby affecting viral infectivity (Waheed 
& Freed 2010). In contrast to other restriction factors such as tetherin, SERINC expression is not 
induced by type I interferon, but S5 and 3 are constitutively expressed at different levels depending 
on the cell type. Four S5 and two S3 isoforms have been predicted. Different isoforms can have 
differential functions  and varying effects on a Nef-deficient virus. The data presented in this chapter 
show that S5 isoform 4 has a significantly stronger inhibitory effect on viral infectivity than all the 
other S5 and 3 isoforms. The determinants responsible for the increased efficiency can be found in 
the C-terminal portion of the protein that is absent from the other S5 isoforms. Further experiments 
are required to confirm this phenotype and define the residues required for SERINC’s function. 
Furthermore, it remains to be determined whether SERINC isoform function correlates with 
localization and/or virion incorporation or not. 
It was shown that S5 almost exclusively localizes to the plasma membrane where it gets 
incorporated into budding virions and that Nef counteracts S5 by preventing its incorporation. 
Interestingly, human S5 is antagonised by various Nef proteins, including SIV Nefs, and also 
glycoGag, suggesting that there is a low species specificity (Usami et al. 2015; Rosa et al. 2015). 
Pseudotyping Nef-deficient HIV-1 with VSV-G or EBOV GP made the virus completely resistant to 
S5, however, it did not prevent its incorporation into the budding virions. Therefore, these envelopes 
must differ from Nef in the manner in which they overcome the inhibiting effect of S5. HIV-1 Nef 
induces the downregulation of S5 from the cell surface, which could explain why enhancement of 
infectivity by Nef is dependent on dynamin 2 and clathrin adaptor AP-2 (Usami et al. 2014; Pizzato 
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et al. 2007). It was suggested that S5 acts by inhibiting virus entry into target cells, as production 
of reverse transcription products is strongly inhibited in its presence and fusion with target cells is 
reduced to a certain extent (Usami et al. 2015; Rosa et al. 2015).  Notably, the inhibitory effect of 
SERINC on fusion seemed to be much lower than its effect on infectious virus release. Also, the 
role of Nef on virus-cell fusion is a controversial matter (Day et al. 2004; Tobiume et al. 2003; 
Cavrois et al. 2004). It was therefore proposed that the effect of SERINC on infectivity may 
potentially be due to the inhibition of fusion pore expansion, which is the highest energy requiring 
step in the fusion process (Cohen & Melikyan 2004). Whilst small molecules may still be able to 
pass through the formed fusion pore, the translocation of the much bigger viral core could be 
prevented, which would explain the discrepant data. This would be in keeping with data showing 
that Nef enhances the translocation of the viral core (Schaeffer et al. 2001). 
Interestingly, different HIV-1 envelope proteins vary in their Nef responsiveness, which also 
correlates with their sensitivity to S5. For example, the primary HIV-1 isolate JRFL is less Nef-
responsive and less sensitive to S5 than another primary HIV-1 isolate, SF162. The determinants 
for this difference have been attributed to the V1/V2 loop of gp120 (Usami & Göttlinger 2013; Rosa 
et al. 2015). This region is also involved in the neutralization sensitivity of an envelope and this 
sensitivity has been found to correlate with an envelope’s Nef responsiveness (Lai et al. 2011; 
Pinter et al. 2004). Additionally, the entry stoichiometry differs between envelopes and the number 
of envelope trimers on the surface of a virus determines its infectivity (Brandenberg et al. 2015). 
Furthermore, different HIV-1 envelopes may deliver different energies towards fusion, which could 
also potentially explain the difference in infectivity and requirement for Nef. It was hypothesized that 
S5 acts by inhibiting the clustering of envelope trimers (Usami et al. 2015). Envelopes from viruses 
that fuse in a pH-dependent manner, such as VSV-G and EBOV GP, are resistant to S5 without 
the requirement for Nef (Chazal et al. 2001; Usami et al. 2015; Rosa et al. 2015). Whether this is 
due to an increased amount of envelope protein on the viral surface or fusion at low pH is yet 
unknown.  
IFITM proteins have recently been shown to inhibit virus entry (Lu et al. 2011; Compton et al. 
2014; Yu et al. 2015). Whether IFITM proteins have any involvement in SERINC function or if both 
have a synergistic effect on viral infectivity is unclear. Data presented in this chapter indicates that 
there is no involvement of IFITM proteins in the effect of SERINC when IFITMs are expressed in 
target cells. However, whether IFITM expression in producer cells and potentially simultaneous 
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incorporation of SERINC and IFITM proteins into virions has an influence on viral infectivity is so 
far unclear and requires further experimentation.  
Altogether, further investigation is needed to determine the mode of action of S5. Considering 
that this restriction factor is counteracted by two evolutionarily distant viruses (HIV-1 with Nef and 
MLV with glycoGag) suggests that it has an important role in antiviral immunity. Future work will 
focus on determining the requirements in S5 for its antiviral function and whether SERINC isoforms 
have differential effects due to differences in localization and/or incorporation. In addition, whether 
IFITM proteins have any role in SERINC function or whether there is a synergistic effect remains to 
be answered. It will also be interesting to investigate why some envelope pseudotypes are much 





Chapter 6 General Conclusion  
More than 30 years after the discovery of HIV-1 and extensive research, the worldwide HIV-1 
pandemic still persists. Our understanding of primate lentiviral replication increased immensely over 
the years, but many questions remain to be answered. Antiviral, cellular restriction factors have 
become a broad field of research with new factors being discovered constantly. It is clear that many 
of these factors evolved under selective pressure from pathogens and their functions shaped during 
host/virus co-evolution. Simultaneously, primate lentiviruses evolved accessory proteins to combat 
these host restrictions. Accessory proteins such as Vpu and Nef are essential for efficient viral 
replication in vivo. It becomes more and more apparent that these proteins have various functions 
and interact with diverse proteins to create an environment most favourable for viral replication. 
This involves the antagonism of physical restrictions as well as the evasion of systemic host 
immunity. Interestingly, Nef and Vpu have shared some of their cellular targets during the evolution 
of primate lentiviruses. They both downregulate CD4 from the surface and affect proinflammatory 
NF-κB signalling. While Nef is expressed early on in the replication cycle, Vpu appears later. A 
picture emerges where the timing of viral protein expression may be a key to the regulation of 
opposing effects and differing mechanisms of counteraction. Other cellular targets are unique to 
HIV-1 Vpu or Nef such as tetherin counteraction by Vpu (with the exception of some SIV Nefs) and 
the recently reported SERINC3/5 antagonism of Nef. Both of these cellular restriction factors are 
expressed in the primary target of HIV-1, CD4+ T cells, and they have a strong inhibitory effect on 
HIV-1 lacking their countermeasure. Advancing the knowledge of the interplay between viral 
accessory proteins and restricting host cell factors may provide us with new opportunities for 
antiviral therapy. This results presented in this thesis focused on aspects of tetherin antagonism by 
Vpu and other primate lentiviruses as well as Nef-mediated counteraction of SERINC3/5.  
In chapter 3 the differential sensitivity of the two human tetherin isoforms was addressed. The 
existence of two human isoforms was described recently and it was suggested that S-tetherin is 
less sensitive to HIV-1 NL4.3 Vpu (Cocka & Bates 2012). In the study presented in this thesis, a 
range of HIV and KSHV encoded tetherin antagonists were tested against human L- and S-tetherin. 
SIV Nef and Vpu proteins were analysed for their antagonism of monkey tetherin isoforms. In 
summary, all antagonists tested in this study were able to overcome the restriction of both L- and 
S-tetherin to equal levels with one exception. The Vpu proteins from HIV-1 group M efficiently 
antagonised L-tetherin, but S-tetherin was considerably less sensitive to their counteraction. The 
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increased sensitivity of L-tetherin mapped to serine, threonine and tyrosine residues in the 
cytoplasmic tail that are missing in S-tetherin. These are residues that were implicated in 
ubiquitination, endocytosis and signalling (Tokarev et al. 2011; Cocka & Bates 2012; Galão et al. 
2012). The major group M is responsible for the worldwide pandemic and interestingly, this is the 
only group of HIV that evolved an efficient tetherin countermeasure that is also able to induce 
tetherin degradation. The reason why group M Vpu is the only tetherin antagonist out of the ones 
tested here that differentiates between the human tetherin isoforms and only counteracts and 
degrades L-tetherin is unclear.  However, one hypothetical explanation may be the immunological 
pressure imposed by L-tetherin. As described earlier, restriction by both tetherin isoforms potentially 
has several immunological consequences, with some limited to L-tetherin (Figure 1.20). Human L-
tetherin homodimers directly induce NF-κB signalling, while S-tetherin dominantly interferes with 
this function. In addition, only L-tetherin is efficiently endocytosed and delivers restricted virions to 
endosomes, potentially mediating their degradation and liberation of viral antigens for PRR 
recognition. Importantly, the in vivo relevance of tetherin isoforms, surface expression and 
endocytosis has been demonstrated in infected mice (Barrett et al. 2012; Li et al. 2014). A 
polymorphism in the bst-2 gene of NZW mice leads to the expression of a truncated tetherin, similar 
to the short version in humans. This was associated with increased surface expression of tetherin 
and reduced Friend retrovirus (FV) acute viremia and pathogenesis (Barrett et al. 2012). Later 
however, using mice with a different MHC haplotype, it was shown that endocytosis competent 
tetherin correlated with better control of FV replication and disease in vivo, because it was able to 
promote a stronger cell-mediated immune response (Li et al. 2014). In addition, tetherin was 
recently confirmed to have an inhibitory effect on type-I IFN production through interaction with ILT-
7 (Bego et al. 2015). Virus restriction relieves this inhibitory effect and enhances IFN production. 
Interestingly, Vpu was reported to mediate the downregulation of tetherin and to relocate remaining 
pools of the protein away from the site of viral budding. Thus, Vpu promotes virion release and the 
inhibition of pDC signalling through tetherin/ILT7 interaction (Bego et al. 2015). Whether the tetherin 
pools that remain at the surface are comprised of short tetherin that cannot be downregulated by 
Vpu is unclear. However, these studies exemplify potential functions for both L- and S-tetherin in 
vivo and may be an explanation for the maintenance of both isoforms in mammals. The pandemic 
HIV-1 group M Vpu proteins evolved to specifically antagonise L-tetherin efficiently. One might 
speculate that the signalling function of L-tetherin had a major effect on the adaption of Vpu during 
zoonotic transmission. Also, the findings by Bego et al. indicate that it can be immunologically 
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beneficial for a virus to leave some levels of tetherin on the cell surface, similar to what has been 
reported for MHC-I downregulation by HIV-1 Nef where surface expression of HLA-A and –B is 
modulated, whilst HLA-C, -E and -G remain at the plasma membrane (Cohen et al. 1999; Pizzato 
et al. 2004; Specht et al. 2008).  
The antagonism of tetherin by Vpu requires clathrin-dependent aberrant trafficking of the 
protein away from the plasma membrane and site of viral assembly, and subsequent delivery for 
endo-lysosomal degradation. This requires the formation of a ternary complex between Vpu, 
clathrin adaptor AP-1 and tetherin (Jia et al. 2014). The dual-tyrosine motif in tetherin and the 
ExxxLV motif in Vpu are essential for this interaction and additionally, residues in the first alpha 
helix of Vpu (R44/L45; corresponding to the LILI mutant) have been shown to make a non-canonical 
contact. Whether the final degradation step of tetherin is required to promote virus release was a 
matter of debate (Mangeat et al. 2009; Mitchell et al. 2009; Tervo et al. 2011). Chapter 4 of this 
thesis aims to elucidate this discrepancy for the role of serine phosphorylation of Vpu, β-TrCP 
recruitment and tetherin degradation in the counteraction of tetherin restriction. The data presented 
here show evidence that β-TrCP recruitment is required for Vpu-induced tetherin degradation, but 
dispensable for counteracting the restriction on virus release. The Vpu phospho-mutant, although 
unable to bind to β-TrCP, has residual anti-tetherin activity that is lost in the context of a tyrosine 
mutant tetherin. The phospho-mutant shares this phenotype with the ELV and the LILI mutant and 
all have a similar peripheral rather than TGN-associated subcellular localization. Interestingly, ELV, 
LILI and the phospho-mutant could be rescued by direct clathrin linkage, bypassing clathrin 
adaptors. Importantly, this did not restore β-TrCP binding of the phospho-mutant. In addition, data 
presented here demonstrate that all three motifs are required for efficient binding of Vpu to clathrin 
adaptors AP-1 and AP-2 in tetherin expressing cells. This is consistent with the structural data 
reported by Jia et al. and suggests a new role for Vpu phosphorylation in regulating binding of Vpu 
to the clathrin machinery. So far the partial and full length structural data on Vpu has been limited 
to studies investigating the protein in isolation or as an tetherin-fused chimeric protein (Willbold et 
al. 1997; Wittlich et al. 2009; Jia et al. 2014; Zhang et al. 2015). However, to gain better insight into 
the conformational changes Vpu is capable of, it will be important to analyse its structure in complex 
with its targets. This will be crucial in the context of exploiting these interactions between Vpu and 
cellular factors  as a target for antiviral drug design.  
205 
 
Recently, the transmembrane proteins SERINC3 and 5 have been described as new restriction 
factors for HIV-1 that are counteracted by HIV-1 Nef and MLV glycoGag (Usami et al. 2015; Rosa 
et al. 2015; Matheson et al. 2015). Particularly SERINC5 decreases the infectivity of Nef-deficient 
virus due to its incorporation into budding virions. Nef prevents this by downregulating SERINC5 
from the cell surface. Pseudotyping Nef-deficient HIV-1 with VSV-G or EBOV GP overcomes 
SERINC5 restriction. Furthermore, some HIV-1 envelopes have been shown to be less sensitive. 
The data presented in chapter 5 of this thesis confirms recently published data. Furthermore, it 
shows that out of several predicted isoforms for SERINC3 and 5, only SERINC5 isoform 4 has an 
inhibiting effect on virion infectivity and this maps to the C-terminus of the protein. Further 
investigation will show the exact requirements in SERINC5 and whether its function depends on 
subcellular localization and/or incorporation. Another group of antiviral proteins that recently 
received more attention are IFITMs. They also act at early stages of the viral life cycle and have 
been proposed to affect HIV-1 entry (Lu et al. 2011; Compton et al. 2014; Yu et al. 2015). The data 
presented in this thesis does not show a synergistic effect between SERINC3/5 function and IFITM 
expression on target cells. However, the effect of IFITM incorporation into virions in the context of 
SERINC will be investigated before a role of IFITMs will be ruled out.  
Both HIV-1 Vpu and Nef fulfil a broad range of functions in the infected cell that allows efficient 
viral replication and escape from the immune system. The counteraction of host cell factors can be 
essential to facilitate this and has been implicated in pathogenesis of HIV-1. Understanding the 
interplay between host and viral proteins can therefore be an important tool for the discovery of 
future drug targets. So far there is no broadly applicable cure for HIV and infected individuals are 
forced to adhere to a drug regime for the rest of their lives. HIV reservoirs persist in the body even 
in the face of combined antiretroviral therapy (cART) and this is what poses a barrier to curing HIV 
infection. Discontinuing the anti-retroviral treatment results in a rebound of virus. Reducing the viral 
reservoir is the essential step to the eradication of the virus. Triggering the right immune responses 
in an infected individual may allow the body to clear infection gradually and potentially reduce the 
reservoir in the context of compounds that reactivate latent viral pools. However, approaches using 
latency-reversing agents (LRAs) in the context of cART, referred to as ‘shock and kill’ were so far 
unsuccessful in reducing the latent HIV-1 reservoir (Reviewed by Rasmussen et al. 2015). This 
may be attributed to insufficient activation of tissue-associated HIV-1 reservoirs and also CTL 
responses. It was suggested that enhancing the innate and adaptive immune response towards 
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infected cells may boost current shock-and-kill approaches. Inhibiting specific virus-host 
interactions between Vpu, Nef and their targets could have immense immunological consequences 
for the virus in vivo and may be beneficial in this context. For example, hindering Vpu-mediated 
counteraction of tetherin would not simply result in the reduced release of virions into the 
extracellular space. Furthermore, presentation of tethered virions to the immunes system, ADCC 
recognition upon CD4 binding and opsonisation would be enhanced. Endocytosed virions may be 
degraded and the antigens may induce PRR signalling in addition to the NF-κB activation of tetherin 
itself. ILT7 inhibition may be relieved and pDCs would produce more type-I IFN. Altogether, the 
antiviral state of the host would be augmented considerably. These are potential outcomes of the 
disruption of only one of Vpu’s functions. Understanding the effects of HIV-1 accessory proteins on 
the host, will therefore provide a starting point for the search for specific and effective antiviral 
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ABSTRACT
Themammalian antiviral membrane protein tetherin (BST2/CD317) can be expressed as two isoforms derived from differential
translational initiation. The shorter isoform of the human protein (S-tetherin) lacks the first 12 amino acids of the longer (L-
tetherin) cytoplasmic tail, which includes a tyrosine motif that acts as both an endocytic recycling signal and a determinant of
virus-induced NF-!B activation. S-tetherin is also reported to be less sensitive to the prototypic viral antagonist human immu-
nodeficiency virus type 1 (HIV-1) Vpu. Here we analyzed the relative sensitivities of L- and S-tetherins to primate lentiviral
countermeasures. We show that the reduced sensitivity of S-tetherin to HIV-1 Vpu is a feature of all groupM proteins, including
those of transmitted founder viruses, primarily because it cannot be targeted for endosomal degradation owing to the truncation
of its cytoplasmic tail. In contrast, both isoforms of the human and rhesus macaque tetherins display the same sensitivity to non-
degradative lentiviral countermeasures of HIV-2 and SIVmac, respectively. Surprisingly, however, the Vpu proteins encoded by
simian immunodeficiency viruses (SIVs) of African guenons, as well as that from recently isolated highly pathogenic HIV-1
group N, do not discriminate between tetherin isoforms. Together, these data suggest that the groupMHIV-1 Vpu primarily
adapted to target L-tetherin upon zoonotic transmission from chimpanzees, and further, we speculate that functions specifically
associated with this isoform, such as proinflammatory signaling, play key roles in human tetherin’s antiviral function in vivo.
IMPORTANCE
The ability of HIV-1 and related viruses to counteract a host antiviral protein, tetherin, is strictly maintained. The adaptation of
the HIV-1 Vpu protein to counteract human tetherin is thought to have been one of the key events in the establishment of the
HIV/AIDS pandemic. Recent evidence shows that tetherin is expressed as two isoforms and that Vpu preferentially targets the
longer form. Here we show that unlike other virus-encoded countermeasures, such as those from primate viruses related to
HIV-1, the enhanced ability to counteract the long tetherin isoform is conserved among HIV-1 strains that make up the majority
of the human pandemic. This correlates with the ability of Vpu to induce long tetherin degradation.We speculate that functions
associated with the human version of this isoform, such as an inflammatory signaling capacity, selected for Vpu’s enhanced tar-
geting of long tetherin during its adaptation to humans.
The interferon (IFN)-induced transmembrane (TM) proteintetherin (BST2/CD317/HM1.24) displays antiviral activity in
vitro and in vivo (reviewed in reference 1). It has been shown to
potently restrict the release of diverse enveloped viruses, including
the members of the families Retroviridae (2, 3) and Herpesviridae
(4–7) and negative-strand RNA viruses (8), from infected cells by
cross-linking them to the plasma membrane (PM). Tetherin is a
dimeric glycoprotein that consists of an N-terminal cytoplasmic
tail, a conventional TM helix, a coiled-coil extracellular domain,
and a C-terminal glycosylphosphatidylinositol (GPI) anchor (1).
This structural arrangement is essential for tetherin’s antiviral ac-
tivity (9); the dual-anchor conformation allows predominantly
the GPI linkage to partition into budding virions, resulting in
stable cross-links of parallel tetherin dimers when viral and cellu-
lar membranes separate (10). Thus, tetherin does not need to in-
teract with any virus-encoded structure, which accounts for its
wide activity against enveloped viruses. Virions retained by teth-
erin cross-links can subsequently be endocytosed and trafficked to
late endosomes (2). Recent data also demonstrate that human
tetherin can mediate signal transduction upon virion retention
that activatesNF-!B andpromotes proinflammatory gene expres-
sion, thereby acting as an innate sensor of viral release (11–13).
There are now several examples of virus-encoded proteins that
have evolved to counteract tetherin, often in a species-specific
manner, highlighting an important selective pressure imposed by
tetherin on viral evolution (1). These viral proteins include the
primate lentiviral accessory proteins human immunodeficiency
virus type 1 (HIV-1) Vpu (2, 14) and simian immunodeficiency
virus (SIV) Nef (15, 16); the envelope glycoproteins encoded by
HIV-2 and SIVtan (Env) (17, 18), Ebola virus (EBOV-G) (19),
and herpes simplex virus 1 (gM) (7); and K5, a membrane-bound
ubiquitin ligase encoded by Kaposi’s sarcoma-associated herpes-
virus (KSHV) (5, 6). Among the primate lentiviruses, genetic ev-
idence strongly suggests that the ability to counteract tetherin is an
essential attribute for viral spread in vivo (20). Furthermore, ad-
aptation to target human tetherin efficiently by the Vpu proteins
of the HIV-1 group M is thought to have been a key event in
determining its spread to become the major agent of the HIV/
AIDS pandemic (21).
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Recently it was shown that tetherin is expressed as a long (L-
tetherin) or short (S-tetherin) isoform because of leaky ribosomal
scanning of its mRNA that results in translational initiations at
two AUG codons (11). S-tetherin lacks the first 12 amino acids of
its cytoplasmic tail (11). Within these 12 residues lies a conserved
tyrosine-based motif that acts both as an endocytic recycling se-
quence (22) and as the determinant of signal transduction in the
humanprotein (11–13).HIV-1Vpu, a smallmembrane phospho-
protein, interacts with human and chimpanzee tetherins via direct
TM domain interactions (23–26) and blocks the transit of newly
synthesized and recycling tetherin to the PM (27, 28). This is then
coupled to tetherin’s endosomal degradation by a clathrin-depen-
dent transport event that requires both an acidic/dileucine motif
in the Vpu cytoplasmic tail and the tyrosine-based sequence in
L-tetherin (29). Endosomal degradation of tetherin is ubiquitin
and ESCRT dependent (30, 31) and is determined by the recruit-
ment the SCF!TRCP1/2 E3 ligase to a conserved phosphoserinemo-
tif (DSGNES) in the Vpu cytoplasmic tail (32, 33). Tetherin can be
ubiquitinated on multiple residues in its cytoplasmic tail, but the
exact requirements for counteraction and/or degradation are un-
clear (34, 35). However, a serine-threonine motif found only in
L-tetherin has been highlighted as important (35). In contrast,
other lentiviral tetherin antagonists do not mediate its degrada-
tion but rather promote its endocytosis from the PM for intracel-
lular sequestration (15, 18, 36–38).
Human S-tetherin has been reported to be less sensitive to Vpu
of the prototypic HIV-1 molecular clone NL4.3 (11). However, it
is not yet known whether such differences in Vpu sensitivity are
observable at physiological expression levels. Also, recent findings
by our group indicate that the majority of primary Vpu isolate
alleles from patients infected with clade B HIV-1 display activity
superior to that of NL4.3 Vpu both for counteraction of tetherin’s
antiviral activity and for suppression of its signaling activity, indi-
cating that it may not be fully representative of wild-type (WT)
Vpu function (39). We therefore characterized the sensitivities of
the L- and S-tetherins to a diverse panel of Vpu proteins, as well as
countermeasures from HIV-2, SIVmac, and KSHV. We found
that differential sensitivity of L- and S-tetherins was a conserved
feature of all of the group M Vpu proteins tested but not SIVmac
Nef, HIV-2 Env, KSHV K5, or the Vpu proteins of SIVs from
African guenons, which represent descendants of the viruses from
which the 5= half of the SIVcpz genome is derived (40).
MATERIALS AND METHODS
Cell lines and plasmids.WT HIV-1 NL4.3 and HIV-1 NL4.3"Vpu have
been described previously (41). The HIV-2 molecular clone pRod10 was
obtained from the Centre for AIDS Research (National Institute for Bio-
logical Standards and Control, Potters Bar, United Kingdom), and enve-
lopemutants and Env-internal ribosome entry site-green fluorescent pro-
tein (Env-IRES-GFP) were described previously (18). SIVmac239 and
SIVmac"Nef proviral plasmids were kindly provided by Theodora Hatzi-
ioannou, Aaron Diamond AIDS Research Center, New York, NY (16).
Tetherin isoforms and species orthologues weremade in pCR3.1, pLHCX
(Clontech), and pCMS28 by standardmolecular biological methods. Vpu
proteins from different clades of HIV-1 or clade B transmitted/founder
viruses (42) were cloned into a rev-dependent expression vector, pCRV1,
as described previously (39). SIVgsnVpu, SIVmonVpu, and groupNVpu
YBF30 orN1FR2011 (43)were synthesized and cloned into pCRV1.Mona
and greater spot-nosed monkey tetherins (21) were similarly synthesized
and cloned into pCR3.1.
HEK293T, HEK293, HT1080, and Jurkat cells were obtained from the
American Type Culture Collection; the HIV reporter TZM-bl HeLa cell
line was kindly provided by JohnKappes through theNIHAIDS Reagents
Repository Program (ARRP). Jurkat-TAg cells were kindly provided by
Marie-Jose Bijlmakers, King’s College London. All adherent cells were
maintained in Dulbecco’s modified Eagle medium (Invitrogen) supple-
mented with 10% fetal calf serum and gentamicin. Derivatives of cell lines
stably expressing human tetherin ormutant forms thereof were produced
by transducing the cells with murine leukemia virus-based retroviral vec-
tors packaging a pLHCXor pCMS28 vector genome encoding the tetherin
construct and selecting the cells in hygromycin (Invitrogen) or puromy-
cin, respectively. Jurkat and Jurkat-TAg cells were maintained in Roswell
ParkMemorial Institutemedium supplementedwith 10% fetal calf serum
and gentamicin.
Production of vector and virus stocks. For full-length vesicular sto-
matitis virus G protein (VSV-G)-pseudotyped HIV-1 stocks, 293T cells
were transfected with 2#g proviral plasmid and 200 ng pCMV-VSV-G by
using polyethylenimine (PEI; 1 mg/ml; Polysciences Europe GmbH). At
48 h posttransfection, supernatants were harvested and endpoint titers
were determined in TZM-bl HeLa cells as described previously (18). For
KSHVK5 andHIV-1 Vpu vectors, cells were transfected with a 3:2:1 ratio
of the pCMS28 K5/Vpu vector plasmid, pMLV-Gag-Pol, and pCMV-
VSV-Gand supernatantswere harvested 48 hposttransfection andused to
transduce HT1080 or 293 cells expressing tetherin isoforms.
Virus release assays. Subconfluent 293T cells were plated on 24-well
plates and transfected with 500 ng HIV-1 NL4.3 WT or "Vpu mutant
provirus and various amounts of tetherin expression vector or a constant
amount (50 ng) of tetherin and various inputs of Vpu plasmid by using 1
#g/ml PEI. Similarly, 500 ng SIVmac or SIVmac"Nef provirus was
cotransfected with various amounts of rhesus macaque tetherin expres-
sion vectors. Themediumwas replaced 6 or 16 h posttransfection, and the
supernatants were harvested after 48 h. The infectivity of viral superna-
tants was determined by infecting TZM-bl HeLa cells, which were assayed
48 h later for !-galactosidase activity with the Tropix GalactoStar chemi-
luminescence kit (Applied Biosystems). For the analysis of physical virion
release, supernatants were filtered (0.22 mm) and pelleted through a 20%
sucrose–phosphate-buffered saline (PBS) cushion at 20,000 $ g for 90
min at 4°C, and pellets were lysed in SDS-PAGE loading buffer. AllHIV-1,
HIV-2, and SIVmac virion and cell lysates were then subjected to SDS-
PAGE and Western blotted for HIV-1 p24 CA (monoclonal antibody
183-H12-5C; kindly provided by B. Chesebro through the NIH ARRP),
rabbit anti-Hsp90 (Santa Cruz Biotechnologies), or polyclonal rabbit an-
titetherin (kindly provided byK. Strebel through theNIHARRP) (44) and
visualized with a LiCor apparatus by using fluorophore-conjugated sec-
ondary antibodies (IRDye 800 goat anti-rabbit, IRDye 680 goat anti-
mouse).
Flow cytometry. Jurkat-TAg cells expressing tetherin isoforms were
infected with VSV-G-pseudotyped HIV-1 NL4.3 WT or "Vpu virus at a
multiplicity of infection (MOI) of 2. Cells were washed at 6 or 16 h postin-
fection. At 48 h postinfection, cells were stained for surface tetherin with a
specific anti-BST2 IgG2amonoclonal antibody (Abnova) and a goat anti-
mouse IgG2a Alexa 633-conjugated secondary antibody (Molecular
Probes, Invitrogen), fixed and permeabilized for 20 min (Cytofix/Cy-
toperm fixation/permeabilization kit; BD Biosciences), and then stained
for intracellular HIV-1 Gag with the KC57 antibody conjugated to phy-
coerythrin (PE) (Beckman-Coulter). Cells were then analyzed with a
FACSCalibur flow cytometer (Becton Dickinson) and FlowJo software.
293 cells expressing tetherin isoforms were plated in 24-well plates and
transfected with 500 ng pCRV1-HIV-2-IRES-GFP vector with PEI. At 48
h posttransfection, the cells were harvested in PBS–5 mM EDTA, stained
for surface tetherin, and analyzed as described above. HT1080 or 293 cells
expressing tetherin isoforms were transduced with K5/K5NTR or differ-
ent Vpu proteins, respectively. After puromycin selection, cells were
stained for surface tetherin with an anti-human CD317-PE antibody
(eBioscience) and analyzed as described above.
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Immunoprecipitation. Jurkat cells treated with IFN (1,000 U/ml) or
left untreated, Jurkat-TAg L-tetherin, Jurkat-TAg S-tetherin, and Jurkat-
TAg empty-vector control cells were lysed on ice for 20 min in buffer
containing 50 mM Tris (pH 7.4), 150 mM NaCl, 200 !M sodium or-
thovanadate, 1% NP-40, 0.5% sodium deoxycholate, 5 mM N-ethylma-
leimide, and complete protease inhibitors (Roche). Lysates were cleared
by centrifugation, and supernatants were incubated with 5 !g/ml mouse
anti-BST2 monoclonal antibody (eBioscience) for 1.5 h at 4°C. Sephar-
ose-protein G beads were washed in lysis buffer before they were added to
the samples and incubated for another 3 h. Beads were washed five times
in lysis buffer before the peptide–N-glycosidase mixture for deglycosyla-
tion was added (New England BioLabs). Samples were incubated at 37°C
overnight and resuspended in SDS-PAGE loading buffer. Cell lysates and
immunoprecipitates were subjected to SDS-PAGE and Western blotting
for tetherin andHsp90. Blots were visualized with a LiCor apparatus. The
secondary antibodies used are described above.
RESULTS
The L- and S-tetherin isoforms are differentially sensitive to
HIV-1 Vpu. To characterize the roles of the recently identified L-
and S-tetherin isoforms (11), we generated constructs encoding
human tetherin with its authentic Kozak consensus (WT teth-
erin), the "1 ATG mutated (S-tetherin), or a semiconservative
M13I mutation (L-tetherin) (Fig. 1A). We first sought to confirm
the data of Cocka and Bates that S-tetherin displayed reduced
sensitivity to HIV-1 Vpu in transient-transfection assays (11).
293T cells were transfected with WT HIV-1 (NL4.3) or a Vpu-
defective proviral plasmid in combination with increasing doses
of each tetherin expression vector. As expected, increasing the
expression of all of the tetherin constructs resulted in an equiva-
lent dose-dependent inhibition of Vpu-defectiveHIV-1 release, as
measured both by infectious titer and by physical virus yield (Fig.
1B and C). All tetherin constructs were well expressed, with the
WT tetherin construct apparently expressing similar amounts of
both isoforms. TheWTviruswas essentially resistant to L-tetherin
at all expression levels. In contrast, above moderate expression
levels, S-tetherin partially restricted the release of WT virus, indi-
cating that Vpu incompletely antagonized it. For the WT tetherin
construct, a milder phenotype was observed, with appreciable re-
striction of WT viral release seen at the highest tetherin input.
Therefore, consistent with the previous report (11), S-tetherin
homodimers are less sensitive to counteraction by Vpu. Further-
more, since L- and S-tetherins should be able to independently
assort to give heterodimers, the approximately 4-fold increased
input ofWT tetherin required for restriction ofWTHIV-1 release
implies that L-S heterodimers are as sensitive to Vpu as L-tetherin
homodimers assuming a 1:2:1 ratio because of independent as-
sortment (compare 50- and 200-ng inputs in Fig. 1B). Finally, we
asked whether S-tetherin displays any evidence of Vpu-induced
degradation. Stable 293–L-tetherin or 239–S-tetherin cells that
express equivalent levels of the respective isoforms (Fig. 1D) were
infected with VSV-G-pseudotyped WT or Vpu-defective virus at
anMOI of 2, and cell lysates were analyzed byWestern blotting 48
h later (Fig. 1E). As expected, L-tetherin levels were degraded in
the presence of the WT virus. However, S-tetherin was not de-
graded under the same conditions. Interestingly, in cells infected
with the WT virus, the apparent molecular mass of S-tetherin
increased. Thismay suggest that a Vpu-inducedmodification, po-
tentially ubiquitination, may underlie the residual antagonistic
effect of Vpu.
Determinants of Vpu antagonism in the human tetherin cyto-
plasmic tail have suggested both a role for the tyrosine-based sort-
ing (YDYCRV)motif (29) and a serine-threonine (STS)motif that
may be ubiquitinated (35), both of which are absent from S-teth-
erin. Mutation of either of these motifs to alanines (STS¡AAA or
YDY¡ADA) (Fig. 2A) reduced the sensitivity ofWT human teth-
erin to Vpu (Fig. 2B), and simultaneous disruption had an addi-
tive effect with the caveat that this protein is more highly ex-
pressed, probably because it lacks sequences important for its
natural turnover. Interestingly, mutation of the tyrosine residues
to phenylalanines (YDY¡FDF) retained sensitivity to Vpu, likely
because Phe residues can, to a certain extent, substitute for ty-
rosines in endocytic sorting motifs (Fig. 2B and C). This site is
known to be required for maximal counteraction by Vpu (29). Of
note, the reduced sensitivity of these mutants to Vpu did not cor-
relate with overall surface tetherin expression (Fig. 2D).
To determine whether tetherin isoforms affect WT virus re-
lease in a relevant cell type, we took advantage of a derivative of
CD4" Jurkat cells, Jurkat-TAg cells, that has been shown to have
no detectable tetherin on its surface (Fig. 3A) (45). Expression of
L- or S-tetherin in these cells resulted in bulk populations whose
surface tetherin expression levels were equivalent to those of pa-
rental Jurkat cells after type 1 IFN treatment (Fig. 3A). Immuno-
precipitation of the tetherin from these cell lines revealed that
while Jurkat cells express equivalent levels of both tetherin iso-
forms and IFN treatment upregulated both equivalently, J-TAg–
L-tetherin and J-TAg–S-tetherin cells expressed only the desired
isoform (Fig. 3B). Thus, we could use these cells to compare the
isoforms in relevant target cells at approximately physiological
expression levels. J-TAg–L-tetherin and J-TAg–S-tetherin cells
were infected withWT andVpu-defectiveHIV-1 and analyzed for
surface tetherin andHIV-1Gag expression 48 h later. As expected,
neither tetherin was downregulated in cells infected with Vpu-
defective virus, with surface levels enhanced in the p24-high cells
probably because of tethered virion accumulation on the surface
(Fig. 3C). While L-tetherin was efficiently downmodulated from
the surface of cells infected with theWT virus, S-tetherin was not,
in keeping with Vpu-mediated targeting for endosomal degrada-
tion. Infectious viral release and physical virion yield from the
same cultures revealed a significant 3- to 4-fold defect in WT vi-
rion release from J-TAg-S-tetherin, demonstrating that at relevant
expression levels, the S-tetherin isoform is poorly antagonized
(Fig. 3D and E). Since L-tetherin is both induced by pattern rec-
ognition (46) and itself capable of proinflammatory signaling
(11), a potential confounding issue here is whetherWTexpression
(i.e., expression of both isoforms) is induced in infected cells.
While this is a possibility in primary cells, we saw no evidence of
tetherin upregulation in infected J-TAg cells (Fig. 3E). Neither did
we see any expression of S-tetherin in 293T–L-tetherin cells trans-
fected with Vpu-defective HIV-1 provirus (Fig. 3F), which under
these conditions triggers NF-#B activation (12; data not shown).
Thus, because of a lack of the cytoplasmic tail residues required for
subcellular trafficking andubiquitination (29, 35), the S-tetherin iso-
form cannot be degraded or downregulated in CD4"T cells and this
accounts for its reduced sensitivity to HIV-1 Vpu. Furthermore, the
residual activity of Vpu against S-tetherin in the absence of surface
removal is in keepingwith the ability ofVpu to exclude tetherin from
virions at the surface to some extent (26, 44).
Differential sensitivity of human tetherin isoforms is a fea-
ture of HIV-1 group M Vpu proteins. We have recently found
that most Vpu alleles from primary isolates display tetherin coun-
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FIG 1 The L- and S-tetherin isoforms are differentially sensitive to HIV-1 Vpu. (A) Schematic representation of the amino acid sequences of WT tetherin (WT
THN), L-tetherin (L-THN), and S-tetherin (S-THN). (B andC) 293T cells were transfectedwith increasing amounts ofWT tetherin, L-tetherin, or S-tetherin and
NL4.3WTor!Vpu proviral plasmid. (B) At 48 h posttransfection, infectious virus release was determinedwith TZM-blHeLa reporter cells. Error bars represent
standard deviations of the means of three independent experiments. RLU, relative light units. (C) Cell lysates and pelleted viral supernatants from panel B were
subjected to SDS-PAGE and analyzed byWestern blotting for Hsp90, tetherin, and p24 CA. The percentages of p24 release into the supernatant indicated at the
bottom are relative to the release of WT NL4.3 or NL4.3!Vpu in the absence of tetherin. (D) 293 cells stably expressing the tetherin isoforms were analyzed for
surface tetherin expression (L-tetherin, solid black line; S-tetherin, solid gray line; empty-vector 293 cells, dashed gray line [No THN]). (E) 293 cells stably
expressing tetherin isoforms were infected with VSV-G-pseudotypedWTNL4.3 or NL4.3!Vpu virus at anMOI of 2. At 48 h postinfection, cells were harvested
and subjected to SDS-PAGE, analyzed by Western blotting for tetherin and Hsp90, and analyzed with a LiCor quantitative imager. The percentages of tetherin
levels indicated below the lanes are relative to the tetherin levels in the corresponding uninfected cell lines. Uninf., uninfected.
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teraction activity superior to that encoded by NL4.3, suggesting
that accessory gene alleles from lab-adapted strains of HIV-1 may
not be representative because of functional drift after prolonged ex
vivo passage (39). We therefore examined the sensitivities of hu-
man tetherin isoforms to a panel of Vpu alleles from transmitted/
founder viruses (42) of HIV-1 subtype B (Fig. 4A) and additional
examples from clades A1, A2, C, F, and H (Fig. 4B). In this case,
293T cells were transfected with a Vpu-defective HIV-1 proviral
plasmid in the presence of a fixed dose (50 ng) of tetherin and
increasing Vpu-encoding plasmid inputs in trans. In all cases
where the Vpu displayed antitetherin activity (C MJ4 and F Vpu
appeared defective against all tetherin isoforms), L-tetherin was
robustly counteracted at low Vpu expression levels. However, as
with NL4.3 Vpu, S-tetherin sensitivity to counteraction wasmuch
FIG 2 Tetherin’s sensitivity to Vpu is dependent on serines, a threonine, and tyrosines. (A) Cytoplasmic tail amino acid sequences of mutant tetherins (THNs)
used to determine the residues required for sensitivity to HIV-1 NL4.3 Vpu. (B and C) 293T cells were transfected with increasing amounts of different mutant
tetherins and a HIV-1 NL4.3 WT or !Vpu proviral plasmid. (B) At 48 h posttransfection, infectious virus release was determined with TZM-bl HeLa reporter
cells. Error bars represent standard deviations of the means of three independent experiments. Solid lines, NL4.3 WT provirus; dashed lines, NL4.3 !Vpu
provirus. RLU, relative light units. (C) Cell lysates and pelleted viral supernatants from panel B were subjected to SDS-PAGE and analyzed by Western blotting
for Hsp90, tetherin, and p24 CA. The percentages of p24 release into the supernatant indicated at the bottom are relative to the release of NL4.3 WT or !Vpu
provirus in the absence of tetherin. (D) 293 cells stably expressing themutant tetherinswere analyzed for surface tetherin expression and are shown in comparison
to 293 cells expressing L-tetherin (solid gray line) and empty-vector 293 cells (dashed gray line).
Sensitivity of Tetherin Isoforms to Lentiviruses
May 2014 Volume 88 Number 10 jvi.asm.org 5849





reduced in comparison. In particular, clade A1 and A2 Vpu pro-
teins displayed only marginal activity against S-tetherin, and the
weak antagonism of L-tetherin by a clade F Vpu suggests that it
may be defective for promotion of degradation. As expected, con-
structs expressing WT tetherin gave an intermediate phenotype
consistent with mixed-isoform expression. Thus, the differential
sensitivity of L- and S-tetherins is a feature of the HIV-1 Vpu
proteins from group M.
Targeting of both tetherin isoforms by an HIV-1 group N
Vpu from Togo and Vpu proteins from SIVgsn and SIVmon.
TheVpuproteins ofHIV-1 groupNdisplay variablyweak tetherin
counteractivity and are unable to degrade CD4 (21). However,
Vpu from a strain isolated from a French national returning
from Togo with acute HIV infection revealed evidence of further
adaptation to human tetherin in HIV-1 group N (43). In particu-
lar, acquisition of a trafficking motif (ExxxLV) found in M-Vpu
proteins that is required for promotion of tetherin degradation
was associated with tetherin counteraction. While this Vpu
(N1.FR.2011) potently targeted L-tetherin in comparison to that
from another group N strain, YBF30 (Fig. 5A and B), at higher
Vpu expression levels, it could also completely counteract S-teth-
erin, in contrast to HIV-1 group M Vpu proteins. This enhanced
ability to counteract S-tetherin prompted us to examine whether
N1.FR.2011 Vpu could downmodulate and degrade S-tetherin.
However, expression ofN1.FR.2011Vpuwas unable to induce the
degradation of S-tetherin (Fig. 5C) and neither did it lead tomore
than the 2-fold reduction of cell surface S-tetherin that was seen
with NL4.3 Vpu (Fig. 5D and E). Thus, N1.FR.2011 Vpu’s en-
hanced activity against S-tetherin may indicate that it is more
efficient than groupMVpu proteins at excluding it from budding
virions at the cell surface.
A similar result was obtained with Vpu proteins from SIVgsn
and SIVmon that target tetherin in their host species, as well as
other primate tetherins, including that from rhesus macaques
FIG 3 Differential sensitivity of tetherin (THN) isoforms to Vpu in CD4! T cell lines. (A) Jurkat-TAg cells stably expressing L-tetherin (solid light gray line) or
S-tetherin (solid dark gray line) were analyzed for surface tetherin expression compared to Jurkat cells treatedwith IFN for 24 h (solid black line) or left untreated
(dashed black line) and to Jurkat-TAg cells (dashed gray line) not expressing tetherin. (B) Jurkat-TAg cells expressing tetherin isoforms and Jurkat cells treated
with IFN or left untreated were lysed and immunoprecipitated with antitetherin antibody and deglycosylated (Deglyco.). Lysates and precipitates were subjected
to SDS-PAGE and analyzed by Western blotting for Hsp90 and tetherin. (C and D) Jurkat-TAg cells expressing L- or S-tetherin were infected with VSV-G-
pseudotyped HIV-1 NL4.3WT or"Vpu at anMOI of 2 for 48 h. (C) Cells were analyzed by flow cytometry for intracellular p24 and surface tetherin expression.
Median fluorescence intensities (MFI) are indicated. (D) Titers of infectious virus in supernatants from infected cells were determined on TZM-bl cells. Data are
from four different experiments, and error bars show the standard errors of themeans. **,P# 0.01 (determined by two-tailed t test); ns, no statistically significant
difference. RLU, relative light units. (E) Cell lysates and pelleted viral supernatants from panel C were subjected to SDS-PAGE and analyzed byWestern blotting
for HIV-1 Hsp90, tetherin, and p24 CA. Percent p24 release relative to WT NL4.3 or NL4.3"Vpu release in the absence of tetherin is indicated at the bottom.
uninf., uninfected. (F) 293 cells expressing no tetherin, L-tetherin, or S-tetherin were infected at an MOI of 2. At 48 h postinfection, cells were lysed and
immunoprecipitated (IP) with antitetherin antibody and deglycosylated. Lysates and precipitates were subjected to SDS-PAGE and analyzed byWestern blotting
for Hsp90 and tetherin.
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(21). These are descendants of the ancestral vpu alleles fromwhich
SIVcpz and HIV-1 Vpu is derived (40). Again, unlike HIV-1 M
Vpu, these proteins equally counteracted the rhesus L- and S-
tetherin isoforms, whereas the Vpu from SIVcpzUS, which com-
pletely lacks tetherin counteractivity (47), had no effect (Fig. 6A
and B). Again, neither SIVgsn nor SIVmon Vpu displayed any
degradative activity against either isoform of rhesus tetherin (Fig.
6C). Furthermore, to rule out species-specific effects on tetherin
counteraction, we tested these Vpu proteins against their cognate
species tetherin isoforms. Although the expression levels of the L
isoforms of the greater spot-nosed and mona monkey tetherins
were lower than those of the WT and short isoforms, the level of
counteraction across Vpu expression levels was equivalent (Fig.
6D toG), again demonstrating equal isoform sensitivity. Thus, the
proteins in the guenon SIV lineage that contributed Vpu toHIV-1
are capable of counteracting both isoforms of tetherin equally.
This suggests that the readaptation of Vpu to target human teth-
erin during the zoonotic spread of SIVcpz to becomeHIV-1 group
M resulted in a countermeasure that targeted only one isoform for
degradation. The apparently higher potency of the guenon SIV
Vpu proteins against S-tetherin suggests that there may be cell
biological differences in the mechanisms of action of these pro-
teins that account for this.
HIV-2 envelope, SIVmac Nef, and KSHV K5 target tetherin
isoforms with equal efficiency.We then examined the sensitivi-
ties of human or rhesus L- and S-tetherins to other virus-encoded
countermeasures. Most SIVs that lack a vpu gene antagonize their
species’ tetherins with Nef (15, 16). SIVmac Nef binds to the cy-
toplasmic tail ofmacaque tetherin and likely forms a ternary com-
plex with clathrin adaptor protein complex 2 (AP2) (36, 37) to
FIG 4 Differential sensitivity of human tetherin (THN) isoforms to Vpu is a feature of groupM. (A and B) 293T cells were transfected with increasing amounts
of Vpu,!Vpu proviral plasmid, and 50 ng of humanWT tetherin, L-tetherin, or S-tetherin. At 48 h posttransfection, infectious virus release was determinedwith
TZM-bl HeLa reporter cells. Error bars represent standard deviations of the means of three independent experiments. RLU, relative light units.
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stimulate tetherin endocytosis and intracellular sequestration.
Nef’s specificity for primate tetherins depends on a (G/D)DIWK
motif that is absent from human tetherin. Therefore, rhesus
macaque L-tetherin (rhL-tetherin) and rhS-tetherin were tested
for the ability to restrict the release of WT or Nef-defective
SIVmac239 from transiently transfected 293T cells. To overcome
the reduced infectivity of Nef-defective viruses, we cotransfected
VSV-G. As with Vpu-defective HIV-1, the release of Nef-defective
SIVmac239was equally sensitive to restriction by either isoformof
rh-tetherin (Fig. 7A and B). However, in contrast, the WT virus
was resistant to all rh-tetherin isoforms, indicating that the ab-
sence of the first 12 amino acids of the tetherin cytoplasmic tail has
no effect on its sensitivity to Nef-mediated antagonism. This was
also the case for HIV-2, which uses its envelope to target tetherin,
again in an AP2-dependent manner (18, 38). Despite being a
relatively weak tetherin antagonist, the release of WT HIV-2
Rod10 particles from cells transfected with L-tetherin and S-teth-
erin was equally superior to a viral Env mutant lacking the major
AP2 binding site GYXXV (HIV-2 Rod10 GY-AA) in its cytoplas-
mic tail (Fig. 7C). Furthermore, expression of the HIV-2 Rod10
envelope protein in 293–L- or 293–S-tetherin cells could reduce
cell surface tetherin levels dependent on theAP2-binding site (Fig.
7D). Thus, tetherin counteraction and surface downregulation by
both SIVmac Nef and HIV-2 Env are independent of trafficking
and ubiquitination motifs that are required for Vpu to target hu-
man tetherin for degradation.
We finally asked whether the K5 ubiquitin ligase encoded by
KSHV could also target both tetherin isoforms. K5 targets a single
lysine residue (K18) in human tetherin to promote ESCRT-de-
pendent endosomal degradation (5).However, becauseK5 cannot
FIG5 Targeting of both tetherin (THN) isoforms by groupNHIV-1Vpu fromTogo. (A) 293T cells were transiently transfectedwith increasing amounts ofVpu;
!Vpuproviral plasmid; and 50ng of humanWT tetherin, L-tetherin, or S-tetherin. At 48 h posttransfection, infectious virus releasewas determinedwithTZM-bl
HeLa reporter cells. Error bars represent standard deviations of the means of three independent experiments. RLU, relative light units. (B) Cell lysates and
pelleted viral supernatants from panel A were subjected to SDS-PAGE and analyzed byWestern blotting for Hsp90 and p24 CA. The fold increases in p24 release
into the supernatant indicated at the bottom are relative to the release of NL4.3!Vpu in the absence of Vpu. (C) 293 cells stably expressing L- or S-tetherin were
transduced with retroviral vectors encoding different Vpu proteins. Cell lysates were analyzed for tetherin expression by SDS-PAGE and Western blotting. (D)
Vpu-transduced cells from panel C were stained for surface tetherin and analyzed by flow cytometry. Empty-vector 293 cells (not expressing tetherin), dashed
gray line. (E) Median fluorescence intensity (MFI) of tetherin in cells from panel D.
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target rhesus tetherin, it is possible that cytoplasmic tail residues
play a role in this specificity. Since 293T cells do not support effi-
cient K5 function (5), HT1080 cells encoding human tetherin iso-
forms were transduced with puromycin-selective retroviral vec-
tors encoding K5 or amutant form, K5NTR, bearing a lesion in its
C-terminal cytoplasmic tail that abolishes its activity (48). Puro-
mycin-resistant cells expressing K5, but not K5NTR, displayed a
marked reduction in the cell surface expression levels of both teth-
FIG 6 Targeting of both tetherin (THN) isoforms by ancestral Vpu proteins from SIVgsn and SIVmon. (A) 293T cells were transiently transfected with
increasing amounts of Vpu;!Vpuproviral plasmid; and 50 ng of rhesusmacaqueWT tetherin, L-tetherin, or S-tetherin. At 48 h posttransfection, infectious virus
release was determined with TZM-bl HeLa reporter cells. Error bars represent standard deviations of themeans of three independent experiments. RLU, relative
light units. Rh, rhesus. (B) Cell lysates and pelleted viral supernatants frompanel Awere subjected to SDS-PAGE and analyzed byWestern blotting forHsp90 and
p24CA. The fold increases in p24 release into the supernatant indicated at the bottom are relative to the release ofNL4.3!Vpu in the absence of Vpu. (C) 293 cells
stably expressing L- or S-tetherin were transduced with retroviral vectors encoding different Vpu proteins. Cell lysates were analyzed for tetherin expression by
SDS-PAGE and Western blotting. (D and F) 293T cells were transiently transfected with increasing amounts of greater spot-nosed monkey (Gsn) Vpu (D) or
mona monkey (Mon) Vpu (F); !Vpu proviral plasmid; and 50 ng of Gsn (D) or Mon (F) WT tetherin, L-tetherin, or S-tetherin. At 48 h posttransfection,
infectious virus release was determined with TZM-bl HeLa reporter cells. Error bars represent standard deviations of the means of three independent experi-
ments. (E and G) Cell lysates and pelleted viral supernatants from panels D and F were subjected to SDS-PAGE and analyzed by Western blotting for Hsp90,
tetherin, and p24CA. The fold increases in p24 release into the supernatant indicated at the bottomare relative to the release ofNL4.3!Vpu in the absence ofVpu.
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FIG 7 HIV-2 envelope, SIVmac Nef, and KSHV K5 target tetherin (THN) isoforms with equal efficiency. (A and B) 293T cells were transfected with increasing
amounts of rhesus (Rh)macaqueWT, L-, or S-tetherin and SIVmac or SIVmac!Nef proviral plasmid. (A) Titers of infectious virus released from transfected cells
were determined on TZM-bl HeLa reporter cells. Solid lines, SIVmac; dashed lines, SIVmac!Nef. RLU, relative light units. (B) Cell lysates and pelleted
supernatant virions were subjected to SDS-PAGE and analyzed by Western blotting for Hsp90, rhesus tetherin, and p27 CA expression. The percentages of p27
CA in the supernatant, relative to virus release in the absence of tetherin, are indicated at the bottom. (C) 293T cells were transfected with increasing amounts of
humanWT, L-, or S-tetherin and HIV-2 ROD10 or the ROD10 GY-AAmutant proviral plasmid. Cell lysates and pelleted supernatant virions were subjected to
SDS-PAGE and analyzed byWestern blotting for Hsp90, tetherin, and p26 CA expression. The percentages of p26 CA in the supernatant, relative to virus release
in the absence of tetherin, are indicated at the bottom. (D) 293 cells stably expressing L- or S-tetherin were transfected with HIV-2 ROD10 Env-IRES-GFP or
HIV-2 ROD10 GY-AA mutant Env-IRES-GFP. At 48 h posttransfection, cells were analyzed by flow cytometry for surface GFP and tetherin expression. (E)
HT1080 cells stably expressing tetherin isoformswere transducedwith K5 ormutant K5 (K5NTR) defective for tetherin antagonism and selected. Cells were then
analyzed by flow cytometry for surface tetherin expression. Dotted gray lines, tetherin-negative HT1080 cells; gray lines, nontransduced tetherin-expressing
HT1080 cells; black lines, tetherin-expressing cells transduced with WT K5 (top) or a mutant form (K5NTR; bottom). The graph indicates the surface tetherin
expression on transduced cell lines, shown as percentages of the fluorescence of the corresponding nontransduced (Untransd.) tetherin-expressing cell line. (F)
Lysates of transduced and nontransduced cells were subjected to SDS-PAGE and analyzed by Western blotting for Hsp90 and tetherin expression. Tetherin
expression in lysates as a percentage of that in nontransduced cells is shown at the bottom.
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erin isoforms, indicating equal sensitivity to K5 (Fig. 7E). Total
tetherin levels in the lysates of the same cells revealed evidence that
both tetherin isoforms are sensitive to K5-mediated degradation
(Fig. 7F). Together, these data indicate that, unlike Vpu, the first
12 amino acids of the tetherin cytoplasmic tail are dispensable for
counteraction by other viral antagonists, thus rendering both iso-
forms equally sensitive, and further suggest that trafficking deter-
minants in these countermeasures act independently of tetherin’s
normal recycling mechanism.
DISCUSSION
In this study, we have examined the sensitivities of the L- and
S-tetherin isoforms to lentiviral antagonists and found that,
uniquely among those studied, the Vpu proteins of HIV-1 group
M differ in the potency with which they target isoforms of human
tetherin. For the most part, this parallels the ability of M-Vpu to
reduce cell surface levels of tetherin and target it for ESCRT-de-
pendent degradation (1). Similarly to a recent study (11), this is
determined by the lack of both a clathrin-dependent recycling
sequence (YDYCRV) and a putative serine-threonine motif pre-
viously reported to act as a ubiquitin acceptor site (35). These data
are consistent with the notion that for maximal counteraction of
tetherin, Vpu blocks its transit from the trans-Golgi network to
the PM and routes it to late endosomes, which requires trafficking
motifs in the cytoplasmic tails of both proteins (1). In contrast,
SIV Nef and HIV-2 Env do not mediate tetherin degradation but
rather lead to tetherin’s intracellular sequestration following en-
hanced internalization from the surface. This is dependent onAP2
binding sites in both viral proteins (18, 36–38, 49). For Nef (36)
and also for Env, as shown here, this does not require the presence
of the endocytic signal in tetherin itself.
Most of themammalian tetherins so far sequenced have a second
ATGin theirfirst exon that canact as a translation initiation site in the
mRNA, leading to the potential to express the L- and S-tetherin iso-
forms (11). The data so far indicate that both isoforms are expressed
equally, and since tetherin is a dimer, independent assembly could
give rise to a distribution of homodimers and heterodimers in a 1:2:1
ratio (11). This is borne out in our data showing that approximately
4-fold more expression of WT tetherin than of the short isoform is
required to restrict WT HIV-1 release. Polymorphisms in the !1
ATG site have been observed three times so far in differentmamma-
lian species. Both the domestic cat (50, 51) and horse (52) tetherin
genes lack the !1 ATG, and a similar defect exists in at least one
inbred mouse strain, NZW (53). In the latter case, this has been
shown to lead to higher tetherin expression levels on lymphocytes
and correlateswith a better control ofmurine leukemia virus viremia
(53). The facts that both isoforms are equally potent at restricting
virionreleaseand thatnoneof theother lentiviral tetherinantagonists
tested here differentiate between the isoforms therefore raise the
question of why tetherin counteraction and the determinants of L-
tetherin degradation are so strictly conserved in groupMVpu.
Key issues are whether the expression of L- and S-tetherin can
be differentially regulated and the importance of additional func-
tions associated with the long isoform. The lack of the YDYCRV
motif reduces tetherin endocytosis and recycling (22), and in
keeping with this, HIV-1 virions do not accumulate in late endo-
somes in cells expressing either tyrosinemutant or human S-teth-
erin (12; data not shown). The delivery of retained virions to en-
dosomes for degradation may have immunological consequences
in addition to the physical removal of virions from the cell surface.
Virion componentsmay be targeted for enhanced antigen presen-
tation in some cell types, or liberation of virion associated patho-
gen-associated molecular patterns in endosomes may further
stimulate cognate pattern recognition receptors in cis (1, 12). In
contrast, surface accumulation of virions mediated by S-tetherin
may enhance the opsonization of infected cells and debris for
clearance by phagocytes (1). In support of this notion, very recent
data indicate that tetherin-mediated virion retention sensitizes
infected cells to antibody-dependent cellular cytotoxicity (54).
Furthermore, tetherin itself may directly regulate pattern recogni-
tion receptor function in plasmacytoid dendritic cells through the
inhibitory leukocyte receptor ILT-7 (55), although this has been
recently challenged (56). Thus, other physiological roles of S-teth-
erin and L-tetherin bear further investigation. Finally, the ability
of tetherin to physically restrict cell-to-cell transmission at viro-
logical synapses (VS) of HIV-1 has been controversial (57–59).
Given the differential sensitivity of the L and S isoforms to Vpu, it
will be important to knowwhether they partition differently to the
VS in a manner that may account for these discrepant observa-
tions.
Since most of these attributes should be features of all mam-
malian tetherins, why only the HIV-1 tetherin countermeasure
differentiates between the isoforms so markedly still requires ex-
planation. One further function of tetherin that is limited to the
long isoform is the ability to mediate an NF-"B-dependent signal
upon virion retention (12, 13). This again requires the YDYCRV
motif, and the current data suggest that virion aggregation of teth-
erin at the cell surface upon restriction of release leads to the
recruitment of a TRAF2/TRAF6/TAK1 complex that activates
NF-"B (11–13). In keeping with this, human CD4! T cells in-
fected with Vpu-defective HIV-1 express enhanced levels of pro-
inflammatory cytokines in a tetherin-dependent manner (12).
This activity is so far limited to the human and chimpanzee pro-
teins (12). Species-specific changes in the cytoplasmic tails of great
ape and hominid tetherins are the determinants of its signaling
capacity, with the human protein showing considerably more po-
tent activity (12). Importantly, evidence that S-tetherin domi-
nantly interferes with human tetherin signaling suggests that only
homodimers of L-tetherin can signal (11). Since the threshold for
such a signaling event may be less than efficient virion retention,
we suggest that this function fits well with a further selective pres-
sure exerted specifically by human L-tetherin.
The ability of HIV-1 Vpu to counteract tetherin is a reacquisi-
tion of an ancestral guenon SIV function that was lost in SIVcpz
Vpuproteins (40). Thiswas probably due to redundancywithNef,
which in SIVcpz acts as the tetherin antagonist (21). SIVcpz de-
rives from a recombination between two lineages of SIV with
Vpu- andNef-mediated tetherin counteraction, respectively (40).
However, becauseNef associates directly with tetherin, dependent
in part on a G/DDIWKmotif in the cytoplasmic tail (37) that has
been deleted from hominids (60), SIVcpz was without a tetherin
antagonist upon zoonotic transfer to humans. Thus, Vpu, which
still retained CD4 targeting, adapted to target human tetherin
(21). Sequence divergence in SIVcpz Vpu proteins is associated
with whether the individual zoonotic transfers that gave rise to
groups M, N, O, and P adapted to target human tetherin (40, 43).
In particular, (i) the development of an AxxxAxxxAxxxWbinding
interface in the Vpu TM domain (24, 25), (ii) acidic-dileucine
trafficking motifs (29), and (iii) a well-characterized ubiquitin
ligase binding site (DSGNES) in the cytoplasmic tail (33, 43) are
Sensitivity of Tetherin Isoforms to Lentiviruses
May 2014 Volume 88 Number 10 jvi.asm.org 5855





the key features of the M-Vpu protein that endowed it with teth-
erin counteractivity. The latter two are essential for L-tetherin
degradation byM-Vpu (29, 32, 33). In contrast, O-Vpu lacks teth-
erin binding in the TM domain and fails to target human tetherin
at all, whereas all N-Vpu proteins (save one) have readapted to
bind tetherin but fail to counteract it efficiently or degrade it (21,
61, 62). Thus, it has been proposed that efficient tetherin counter-
action by Vpuwas a key feature in the establishment of the human
HIV/AIDS pandemic by groupMHIV-1 (40). Coincidentally, the
deletion that abolished the Nef sensitivity of human tetherin also
gave rise to the enhanced signaling capacity of the long isoform
(12), the form that all of the M-Vpu proteins tested herein pref-
erentially target. Thus, we speculate that enhanced targeting of
L-tetherin owing to its increased signaling capacity, in addition to
its direct antiviral activity, may have contributed to the successful
spread of HIV-1 group M in humans, whereas groups N and O
remain geographically restricted. In this regard, the increased po-
tency of Vpu from a highly pathogenic groupNHIV-1 fromTogo
is interesting.While it has acquired two cytoplasmic tail attributes
important for counteraction (43), in our studies, it did not de-
grade tetherin. Also, although it is still better at counteracting
L-tetherin, it appears to be superior to many M-Vpu proteins at
counteracting S-tetherin. Therefore, there may be cell biological
differences in its mode of action that account for this. In some
experimental systems, Vpu can counteract tetherin to a certain
extent at the cell surface by physically excluding it from budding
virions without removal from the PM (26). This requires the
ExxxLV trafficking motif in Vpu but not the YDYCRV motif in
tetherin. Since N1.FR.2011 Vpu has acquired this motif (43), fu-
ture work will determine if this surface exclusion activity is more
potent in this Vpu. Moreover, this may also account for the activ-
ity of the SIVgsn and SIVmon Vpu proteins against their cognate
species’ tetherins, although these do not have equivalent acidic
dileucine motifs in their cytoplasmic tails (21). However, given
that surface tetherin levels are not reduced by N1.FR.2011, it will
also be important to examine the capacity of this Vpu, and other
nondegradative tetherin countermeasures such as HIV-2 Env, for
the ability to block tetherin-induced signaling.
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Abstract
HIV-1 Vpu prevents incorporation of tetherin (BST2/ CD317) into budding virions and tar-
gets it for ESCRT-dependent endosomal degradation via a clathrin-dependent process.
This requires a variant acidic dileucine-sorting motif (ExxxLV) in Vpu. Structural studies
demonstrate that recombinant Vpu/tetherin fusions can form a ternary complex with the cla-
thrin adaptor AP-1. However, open questions still exist about Vpu’s mechanism of action.
Particularly, whether endosomal degradation and the recruitment of the E3 ubiquitin ligase
SCFβTRCP1/2 to a conserved phosphorylated binding site, DSGNES, are required for antag-
onism. Re-evaluation of the phenotype of Vpu phosphorylation mutants and naturally occur-
ring allelic variants reveals that the requirement for the Vpu phosphoserine motif in tetherin
antagonism is dissociable from SCFβTRCP1/2 and ESCRT-dependent tetherin degradation.
Vpu phospho-mutants phenocopy ExxxLV mutants, and can be rescued by direct clathrin
interaction in the absence of SCFβTRCP1/2 recruitment. Moreover, we demonstrate physical
interaction between Vpu and AP-1 or AP-2 in cells. This requires Vpu/tetherin transmem-
brane domain interactions as well as the ExxxLV motif. Importantly, it also requires the Vpu
phosphoserine motif and adjacent acidic residues. Taken together these data explain the
discordance between the role of SCFβTRCP1/2 and Vpu phosphorylation in tetherin antago-
nism, and indicate that phosphorylation of Vpu in Vpu/tetherin complexes regulates promis-
cuous recruitment of adaptors, implicating clathrin-dependent sorting as an essential first
step in tetherin antagonism.
Author Summary
Counteraction of tetherin, a host antiviral protein that blocks viral release from infected
cells, is an essential attribute of HIV-1 and its related viruses. The HIV-1 accessory protein
Vpu binds to tetherin, preventing its incorporation into viral particles, and targets it for
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ubiquitin-dependent degradation. This involves mis-trafficking of tetherin by a Vpu-
dependent mechanism through the engagement of clathrin adaptor proteins. Although
structural evidence exists for Vpu and tetherin interacting with clathrin adaptor 1 (AP-1),
evidence that it is required for Vpu-mediated tetherin counteraction is still lacking.
Tetherin degradation by Vpu also requires an E3 ubiquitin ligase, SCFβTRCP1/2 that binds
to phosphorylated serine residues in the Vpu cytoplasmic tail. Again, discrepancies exist
about the importance of this interaction in tetherin’s counteraction. Here we show that
Vpu phosphorylation, in combination with its physical interaction with tetherin, regulates
interaction with both AP-1 and the other major cellular clathrin adaptor, AP-2. These
interactions can be decoupled from SCFβTRCP1/2 recruitment, thus indicating clathrin-
dependent mis-trafficking as a critical step in tetherin antagonism by Vpu. Additionally,
the ability to interact both with AP-1 and AP-2 in a tetherin-dependent manner indicates
a redundancy in host cofactors used by Vpu that explains disparate previous observations
of its mechanism of action.
Introduction
Counteraction of the antiviral membrane protein tetherin (BST2/ CD317) is an essential attri-
bute of primate lentiviruses, and is mediated by either the Vpu or Nef accessory proteins, or
occasionally the viral envelope glycoprotein (reviewed in [1]). In their absence, tetherin
restricts the release of virions assembling at the cell surface [2–6]. By virtue of its N-terminal
transmembrane (TM) domain and C-terminal GPI anchor, partitioning of tetherin dimers into
budding virions allows them to simultaneously span host and viral membranes resulting in
accumulation of cross-linked virions on the plasma membrane (PM) [7,8]. In addition to phys-
ically limiting virion release, tetherin’s activity sensitizes infected cells to antibody-dependent
cellular cytotoxicity [9–12], targets virions for endosomal degradation, and in the case of great
ape tetherins, can directly induce the activation of proinflammatory NF-κB signaling [13–16].
Tetherin recycles to the PM via the trans-Golgi network (TGN) [17]. This requires a dual
tyrosine-based sorting signal (YDYCRV in humans), which can interact with the clathrin adap-
tor AP-1. Lentiviral countermeasures physically interact with tetherin, often in a highly spe-
cies-specific manner [1]. Through their action, tetherin incorporation into virions is blocked,
and this is associated with its reduced cell surface levels. In the case of HIV-1 Vpu, a small
membrane phospho-protein, physical interaction is mediated by the TM domains themselves
[18–20]. HIV-1 Vpu targets human tetherin into an ESCRT-dependent endosomal degrada-
tion pathway [21,22]. This is an ubiquitin driven process and requires a highly conserved
DSGNES motif in the Vpu cytoplasmic tail [23–25]. Phosphorylation of the serine residues
(S52/53 and S56/57 in subtype B depending on the isolate) by casein kinase II (CKII) [26,27]
recruits the β-TrCP1/2 subunits of a Skp1-Cullin1-F-Box (SCF) E3 ubiquitin ligase [28] that
mediates direct ubiquitination of various residues in the tetherin cytoplasmic tail including an
STS motif [29]. However, there is still debate as to whether the recruitment of the SCFβTRCP1/2
to the DSGNES motif in Vpu is required for counteraction of physical retention of virions by
tetherin (hereafter also termed antagonism) as well as its final endosomal degradation. Much
of this discrepancy may be attributable to whether assays are performed in virally infected cells
or those transiently transfected with Vpu, tetherin or both [30]. While ESCRT-I appears to be
dispensable in infected cells [21], evidence that the ESCRT-0 component HRS is required for
tetherin antagonism suggests targeting to endosomal degradation plays a role [22]. Further-
more, mutations of the Vpu serine residues (so called 2/6 mutations) have intermediate
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phenotypes in tetherin antagonism suggesting degradation does not fully explain Vpu function
[24,25,31]. Moreover this defect in antagonism is not recapitulated by siRNA depletion of β-
TrCP1/2 [32]. Indeed evidence that the DSGNES motif might have a dual function in tetherin
trafficking has been proposed [33]. This is consistent with our recent study of Vpu variation in
patients where we found that naturally occurring variants in the NE of the DSGNES imparted
tetherin-specific defects to Vpu without blocking its other SCF-dependent activity, dislocation
of CD4 from the endoplasmic reticulum [34].
Vpu has been shown to block newly synthesized and/or recycling tetherin from trafficking
to the cell surface [33,35]. This requires a variant of an acidic dileucine motif, ExxxLV, in the
second alpha helix of the cytoplasmic tail of most HIV-1 group M clade Vpu [36]. Acidic dileu-
cine sorting signals bind to the σ subunits of the major cellular clathrin adaptors AP-1 (traffick-
ing from TGN to endosomes and vice versa) and AP-2 (clathrin-dependent endocytosis from
the PM) (reviewed in [37]). In keeping with this, Vpu-mediated tetherin antagonism is entirely
clathrin-dependent [36,38]. Mutation of the ExxxLV motif does not block Vpu/tetherin inter-
actions, but reduces the efficiency of counteraction and inhibits degradation [36]. In particular
ExxxLV is essential for counteraction of tetherin in CD4+ T cells upon interferon upregulation,
and mutant phenotypes are exacerbated when tetherin lacks the YDYCRVmotif [36]. A recent
structural and biochemical study has demonstrated that the ExxxLV motif can bind canoni-
cally to the σ subunit of AP-1, whereas the YXXθmotif of tetherin can bind to the μ subunit of
AP-1 [39]. In fusions of Vpu and tetherin cytoplasmic tails both motifs can occupy their
respective binding sites simultaneously [39]. Some density in the structure also indicated other
contacts between Vpu and AP-1μ, and together implied a mechanism whereby the formation
of this ternary complex would modulate AP-1-dependent trafficking of tetherin to endosomes.
However, whilst the localization of Vpu to the TGN suggested AP-1 as the major target,
siRNA-mediated knockdown of AP-1 or expression in AP-1 -/- murine fibroblasts did not
inhibit Vpu function [36]. Neither has physical interaction between AP-1 and the wild-type
Vpu protein been demonstrated in living cells. Expression of tetherin fused at its N-terminus
to the second helix of Vpu is excluded from budding virions at the PM in an ExxxLV-depen-
dent manner [18]. Added to this, tetherin can be expressed as two isoforms, one of which lacks
the YDYCRVmotif and can be antagonized by Vpu to a certain extent without cell surface
downregulation [13,40]. Likewise, Vpu has only a modest effect on tetherin endocytosis
[25,35], and AP-2 knockdown also has little impact on antagonism, contrasting sharply with
SIV Nef and HIV-2 envelopes [38,41,42].
AP1 binding to a non-canonical acidic dileucine motif in CI-M6PR has been associated
with upstream serine phosphorylation by CKII previously [43]. Thus we hypothesized that the
DSGNES in Vpu might regulate clathrin adaptor interaction independently of SCF recruit-
ment. Here we provide evidence that this is indeed the case.
Results
Vpu does not require ESCRT-I, HRS or β-TrCP to counteract tetherin in
HIV-1 infected cells
The importance of the SCFβTRCP1/2 E3 ligase and the ultimate degradation of tetherin to the
counteraction of its physical antiviral activity by Vpu has been controversial. Since the discrep-
ant studies were mostly performed under conditions of transient transfection of tetherin, provi-
rus or both, and which have been shown previously to lead to artifactual effects on tetherin
degradation [30], we re-examined these issues in HIV-1 infected 293T cells stably expressing
surface tetherin at levels similar to those induced by type 1 interferon (Fig 1A). We have previ-
ously shown that an endosomal sorting-specific subunit of ESCRT-I, UBAP1, is essential for
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Fig 1. Vpu does not require ESCRT-I, HRS or βTRCP to counteract tetherin in HIV-1 infected cells. (A) The graph indicates the median fluorescence
intensity of tetherin surface expression for 293T cells, 293T cells treated with 1000 U/ml universal type-I interferon for 24h or the same cells stably expressing
tetherin. (B) 293T tetherin cells were transfected twice over a 48 hour period with siRNA oligonucleotide directed against HRS, UBAP1, TSG101 or non
targeting control. Cells were then infected with NL4.3 HIV-1WT or HIV-1 ΔVpu at an MOI of 0.8. Cell lysates and sucrose purified viral supernatants were
subjected to SDS-PAGE and analyzed byWestern blotting for HSP90, HIV-1 p24CA and Vpu, and analyzed by LiCor quantitative imager. (C) Infectivity of
viral supernatants from (B) was assayed on HeLa-TZMbl reporter cells. Infectious virus release was plotted as β-galactosidase activity in relative light units
(RLU). Error bars represent the standard deviation of three independent experiments. (D) Cells were treated as in (B), but infected with an MOI of 2. Cell
lysates were subjected to SDS-PAGE and analyzed by Western blotting for HSP90 and tetherin, and analyzed by LiCor quantitative imager. (E) Percent of
tetherin in cells transfected with HRS or non-targeting siRNA oligonucleotides and infected with NL4.3 HIV-1WT or HIV-1 ΔVpu. Error bars represent the
standard deviation of three independent experiments. (F-H) 293T or 293T tetherin cells were transfected as in (B) with siRNA oligonucleotide directed
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tetherin’s degradation but not for antagonism [21,36]. Despite efficient levels of knockdown,
similarly efficient siRNA knockdowns of HRS (ESCRT-0) or UBAP1 had only minor effects on
one-round yield of wild-type HIV-1 (HIV-1 wt) from 293T tetherin cells at an MOI of 0.8 (Fig
1B and 1C). As expected, knockdown of the core ESCRT-I subunit TSG101 destablized
UBAP1 [44] and blocked all virion release because of its essential late-domain function [45],
and all siRNA treatments also stabilized Vpu expression (Fig 1B). In keeping with this, cells
infected at an MOI of 2, to ensure at least 90% infection, demonstrated that Vpu-induced deg-
radation was blocked by all siRNA knockdowns (Fig 1D and 1E). These data therefore indicate
that in infected cells expressing physiological levels of Vpu from an integrated HIV-1 provirus,
the core ESCRT pathway and HRS are essential for Vpu-mediated tetherin degradation, but
dispensable for counteraction of tetherin’s physical antiviral activity.
A previous study indicated that HRS interacted with Vpu in immuno-precipitates [22]. We
confirmed this in transfected cells using myc-tagged HRS, and found that HRS truncations
that removed its double-ubiquitin interaction motif (DUIM) inhibited this interaction (S1A
and S1B Fig). Furthermore, point mutations in the DUIM that abolish ubiquitin-interaction
(A266Q/ A228Q) [46], not putative ubiquitin-binding mutants in the VHS domain, completely
abolished HRS/Vpu interactions in co-IPs (S1C Fig). Whilst formally possible that the DUIM
is a direct binding site for Vpu, these data likely suggest that Vpu interactions with HRS are
mediated indirectly through ubiquitination either of cargo, or associated factors in the degrada-
tion pathway.
We next similarly re-evaluated the effect of simultaneously knocking down β-TrCP1 and 2
on Vpu-mediated tetherin-degradation and tetherin-counteraction in infected cells. Again
despite efficient knockdown, we saw little effect of this treatment on HIV-1 WT release (Fig
1F–1H). Of note, there was no evidence that β-TrCP1/2 knockdown reduced wild-type release
to that of a viral mutant lacking the phosphorylated serines at positions 52 and 56 that are
essential for β-TrCP1/2 recruitment (HIV-1 Vpu 2/6A). This was in contrast to a complete
reversal of Vpu-mediated tetherin degradation by β-TrCP1/2 siRNAs in cells infected at an
MOI of 2 (Fig 1H). Therefore whilst tetherin degradation by Vpu requires the SCFβTRCP1/2
complex, under conditions when it is sufficiently depleted to block this, there is no effect on
Vpu-mediated tetherin antagonism.
Phosphorylation-defective Vpu phenocopies trafficking mutants
Since the phospho-mutant of Vpu, Vpu 2/6A, has been shown to be partially defective for
tetherin antagonism [23–25], we revisited whether this impairment could be uncoupled from
the ubiquitin ligase. We recently showed that mutants of clade B Vpu lacking a conserved
ExxxLV sorting signal (Vpu ELV) were also partially defective for tetherin antagonism because
they could not traffic tetherin/Vpu complexes for endosomal degradation [36]. Notably, ELV
mutant Vpu loses all residual activity against tetherin lacking the dual-tyrosine recycling motif,
and a recent study demonstrated that the tetherin and Vpu cytoplasmic tails can assemble into
a ternary complex with clathrin adaptor AP-1 [39]. In addition, hints in the structure suggested
that residues 42 and 43 of the first helix of the cytoplasmic tail make a non-canonical contact
with AP-1μ. We found similar Vpu mutants with tetherin-defective phenotypes in our patient
cohort [34], and mutation of conserved L41I42/L45I46 in the first alpha helix to alanines in the
NL4.3 provirus led to a profound defect in tetherin antagonism and degradation without
against β-TrCP1 and 2 or non-targeting control. Cells were infected with VSV-G pseudotyped NL4.3 HIV-1WT, ΔVpu or Vpu 2/6A mutant at an MOI of 0.8
and processed as in (C) and (D). (H) Cells were treated as in (F) but infected at an MOI of 2. Cell lysates were subjected to SDS-PAGE and analyzed by
Western blotting for HSP90 and tetherin.
doi:10.1371/journal.ppat.1005141.g001
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preventing interaction (S2A–S2E Fig). Since the DSGNES motif is located in an acidic patch
between helix 1 and the ExxxLV site, we hypothesized that Vpu phosphomutants may also be
similarly defective for mis-trafficking tetherin. In one round virus infection assays in 293T/
tetherin cells, LI/LI, ELV and 2/6A mutants all had similarly defective phenotypes for tetherin
antagonism (Fig 2A and 2B). Interestingly, like the ELV mutant [36,39], both LI/LI and 2/6A
mutants lost all their residual activity in cells expressing tetherin Y6,8A whereas release of the
wild-type virus was only slightly affected. Moreover, as expected, all mutants were defective for
tetherin degradation (Fig 2C). Examination of the localization of the three mutants in trans-
fected HeLa cells revealed that, unlike the wild-type, 2/6A and LILI localized prominently to
peripheral endosomal structures as well as the TGN (Fig 2D). This was similar to the localiza-
tion expected for the ELV mutant [36], and quantification of coincidence with TGN46 revealed
that all three mutants had a significantly reduced localization to the TGN consistent with a
trafficking defect (Fig 2E). Importantly there was no significant additive effect of combined 2/6
and ELV mutations in full-length virus release from either the 293T/tetherin cells or primary
CD4+ T cells (S3A–S3C Fig). Also these data could be recapitulated using a highly active pri-
mary Vpu (Vpu 2_87) isolate from our previous patient study [34] (S4A–S4D Fig). Treatment
of 293T tetherin cells infected with wild-type HIV-1 with a CKII inhibitor, Tyrphostin, to
mimic the 2/6A mutation showed a reduction of virus release only in the presence of tetherin,
or more prominently, the Y6,8A mutant (Fig 2F and 2G). Western blot analysis of cell lysates
transfected with HA-tagged Vpu expression vectors and run on an 8% PhosTag gel showed
that in the presence of Tyrphostin, the smear of phosphorylated Vpu was reduced indicating
inhibition of Vpu phosphorylation (Fig 2H). Together, these data therefore suggested that the
defective tetherin antagonism of Vpu 2/6A may be due to phosphorylation-regulated traffick-
ing of Vpu rather than ubiquitin ligase recruitment and degradation.
Functional rescue of Vpu phospho- and trafficking mutants by direct
interaction with clathrin
The current model for Vpu function is that it prevents tetherin trafficking to the PM from the
TGN and sorts it into a clathrin-dependent endosomal trafficking pathway [1,47]. If our above
hypothesis was the case, we reasoned that bypassing clathrin adaptors and linking Vpu directly
to clathrin itself could functionally rescue all ELV, LI/LI and 2/6A mutants. To do this we
appended the AQLISFD clathrin box (CB) from HRS or a mutated sequence, AQAASFD, lack-
ing the leucine and isoleucines essential for clathrin interaction, to the C-termini of Vpu and
the respective mutants (Fig 3A). Transient transfection of increasing doses of Vpu into 293T
tetherin cells effectively rescued Vpu-defective HIV-1 viral release, and neither the clathrin
box nor its mutant impaired wild-type Vpu function (Fig 3B and 3C). Remarkably, however,
Vpu 2/6A, Vpu ELV or Vpu LI/LI function was almost fully restored by fusion of the clathrin
box, whereas grafting the mutated sequence had no effect. All Vpu chimeras were well
expressed, although as shown in Fig 3C, the apparent molecular weight of Vpu and its chimeras
in SDS-PAGE did not reflect amino acid length. Similar results were obtained for a heterolo-
gous clathrin box (RNLLDLL) derived from GGA2 (available on request). The clathrin
box also fully restored downregulation of tetherin from the surface of transiently transfected
HeLa-TZMbl cells to all the mutants (Figs 3D and S5A–S5D). To show that this rescue of func-
tion was clathrin-dependent, we depleted clathrin membrane binding with the C-terminal frag-
ment of the neuronal clathrin-adaptor AP180 (AP180c). As expected, rescue of wild-type Vpu-
dependent virus release was inhibited by AP180c whereas residual viral release in the presence
of tetherin was not [36]. In all cases, the same held true for clathrin box fusions (Fig 4A). Thus,
direct linkage to the clathrin machinery was sufficient to rescue both Vpu 2/6A and the
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Fig 2. Phosphorylation-defective Vpu phenocopies traffickingmutants. (A-B) 293T, 293T tetherin or Y6,8A tetherin cells were infected with VSV-G
pseudotyped NL4.3WT or mutant virus at anMOI of 0.8. (A) 48 hours post infection viral supernatants were assayed for infectivity using HeLa-TZMbl reporter
cells as in Fig 1. Error bars represent the standard deviation of three independent experiments. (B) Cell lysates and sucrose purified viral supernatants were
subjected to SDS-PAGE and analyzed byWestern blotting as in Fig 1. (C) 293T tetherin cells were infected with NL4.3 HIV-1WT, ΔVpu, Vpu LILI, Vpu ELV or
Vpu 2/6Amutants at anMOI of 2. 48 hours post infection cell lysates were subjected to SDS-PAGE and analyzed byWestern blotting for HSP90 and tetherin,
and analyzed by LiCor quantitative imager. (D) 293T tetherin expressing cells were transfected with 50 ng of pCR3.1 Vpu-HA or indicated mutants. 16 hours
post transfection cells were fixed and stained for HA (green) and the TGNmarker TGN46 (red) and examined by widefield fluorescent microscopy. Panels are of
representative examples. Bars = 10 μm. (E) Z stacks were taken of all cells (n = 15), images were deconvolved using the AutoQuant X3 software and Pearson’s
correlations were calculated for all Z stacks using ImageJ. Results were analyzed by unpaired 2-tailed t-test—*** P = 10–5 or lower. (F) 293T, 293T tetherin or
Y6,8A tetherin cells were infected with VSV-G pseudotyped NL4.3WT at anMOI of 0.8. 6 hours post infection DMSO or 50 μMTyrphostin was added to the
medium. 48 hours post infection supernatants were assayed as in (A). (G) Cell lysates and sucrose purified viral supernatants were processed as in (B). (H)
293T tetherin cells were transfected with 2 μg pCR3.1 Vpu-HA or 2/6 Vpu-HA and treated with DMSO or 50 μMTyrphostin for 24 h. Cell lysates were
electrophoresed as before, or on a 8%, 50 μMPhos-tag gel to separate the phosphorylated species.
doi:10.1371/journal.ppat.1005141.g002
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trafficking mutants. Moreover, in cells stably expressing the Vpu chimeras, no reduction of
tetherin steady state levels was observed upon CB fusion to any of the chimeras (Fig 4B), nor
was β-TrCP interaction restored to the 2/6A mutant fusion (Fig 4C), indicating this was inde-
pendent of SCF and ESCRT function. Wild-type subcellular localization was restored to all
mutants; 2/6A, ELV and LI/LI localization was significantly restored to TGN-associated com-
partments upon CB fusion (Fig 4D and 4E).
To further characterize these Vpu chimeras, we next examined whether they were func-
tional against tetherin bearing tyrosine (trafficking) and serine/threonine (the proposed
SCFβTRCP ubiquitination site [29]) mutations in the cytoplasmic tail. In the case of 293T
tetherin-STS-AAA cells, the Vpu CB chimeras behaved as they did against the wild-type pro-
tein, effectively fully rescuing the 2/6A, LILI or ELV lesion (Fig 5A). Importantly, stable expres-
sion of an STS mutant tetherin had no detectable effect on the efficiency of counteraction by
wild-type Vpu, and the CB addition had no effect, indicating that there is no reduction in Vpu
antagonism when tetherin lacks the residues proposed to be important for ubiquitination.
Fig 3. Functional rescue of Vpu phospho- and traffickingmutants by direct interaction with clathrin. (A) Schematic representation of Vpu CB chimera
constructs. (B) 293T tetherin cells were transfected with NL4.3 ΔVpu proviral plasmid in combination with YFP expression vector and pCR3.1 Vpu, pCR3.1
Vpu CB or Vpu CBmut or Vpu mutants thereof. 48 hours post transfection infectivity of viral supernatants was determined on HeLa-TZMbl cells as in Fig 1.
Error bars represent standard deviation of three independent experiments. (C) Cell lysates and pelleted supernatant virions from (B) were harvested and
subjected to SDS-PAGE and analyzed byWestern blotting for HIV-1 p24CA, Vpu and HSP90, and analyzed by LiCor quantitative imager. (D) HeLa-TZMbl
cells were co-transfected with pCR3.1 Vpu or indicated mutant and a GFP expression vector. Cell-surface tetherin levels were analyzed 48 hours post
transfection by flow cytometry in the GFP positive cells. The percentages of tetherin surface expression levels are calculated frommedian fluorescence
intensities.
doi:10.1371/journal.ppat.1005141.g003
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However, in the case of 293T tetherin Y6,8A cells, whilst Vpu wild-type and CB fusions
remained active, the mutant chimeras remained completely defective (Fig 5B). These data
Fig 4. Clathrin binding rescues Vpu localization without restoring β-TrCP binding or tetherin degradation. (A) 293T tetherin expressing cells were co-
transfected with NL4.3 ΔVpu proviral plasmid and YFP, pCR3.1 Vpu, Vpu CB, Vpu CBmut expression vector or indicated mutant in combination with
AP180c. 48 hours post transfection cell lysates and pelleted supernatant virions were harvested and subjected to SDS-PAGE and analyzed byWestern
blotting for HIV-1 p24CA, Vpu and HSP90, and analyzed by LiCor quantitative imager. (B) 293T tetherin cells were transfected with pCR3.1 Vpu or indicated
mutant. 48 hours post infection cell lysates were subjected to SDS-PAGE and analyzed byWestern blotting for HSP90, tetherin and Vpu, and analyzed by
LiCor quantitative imager. (C) 293T cells were transfected with pCR3.1 Vpu or indicated mutant in combination with a pCR3.1 myc-β-TrCP2 expression
vector. 48 hours post transfection cells were lysed and immunoprecipitated with anti-myc antibody, using PFA (0.05%w/v) as a cross-linking agent. Total cell
lysates and precipitates were subjected to SDS-PAGE and analyzed byWestern blotting for myc-β-TrCP2 and Vpu-HA, and analyzed by ImageQuant. (D-E)
Hela cells were transfected with 100 ng of pCR3.1 Vpu-HA or Vpu-HA CB or indicated mutants and processed as in Fig 2. Vpu-HA (green); TGNmarker
TGN46 (red). (G) Bars = 10 μm. (E) Asterisks inside the bars represent significant localization differences between the mutant andWT Vpu, those above
between mutant and mutant clathrin box fusion.
doi:10.1371/journal.ppat.1005141.g004
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imply that unlike the ExxxLV motif, the clathrin box addition is not dominant over the tetherin
tyrosine-based sorting motif. This therefore suggests that tetherin sorting into clathrin-rich
domains in the recycling compartment is essential for clathrin box chimera rescue, which then
anchors the Vpu/tetherin complex. Subsequent endosomal trafficking, and importantly, any
requirement for serine/threonine ubiquitination are downstream of this event. It also further
reinforces the notion that the primary lesion in tetherin antagonism of the 2/6A mutant, like
ELV and LI/LI, is at the level of clathrin-dependent sorting, not ubiquitin ligase recruitment.
Finally we examined mutations within the DSGNES motif itself. The consensus for a β-
TrCP-binding site is DSGxxS, yet the N55/E56 in group M Vpu is almost universally con-
served. We found rare mutations (N55H/E56G) in patients that displayed impaired tetherin
antagonism despite retaining β-TrCP interaction [34]. Similarly, examination of a Vpu N55H/
E56G mutation in the context of the NL4.3 Vpu revealed defects in tetherin counteraction in
293T tetherin cells (S3 and S4 Figs), which again could be rescued by a clathrin box fusion
unless tetherin itself contained tyrosine mutations (Fig 5C and 5D). Together with the
above data, these observations suggest that structural constraints or flexibility within the
Fig 5. Clathrin box rescue of Vpumutants is dependent on tetherin’s Y6,8 sorting signal. (A-B) 293T tetherin STS or 293T tetherin Y6,8A cells were
transfected with NL4.3 ΔVpu proviral plasmid in combination with YFP expression vector and increasing concentrations of pCR3.1 Vpu or indicated mutant.
48 hours post transfection infectivity of viral supernatants was determined on HeLa-TZMbl cells as in Fig 1. (C) 293T tetherin or 293T tetherin Y6,8A cells
were transfected as in (A) with pCR3.1 Vpu or the N54H,E55G (NE) mutant. 48 hours post transfection infectivity of viral supernatants was determined on
HeLa-TZMbl cells as in Fig 1. Error bars represent standard deviation of three independent experiments. (D) Cell lysates and pelleted supernatant virions
from (A) were harvested and subjected to SDS-PAGE and analyzed byWestern blotting for HIV-1 p24CA, Vpu and HSP90, and analyzed by LiCor
quantitative imager.
doi:10.1371/journal.ppat.1005141.g005
Vpu Phosphorylation Regulates Clathrin Adaptor Interaction
PLOS Pathogens | DOI:10.1371/journal.ppat.1005141 August 28, 2015 10 / 26
phosphoserine motif may underlie the reason why the 2/6A mutant is defective for tetherin
mis-trafficking.
Vpu interacts with clathrin adaptors AP-1 and AP-2 in tetherin-
expressing cells
Our previous characterization of the ExxxLV motif and the data presented herein indicate that
clathrin-dependent sorting of Vpu/tetherin complexes is an essential step in tetherin antago-
nism, prior to ubiquitin-dependent degradation. The demonstration that the ExxxLV motif of
Vpu and the YDYCRV site in tetherin can form a ternary complex with AP-1 [39] is consistent
with the cell biological observations that Vpu primarily blocks tetherin recycling and transit to
the PM rather than stimulating its endocytosis [33,35]. However, demonstration that Vpu can
interact with AP-1 in cells is lacking, and neither siRNA depletion of AP-1, nor deletion of γ-
adaptin in murine fibroblasts, affects tetherin antagonism [36]. Clathrin adaptor interactions
with their cargoes can sometimes (but not universally) be detected in yeast 2 or 3-hybrid assays
or with recombinant proteins, but the relative weakness of their affinities often precludes direct
demonstration of their interactions in vivo by conventional immunoprecipitations. To examine
Vpu interaction with AP-1, we initially employed a proximity-based biotin ligase assay (S6A
Fig). A consenus clade B Vpu or indicated mutant (note the phosphomutant S53,57A is labeled
S3/7A), was fused to a myc-tagged E coli biotin ligase BirA-R113G, which itself does not com-
promise Vpu activity (S6B Fig). These constructs were then transfected into 293T or 293T
tetherin cells. 6 hours after transfection the cells were incubated with free-biotin overnight in
the presence of concanamycin A to block any tetherin degradation by the wild-type Vpu pro-
tein. Cell lysates were precipitated with streptavidin beads, and recovered proteins analyzed by
Western blotting. Such treatment will lead to promiscuous biotinylation of proteins in close
proximity with Vpu, potentially allowing us to detect interacting factors with weak affinities.
As shown in S6C Fig, addition of biotin led to an accumulation of biotinylated proteins in cell
lysates, including a strong band that is auto-biotinylation Vpu-BirA fusion itself. Importantly,
β-TrCP was detected for all mutants tested in both 293T and 293T tetherin cells except the 2/
6A mutant. Interestingly AP-1 γ-adaptin was detected only in streptavidin precipitates from
293T tetherin cells transfected with wild-type Vpu-BirA fusion, and not cells lacking tetherin
expression. Furthermore, in 293T tetherin cells both ELV and LI/LI mutants failed to biotiny-
late AP-1. Interestingly, this was observed for the 2/6A mutant and also a Vpu A14L/W22A
mutant that lacks tetherin binding. Thus, proximity-based tagging suggested Vpu does indeed
interact with AP-1 in living cells. This appears to be dependent on tetherin binding and
requires both the predicted AP-1σ binding site in Vpu, ExxxLV, and the non-canonical AP-1μ
contact proposed to imparted by LI/LI. Furthermore, the lack of the 2/6A mutant to biotinylate
AP-1γ suggests that Vpu phosphorylation is required to promote interaction, consistent with
its cellular phenotype.
Whilst this data is strongly suggestive, it does not rule out that conformational changes in
the mutants position the BirA in a context where AP-1 cannot be biotinylated. To strengthen
these observations, we performed cross-linking immunoprecipitations in 293T tetherin cells
transfected with HA-tagged Vpu or all of the above Vpu mutants. This revealed that AP-1γ
could be detected in immunoprecipitates of Vpu-HA (Fig 6A). This was not detected for the
A14L/W22A mutant, again indicating a requirement for tetherin interaction. A reduced
amount of AP-1γ was detected in the 2/6A and ELV mutant immunoprecipitates, and this var-
ied between replicates (see histogram below blot). Since tetherin’s YDYCRVmotif also binds
to AP-1 (Jia et al., 2014), we repeated the immunoprecipitations in 293T tetherin Y6,8A cells
(Fig 6B). Whilst AP-1 precipitation was preserved for the wild-type protein, this effectively
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removed all detectable AP-1 interactions with any of the mutants, including the NE mutation
between the two serines, indicating the reduced detection was due to tetherin/AP-1 interac-
tions. To confirm these data, we also performed the same precipitations in 293T cells express-
ing a rhesus macaque tetherin to which HIV-1 Vpu cannot bind (Fig 6C), or parental 293T
cells (S7A Fig) and found that no AP-1 could be detected under any conditions. These data
also held true for the patient isolate Vpu 2_87 (S7B Fig). Therefore, these data demonstrate for
the first time that Vpu does interact with AP-1 in vivo. Tetherin/Vpu TM-domain interactions
are essential for this interaction, as are the predicted AP-1 binding sites in Vpu. Moreover, the
lack of interaction of the 2/6A mutant indicates that phosphorylation of Vpu upstream of the
ExxxLV regulates AP-1 interaction, and these data correlate well will the clathrin dependency
presented in Fig 4.
The ExxxLV motif has the potential to bind to other clathrin adaptor σ subunits[39]. Since
AP-1 depletion does not block Vpu function, we wondered whether Vpu interaction with the
clathrin machinery might also occur through AP-2. We therefore analyzed the precipitations
from cells expressing tetherin Y6,8A for the AP-2α adaptin subunit (Figs 6A, 6B and S7B).
Surprisingly this could also be detected with the wild-type protein, but was absent for all the
Fig 6. Vpu interacts with clathrin adaptors AP-1 and AP-2 in tetherin-expressing cells. (A-C) 293T tetherin (A), 293T tetherin Y6,8A (B) or 293 rhesus
tetherin (C) cells were transfected with pCR3.1 Vpu-HA, Vpu A14L/W22A-HA, Vpu ELV-HA, Vpu 2/6A-HA, Vpu LILI-HA or Vpu NE-HA mutants. 48 h post
transfection, cells were lysed and cross-linked using PFA (0.05%w/v) and immunoprecipitated with anti-HA antibody. Total cell lysates and precipitates were
subjected to SDS-PAGE and analyzed byWestern blotting for Vpu-HA, tetherin, AP-1γ or AP-2α. Panels are of representative experiments. Histograms
represent western blot quantification of the relative AP-1 or AP-2 binding normalized to input control. Error bars represent the standard deviation of three
independent experiments.
doi:10.1371/journal.ppat.1005141.g006
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mutants, indicating ExxxLV also regulates this interaction. Thus, Vpu interacts promiscuously
with both major cellular clathrin adaptors in a manner dependent on its ability to bind to
tetherin. This is likely to account for why individual adaptor knockdowns fail to block Vpu
function, and suggest that AP-2 might represent a compensatory clathrin-dependent traffick-
ing mechanism for counteracting tetherin.
Finally, to provide direct evidence that it was phosphorylation of Vpu that permitted AP1/
AP2 interactions, we repeated these immunoprecipitations in 293T tetherin Y6,8A cells treated
with Tyrphostin (Fig 7). Under these conditions the ability of wildtype Vpu to interact with
AP1 or AP2 was abolished, indicating that CKII-mediated phosphorylation for Vpu is required
for recruitment of clathrin transport machinery.
Discussion
In this study we have re-evaluated discrepancies in the literature regarding the role of
SCFβTRCP1/2 and ESCRT in Vpu-mediated tetherin degradation and antagonism of its physical
antiviral activity. We find that whilst essential for the former, they are dispensable for the latter
in HIV-1 infected cells. We further show that phospho-serine mutants of Vpu have a distinct
phenotype, displaying defects in tetherin antagonism because they cannot engage with cla-
thrin-dependent trafficking pathways. We demonstrate that in cellulo Vpu/tetherin TM inter-
actions induce Vpu binding to either clathrin adaptors AP-1 or AP-2. This interaction requires
the ExxxLV trafficking motif, validating the recent structural study [39]. Importantly, phos-
phomutants of Vpu are also defective for clathrin adaptor engagement, implying that CKII-
mediated phosphorylation not only regulates SCFβTRCP1/2 recruitment, but also regulates Vpu
trafficking. Together these data clarify the role of the Vpu DSGNES motif in tetherin counter-
action and provide strong evidence that sorting of Vpu/tetherin complexes into clathrin-rich
domains of the endocytic pathway is the critical event in efficient tetherin antagonism. Further-
more, the observation that Vpu can interact both with AP-1 or AP-2 suggests a redundancy in
adaptor protein requirement for tetherin counteraction that provides a plausible explanation
for why depletion of either AP-1 or AP-2 is not sufficient to compromise Vpu function[36].
Thus potentially, tetherin/Vpu complexes that escape AP-1 in the TGN, and which traffic to
the PM, can be retrieved by AP-2. Such a model would also rationalize why in some cases
tetherin counteraction by Vpu can be observed with minimal evidence of surface downregula-
tion [18,48].
Much of the discrepant literature regarding the mechanism of Vpu-mediated tetherin antago-
nism comes from experiments where tetherin, provirus and/or Vpu are transiently transfected
into cells. Whilst these experiments are useful for understanding much of the biology of tetherin/
HIV interactions, they are prone to artifacts when interpreting the cell biology and importance of
Vpu-mediated degradation. Overexpression of tetherin or Vpu at non-physiological levels has
been shown to induce ER-associated degradation [30]. This is not observed in infected cells,
where tetherin is degraded in endosomes. Also, because of the nature of transient transfections,
there is a huge variability of expression levels of the transfected components between cells within
the culture. Under these conditions strong blocks to degradation may lead to tetherin accumula-
tion, and an overwhelming of the endosomal system, giving the appearance of a direct inhibition
of counteraction. By infecting tetherin-expressing cells at relevant multiplicities of infection, to
ensure each cell has on average one productive infection event, these issues can be mitigated and
this has allowed us to separate the requirement of the phospho-serine motif in counteraction
from the recruitment of SCFβTRCP1/2 and the ESCRTmachinery for degradation.
Our in cellulo data validates the structural and biochemical studies by Jia et al [39], in which
AP-1 interaction requires the ExxxLV motif that occupies the acidic-dileucine binding site in
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Fig 7. Vpu interactionwith clathrin adaptors AP-1 and AP-2 is abrogated following treatment with CKII
inhibitor, Tyrphostin. 293T tetherin Y6,8A cells were transfected with pCR3.1 Vpu-HA, Vpu A14L/W22A-HA,
Vpu ELV-HA, Vpu 2/6A-HA, Vpu LILI-HA or Vpu NE-HAmutants. 24h post-transfection cells were treated with
DMSO or 50 μMTyrphostin. Cells were lysed and cross-linked, 48 h post transfection, using PFA (0.05%w/v)
and immunoprecipitated with anti-HA antibody. Total cell lysates and precipitates were subjected to SDS-PAGE
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AP-1σ. We also provide evidence that in cells, this motif can also bind to AP-2. Furthermore,
the phenotype of our LI/LI mutant is consistent with the proposed non-canonical interaction
of R44/L45 with AP-1μ suggested by densities in the crystal. However, because the constructs
used by the authors to determine the structural requirements for AP-1/tetherin/Vpu interac-
tion required artificial Vpu/tetherin fusions, they may not faithfully represent how AP-1 is ini-
tially recruited. Thus, the requirements for the DSGNES and Vpu/tetherin transmembrane
domain interactions that we have uncovered in cells were not previously observed.
We propose a model whereby phosphorylation of Vpu regulates the AP interaction with the
ELV motif (Fig 8). Whilst we cannot formally rule out that the phosphoserine directly contrib-
utes to AP-1 interaction itself, the lack of a significant additive phenotype in terms of virus
release and AP-1 interaction makes this the most consistent explanation of our data. Further-
more there is precedence for phosphorylation upstream of certain acidic dileucine motifs inter-
actions with the clathrin transport machinery [43]. In particular, a CKII phosphorylation
upstream of a non-canonical RDDHLL site in the cation-independent mannose-6-phosphate
receptor regulates its interaction with AP1. Another context-dependent feature of acidic dileu-
cine signals is an adjacent acidic patch [37]. Interestingly, this feature is present in HIV-1 Vpu.
Furthermore, the laboratory strain NL4.3 Vpu, which has a reduced anti-tetherin activity com-
pared to most primary isolates, has a shorter acidic patch between the DSGNES and ExxxLV
motifs [34]. The requirement for TM interactions in addition to the phospho-serines in “prim-
ing” Vpu for clathrin adaptor interaction would imply that tetherin binding contributes to con-
formational changes that are required for antagonism. Since β-TrCP binding does not require
the presence of tetherin (or CD4), phosphorylation must be an independent event. However,
whether β-TrCP and AP-1/2 binding can occur simultaneously or are mutually exclusive is
unknown. Another interesting point to note is that the LI/LI mutation is more severely com-
promised than either the 2/6 or the ELV mutations in some contexts. As it also compromises
and analyzed byWestern blotting for Vpu-HA, tetherin, AP-1γ or AP-2α. Panels are of representative
experiments. Histograms represent quantification of the relative AP-1 or AP-2 binding normalized to input
control. Error bars represent the standard deviation of three independent experiments.
doi:10.1371/journal.ppat.1005141.g007
Fig 8. A proposedmodel for Vpu engagement of clathrin adaptors during tetherin counteraction. Vpu and tetherin interactions via TM/TM domain
interactions and casein kinase II phosphorylation promote Vpu recruitment of AP-1 or AP-2. This allows the EXXXLV motif to bind to the σ subunit, and
potentially through non-canonical interactions between its first alpha helix with the AP-1 or 2 μ subunits. In addition the YCRVmotif in tetherin binds to the
AP1μ. Thus tetherin/Vpu complexes are sorted into clathrin rich domains of the TGN or PM for subsequent trafficking and ubiquitination.
doi:10.1371/journal.ppat.1005141.g008
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AP binding, the non-canonical interaction of the R45,L46 with AP-1μmay also play an essen-
tial contextual role in positioning the ELV motif. This interaction may also explain why the
residual activities of 2/6 and ELV mutations are sensitive to clathrin depletion.
Structural information on the Vpu cytoplasmic tail is limited at present. Partial NMR struc-
tures in solution and associated with lipids have been determined [49–52]. In a lipid environ-
ment, the ExxxLV is embedded within helix 2 of the cytoplasmic tail [52], but adopts an
extended conformation in solution [51]. To bind to AP-1, the ExxxLV site cannot be helical.
However, the lipid-associated structure has a very interesting feature: a highly conserved C-ter-
minal tryptophan residue appears to pack against the DSGNES, almost as if locking the struc-
ture. Mutations in the W residue have context-dependent defects in tetherin antagonism
depending on the Vpu used [34,53]. Importantly, NMR studies on the effects of serine phos-
phorylation suggests that it leads to conformational changes within the C-terminal region of
the Vpu cytoplasmic tail that promotes βTRCP binding. In some studies [49,50], but not others
[54], these conformational changes are consistent with an opening up of the ELV site. How-
ever, all these studies have thusfar been performed in the absence of target binding using solu-
ble Vpu cytoplasmic tails, and so how representative they are of the wildtype protein is unclear.
Furthermore, upregulation of SCYL2, a clathrin associated protein that modulates protein
phosphatase 2A (PP2A), induces Vpu de-phosphorylation and reduces tetherin antagonism
[55]. Thus, there is scope for regulated phosphorylation and subsequent dephosphorylation
cycles in regulation of Vpu activity. We suggest that this would occur at the level of clathrin-
dependent transport rather than SCFβTRCP1/2 interactions.
There is much indirect evidence consistent with AP-1 being the major clathrin adaptor used
by Vpu. The block to tetherin transport to the surface, the predominant localization to the
TGN, and of course the recent structure discussed above [33,35,36,39]. However, AP-1 knock-
down is difficult to efficiently achieve and does not compromise Vpu function [36]. AP-1 has
multiple orthologs for some of its subunits, and there is potential redundancy in the adaptor
machinery allowing the cell to compensate for its absence [37]. Our observation that Vpu can
interact also with AP-2 in an ExxxLV-dependent manner is therefore an important observation
for several reasons. Firstly, it suggests that Vpu is promiscuous and if one adaptor is compro-
mised, another can be used, explaining why neither AP-1 nor AP-2 have been unambiguously
identified as Vpu cofactors [25,36]. Secondly, it might explain why in some studies, Vpu has
been observed to induce a weak enhancement of tetherin endocytosis [35]. Artificial tetherin/
Vpu linked chimeric proteins are excluded from budding virions, and this is dependent on the
ExxxLV motif [18], which would be consistent with anchoring by AP-2 into clathrin-rich
domains at the plasma membrane. The YDYCRVmotif of tetherin cannot interact with AP-2μ
as a YXXθ signal because of a steric clash of Y6 in the binding pocket [39]. The YDYCRV motif
is essential for the “slow”, AP-1-dependent recycling of tetherin to the PM via the TGN
[17,33]. Therefore, Vpu is likely to meet the majority of its target (newly synthesized and recy-
cling tetherin) in the TGN. Since AP-1 has been proposed to regulate bidirectional traffic
between the TGN and endosomal compartments [37], AP-1 is likely to be the major player in
tetherin counteraction. However, the ExxxLV motif is dominant over the tetherin recycling
motif [36]. Therefore we would predict that tetherin/Vpu complexes that escape re-routing in
the TGN and make it to the PM would be excluded from virions and AP-2 would promote
their endocytosis, much in the same way that SIV Nef proteins and HIV-2 envelopes antago-
nize tetherin [6,38,56]. More importantly, it also accounts for why Vpu still has some activity
against the short tetherin isoform without appreciable cell surface downregulation [13,40]. The
relative role of AP-1 and AP-2 will reflect the kinetics of their respective activities in different
cell types. We suggest the combination of some or all of the above accounts for the variable
importance that downregulation of tetherin from the PM has been given to its antagonism.
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The requirement for the ExxxLV and DSGNES motifs is not absolute when tetherin levels are
low. At higher expression levels, such as upon IFN treatment of primary CD4+ T cells, they
become essential for tetherin antagonism [36]. This residual function requires tetherin’s sorting
motif, suggestive of competition between the clathrin-dependent trafficking and virion reten-
tion. Tetherin/Vpu interaction may simply tip this balance, reducing tetherin partitioning into
virions sufficiently when its expression levels are low. It is this that we propose to augment via
our clathrin box fusion rescue, locking the tetherin/Vpu complex into clathrin-rich domains in
the recycling pathway from where they cannot be transited to the PM.
Decoupling tetherin degradation (which amongst primate lentiviruses is so far peculiar to
HIV-1 group M Vpu) from subversion of trafficking (counteraction) suggests that the impor-
tance of the former might reflect downstream consequences of tetherin restriction. Enhanced
antagonism of the long tetherin isoform by Vpu could be required because of its signal trans-
duction or its ability to deliver retained virions to endosomes [14,40]. Our data shows that in
stable tetherin expressing cells, STS mutations impart little resistance to Vpu and that they are
still sensitive to Vpu-clathrin box fusions. Since neither LI/LI nor ELV mutations block binding
of Vpu to β-TrCP or tetherin, ubiquitination may still occur on serine and threonine residues.
However, its effect is likely to be subsequent to antagonism by clathrin-dependent mis-traffick-
ing. Strong reduction of tetherin at the cell surface by Vpu coupled to endosomal degradation
would therefore be a potent way of suppressing signal transduction, or blocking the routing of
virions for degradation where they may encounter other host pattern recognition receptors or
antigen processing machinery. These will be important attributes to maintain in vivo without
necessarily being essential for physical antagonism of tetherin.
Materials and Methods
Cells, plasmids and reagents
HEK293T cells were obtained from ATCC (American Tissue Culture Collection). 293T
tetherin cell lines stably expressing human tetherin and mutants were previously described
[4,57]. The HeLa-TZMbl reporter cell line, was kindly provided by John Kappes through the
NIH AIDS Reagents Repository Program (ARRP). Cells were maintained in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal calf serum and Gentamycin
(Invitrogen, UK). Wildtype HIV-1 NL4.3 (obtained from NIH-ARRP), a Vpu-defective coun-
terpart and a codon optimized pCR3.1 Vpu-HA has been described previously [58]. The Vpu
A14L/W22A, ELV, 2/6A, LILI and NE mutants in pCR3.1 Vpu-HA and in the NL4.3 proviral
genome were generated by Quick-change site-directed mutagenesis PCR according to standard
protocols using Phusion-II polymerase (New England Biolabs). A codon-optimised version of
the previously described primary wild-type HIV-1 Vpu 2_87 [34] was HA-tagged and cloned
into pCR3.1. The Vpu A15L/W23A, ELV, 2/6A, LILI and NE mutants were generated in
pCR3.1 Vpu 2_87-HA by Quick-change site-directed mutagenesis as described above. Consen-
sus B codon-optimised Vpu-myc-BirA-R188G fusion was synthesized (Life Technologies) and
cloned into the lentiviral vector pAIP (kindly provided by A Cimarelli). The Vpu A15L/W23A,
ELV, 2/6A and LILI mutants were generated by Quick-change site-directed mutagenesis as
described above. The pCR3.1 myc-β-TrCP2 was previously described by [36] and the pCR3.1
myc-HRS expression vector was kindly provided by Juan Martin-Serrano [59].
Primary human CD4+ T cells were isolated from fresh venous blood drawn from healthy
volunteers. CD4+ T cells were purified from total peripheral blood mononuclear cells (PBMC)
isolated by lymphoprep (AXIS-SHIELD) gradient centrifugation using a CD4+ T cell Dyna-
beads isolation kit (Invitrogen). T cells were then activated for 48 h using anti-CD3/anti-CD28
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magnetic beads (Invitrogen). The beads were then removed cells were then maintained in
rhIL-2 (20 U/ml) (Roche).
Production of VSV-G pseudotyped viral stocks
For full-length HIV-1 WT, HIV-1 ΔVpu, HIV-1 Vpu LILI, HIV-1 Vpu ELV, HIV-1 Vpu LILI/
ELV, HIV-1 Vpu 2/6A, HIV-1 Vpu 2/6A/ELV virus stocks pseudotyped with the Vesicular
Stomatitis Virus Glycoprotein (VSV-G), 293T cells were transfected with 2 μg of proviral plas-
mid in combination with 200 ng of pCMV VSV-G. 48 hours post-transfection, the supernatant
containing virions was harvested and endpoint titers were determined on HeLa-TZMbl cells as
described previously [3].
Virus release assay
For virus release assays using transient transfection, subconfluent 293T cells or derivatives
were plated in 24 well plates and transfected with 500 ng of NL4.3 proviral plasmid, in combi-
nation with increasing concentrations of tetherin (0 ng, 25 ng, 50 ng and 100 ng) and fixed 25
ng of Vpu-HA or mutants using 1 μg/ml polyethyleneimine (Polysciences). Medium was
replaced 8 hours post-transfection and cells and supernatants were harvested after 48 hours.
The infectivity of viral supernatants was determined by infecting HeLa-TZMbl and assayed for
β-galactosidase activity as previously described [36]. For biochemical analysis of physical virus
particle release, supernatants were filtered (0.22 μm) (Merck Millipore) and pelleted through a
20% sucrose/ PBS cushion at 20,000 x g for 90 min at 4°C. Virion and cell lysates were sub-
jected to SDS-PAGE andWestern blotted for rabbit anti-HSP90 (Santa Cruz Biotechnologies),
HIV-1 p24CA (monoclonal antibody 183-H12-5C; kindly provided by B Chesebro through the
NIH ARRP), monoclonal mouse anti-HA.11 (Covance), polyclonal rabbit anti-HA (Rockland)
and/ or Vpu (rabbit polyclonal; kindly provided by K. Strebel through the NIH ARRP [60]. For
CK-II inhibition, we used Tyrphostin AG1112 (Sigma) reconstituted in DMSO at a concentra-
tion of 50 μM.Where indicated, Phos-tag (Wako Chemicals, Japan) and MnCl2 (Sigma) were
added to the composition of 8% polyacrylamide gels to induce mobility shifts in phosphory-
lated proteins, to final concentrations of 25 μM and 50 μM, respectively.
Tetherin degradation assay
1.5 x 105 293T tetherin cells were infected with VSV-G-pseudotyped HIV-1 WT, HIV-1 ΔVpu,
HIV-1 Vpu LILI, HIV-1 Vpu ELV or HIV-1 Vpu 2/6A at an MOI of 2. The medium was
replaced 4 hours after infection. 48 hours post infection cell lysates were harvested and sub-
jected to SDS-PAGE andWestern blotted for rabbit anti-HSP90 (Santa Cruz Biotechnologies)
and polyclonal rabbit anti-tetherin antibody (kindly provided by K Strebel through the NIH
ARRP) [48], and processed as described above.
siRNAmediated protein knockdown
293T tetherin cells were seeded at a density of 2 x 105 cells per well in a 12 well plate. After
6 hours, the first transfection was performed. For each well, 2 μl Dharmafect (Thermo Scien-
tific) was added to 98 μl of Opti-MEM (Life Technologies), this solution was added to 5 μl of
20 μM siRNA in 95 μl of Opti-MEM according to manufactures protocol. For HRS knock-
down, siRNA oligonucleotide against HGS targeting the CCGGAACGAGCCCAAGTACAA
sequence (Qiagen) was used. For UBAP1 knockdown, siRNA oligonucleotide against UBAP1
targeting CTCGACTATCTCTTTGCACAT (Qiagen) was used. For TSG101 knockdown,
siRNA oligonucleotide sequence CCUCCAGUCUUCUCUCGUCUU (Thermo Scientific) was
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used. For β-TrCP1 and 2 knockdown, SMARTpool siRNA against human BTRC and FBXW11
(Thermo Scientific) were used. A non-targeting siRNA was used as control (Thermo Scien-
tific). The cells were re-seeded into a 24 well plate on day 2 and a second transfection was per-
formed according to manufactures protocol. The cells were infected 3 hours post transfection
with VSV-G-pseudotyped HIV-1 WT, HIV-1 ΔVpu at an MOI of 0.8. The infectivity of viral
supernatants was determined by infecting HeLa-TZMbl as described above. Cell lysates and
viral particles were subjected to SDS-PAGE, andWestern blot assays were performed using a
rabbit polyclonal anti-HRS (HGS) antibody (Millipore), a polyclonal rabbit anti-UBAP1 anti-
body (Proteintech) and a monoclonal mouse anti-TSG101 antibody (Abcam).
Flow cytometry
HeLa-TZMbl cells were transfected with 400 ng of pCR3.1 GFP and 400 ng of pCR3.1 Vpu-
HA or indicated mutants. 48 hours post transfection the cells were harvested and stained for
surface tetherin using a monoclonal anti-BST2 IgG2a antibody (Abnova) and a goat-anti-
mouse IgG2a-Alexa633 conjugated secondary antibody (Molecular Probes, Invitrogen, UK).
Tetherin expression on GFP positive cells was then analyzed using a BD FACSCanto II flow-
cytometer (Becton Dickinson) and the FlowJo software.
Immunoprecipitation
For Vpu/HRS coIP, 293T tetherin cells were transfected with 700 ng of pCR3.1 myc-HRS or
indicated mutants/truncations in combination with pCR3.1 Vpu-HA or indicated mutant
or pCR3.1 GFP expression plasmids. 48 hours post transfection the cells were lysed in buffer
containing 50 mM Tris pH 7.4, 150 mMNaCl, 200 μM sodium ortho-vanadate, 5 mM NEM,
complete protease inhibitors (Roche) and 1% digitonin. After removal of the nuclei, the
supernatants were immunoprecipitated with 5 μg/ml monoclonal mouse anti-myc antibody
previously described (Kueck and Neil, 2012). Western blot assays were performed using a poly-
clonal rabbit anti-HA antibody (Rockland) and rabbit polyclonal anti-HRS (HGS) antibody
(Millipore). For Vpu/tetherin coIP, 293T cells were transfected twice over 48 hours with
siRNA oligonucleotide against UBAP1 targeting CTCGACTATCTCTTTGCACAT or Non-
targeting siRNA was used as control (Dharmacon). The cells were then infected with VSV-G-
pseudotyped HIV-1 WT, HIV-1 ΔVpu, HIV-1 Vpu LILI or HIV-1 Vpu A14LW22A at an
MOI of 2. 48 hours post infection the cells were lysed on ice for 30 min in buffer containing
50 mM Tris pH 7.4, 150 mMNaCl, complete protease inhibitors (Roche) and 1% digitonin
(Calbiochem). Immunoprecipitation was performed as previously described [36] andWestern
blot assays were performed using a rabbit anti-Vpu antibody polyclonal rabbit anti-tetherin
antibody and polyclonal rabbit anti-UBAP1 antibody (Proteintech), and visualized by Image-
Quant using corresponding HRP-linked secondary antibodies (New England Biolabs, UK).
Immunofluorescence
Hela cells were grown on coverslips, transfected with 50 ng of pCR3.1 Vpu-HA or indicated
mutant. 16 hours later cells were fixed in 4% paraformaldehyde/ PBS, washed with 10 mM gly-
cine/ PBS, and permeabilized in 1% bovine serum albumin/ 0.1% Triton-X100/ PBS for 15
min. Cells were stained using anti-rabbit polyclonal HA antibody (Rockland) in combination
with sheep anti-human TGN46 (AbD Serotec), followed by the appropriate secondary antibod-
ies conjugated to Alexa 488 or 594 fluorophores (Molecular Probes, Invitrogen). Cells were
mounted on glass slides using ProLong AntiFade- 4’,6-diamidino-2-phenylindole (DAPI)
mounting solution (Molecular Probes, Invitrogen) and images were captured with a Nikon
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ESCLIPSE Ti inverted microscope. Z stacks were taken of all cells, images deconvolved using
AutoQuant X3 and analyzed using the ImageJ software.
Cross-linking IP
293T, 293T tetherin, 293T tetherin Y6,8A or 293 Rhesus tetherin cells were transfected with
8 μg GFP expression construct, pCR3.1 Vpu-HA or mutant thereof. Transfection media was
changed 6 hours post transfection and cells incubated with 50 nM concanamycin. In the case
of CKII inhibitor treatment, cells were treated with 50 μM final Tyrphostin 24 hours prior to
harvesting. 48 hours post transfection, cells were trypsinised and washed in PBS. Cells were
cross-linked with 0.05% HCHO/PBS for 10 min at 37°C. The cross-linking reaction was then
quenched by incubating cells in 0.25 M glycine for 5 min. Cells were washed once in PBS before
resuspension in lysis buffer (10 mMHepes pH 7, 150 mMNaCl, 6 mMMgCl2, 2 mMDTT,
10% glycerol, 0.5% NP40, 200 μM sodium orthvanadate and 1x Complete protease inhibitors
(Roche)). Cells were lysed on ice for 10 min followed by repeated sonication (3 x 10 s cycles
with 20 s rests). The cell lysates were clarified by centrifugation at 1000 x g for 10 min and
supernatants were immunoprecipitated with 5 μg/ml mouse monoclonal anti-HA.11 antibody
(Covance) or rabbit polyclonal anti-HA antibody (Rockland) on Dynabeads protein G beads
(Life Technologies) for 4 hours at 4°C. Beads were collected post incubation and washed 5
times in lysis buffer before cross-links were reversed in 1% SDS, 10 mM EDTA and 5 mm DTT
at 65°C for 45 min. Western blot assays were performed using rabbit polyclonal anti-HA anti-
body (Rockland), polyclonal rabbit anti-tetherin antibody, mouse monoclonal anti-HA.11
antibody, mouse monoclonal anti-AP-1γ1 antibody (Sigma) and mouse monoclonal anti-AP-
2α antibody (Sigma). Vpu/β-TrCP2 cross-linking IP was previously described by [36].
Affinity purification of biotinylated proteins
[61] 293T or 293T tetherin cells were transiently transfected with 8 μg empty BirA vector,
Vpu-myc-BirA or relevant mutant constructs using polyethylenimine (PEI). Cells were incu-
bated for 8 hours prior to changing medium and treated overnight with 100 nM Concanamy-
cin A (Invitrogen) and 150 μM biotin (Invitrogen). Cells were washed twice in PBS and lysed
in 1 ml lysis buffer (50 mM Tris pH 7.4, 500 mMNaCl, 0.4% SDS, 5 mM EDTA, 1 mM DTT
and 1x Complete protease inhibitor (Roche)) before sonication. Triton-X-100 was added to a
final concentration of 2% before further sonication and an equal volume of 50 mM Tris pH 7.4
was added to the cell lysates before clarification at 14,000 rpm for 5 minutes. Supernatants
were incubated with 200 μl avidin agarose (Pierce) for 4 hours at 4°C. Beads were collected and
washed four times in 1 ml lysis buffer before resuspension in 100 μl Laemmli-SDS sample
buffer supplemented with free biotin. Cell lysates and precipitates were analysed by Western
blot using HRP-conjugated streptavidin (Invitrogen), mouse monoclonal anti-myc antibody
(Covance), rabbit monoclonal β-TrCP antibody (Cell signaling Technology) and mouse mono-
clonal anti-AP-1γ1 antibody (Sigma).
Ethical information
Permission to isolate primary human CD4+ T cells from healthy consenting donors was pro-
vided by the KCL Infectious Disease BioBank Local Research Ethics Committee, reference SN-
1/6/7/9.
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Supporting Information
S1 Fig. Vpu/HRS interaction is dependent on residues in the DUIM of HRS that bind ubi-
quitin. (A) Schematic representation of HRS C-terminal truncations. (B) 293T cells were
transfected with pCR3.1 Vpu-HA in combination with a pCR3.1 myc-HRS or myc-HRS trun-
cation expression vector. 48 hours post transfection cells were lysed and immunoprecipitated
with anti-myc antibody. Total cell lysates and precipitates were subjected to SDS-PAGE and
analysed by Western blotting for myc-HRS and Vpu, and analyzed by ImageQuant. Asterisk:
anti-HA antibody heavy chain (C) Immunoprecipitation was performed as in (B) but with
myc-HRS W25A L29D and myc-HRS A266Q A268Q mutants.
(TIF)
S2 Fig. Vpu LI/LI mutant exhibits impaired tetherin counteractivity. (A) LogoPlots of the
first alpha helix of the Vpu cytoplasmic tail from HIV-1 subgroup M clades A, B, C, D, G and
H generated from sequences obtained from the Los Alamos database (www.hiv.lanl.gov). (B)
293T cells were transfected with NL4.3 HIV-1 WT, ΔVpu, Vpu LILI, Vpu ELV or Vpu 2/6A
mutant together with increasing concentrations of pCR3.1 tetherin-HA expression plasmid.
Cell lysates and sucrose purified viral supernatants from 50 ng tetherin input were subjected to
SDS-PAGE and analyzed by Western blotting for HSP90, HIV-1 p24CA and Vpu, and ana-
lyzed by LiCor quantitative imager. Asterisk: non-specific band. (C) Infectivity of viral super-
natants was assayed on HeLa-TZMbl reporter cells. Infectious virus release was plotted as β-
galactosidase activity in relative light units (RLU). Error bars represent the standard deviation
of three independent experiments. (D) HeLa-TZMbl cells were co-transfected with pCR3.1
Vpu-HA or indicated mutant and a GFP expression vector. Cell-surface tetherin levels were
analysed 48 hours post transfection by flow cytometry. GFP positive cells were gated and
tetherin levels (solid lines) were compared to un-transfected cells or transfected with indicated
Vpu (dotted lines). Numbers indicate median fluorescence intensities of endogenous tetherin
surface levels. The solid peak in the upper histogram in the middle of the panel represents
binding of the isotype control. (E) 293T tetherin expressing cells were transfected twice over a
48 hour period with siRNA oligonucleotides directed against UBAP1 or non-targeting control.
The cells were then infected with HIV-1 WT, HIV-1 Vpu LILI, HIV-1 Vpu A14LW22A or
HIV-1 ΔVpu at an MOI of 2. 48 hours later, cells were lysed and immunoprecipitated with
anti-tetherin antibody. Total cell lysates and precipitates were subjected to SDS-PAGE and
analyzed by Western blotting for tetherin, UBAP1 and Vpu, and analyzed by ImageQuant.
(TIF)
S3 Fig. Further Vpu mutants show similar phenotypes in infected primary CD4+ T cells
and in 293T cells. (A-B) 293T, 293T tetherin or Y6,8A tetherin cells were infected with VSV-G
pseudotyped NL4.3 wt or mutant virus at anMOI of 0.8. (A) 48 hours post infection viral superna-
tants were assayed for infectivity using HeLa-TZMbl reporter cells as in Fig 1. Error bars represent
the standard deviation of three independent experiments. (B) Cell lysates and sucrose purified
viral supernatants were subjected to SDS-PAGE and analyzed byWestern blotting as in Fig 1. (C)
Primary human CD4+ T cells were infected with the indicated HIV-1 mutant at anMOI of 0.8. 16
h later the cells were treated or not with 5000 U/ml universal type-I interferon. Cell lysates and
viral supernatants were harvested a further 24 h later and analyzed for infectivity on HeLa-TZMbl
cells (A) or physical particle yield and cellular viral expression by quantitativeWestern blotting.
(TIF)
S4 Fig. A primary isolate Vpu allele and its mutants exhibit a comparable phenotype to
NL4.3 Vpu. (A) 293T tetherin cells were transfected with NL4.3 ΔVpu proviral plasmid in
combination with YFP expression vector and pCR3.1 2_87 Vpu or mutants thereof. 48 hours
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post transfection infectivity of viral supernatants was determined on HeLa-TZMbl cells as in
Fig 1. (B) Cell lysates and pelleted supernatant virions from (A) were harvested and subjected
to SDS-PAGE and analyzed by Western blotting for HIV-1 p24CA, Vpu and HSP90, and ana-
lyzed by LiCor quantitative imager. (C) Hela cells were transfected with 100 ng of pCR3.1 2_87
Vpu-HA or indicated mutants. 16 hours post transfection cells were fixed and stained for HA
(green) and the TGN marker TGN46 (red) and examined by widefield fluorescent microscopy.
Panels are of representative examples. Bars = 10 μm. (D) Z stacks were taken of all cells
(n = 15), images were deconvolved using the AutoQuant X3 software and Pearson’s correla-
tions were calculated for all Z stacks using ImageJ. Results were analyzed by unpaired 2-tailed
t-test—!!! P = 10–5 or lower.
(TIF)
S5 Fig. Clathrin binding restores the tetherin downregulation capacity of Vpu mutants. (A
to D) HeLa-TZMbl cells were co-transfected with pCR3.1 Vpu-HA or indicated mutant and a
GFP expression vector. Cell-surface tetherin levels were analyzed 48 hours post transfection by
flow cytometry. GFP positive cells were gated and tetherin levels (solid lines) were compared to
un-transfected cells or transfected with indicated Vpu (dotted lines). Numbers indicate median
fluorescence intensities of endogenous tetherin surface levels. The solid peak in the upper his-
togram in the middle of the panel represents binding of the isotype control.
(TIF)
S6 Fig. Proximity-based biotin ligase assay suggests Vpu/AP-1 interaction. (A) Schematic
representation of proximity-based biotin ligase assay. (B) 293T tetherin cells were transfected
with NL4.3 ΔVpu proviral plasmid in combination with YFP expression vector and pCR3.1
Vpu or indicated mutant thereof. 48 hours post transfection infectivity of viral supernatants
was determined on HeLa-TZMbl cells as in Fig 1. (C) 293T or 293T tetherin cells were trans-
fected with Vpu-myc-BirA, B Vpu ELV-myc-BirA, B Vpu A15L/W23A-myc-BirA, B Vpu S3/
7A- myc-BirA (phospho-mutant), B Vpu LILI-myc-BirA or empty vector control. 6 hours post
transfection, cells were treated with 100 nM concanamycin A in the presence of 150 μM free
biotin. 16 hours later, cells were washed, lysed, sonicated and biotinylated proteins were recov-
ered on streptavidin-conjugated beads and analysed by Western blot for avidin, Vpu-myc-
BirA, β-TrCP or AP-1 γ. Asterisk: Vpu-myc-BirA band.
(TIF)
S7 Fig. Vpu binding to clathrin adaptors AP-1 and AP-2 is dependent on tetherin binding
(A) and binding to AP-1 and AP-2 is conserved by primary Vpu 2_87 in tetherin expressing
cells (B). (A) 293T cells were transfected with pCR3.1 Vpu-HA, Vpu ELV-HA, Vpu 3/7A-HA,
Vpu LILI-HA or Vpu NE-HA mutants. (B) 293T tetherin Y6,8A were transfected with pCR3.1
Vpu-HA, Vpu A15L/W23A-HA, Vpu ELV-HA, Vpu 3/7A-HA, Vpu LILI-HA or Vpu NE-HA
mutants. 48 h post transfection, cells were lysed and cross-linked using PFA (0.05% w/v) and
immunoprecipitated with anti-HA antibody. Total cell lysates and precipitates were subjected
to SDS-PAGE and analyzed by Western blotting for Vpu-HA, AP-1 Ɣ or AP-2 α. Panels are of
representative experiments. Histograms represent quantification of the relative AP-1 or AP-2
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!S1#Fig.#Vpu/HRS#interaction#is#dependent#on#residues#in#the#DUIM#of#HRS#that#bind#ubiquitin.#
(A)$ Schematic$ representation$ of$ HRS$ C6terminal$ truncations.$ (B)$ 293T$ cells$ were$ transfected$ with$
pCR3.1$Vpu6HA$in$combination$with$a$pCR3.1$myc6HRS$or$myc6HRS$truncation$expression$vector.$48$
hours$ post$ transfection$ cells$ were$ lysed$ and$ immunoprecipitated$ with$ anti6myc$ antibody.$ Total$ cell$
lysates$and$precipitates$were$subjected$to$SDS6PAGE$and$analysed$by$Western$blotting$for$myc6HRS$
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!S6# Fig.# ProximityRbased# biotin# ligase# assay# suggests# Vpu/APR1# interaction.# (A)$ Schematic$
representation$ of$ proximity6based$ biotin$ ligase$ assay.$ (B)$ 293T$ tetherin$ cells$were$ transfected$with$
NL4.3$ΔVpu$proviral$plasmid$in$combination$with$YFP$expression$vector$and$pCR3.1$Vpu$or$indicated$
mutant$ thereof.$48$hours$post$ transfection$ infectivity$of$viral$supernatants$was$determined$on$HeLa6
TZMbl$cells$as$ in$Fig$1.$(C)$293T$or$293T$tetherin$cells$were$transfected$with$Vpu6myc6BirA,$B$Vpu$
ELV6myc6BirA,$B$Vpu$A15L/W23A6myc6BirA,$B$Vpu$S3/7A6$myc6BirA$(phospho6mutant),$B$Vpu$LILI6
myc6BirA$ or$ empty$ vector$ control.$ 6$ hours$ post$ transfection,$ cells$ were$ treated$ with$ 100$ nM$
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SUMMARY
Critical cell surface immunoreceptors downregu-
lated during HIV infection have previously been iden-
tified using non-systematic, candidate approaches.
To gain a comprehensive, unbiased overview of
how HIV infection remodels the T cell surface, we
took a distinct, systems-level, quantitative proteomic
approach. >100 plasma membrane proteins, many
without characterized immune functions, were
downregulated during HIV infection. Host factors tar-
geted by the viral accessory proteins Vpu or Nef
included the amino acid transporter SNAT1 and the
serine carriers SERINC3/5. We focused on SNAT1,
a b-TrCP-dependent Vpu substrate. SNAT1 antago-
nism was acquired by Vpu variants from the lineage
of SIVcpz/HIV-1 viruses responsible for pandemic
AIDS. We found marked SNAT1 induction in acti-
vated primary human CD4+ T cells, and used Con-
sumption and Release (CoRe) metabolomics to
identify alanine as an endogenous SNAT1 substrate
required for T cell mitogenesis. Downregulation of
SNAT1 therefore defines a unique paradigm of HIV
interference with immunometabolism.
INTRODUCTION
HIV-1 viruses of the AIDS pandemic encode four ‘‘accessory
proteins’’ (Vif, Vpr, Vpu, and Nef) dispensable for viral
replication in vitro, but essential for viral pathogenesis in vivo
(Malim and Emerman, 2008). Vpu and Nef are multifunctional
adaptors that downregulate cell surface proteins to counteract
host-cell restriction and evade the immune response (Haller
et al., 2014; Tokarev and Guatelli, 2011). Targets have typically
been identified using non-systematic, candidate approaches
and include the HIV receptor CD4, the restriction factor teth-
erin, and the MHC I molecules HLA-A/B (Tokarev and Guatelli,
2011).
Among primate lentiviruses, a correlation is observed between
viral pathogenicity and expression of Vpu, with CD4+ T cell
decline and progression to AIDS markedly faster in HIV-1 than
HIV-2, and increased mortality in chimpanzees infected with
SIVcpz (Keele et al., 2009). Vpu induces substrate-specific
ubiquitination of CD4 and tetherin through recruitment of the
SCF-b-TrCP E3 ligase complex via a constitutively phosphory-
lated phosphodegron in its cytoplasmic tail (Douglas et al.,
2009; Margottin et al., 1998; Mitchell et al., 2009). In the SIV-
HIV (SHIV) macaque model of HIV, CD4+ T cell loss is abrogated
by deletion of Vpu, scrambling of its transmembrane domain, or
mutation of its b-TrCP-binding phosphodegron (Hout et al.,
2005; Singh et al., 2003; Stephens et al., 2002). This effect is un-
likely to be attributable to loss of Vpu-mediated downregulation
of macaque CD4 or tetherin because CD4 is also efficiently
downregulated by Nef, and pig-tailed macaque tetherin is antag-
onized by SIVmac Nef, but not by HIV-1 Vpu (Zhang et al., 2009).
Together, these data point to the existence of additional, biolog-
ically important, b-TrCP-dependent Vpu substrates.
In this study, we combine plasma membrane enrichment
through selective aminooxy-biotinylation (Plasma Membrane
Profiling; PMP) with TandemMass Tag (TMT) and Stable Isotope
Labeling by Amino Acids in Cell Culture (SILAC)-based quantita-
tive proteomics to describe global changes in the cell surface
landscape of an HIV-infected T cell, including expression time
courses of >800 plasma membrane proteins (Weekes et al.,
2013, 2014). Our unbiased, comprehensive analysis reveals
downregulation of >100 HIV-1 targets, particularly proteins
involved in cell adhesion, leukocyte activation, and transmem-
brane transport, and is presented as a searchable database to
facilitate data mining.
In addition to their known substrates, we show that Vpu is
necessary and sufficient for b-TrCP-dependent degradation of
the amino acid transporter SNAT1, and Nef is sufficient for
downregulation of the serine carriers SERINC3 and SERINC5.
We apply an unbiased, CoRe metabolomic approach to identify
the non-essential amino acid alanine as an endogenous SNAT1
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Figure 1. TMT-Based Proteomic Time Course of Plasma Membrane Protein Expression in HIV-1-Infected Cells
(A) Workflow of TMT-based 6-plex PMP time course experiment. In subsequent figures, time points 1–5 show plasma membrane protein expression 0, 6, 24, 48,
and 72 hr after HIV-1 infection (where 0 hr = uninfected cells), and time point 6 shows plasma membrane protein expression 72 hr after HIV-1 infection in the
presence of reverse transcriptase inhibitors (RTi). NL4-3-deltaE-EGFP HIV-1 viruses at an MOI of 10 were used for all proteomic experiments.
(B) Comparison of temporal profiles of CD4 and tetherin obtained by proteomic (TMT) versus flow cytometric quantitation. Cells from (A) were stained with anti-
CD4 and anti-tetherin antibodies at the indicated time points and analyzed by flow cytometry. Relative abundance is expressed as a fraction of maximum TMT
reporter ion or fluorescence intensity. For linear regression, log2(fold change compared with uninfected cells) is shown.
(C) Temporal profiles of previously reported targets for HIV-mediated downregulation.
(legend continued on next page)
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substrate in primary human CD4+ T cells, and show that extra-
cellular alanine is critical for T cell mitogenesis. Restricting
alanine uptake through Vpu-mediated downregulation of
SNAT1 therefore represents a viral strategy to regulate immune
cell activation.
RESULTS
Systematic Time Course Analysis of T Cell Surface
Protein Expression during HIV-1 Infection
To gain a comprehensive, unbiased overview of plasma mem-
brane protein regulation by HIV-1, we used PMP to measure
expression levels of cell surface proteins in CEM-T4 T cells in-
fected with HIV-1 (Figure 1A) (Weekes et al., 2013, 2014). By spi-
noculating cells with Env-deficient, VSVg-pseudotyped virus, we
ensured a synchronous, single-round infection, and by using a
multiplicity of infection (MOI) sufficient to infect >90% of cells,
we minimized confounding effects from bystander (uninfected)
cells (Figure S1A). We exploited 6-plex TMT quantitation to
compare plasma membrane protein abundance in uninfected
cells (0 hr), at 4 time points following HIV-1 infection (6, 24, 48,
and 72 hr) and, to control for cellular changes occurring in the
absence of de novo viral gene expression, in cells infected for
72 hr in the presence of reverse transcriptase inhibitors (RTi).
In total, 2,320 proteins were quantitated, including 804 proteins
previously reported to localize to the plasma membrane (Fig-
ure S1B). The complete dataset is shown in interactive Table
S1, which allows generation of temporal profiles for any quanti-
tated genes of interest.
We observed a strong correlation between expression time
courses determined by mass spectrometry and flow cytometry
for CD4 (R2 = 0.98) and tetherin (R2 = 0.90) (Figure 1B), saw
marked time-dependent depletion of cell surface HLA-A, and
confirmed progressive downregulation of other known HIV-1 tar-
gets (CCR7, CD28, NTB-A, SELL, and the tetraspanins CD37/
53/63/81/82) (Figure 1C) (Haller et al., 2014; Lambele´ et al.,
2015; Ramirez et al., 2014; Shah et al., 2010; Swigut et al.,
2001; Vassena et al., 2015). Downregulation of CD71 and the
chemokine receptors is controversial, with our data suggesting
depletion of cell surface CD71, CXCR4, and CCR5 (Figure S1C).
As expected, VSVg levels increased immediately after infection,
then rapidly declined (Figure S1D).
Discovery of Cell Surface Targets Depleted by HIV-1
To identify host factors regulated by HIV-1 without observer bias
based on known biological function, we used the Short Time
Series Expression Miner (STEM) to cluster proteins according
to patterns of temporal expression and identify profiles occurring
more frequently than expected by chance (Figure 1D). The most
enriched profile comprised 134 proteins showing progressive
time-dependent downregulation, abolished by reverse tran-
scriptase inhibitors (Cluster #35; p = 10!78). Proteins in this
cluster, which include CD4, tetherin, and HLA-A, represent
candidate HIV-1 cell surface targets (Table S2).
We validated these candidates in an independent infection
time course experiment using SILAC as an alternative quantita-
tive proteomic approach (Figures 2A and 2B) and confirmed
downregulation of a functionally and structurally diverse set of
proteins with available antibody reagents (CD43/47/162 and
NOTCH1) by flow cytometry in CEM-T4s and primary human
CD4+ T cells infected with HIV-1 (Figure S2A).
Functional Analysis of Progressively Downregulated
HIV-1 Targets
To identify biological functions targeted by HIV-1 in an unbiased
fashion, we used the Database for Annotation, Visualization and
Integrated Discovery (DAVID) to determine gene ontology
‘‘molecular function’’ and ‘‘biological process’’ annotations
over-represented in Cluster #35 compared with other quanti-
tated proteins. The cluster was enriched for terms relating to
cell adhesion, leukocyte activation, and transmembrane trans-
port. These categories intersect processes known to be modu-
lated by HIV-1 and provide a framework for interpreting both
previously identified and novel HIV-1 targets. We therefore
mined our data for downregulated proteins with closely related
functions (Figures 2C–2F and Table S3).
Cell adhesion molecules regulate leukocyte trafficking and NK
cell killing. Modulation of lymphocytemigration through targeting
of SELL and CCR7 (Figure 1C) is proposed to facilitate HIV-1 im-
mune avoidance (Ramirez et al., 2014; Vassena et al., 2015), and
downregulation of NTB-A (Figure 1C) protects HIV-infected cells
from NK cell lysis (Shah et al., 2010). We now show that HIV-1
also downregulates NCR3LG1 (B7H6; Figure 2D), a ligand for
the NK activating receptor NKp30 found on activated monocytic
cells in vivo (Brandt et al., 2009; Matta et al., 2013). Flow cytom-
etry confirmed reduced Ig-NKp30 binding to HIV-1-infected
CEM-T4 cells (Figure S2B).
HIV-1 replication is critically dependent on the activation state
of infected cells, and the virus employs multiple strategies to
modulate T cell activation and maximize replication in vivo
(Abraham and Fackler, 2012). Attention has focused on downre-
gulation of CD3 by Nef variants of non-pathogenic SIVs, attenu-
ated in HIV-1 Nef (Schindler et al., 2006). Conversely, our data
revealed downregulation of numerous other immunoreceptors
with important functions in T cell activation (Figure 2E), along
with a range of transmembrane transporters with no known roles
in the immune system, particularly amino acid transporters (Fig-
ure 2F). Since T cell activation requires profound upregulation in
amino acid metabolism (Wang et al., 2011), we predict that these
proteins have important, but unrecognized, functions in T cell
biology.
Systematic Plasma Membrane Proteomic Analysis of
HIV-1 Accessory Proteins Vpu and Nef
Depletion of most known HIV-1 cell surface targets has been
attributed to Vpu and/or Nef (Haller et al., 2014; Tokarev
and Guatelli, 2011). To assign downregulation of proteins in
Cluster #35 to particular viral genes, we applied an unbiased,
(D) Identification of enriched temporal profiles by STEM. Model temporal profiles (black) and matched experimental protein expression profiles (red) are shown.
Each box includes a profile identification number (top left) and an unadjusted p value (bottom left). Colored boxes indicate model profiles assigned more proteins
than expected by chance alone (Bonferroni-adjusted p values < 0.05).
See also Figure S1 and Tables S1 and S2.




Figure 2. SILAC-Based Proteomic Validation and Functional Analysis of Cell Surface Targets Downregulated by HIV-1
(A) Workflow of SILAC-based 3-way PMP time course experiment.
(B) Validation of HIV-1 targets (upper panel) and comparison between SILAC- and TMT-based time course experiments (lower panel). Log2(fold change
compared withmock/uninfected cells) at 24, 48, and 72 hr is shown for proteins fromCluster #35 (red) versus all other quantitated proteins (gray). Downregulation
by HIV-1 is indicated by dotted arrows. Proteins identified by >1 unique peptide in both TMT and SILAC experiments are shown. Crosses indicate mean values.
*p < 0.05; ***p < 0.001.
(legend continued on next page)
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systematic approach to define Vpu and Nef substrates. SILAC-
based PMP was used to compare expression levels of cell
surface proteins in CEM-T4s infected with either Vpu- or Nef-
deficient viruses (Figures 3A and S3A), or transduced with Vpu
or Nef as single genes (Figures 3B and S3B). As positive controls,
we found that Vpu depleted cell surface CD4 and tetherin, while
Nef depleted cell surface CD4 and HLA-A (Figures 3A and 3B).
Surprisingly, many HIV-1 cell surface targets were downregu-
lated efficiently by both Vpu- and Nef-deficient viruses and not
by overexpression of Vpu and Nef as single genes, suggesting
Vpu- and Nef-independent mechanisms.
Targeting of Amino Acid Metabolism by Vpu and Nef
As well as their known targets, we found Vpu to be both neces-
sary and sufficient for downregulation of the amino acid trans-
porter SNAT1 (Figures 2F and 3A–3B), and Nef to be sufficient
for downregulation of the serine carriers SERINC3 and SERINC5
(Figures 2F and 3A–3B). This effect was specific within the
SERINC family, because SERINC1 was induced rather than
downregulated (Figure S1E).While this manuscript was in prepa-
ration, SERINC3 and SERINC5 were independently identified as
HIV-1 restriction factors using orthogonal approaches (M. Piz-
zato, personal communication; H.Gottlinger, personal communi-
cation).We confirmed restriction of infectiousHIV-1 viral produc-
tion by SERINC5, antagonized by Nef (Figure S3C). Conversely,
SNAT1 does not act as an HIV-1 restriction factor (Figure S3D).
Instead, we hypothesized that antagonism of SNAT1-dependent
amino acid transport by Vpu may modulate T cell activation.
We confirmed Vpu-dependent depletion of endogenous
SNAT1 from the plasma membrane of transduced cells by
confocal and total internal reflection (TIRF) microscopy (Figures
S4A and S4B). As well as decreased expression at the cell sur-
face, depletion of total SNAT1 was seen by immunoblot of
CEM-T4s infected with WT or Nef-deficient HIV-1, but not with
Vpu-deficient virus (Figures 3C, lanes 2–4, 3D, lanes 2 and 4,
and S4C), and by immunoblot of CEM-T4s transduced with
Vpu, but not Nef (Figure 3E, lane 5).
Previous studies have suggested that SNAT1 is predominantly
expressed in the CNS (Gu et al., 2001; Varoqui et al., 2000). We
found SNAT1 protein to be poorly expressed in resting primary
human CD4+ T cells but dramatically induced following mito-
genic T cell stimulation (Figures 3F, lanes 2–5, and 3G, panel 2).
Furthermore, Vpu depletes SNAT1 from activated primary hu-
man CD4+ T cells both in the context of viral infection (Figures
S4D and S4E) and as a single gene in transduced cells purified
by Antibody-Free Magnetic Cell Sorting (AFMACS; Figures 3G,
panel 5, 3H, lane 5, and S4F) (Matheson et al., 2014).
Ubiquitination and b-TrCP-Dependent Endolysosomal
Degradation of SNAT1
To probe the mechanism of Vpu-mediated SNAT1 depletion, we
confirmed that Vpu binds endogenous SNAT1 (Figure 4A, lanes 2
and 4) and leads to SNAT1 ubiquitination (Figure 4B, lane 5). As
with CD4 and tetherin, downregulation of SNAT1 is rescued by
mutation of the Vpu phosphodegron responsible for b-TrCP
recruitment (S52, 56A) (Figures 3G, panel 6, 3H, lane 6, 4F,
and S5A) and by RNAi-mediated depletion of b-TrCP (Figure 4C,
lane 3).
Vpu mediates degradation of CD4 by hijacking the endo-
plasmic reticulum-associated degradation (ERAD) pathway
(Margottin et al., 1998; Schubert et al., 1998) and antagonizes
tetherin by co-opting the endolysosomal degradative pathway
(Douglas et al., 2009; Mitchell et al., 2009). SNAT1 degradation
is rescued by incubation with vacuolar ATPase inhibitors, but
not proteasome inhibitors (Figure 4D, lanes 5 and 6), and by
RNAi-mediated depletion of TSG101 (Figure 4E, lane 3), sug-
gesting that, as for tetherin, SNAT1 is degraded in endolyso-
somes by the ESCRT machinery.
Downregulation of tetherin is abolished by substitution of
conserved amino acid residues W22 or A14 in the trans-
membrane domain of Vpu, and W22 is also critical for
downregulation of CD4 (Vigan and Neil, 2010). While the
W22A mutation abolished downregulation of all 3 Vpu sub-
strates, SNAT1 and CD4 downregulation were preserved
in the presence of the A14L mutation (Figure 4F, lane 4, and
Figure S4A). The same pattern of SNAT1 downregulation
was observed with equivalent mutations in a patient-derived
Vpu (Figure S5B) and with Vpu mutants in the context of viral
infection (Figure S5C). The pathway for SNAT1 degradation
by Vpu therefore shares the cellular machinery used for
antagonism of tetherin but occurs independently of tetherin
downregulation and may be dissociated from it by the A14L
mutation.
CoReMetabolomic Analysis of SNAT1-Depleted Primary
Human CD4+ T Cells
When overexpressed in vitro, SNAT1mediates uptake of a range
of small neutral amino acids (Gu et al., 2001; Varoqui et al., 2000).
Transport by SNAT1 is Na dependent and sensitive to competi-
tion by the model substrate a-methylaminoisobutyric acid
(MeAIB), a specific inhibitor of amino acid transport System A
(Mackenzie and Erickson, 2004). Based on its functional charac-
teristics and pattern of expression, SNAT1 has primarily been
considered a neuronal glutamine transporter (Chaudhry et al.,
2002).
To identify endogenous SNAT1 substrates in primary human
CD4+ T cells in an unbiased fashion, we combined an ‘‘activa-
tion-rest’’ strategy for shRNA knockdown (Monroe et al., 2014)
with Consumption and Release (CoRe) metabolomics (Jain
et al., 2012) (Figure 5A). Pure populations of transduced cells ex-
pressing control or SNAT1-specific shRNAs were generated by
AFMACS (Figures 5B and S6A) (Matheson et al., 2014). After
resting for 7–10 days, control and SNAT1-depleted cells were
re-stimulated using CD3/CD28 Dynabeads. A marked reduction
(C) Gene ontology ‘‘molecular function’’ and ‘‘biological process’’ terms enriched among proteins from Cluster #35. DAVID functional annotation clusters with
adjusted p values < 0.05 and containing terms with Bonferroni-adjusted p values < 0.05 are shown. Further details are included in Table S3.
(D–F) Temporal profiles of downregulated proteins associated with cell adhesion (D), leukocyte activation (E), and transmembrane transport (F). Proteomic
quantitation and time points are as for Figures 1B–1C. Proteins exhibiting >2-fold downregulation compared with uninfected cells in both TMT and SILAC
experiments are shown, and proteins subsequently validated using flow cytometry or immunoblot are underlined.
See also Figure S2 and Table S2.
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Figure 3. Proteomic Analysis of Vpu and Nef Targets and Identification of SNAT1 as a Vpu Substrate
(A and B) SILAC-based quantitation of plasma membrane proteins in cells infected with Vpu-deficient (y axis) versus Nef-deficient (x axis) HIV-1 viruses (A)
and cells transduced with Vpu (x axis) versus Nef (y axis) as single genes (B). Log2(fold change compared with uninfected [A] or GFP-transduced [B] cells)
(legend continued on next page)
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in proliferation of SNAT1-depleted cells was observed (Figures
5C and S6A). Culture supernatants were sampled at baseline,
24, and 48 hr, and extracellular metabolite fluxes were calculated
on a per-cell basis. In total, data for consumption and release of
126 metabolites, including 19 natural amino acids, were used to
derive CoRe metabolomic profiles of control and SNAT1-
depleted cells. Principal component analysis readily distin-
guished these profiles, particularly at 48 hr (Figure 5D, upper
panels). Surprisingly, across all measured metabolites, the
most significant difference was in net alanine release, with no dif-
ference in net glutamine consumption (Figure 5D, middle and
lower panels).
is shown for proteins from Cluster #35. Figures S3A and S3B selectively enlarge the lower left quadrant of each scatterplot. Proteins identified by >1 unique
peptide are shown.
(C) SNAT1 depletion by HIV-1 infection. CEM-T4s infected withWT NL4-3-deltaE-EGFP HIV-1 virus in the presence or absence of RTi were immunoblotted at the
indicated time points. An MOI of 10 was used, and infection controls are shown in Figure S4C.
(D) Rescue of SNAT1 in the absence of Vpu. CEM-T4s infectedwithWT, Vpu-deficient, or Nef-deficient HIV-1 NL4-3-deltaE-EGFP viruseswere immunoblotted at
48 hr. An MOI of 10 was used, and infection controls are shown in Figure S4C.
(E) SNAT1 depletion by Vpu. CEM-T4s stably transduced with GFP, Vpu, or Nef were immunoblotted. Untransduced CEM-T4s and CEM-T4s stably transduced
with control or SNAT1-specific shRNAs were included as controls.
(F) SNAT1 induction in activated primary T cells. Primary human CD4+ T cells activated with CD3/CD28 Dynabeads were immunoblotted at the indicated time
points.
(G and H) SNAT1 depletion by Vpu in activated primary T cells. Primary human CD4+ T cells were activated with CD3/CD28 Dynabeads and mock transduced or
transduced with the indicated shRNA or Vpu constructs. After purification by AFMACS (Figure S4F), cells were either rested or re-stimulated with CD3/CD28
Dynabeads and immunoblotted (G) or analyzed by confocal microscopy (H) at 48 hr.
See also Figures S3 and S4.
A B C
D E F
Figure 4. Mechanism of SNAT1 Depletion
by Vpu
(A) Interaction of SNAT1with Vpu. HeLa cells stably
transducedwith Vpu-HAwere immunoprecipitated
with anti-SNAT1 (G63; first panel) or anti-HA
(second panel) antibodies and immunoblotted with
anti-SNAT1 (H60) or anti-Vpu antibodies. Un-
transduced HeLas transfected with SNAT1-spe-
cific siRNA were included as controls.
(B) Ubiquitination of SNAT1 by Vpu. HeLa cells
stably transduced with Vpu-HA were either
immunoblotted with anti-SNAT1 (H60) and anti-
ubiquitin antibodies (first panel) or immunoprecip-
itated with anti-SNAT1 (G63) antibody, re-immu-
noprecipitated with anti-SNAT1 (H60) antibody,
and immunoblotted with anti-SNAT1 (H60) and
anti-ubiquitin antibodies (second panel). Un-
transduced HeLas transfected with SNAT1-
specific siRNA were included as controls.
Ubiquitinated SNAT1 in control (blue arrow) and
Vpu-expressing (red arrow) HeLas is highlighted.
(C) b-TrCP-dependent depletion of SNAT1. HeLa
cells stably transduced with Vpu-HA were trans-
fected with control or b-TrCP-specific siRNA then
immunoblotted.
(D and E) SNAT1 depletion via an endolysosomal
pathway. HeLa cells stably transduced with Vpu-
HA were either treated with MG132, lactacystin,
concanamycin, or bafilomycin (D) or transfected
with control or TSG101-specific siRNA (E) then
immunoblotted.
(F) Molecular determinants of SNAT1 down-
regulation. Jurkats stably expressing Vpu WT or
indicated Vpu mutants were immunoblotted. Cells
transduced with empty vector (blue), Vpu WT (red),
and Vpu A14L (pink) are highlighted. The same
cells stained with anti-CD4 or anti-tetherin anti-
bodies and analyzed by flow cytometry are shown
in Figure S5A.
See also Figure S5.




Figure 5. CoRe Metabolomics of Proliferating T Cells and Identification of Alanine Transport by SNAT1
(A) Workflow of CoRe metabolomics experiment.
(B) SNAT1 knockdown for CoRe metabolomics experiment. Primary human CD4+ T cells were activated with CD3/CD28 Dynabeads and mock transduced or
transduced with the indicated shRNAs. After purification by AFMACS (Figure S6A), cells were either rested or re-stimulated with CD3/CD28 Dynabeads, then
immunoblotted at 48 hr.
(legend continued on next page)
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Alanine Transport by Endogenous SNAT1 in T Cells
While attention has focused on glutamine, alanine is the paradig-
matic substrate for System A amino acid transport (Oxender and
Christensen, 1963) and has consistently been found to be a high-
affinity substrate for SNAT1 in overexpression studies (Gu et al.,
2001; Mackenzie and Erickson, 2004; Varoqui et al., 2000). We
therefore hypothesized that the increase in net alanine release
caused by SNAT1 depletion may be explained by a decrease
in SNAT1-mediated alanine uptake. To test this, 3H-alanine
transport was measured directly in AFMACS-purified primary
human CD4+ T cells depleted of SNAT1 by expression of a
SNAT1-specific shRNA (Figure 5E) or wild-type Vpu (Figure 5F).
Whereas alanine uptake in control T cells was markedly reduced
by the System A transport inhibitor MeAIB, this effect was abol-
ished in SNAT1-depleted T cells (Figures 5E and 5F), confirming
alanine transport by endogenous SNAT1.
Critical Requirement for Extracellular Alanine in T Cell
Mitogenesis
Since alanine is both a non-essential amino acid and excreted by
proliferating cells (Jain et al., 2012), including lymphocytes (Fig-
ure 5D, lower panels), it appears paradoxical to suggest that a
reduction in alanine uptake could result in the mitogenic
defect observed in T cells depleted of SNAT1. Nonetheless,
we observed a dose-dependent increase in proliferation of
CEM-T4 and Jurkat T cells cultured in increasing alanine con-
centrations (Figure S7A), and a supply of exogenous alanine is
required for optimal lymphocyte proliferation in response to
PHA (Chuang et al., 1990; Rotter et al., 1979).
We investigated this requirement in primary human CD4+
T cells by activating cells with CD3/CD28 Dynabeads in media
supplemented with increasing alanine concentrations. A clear
dose response in proliferation from 0 to 0.1 mM was observed
(Figure 6A). Furthermore, the effect of increasing alanine con-
centration was inhibited by MeAIB in a dose-dependent fashion,
supporting a role for System A transport in alanine uptake (Fig-
ure 6B). Interestingly, exogenous alanine had no effect on the
expression of the early T cell activation markers CD69 and
CD25 (Figure S7B). The same dissociation of proliferation from
early activation has been reported for T cells stimulated in the
absence of glutamine (Carr et al., 2010).
Contribution of Extracellular Alanine to the Free
Intracellular Amino Acid Pool
To explain the requirement for exogenous alanine in T cell mito-
genesis, we hypothesized that bidirectional transport of alanine
at the plasma membrane could result in both uptake of extracel-
lular alanine and net alanine excretion (Figure S7C). We therefore
measured the size of the free intracellular alanine pool of primary
human CD4+ T cells re-stimulated with CD3/CD28 Dynabeads
and resuspended in media either lacking alanine or supple-
mented with a physiological alanine concentration (Figures 6C
and S7D). Intracellular alanine levels were markedly reduced
by extracellular alanine depletion, but increased by extracellular
alanine supplementation, an effect abolished in the presence of
MeAIB. These observations confirm bidirectional flux of alanine
across the plasma membrane, resulting in equilibration of intra-
cellular and extracellular alanine concentrations, with alanine up-
take mediated by System A transport.
The free intracellular alanine pool may be filled by de novo syn-
thesis through transamination of pyruvate, by release of alanine
from proteins by proteasomal or lysosomal degradation, or by
uptake of extracellular alanine. To formally distinguish these
possibilities, and assess their relative contributions, we resus-
pended washed cells in media supplemented with physiological
levels of heavy isotopologue-labeled 13C6-glucose and 15N-
alanine (Figure 6D). The free intracellular alanine pool was rapidly
reconstituted by extracellular 15N-alanine, an effect markedly in-
hibited by MeAIB, with little contribution from unlabeled alanine
or alanine generated from 13C-glucose-derived pyruvate (Fig-
ures 6E and S7D). Conversely, almost all lactate released from
cells was derived from glycolysis of 13C6-glucose (Figures 6F).
Finally, MeAIB-inhibitable transamination of 15N-alanine to
15N-glutamate was observed (Figure S7E). Extracellular alanine
is therefore rapidly taken up by System A transport in primary
human CD4+ T cells and incorporated into the wider cellular
metabolite pool.
Modulation of T Cell Mitogenesis by SNAT1
Downregulation in HIV-1 Infection
As a functional readout for SNAT1 downregulation in the context
of viral infection, we examined the effect of Vpu expression on
proliferation of primary human CD4+ T cells. Similar to transduc-
tion with SNAT1 shRNA, lentiviral delivery of WT Vpu (but not the
Vpu S53, 57A phosphodegron mutant) retarded T cell prolifera-
tion (Figure S7F). Remarkably, despite antagonism of cell-cycle
progression by Vpr (Malim and Emerman, 2008), and Vpu-inde-
pendent modulation of a range of mitogenic cell surface proteins
(Figure 2E), we also observed a significant reduction in prolifera-
tion of T cells infected with WT HIV-1, as compared with Vpu-
deficient or Vpu S53, 57A phosphodegron mutant viruses
(Figure 6G).
(C) Defective proliferation of SNAT1-depleted primary T cells. Re-stimulated cells from (B) were seeded at equal densities and viable cells enumerated at the
indicated time points using CytoCount beads. Data were obtained in triplicate. **p < 0.01. No difference in cell size between the two populations was seen by flow
cytometry (Figure S6B).
(D) CoRemetabolomic analysis of control and SNAT1-depleted primary T cells. Metabolite compositions of culture supernatants from (C) were determined by LC-
MS at baseline, 24, and 48 hr. Data were obtained in triplicate, and Principal component analysis was used to compare net consumption or release of metabolites
by control and SNAT1-depleted cells (upper panels). 95% confidence regions are shown. p values for differences in consumption or release of individual
metabolites at 48 hr are shown on a negative log scale (middle panel). Net consumption or release of alanine and glutamine is shown scaled to amaximumchange
of 1 (lower panels). **p < 0.01.
(E and F) Impaired alanine uptake by primary T cells depleted of SNAT1 by shRNA (E) or Vpu (F). Cells from Figures 3G–3H were re-stimulated for 48 hr with CD3/
CD28 Dynabeads and uptake (counts perminutes; CPM) of 3H-alanine measured at time points from 30 s to 5min. 3H-alanine transport in the presence ofMeAIB
is included as a control, and MeAIB-inhibitable uptake is highlighted (black arrows). 95% confidence bands on linear regression lines (indicating rates of uptake)
are shown in gray. **p < 0.01.
See also Figure S6.





Figure 6. Requirement for Extracellular Alanine in T Cell Mitogenesis
(A) Dose-dependent proliferation of primary T cells in response to exogenous alanine. Primary human CD4+ T cells were stained with CFSE, stimulated with CD3/
CD28 Dynabeads in media supplemented with alanine at the concentrations indicated, and analyzed by flow cytometry after 120 hr (green filled histograms).
Peaks are labeled by division number, and unstimulated cells were included as a control (black dotted lines). Representative data from three independent ex-
periments are shown.
(B) Dose-dependent inhibition of primary T cell proliferation by MeAIB. Primary human CD4+ T cells were stimulated with CD3/CD28 Dynabeads in media
supplemented with alanine andMeAIB at the concentrations indicated. Viable cells were enumerated using CytoCount beads after 72 hr and numbers expressed
as a fraction of the maximum.
(C) Regulation of free intracellular alanine pool by SystemA-dependent alanine uptake. Primary humanCD4+ T cells were expanded, rested, and re-stimulated for
48 hr with CD3/CD28 Dynabeads. Cells were then resuspended in media supplemented with alanine at the concentrations indicated in the presence or absence
(legend continued on next page)
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SNAT1 Downregulation by Vpu Variants of Pandemic
HIV-1 Viruses
HIV-1 viruses form three main groups, each representing a
separate transmission of chimpanzee SIVcpz or gorilla SIVgor
to humans: M (or Main, responsible for the AIDS pandemic),
O (or Outlier), and N (or New or Non-M, Non-O). Group M
viruses are responsible for greater than 90% of all HIV infec-
tions and cluster into genetically distinct clades, of which the
most widespread are A (East Africa), B (Europe and North
America), and C (Southern Africa) (Hemelaar et al., 2011).
Among non-human primates, Vpu is found in viruses of the
SIVcpz lineage (including HIV-1 and SIVgor), as well as more
distantly related guenon monkey viruses (SIVgsn, SIVmus,
and SIVmon).
To explore the phylogenetic history of Vpu-mediated SNAT1
downregulation, we generated a stable 293T cell line expressing
SNAT1-FLAG and CD4 and compared the effects of different
Vpu-IRES-GFP constructs. CD4 downregulation is widely
conserved and therefore represents a positive control for func-
tional Vpu expression (Sauter et al., 2009). As expected, whereas
NL4-3 Vpu (but not Vpu S52A) downregulated both CD4 and
SNAT1-FLAG, Nef only downregulated CD4 (Figure 7A). Deple-
tion of cell surface SNAT1-FLAG was conserved across all 6
HIV-1 clade A, B, and C Vpu variants tested (Figures 7A and
7B), but restricted to the SIVcpz Ptt lineage giving rise to
pandemic HIV-1 group M viruses (Figure 7C). The ability of Vpu
to downregulate SNAT1 has therefore been acquired recently
and may be critical for the in vivo replication or enhanced path-
ogenicity of HIV-1 viruses.
DISCUSSION
In this study, we provide a comprehensive, unbiased temporal
map of the cell surface of an HIV-1-infected T cell. Our plasma
membrane proteomic approach captures transcriptional and
post-transcriptional effects, including protein sequestration
and redistribution, and is not limited to known T cell immunore-
ceptors (Weekes et al., 2014). The study of cell surface proteins
downregulated by viruses has uncovered important areas of im-
munobiology, and manipulation by HIV-1 therefore suggests
host factors with unsuspected functions in both viral pathogen-
esis and cellular physiology. Downregulation is unlikely to reflect
a non-specific cellular response to productive viral infection
because plasma membrane proteins depleted by HIV-1 exhibit
contrasting temporal regulation in cells infected with human
cytomegalovirus, even within protein families (Figures S1F and
S1G) (Weekes et al., 2014).
Along with CD4 and tetherin, our data identify SNAT1 as the
third b-TrCP-dependent Vpu substrate. Other Vpu targets
have been proposed, based on candidate approaches: NTB-A,
CCR7, CD1d, PVR, SELL, and the tetraspanins CD37/53/63/
81/82 (Haller et al., 2014; Lambele´ et al., 2015; Matusali et al.,
2012; Moll et al., 2010; Ramirez et al., 2014; Shah et al., 2010;
Vassena et al., 2015). In general, the mechanisms are not
b-TrCP dependent, remain poorly characterized, and may be in-
direct. Furthermore, the magnitude of downregulation reported
has been modest, which may contribute to less-robust pheno-
types (Sato et al., 2012). Compared with these targets, our sys-
tematic analysis suggests that downregulation of CD4, tetherin,
and SNAT1 is qualitatively distinct (Figure S3E), reflecting
recruitment of b-TrCP and hijack of enzymatic ubiquitin-medi-
ated degradation. Together with downregulation of CD4,
MHC-I, SERINC3, and SERINC5 by Nef, we therefore define a
more limited group of highly downregulated HIV-1 accessory
protein targets.
Vpu and Nef co-operate in the downregulation of CD4 and
tetherin, and loss of function in one gene may be compensated
by gain of function in the other (Sauter et al., 2009). The Nef pro-
teins of HIV-2 and most SIVs are able to modulate T cell activa-
tion by downregulating CD3 from the surface of infected cells,
but Nef has lost this ability in most Vpu-containing viruses. Vpu
has therefore been suspected to modulate T cell activation via
an alternative pathway (Kirchhoff, 2009).We focused on downre-
gulation of SNAT1 both because it is a direct Vpu target and
because the importance of amino acid transport in regulating
T cell activation is increasingly recognized (Nakaya et al., 2014;
Sinclair et al., 2013). Furthermore, while many transporters are
poorly characterized multi-pass transmembrane proteins with
few reliable reagents, their plasma membrane location makes
them potentially druggable therapeutic targets, and inhibitors
already exist for many biochemically defined transport systems.
Induction of SNAT1 mRNA correlates with increased gluta-
mine uptake during activation of murine T cells (Carr et al.,
2010), but other candidate glutamine transporters are also
induced (Nakaya et al., 2014; Wang et al., 2011), and pre-
genomic studies attributed lymphocyte glutamine transport to
Systems ASC, L, and N, not System A (Segel, 1992). We there-
fore used an unbiased systematic approach to identify SNAT1
substrates in primary humanCD4+ T cells. Measured differences
between alanine fluxes of control and SNAT1-depleted cells
could potentially reflect both direct transport effects and sec-
ondary effects on synthesis or utilization. Alanine may be
synthesized by transamination of pyruvate and glutamine-
derived glutamate, and re-analysis of data from a previous
of MeAIB. Abundance of free intracellular alanine at baseline and 60 min is expressed as a fraction of the maximum. Mean values and 95% confidence intervals
are shown for data obtained in triplicate. No difference in cell size was observed between 0 and 0.5 mM alanine (Figure S7D, left panel).
(D–F) Reconstitution of free intracellular alanine pool by extracellular alanine. Washed cells prepared as in (C) were resuspended in media supplemented with
5.6 mM 13C6-glucose and 0.5 mM 15N-alanine (D) in the presence or absence of MeAIB. Abundances of labeled and unlabeled free intracellular alanine (E) and
supernatant lactate (F) at the indicated time points are expressed as a fraction of the maximum. Mean values and 95% confidence intervals are shown for data
obtained in triplicate. No difference in cell size was observed in the presence or absence of MeAIB (Figure S7D, right panel).
(G) Defective proliferation of primary T cells depleted of SNAT1 by HIV-1. Primary human CD4+ T cells were stained with CellTrace Violet, stimulated with CD3/
CD28 Dynabeads, infected with the indicated NL4-3 Vpu 2_87 HIV-1 viruses at an MOI of 3, and analyzed by flow cytometry after 120 hr (violet filled histograms).
Peaks are labeled by division number, and unstimulated cells are included as a control (black dotted lines). Representative data for infected (p24+) and uninfected
(p24!) cells are shown. Mean percent of infected cells in each generation from four independent experiments are depicted as stacked columns. Error bars
indicate SEM. **p < 0.01.
See also Figure S7.
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CoRe metabolomic screen of NCI-60 cancer cell lines confirmed
that release of alanine typically correlates with release of lactate
and consumption of glucose and glutamine (Jain et al., 2012).
Conversely, we saw no difference between control and
SNAT1-depleted cells in release of lactate or consumption of
glucose and glutamine (Figures 5D and S6C), suggesting similar
rates of alanine synthesis, and confirmed alanine uptake by
SNAT1 in primary human CD4+ T cells using a formal transport
assay and a concentration of alanine approximating that seen
in vivo.
Alanine is the second most abundant amino acid in human
plasma, but absent from standard media such as RPMI, and
contributed to in vitro cell culture systems by serum supplemen-
tation (Rotter et al., 1979). Despite net excretion, we show that
the concentration of extracellular alanine dramatically impacts
T cell mitogenesis, and uptake of exogenous alanine by System
A transport is critical to maintain the free intracellular alanine
pool. Alanine is a major constituent of mammalian proteins and
may be incorporated into the wider cellular metabolite pool by
A B
C
Figure 7. SNAT1 Downregulation by Vpu
Variants from Pandemic HIV-1 Viruses
(A) Screening strategy for SNAT1 downregulation
by naturally occurring Vpu variants. 293Ts stably
expressing SNAT1-FLAG and CD4 were trans-
fected with the indicated pCG-IRES-GFP con-
structs (all based on HIV-1 groupM, clade B, strain
NL4-3 virus) and analyzed by flow cytometry at
36 hr. Target downregulation is indicated by a shift
in the transfected (GFP+) cells toward the lower left
quadrant (red arrows).
(B) SNAT1-FLAG downregulation by Vpu variants
from pandemic HIV-1 group M clade A/B/C vi-
ruses. As for (A), but cells were transfected with
pCG-IRES-GFP constructs encoding Vpu variants
from the indicated strains of HIV-1.
(C) Phylogenetic analysis of SNAT1-FLAG down-
regulation by Vpu variants of HIV-1 and SIV viruses.
As for (A) and (B), but cells were transfected with
pCG-IRES-GFP constructs encoding Vpu variants
from the indicated strains of HIV-1 or SIV and
downregulation of SNAT1-FLAG or CD4 expressed
as ratio of geomean fluorescence intensity between
transfected (GFP+) and untransfected (GFP!) cells.
Illustrativephylogenetic relationshipsareshown,and
branch lengths are arbitrary (further details are
included inSupplementalExperimentalProcedures).
HIV-1/M/N/O (HIV-1 group M, N, or O viruses);
SIVcpz Ptt (SIVs infecting central P. t. troglodytes
chimpanzees); SIVcpz Pts (SIVs infecting eastern
P. t. schweinfruthii chimpanzees); SIVgor (gorilla
SIV); SIVguenon (SIVs infecting guenon monkeys).
transamination. In addition, bidirectional
transport of alanine at the plasma mem-
brane may be used to drive tertiary active
transport of other amino acids (Nicklin
et al., 2009). The relative significance of
these effects remains to be determined.
While amino acid availability is known to
regulate immune activation in multiple
settings, antagonism of SNAT1 by HIV-1
Vpu is a specific example of viral interference with amino acid
immunometabolism.
Modulation of cell surface targets by virusesmay enhance viral
replication directly, in a cell-autonomous fashion, or indirectly,
through effects on non-infected cells or the immune response.
It is difficult to account for indirect effects on virus production
in vivo using in vitro models. For example, tetherin restricts
(Neil et al., 2008) or enhances (Jolly et al., 2010) HIV-1 replication,
depending on the assay used. The significance of tetherin as a
restriction factor is instead proven by conservation of antago-
nism across a range of HIV and SIV viruses, and we therefore
sought analagous genetic evidence for the importance of
SNAT1 in the host-HIV interaction. SNAT1 antagonism was
observed for HIV-1 group M Vpu variants from laboratory-
adapted viruses and primary patient isolates, including a founder
virus strain, X4 and R5 tropic viruses, and related HIV-1 group N
and SIVcpz Ptt Vpu variants. Remarkably, despite the extraordi-
nary sequence diversity of HIV-1, and the potential to dissociate
SNAT1 downregulation from that of CD4 and tetherin, the ability
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of Vpu to target SNAT1 is therefore conserved across pandemic
HIV-1 viruses, suggesting a significant selective advantage.
Furthermore, the restriction of SNAT1 downregulation to Vpu
variants from the SIVcpz/HIV-1 lineage suggests a specific role
in the pathogenesis of these viruses.
EXPERIMENTAL PROCEDURES
HIV-1 Infections
For proteomic time course analysis, CEM-T4 T cells were spinoculated with
VSVg-pseudotyped NL4-3-dE-EGFP HIV-1 virus at an MOI of 10, aliquots of
infected cells harvested sequentially at the indicated time points, and dead
cells removed by immunomagnetic depletion prior to PMP.
Plasma Membrane Enrichment and Peptide Labeling
PMPwas performed as previously described (Weekes et al., 2013, 2014) using
23 107 viable cells per condition and a ‘‘one pot’’ oxidation and aminooxy-bio-
tinylation reaction to selectively biotinylate plasma membrane glycoproteins
before immunoprecipitation with streptavidin beads and on-bead tryptic
digestion. For TMT quantitation, cells from each condition were processed
separately, and peptide samples were labeled with TMT reagents before pool-
ing. For SILAC quantitation, cells were pre-labeled by propagation in SILAC
media and pooled prior to processing together.
Proteomics and Data Analysis
Peptide samples were fractionated by high-pH reverse-phase high-pressure
liquid chromatography (HpRP-HPLC) and analyzed by liquid chromatography
coupled to triple-stage (TMT) or tandem (SILAC) mass spectrometry using an
Orbitrap Fusion Tribrid (TMT) or Q Exactive (SILAC) mass spectrometer.
Reporter ions from TMT-labeled peptides were quantitated from an MS3
scan using Proteome Discoverer. SILAC-labeled peptides were quantitated
using MaxQuant.
Primary Cell Knockdowns
Primary human CD4+ T cells were activated with CD3/CD28 Dynabeads and
transduced with lentiviral constructs encoding U6-shRNA knockdown and
SFFV-SBP-DLNGFR streptavidin-binding affinity tag cassettes. Transduced
cells were selected with streptavidin Dynabeads then released by incubation
with excess biotin as previously described (AFMACS) (Matheson et al.,
2014). Ethical permission for this project was granted by the Cambridgeshire
2 Research Ethics Committee (REC reference 97/092). Informed written con-
sent was obtained from all of the volunteers included in this study prior to
providing blood samples.
CoRe Metabolomics and Data Analysis
AFMACS-purified primary human CD4+ T cells expressing control or SNAT1-
specific shRNAs were re-stimulated using CD3/CD28 Dynabeads. After 24 hr,
cells were resuspended in 20% conditioned media at equal densities and su-
pernatant samples at baseline, 24, and 48 hr were analyzed by liquid chroma-
tography coupled to mass spectrometry (LC-MS) as previously described
(Jain et al., 2012). To account for differential proliferation, viable cells were
enumerated at each time point and changes in metabolite concentrations
normalized based on average cell numbers.
3H-Alanine Uptake
AFMACS-purified primary human CD4+ T cells expressing control or SNAT1-
specific shRNAs were re-stimulated using CD3/CD2 min8 Dynabeads. After
48 hr, cells were starved to reduce trans-inhibition then resuspended at
37!C in Tyrode’s buffer supplemented with 3H-alanine at a final concentration
of 0.5 mM. Aliquots of cells were harvested sequentially over 5 min and uptake
terminated by filtering centrifugation through silicone oil before liquid scintilla-
tion counting.
Free Intracellular Amino Acids
Primary human CD4+ T cells were expanded once and then re-stimulated
using CD3/CD28 Dynabeads. After 48 hr, cells were resuspended in media
supplemented with dialyzed FCS and either unlabeled alanine and glucose
or (for stable isotopologue-resolved metabolomics) 15N-alanine and 13C6-
glucose at concentrations of 0.5 mM and 5.6 mM, respectively. Aliquots of
cells were harvested sequentially over 1 hr, and free intracellular amino acids
were extracted from washed cells using dry ice-cold 50% methanol 30%
acetonitrile before analysis by LC-MS. Please see Supplemental Experimental
Procedures for further details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chom.2015.09.003.
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Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by 
Vpu and Nef 
Nicholas J. Matheson, Jonathan Sumner, Kim Wals, Radu Rapiteanu, Michael P. Weekes, Raphael Vigan, 
Julia Weinelt, Michael Schindler, Robin Antrobus, Ana S.H. Costa, Christian Frezza, Clary B. Clish, 
Stuart J.D. Neil, and Paul J. Lehner 
Figure S1. Controls for TMT-based Proteomic Timecourse and Comparison with 
HCMV Infection, Related to Figure 1 
(A) Identification of HIV-infected cells. Cells from Figure 1A were stained with anti-CD4 
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3-deltaE-EGFP virus results in expression of GFP and downregulation of CD4 by Nef and 
Vpu. Uninfected cells (grey), cells infected for 24 and 72 hrs (red) and cells infected for 72 
hrs in the presence of reverse transcriptase inhibitors (blue) are shown.  
(B) Gene Ontology Cellular Compartment (GOCC) annotation of quantitated proteins. PM, 
plasma membrane; CS, cell surface; XC, extracellular; ShG, short GOCC (a subset of 
proteins with short membrane-specific GOCC terms but no subcellular assignment (Weekes 
et al., 2012); Mem, membrane. 1,846 of 2,320 quantitated proteins had GOCC annotations, 
of which 804 (44%) were indicative of plasma membrane localisation.  
(C) Temporal profiles of other reported targets for HIV-mediated downregulation (Drakesmith 
et al., 2005; Koppensteiner et al., 2014; Michel et al., 2006; Ramirez et al., 2014). 
(D) Temporal profile of VSVg. 
(E) Temporal profile of SERINC1.  
(F) Differential regulation of cell surface proteins by HIV and HCMV infection. 79 proteins 
from Cluster #35 (cell surface proteins progressively downregulated by HIV) were previously 
quantitated in HCMV-infected fibroblasts (Weekes et al., 2014) and found to be variably 
upregulated, downregulated, or unchanged by HCMV infection.  
(G) Temporal profiles of nectins (PVRL1-3) revealing differential regulation by HIV and 
HCMV. Nectin-2 (PVRL2, CD112) is targeted for proteasomal degradation by co-operation 
between the HCMV proteins UL141 and US2. Conversely, in HIV-1-infected cells (as 
shown), we observed downregulation of nectin-1 (PVRL1, CD111) and nectin-3 (PVRL3, 
CD113), but not nectin-2. 
Figure S2. Flow Cytometric Validation of Novel HIV-1 Targets, Related to Figure 2 
(A) Validation of novel HIV-1 targets by flow cytometry in CEM-T4s and primary T-cells. 
CEM-T4s or primary human CD4+ T-cells stimulated with CD3/CD28 Dynabeads were 







































































EGFP HIV-1 virus typically at an MOI of 1. Target expression is shown for GFP low, medium 
and high cells and fold-change in geomean fluorescence intensity high/low is indicated. 
Negative values denote downregulation in productively infected (GFP-expressing) cells. 
CD50 abundance was unchanged by HIV-infection in the TMT dataset and is included as a 
control.  
(B) Downregulation of NCR3LG1. CEM-T4s were stained with NKp30-Ig fusion protein 
(endogenous NCR3LG1 ligand) 48 hrs after infection with NL4-3-deltaE-EGFP HIV-1 virus at 
an MOI of 1. As in (A) NKp30-Ig binding is shown for GFP low, medium and high cells and 
fold-change high/low is indicated. 
Figure S3. Novel Vpu and Nef targets, Related to Figure 3 
(A-B) SILAC-based quantitation of plasma membrane proteins in cells infected with Vpu-
deficient (y-axis) versus Nef-deficient (x-axis) viruses (A; enlarged left lower quadrant of 
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genes (B; enlarged left lower quadrant of scatterplot shown in Figure 3B). Outliers of 
potential interest are labelled.  
(C) Restriction of HIV-1 virus production by SERINC5. 293Ts were co-transfected with the 
indicated pNL4-3 HIV-1 molecular clones plus increasing concentrations of pCR3.1-
SERINC5 and 48 hr culture supernatants assayed for infectious viral release using HeLa-
TZM-bl cells. Mean values and 95% confidence intervals are shown.   
(D) No effect on HIV-1 virus production by SNAT1. Control and SNAT1-HA-expressing 
293Ts were infected with the indicated VSVg-pseudotyped NL4-3 HIV-1 viruses at an MOI of 
2 and 48 hr culture supernatants assayed for infectious virus release using HeLa-TZM-bl 
cells. Mean values and 95% confidence intervals are shown.  
(E) Comparison of SNAT1 with known Vpu targets. As for (B) and Figure 3B, but showing 
downregulation of SNAT1, CD4 and tetherin compared with previously reported Vpu targets 
NTB-A, SELL, CD37, CD53, CD63, CD81 and CD82. HLA-A (downregulated by Nef) is also 
shown. CCR7, CD1d and PVR (CD155) were not quantitated in this experiment, but CCR7 
was downregulated by both ΔVpu and ΔNef viruses. CD53 was quantitated on the basis of a 
single PSM. 
Figure S4.  Validation of SNAT1 Depletion, Related to Figure 3 
(A-B) Cell surface SNAT1 depletion by Vpu. Cells from Figure 3E were stained with anti-
SNAT1 antibody (green) and DAPI (blue) and analysed by confocal microscopy (A) or TIRF 
B 
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microscopy (B). TIRF microscopy enables selective visualisation of the plasma membrane 
(SNAT1; lower panels) with widefield images (DAPI; upper panels) included as controls.  
(C) Infection controls for Figures 3C-D. Cells from Figures 3C-D were analysed by flow 
cytometry 48 hrs after infection with the indicated NL4-3-deltaE-EGFP HIV-1 viruses. In each 
case % productively infected (GFP+) cells is indicated. Uninfected cells (grey) are also 
shown. 
Figure S5. Controls for Mechanism of SNAT1 Depletion, Related to Figure 4 
(A) Molecular determinants of CD4 and tetherin downregulation. Cells from Figure 4F were 
stained with anti-CD4 or anti-tetherin antibodies and analysed by flow cytometry. Jurkats 
transduced with empty vector (blue) or Vpu variants (red) are shown. Unstained cells (CD4) 
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(B) Depletion of SNAT1 by Vpu 2_87. 293Ts stably expressing SNAT1-HA were transduced 
with the indicated Vpu constructs at an MOI of 2 then immunoblotted with anti-HA and 
HSP90 (loading control) antibodies.  
(C) Molecular determinants of SNAT1 depletion by HIV-1. 293Ts stably expressing SNAT1-
HA were infected with the indicated VSVg-pseudotyped NL4-3 HIV-1 viruses at an MOI of 2 
then immunoblotted with anti-HA, anti-p24, anti-Vpu and anti-HSP90 (loading control) 
antibodies.  
Figure S6. Controls for CoRe Metabolomics, Related to Figure 5 
(A) Enrichment of transduced cells by AFMACS. Transduced cells from Figures 5A-D were 
stained with anti-LNGFR antibody before and after selection by AFMACS (red and blue 
lines). In each case, unstained cells (grey) and control cells stained with anti-LNGFR 
antibody (dotted line) are included and % LNGFR positive cells after selection are shown.  
(B) No change in size of T-cells in response to SNAT1 depletion. Cells from Figure 5B were 
analysed by flow cytometry 48 hrs after re-stimulation with CD3/CD28 Dynabeads. Cell size 
is indicated by intensity of forward-scattered light (FSC). Mean values and 95% confidence 
intervals are shown for data obtained in triplicate. 
(C) No change in glucose uptake or lactate release by SNAT1 depleted T-cells. As for 
Figure 5D, but net consumption or release of glucose and lactate by control and SNAT1-
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Figure S7. Controls for Free Intracellular Amino Acids, Related to Figure 6 
(A) Dose-dependent proliferation of CEM-T4s and Jurkats in response to exogenous 
alanine. CEM-T4 and Jurkat T-cells were seeded in phenol red-free media supplemented 
with alanine at the concentrations indicated. Viable cells were enumerated using an MTT 
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(B) Preserved CD69 and CD25 expression in the absence of alanine. As for Figure 6A but 
cells were stained with conjugated antibodies against CD69 and CD25 and analysed by flow 
cytometry after 24 hrs.  
